


**CUMULATIVE
SUPPLEMENT 08**
August 2010



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

30th EDITION

Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research
Office of Generic Drugs

Prepared By
Office of Generic Drugs
Center for Drug Evaluation and Research
Food and Drug Administration

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

30th EDITION

Cumulative Supplement 08

August 2010

CONTENTS

| | <i>PAGE</i> |
|--|-------------|
| 1.0 INTRODUCTION | iii |
| 1.1 How to use the Cumulative Supplement | iii |
| 1.2 Cumulative Supplement Content..... | iv |
| 1.3 Applicant Name Changes..... | v |
| 1.4 Availability of the Edition | vi |
| 1.5 Report of Counts for the Prescription Drug Product List | vii |
| 1.6 Cumulative Supplement Legend | viii |
| DRUG PRODUCT LISTS | |
| Prescription Drug Product List | 1-1 |
| OTC Drug Product List | 2-1 |
| Drug Products with Approval under Section 505 of the Act | |
| Administered by the Center for Biologics Evaluation and Research List..... | 3-1 |
| Orphan Product Designations and Approvals List | 4-1 |
| Drug Products Which Must Demonstrate <i>in vivo</i> Bioavailability | |
| Only if Product Fails to Achieve Adequate Dissolution | 5-1 |
| PATENT AND EXCLUSIVITY INFORMATION ADDENDUM | |
| A. Patent and Exclusivity Lists | A-1 |
| B. Patent and Exclusivity Terms | B-1 |

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

30th EDITION

**CUMULATIVE SUPPLEMENT 08
August 2010**

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 30th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; over-the-counter (OTC) drug products that require approved applications as a condition of marketing; drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research; and products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, or have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 30th Edition List will then be added to the "Discontinued Drug Product List" appearing in the 31st Edition. The current Edition Section 2., How To Use The Drug Product Lists, describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
 - o Refer to CS Section 1.8 Cumulative Supplement Legend for types of changes
 - o Discontinued products will be processed as of the date of publication. There will be circumstances where a product is discontinued in one month, however, it will be reported in a different month's CS. For example, the Orange Book Staff received a letter November 7 that the product has been discontinued from manufacturing and marketing. The Orange Book subsequently publishes the October CS on November 14. The product will show in the October CS that it is discontinued even though the date of discontinuance is the day that the Orange Book Staff receives notification (November 7).
- New Drug Application (NDA) approvals (20,000 and 50,000 series) appear in the CS month they were approved.

- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and current to the date of publication.

Every effort is made to ensure the Cumulative Supplement is current and accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at drugproducts@fda.hhs.gov. Send Changes by FAX: 240-276-8974; mail to:

FDA/CDER Orange Book Staff
Office of Generic Drugs, HFD-610
7500 Standish Place
Rockville, MD 20855-2773

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively, to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

| <u>FORMER APPLICANT NAME</u> <u>(FORMER ABBREVIATED NAME)</u> | <u>NEW APPLICANT NAME</u> <u>(NEW ABBREVIATED NAME)</u> |
|--|--|
| ASCENT PEDIATRICS INC (ASCENT PEDS) | SHIONOGI PHARMA INC (SHIONOGI PHARMA) |
| GOLDLINE LABORATORIES INC (GOLDLINE) | IVAX PHARMACEUTICALS INC SUB TEVA PHARMACEUTICALS USA (IVAX SUB TEVA PHARMS) |
| HLR TECHNOLOGY (HLR) | HOFFMANN LA ROCHE INC (HOFFMANN LA ROCHE) |
| IVAX PHARMACEUTICALS INC (IVAX PHARMS) | IVAX PHARMACEUTICALS INC SUB TEVA PHARMACEUTICALS USA (IVAX SUB TEVA PHARMS) |
| KALI LABORATORIES INC (KALI LABS) | PAR PHARMACEUTICAL INC (PAR PHARM) |
| KALI LABS INC (KALI LABS) | PAR PHARMACEUTICAL INC (PAR PHARM) |

| | |
|---|--|
| MEDICIS PHARMACEUTICAL CORP (MEDICIS) | SHIONOGI PHARMA INC (SHIONOGI PHARMA) |
| MINRAD INC (MINRAD) | PIRAMAL CRITICAL CARE INC (PIRAMAL CRITICAL) |
| MORTON GROVE ACQUISITION CORP (MORTON GROVE) | WOCKHARDT EU OPERATIONS (SWISS)AG (WOCKHARDT) |
| MORTON GROVE PHARMACEUTICALS (MORTON GROVE) | WOCKHARDT EU OPERATIONS (SWISS)AG (WOCKHARDT) |
| MORTON GROVE PHARMACEUTICALS INC (MORTON GROVE PHARMS) | WOCKHARDT EU OPERATIONS (SWISS)AG (WOCKHARDT) |
| PROCTER AND GAMBLE CO (PROCTER AND GAMBLE) | WARNER CHILCOTT CO LLC (WARNER CHILCOTT) |
| PROCTER AND GAMBLE CO PHARMACEUTICALS INC SUB PROCTER AND GAMBLE CO (PROCTER AND GAMBLE) | WARNER CHILCOTT CO LLC (WARNER CHILCOTT) |
| SCIELE PHARMA INC (SCIELE PHARMA INC) | SHIONOGI PHARMA INC (SHIONOGI PHARMA) |
| TEVA PHARMACEUTICALS USA (TEVA PHARMS) | IVAX PHARMACEUTICALS INC SUB TEVA PHARMACEUTICALS USA (IVAX SUB TEVA PHARMS) |
| ZENITH GOLDLINE LABORATORIES INC (ZENITH GOLDLINE) ZENITH GOLDLINE PHARMACEUTICALS (ZENITH GOLDLINE) | IVAX PHARMACEUTICALS INC SUB TEVA PHARMACEUTICALS USA (IVAX SUB TEVA PHARMS) IVAX PHARMACEUTICALS INC SUB TEVA PHARMACEUTICALS USA (IVAX SUB TEVA PHARMS) |
| ZENITH GOLDLINE PHARMACEUTICALS INC (ZENITH GOLDLINE) | IVAX PHARMACEUTICALS INC SUB TEVA PHARMACEUTICALS USA (IVAX SUB TEVA PHARMS) |

1.4 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, <http://www.fda.gov/opacom/morechoices/fdaforms/default.html>.

The current listing of the Orphan Product Designations and Approvals is available at <http://www.fda.gov/orphan/designat/list.htm>.

1.5 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 2008) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST COUNTS CUMULATIVE BY QUARTER

| CATEGORIES COUNTED | DEC 2009 | MAR 2010 | JUN 2010 | SEPT 2010 | DEC 2010 |
|----------------------|------------------|------------------|------------------|-----------|----------|
| DRUG PRODUCTS LISTED | 13065 | 13216 | 13445 | | |
| SINGLE SOURCE | 2460 (18.8%) | 2474 (18.7%) | 2466 (18.3%) | | |
| MULTISOURCE | 10516 (80.5%) | 10653 (80.6%) | 10890 (81.0%) | | |

| | | | |
|---------------------------------|------------------|------------------|------------------|
| THERAPEUTICALLY EQUIVALENT | 10367 (79.3%) | 10502 (79.5%) | 10732 (79.8%) |
| NOT THERAPEUTICALLY EQUIVALENT | 149 (1.1%) | 151 (1.1%) | 158 (1.2%) |
| EXCEPTIONS ¹ | 89 (0.7%) | 89 (0.7%) | 89 (0.7%) |
| NEW MOLECULAR ENTITIES APPROVED | 3 | 5 | 1 |
| NUMBER OF APPLICANTS | 718 | 727 | 729 |

¹Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.6 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route and then by trade name.

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form; route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be proceeded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

| | |
|------|---|
| NEWA | New drug product approval usually in the supplement month. |
| CAHN | Applicant holder firm name has changed. |
| CAIN | Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name. |
| CDFR | Change. Dosage Form; Route of Administration. |
| CFTG | Change. A first time generic for the innovator product. A TE Code is added. |
| CMFD | Change. The product is moved from the Discontinued Section due to a change in marketing status. |
| CMS1 | Change. Miscellaneous addition to list. |
| CMS2 | Change. Miscellaneous deletion from list. |
| CPOT | Change. Potency amount/unit. |
| CRLD | Change. Reference Listed Drug. |
| CTEC | Change. Therapeutic Equivalence Code. |
| CTNA | Change. Trade Name. |
| DISC | Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition. |

PRESCRIPTION DRUG PRODUCT LIST - 30TH EDITION

RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2010

1-1

ACARBOSE

TABLET; ORAL

ACARBOSE

| | | | | | | |
|----|-------------|-------|-------------|--------------|-----|------|
| AB | WATSON LABS | 25MG | A077532 001 | May 07, 2008 | Jun | CAHN |
| AB | | 50MG | A077532 002 | May 07, 2008 | Jun | CAHN |
| AB | | 100MG | A077532 003 | May 07, 2008 | Jun | CAHN |

ACETAMINOPHEN; ASPIRIN; CODEINE PHOSPHATE

CAPSULE; ORAL

ACETAMINOPHEN, ASPIRIN, AND CODEINE PHOSPHATE

@ MIKART 150MG;180MG;30MG

A081096 001 Oct 26, 1990 May DISC

ACETAMINOPHEN; BUTALBITAL

TABLET; ORAL

BUTAPAP

| | | | | | | |
|----|-----------|------------|-------------|--------------|-----|------|
| AA | MIKART | 325MG;50MG | A089987 001 | Oct 26, 1992 | Feb | CTEC |
| AA | + VALEANT | 325MG;50MG | A087811 001 | Jun 19, 1985 | Feb | CTEC |

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

+ NEXGEN PHARMA 300MG;50MG;40MG

A040885 001 Nov 16, 2009 Feb CRLD

| | | |
|----|--------------|-----------------|
| AA | WEST WARD | 500MG;50MG;40MG |
| AA | + ESGIC-PLUS | 500MG;50MG;40MG |

A040261 001 Oct 28, 1998 Feb CTEC

| | | |
|----|----------|-----------------|
| AA | + MIKART | 500MG;50MG;40MG |
|----|----------|-----------------|

A040085 001 Mar 28, 1996 Feb CTEC

TABLET; ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

| | | |
|----|-----------------|-----------------|
| AA | CONCORD LABS NJ | 325MG;50MG;40MG |
| AA | | 500MG;50MG;40MG |

A040864 001 Dec 01, 2008 Feb CTEC

| | | |
|----|--------------|-----------------|
| AA | MALLINCKRODT | 325MG;50MG;40MG |
| AA | + MIKART | 325MG;50MG;40MG |

A040883 001 Dec 23, 2008 Feb CTEC

| | | |
|----|----------------|-----------------|
| AA | VINTAGE PHARMS | 325MG;50MG;40MG |
| AA | | 500MG;50MG;40MG |

A087804 001 Jan 24, 1985 Feb CTEC

| | | |
|----|-------------|-----------------|
| AA | WATSON LABS | 500MG;50MG;40MG |
| AA | + WEST WARD | 325MG;50MG;40MG |

A089175 001 Jan 21, 1987 Feb CTEC

| | | |
|----|-------------|-----------------|
| AA | WATSON LABS | 500MG;50MG;40MG |
| AA | + WEST WARD | 325MG;50MG;40MG |

A040511 001 Aug 27, 2003 Feb CTEC

| | | |
|----|-------------|-----------------|
| AA | WATSON LABS | 500MG;50MG;40MG |
| AA | + WEST WARD | 325MG;50MG;40MG |

A040513 001 Aug 25, 2003 Feb CTEC

| | | |
|----|-------------|-----------------|
| AA | WATSON LABS | 500MG;50MG;40MG |
| AA | + WEST WARD | 325MG;50MG;40MG |

A040267 001 Jul 30, 1998 Feb CTEC

| | | |
|----|-------------|-----------------|
| AA | WATSON LABS | 500MG;50MG;40MG |
| AA | + WEST WARD | 325MG;50MG;40MG |

A089718 001 Jun 12, 1995 Feb CTEC

| | | |
|----|-------------|-----------------|
| AA | WATSON LABS | 500MG;50MG;40MG |
| AA | + WEST WARD | 325MG;50MG;40MG |

A040336 001 Aug 18, 1999 Feb CTEC

ESGIC-PLUS

| | | |
|----|------------|-----------------|
| AA | + MIKART | 500MG;50MG;40MG |
| AA | + FIORICET | |

A089451 001 May 23, 1988 Feb CTEC

| | | |
|----|-----------------|-----------------|
| AA | + WATSON PHARMS | 325MG;50MG;40MG |
| AA | + WATSON PHARMS | 325MG;50MG;40MG |

A088616 001 Nov 09, 1984 Feb CTEC

ACETAMINOPHEN; HYDROCODONE BITARTRATE

SOLUTION; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

+ MIKART 300MG/15ML;10MG/15ML

A040881 001 Feb 25, 2010 Feb NEWA

TABLET; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

MIKART 325MG;2.5MG

A040846 001 Jun 09, 2010 May NEWA

650MG;5MG

A040849 001 Jun 09, 2010 May NEWA

@ SANDOZ 500MG;5MG

A040149 001 Jan 27, 1997 Jul DISC

@ 750MG;7.5MG

A040149 002 Jan 27, 1997 Jul DISC

ACETAMINOPHEN; PENTAZOCINE HYDROCHLORIDE

TABLET; ORAL

ACETAMINOPHEN AND PENTAZOCINE HYDROCHLORIDE

| | | | | |
|----|---|-------------------|--------------------|-----------------------------------|
| AB | + | WATSON LABS | 650MG;EQ 25MG BASE | A074699 001 Mar 24, 2000 Feb CRLD |
| | | TALACEN | | |
| | @ | SANOFI AVENTIS US | 650MG;EQ 25MG BASE | N018458 001 Sep 23, 1982 Feb DISC |

ACITRETIN

CAPSULE; ORAL

SORIATANE

| | | |
|------------------|--------|-----------------------------------|
| STIEFEL LABS INC | 17.5MG | N019821 003 Aug 06, 2009 Jan NEWA |
| | 22.5MG | N019821 004 Aug 06, 2009 Jan NEWA |

ACYCLOVIR

CAPSULE; ORAL

ACYCLOVIR

| | | |
|------------------------|-------|-----------------------------------|
| @ IVAX SUB TEVA PHARMS | 200MG | A074674 001 Apr 22, 1997 Apr DISC |
| AB MYLAN | 200MG | A074727 001 Apr 22, 1997 Mar CMFD |

TABLET; ORAL

ACYCLOVIR

| | | |
|------------------------|-------|-----------------------------------|
| @ IVAX SUB TEVA PHARMS | 400MG | A074836 001 Apr 22, 1997 Apr DISC |
| @ | 800MG | A074836 002 Apr 22, 1997 Apr DISC |

| | | |
|----------|-------|-----------------------------------|
| AB MYLAN | 400MG | A075211 001 Sep 28, 1998 Mar CMFD |
| AB | 800MG | A075211 002 Sep 28, 1998 Mar CMFD |

ACYCLOVIR; HYDROCORTISONE

CREAM; TOPICAL

ACYCLOVIR AND HYDROCORTISONE

| | | |
|---------------|-------|-----------------------------------|
| + MEDA PHARMS | 5%;1% | N022436 001 Jul 31, 2009 Jul CAHN |
|---------------|-------|-----------------------------------|

ADAPALENE

CREAM; TOPICAL

ADAPALENE

| | | |
|-----------------------|------|-----------------------------------|
| AB NYCOMED US | 0.1% | A090824 001 Jun 30, 2010 Jun NEWA |
| AB + GALDERMA LABS LP | 0.1% | N020748 001 May 26, 2000 Jun CFTG |

GEL; TOPICAL

ADAPALENE

| | | |
|-----------------------|------|-----------------------------------|
| AB GLENMARK GENERICS | 0.1% | A091314 001 Jul 01, 2010 Jun NEWA |
| AB PLIVA HRVATSKA DOO | 0.1% | A090962 001 Jun 02, 2010 May NEWA |

DIFERIN

| | | |
|-----------------------|------|-----------------------------------|
| AB + GALDERMA LABS LP | 0.1% | N020380 001 May 31, 1996 May CFTG |
| LOTION; TOPICAL | | |

DIFERIN

| | | |
|--------------------|------|-----------------------------------|
| + GALDERMA R AND D | 0.1% | N022502 001 Mar 17, 2010 Mar NEWA |
|--------------------|------|-----------------------------------|

ALBENDAZOLE

TABLET; ORAL

ALBENZA

| | | |
|-----------------------|-------|-----------------------------------|
| + GLAXOSMITHKLINE LLC | 200MG | N020666 001 Jun 11, 1996 Jun CAHN |
|-----------------------|-------|-----------------------------------|

ALBUTEROL SULFATE

SOLUTION; INHALATION

ALBUTEROL SULFATE

| | | |
|---------------|----------------|-----------------------------------|
| AN APOTEX INC | EQ 0.021% BASE | A078623 001 Apr 05, 2010 Mar NEWA |
|---------------|----------------|-----------------------------------|

SOLUTION; INHALATIONALBUTEROL SULFATE

| | | | | | | |
|--------------------------|---------------|-----------------|-------------|--------------|-----|------|
| AN | APOTEX INC | EQ 0.042% BASE | A078623 002 | Apr 05, 2010 | Mar | NEWA |
| AN | NEPHRON | EQ 0.021% BASE | A076355 002 | Mar 31, 2010 | Mar | NEWA |
| <u>SYRUP; ORAL</u> | | | | | | |
| <u>ALBUTEROL SULFATE</u> | | | | | | |
| AA | AMNEAL PHARMS | EQ 2MG BASE/5ML | A079241 001 | May 12, 2010 | May | NEWA |

ALBUTEROL SULFATE; IPRATROPIUM BROMIDESOLUTION; INHALATIONALBUTEROL SULFATE AND IPRATROPIUM BROMIDE

| | | | | | | | |
|-----|----|-----------------|-----------------------|-------------|--------------|-----|------|
| >D> | AN | COBALT LABS INC | EQ 0.083% BASE;0.017% | A077063 001 | Dec 31, 2007 | Aug | CAHN |
| >A> | AN | WATSON LABS | EQ 0.083% BASE;0.017% | A077063 001 | Dec 31, 2007 | Aug | CAHN |

ALCRAFTADINESOLUTION/DROPS; OPHTHALMICLASTACAF

| | | | | | | |
|---|---------------------|-------|-------------|--------------|-----|------|
| + | VISTAKON PHARMS LLC | 0.25% | N022134 001 | Jul 28, 2010 | Jul | NEWA |
|---|---------------------|-------|-------------|--------------|-----|------|

ALCLOMETASONE DIPROPIONATECREAM; TOPICALACLOVATE

| | | | | | | | |
|----|---|------------|-------|-------------|--------------|-----|------|
| AB | + | NYCOMED US | 0.05% | N018707 001 | Dec 14, 1982 | May | CAHN |
|----|---|------------|-------|-------------|--------------|-----|------|

ALENDRONATE SODIUMTABLET; ORALALENDRONATE SODIUM

| | | | | | | |
|----|-------------------|--------------|-------------|--------------|-----|------|
| AB | CADISTA PHARMS | EQ 5MG BASE | A090557 001 | Feb 18, 2010 | Jan | NEWA |
| AB | | EQ 10MG BASE | A090557 002 | Feb 18, 2010 | Jan | NEWA |
| AB | | EQ 35MG BASE | A090557 003 | Feb 18, 2010 | Jan | NEWA |
| AB | | EQ 70MG BASE | A090557 004 | Feb 18, 2010 | Jan | NEWA |
| AB | SUN PHARMA GLOBAL | EQ 5MG BASE | A090022 001 | Sep 10, 2008 | Jun | CAHN |
| AB | | EQ 10MG BASE | A090022 002 | Sep 10, 2008 | Jun | CAHN |
| AB | | EQ 35MG BASE | A090022 003 | Sep 10, 2008 | Jun | CAHN |
| AB | | EQ 70MG BASE | A090022 004 | Sep 10, 2008 | Jun | CAHN |
| AB | WATSON LABS | EQ 35MG BASE | A076984 001 | Aug 04, 2008 | Jun | CAHN |
| AB | | EQ 40MG BASE | A076984 002 | Aug 04, 2008 | Jun | CAHN |
| AB | | EQ 70MG BASE | A076984 003 | Aug 04, 2008 | Jun | CAHN |

>A> ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE

| | | | | | | | |
|-----|--------------|----------------------------|-------------|--------------|-----|------|--|
| >A> | TABLET; ORAL | | | | | | |
| >A> | TEKAMLO | | | | | | |
| >A> | NOVARTIS | EQ 150MG BASE;EQ 5MG BASE | N022545 001 | Aug 26, 2010 | Aug | NEWA | |
| >A> | | EQ 150MG BASE;EQ 10MG BASE | N022545 002 | Aug 26, 2010 | Aug | NEWA | |
| >A> | | EQ 300MG BASE;EQ 5MG BASE | N022545 003 | Aug 26, 2010 | Aug | NEWA | |
| >A> | + | EQ 300MG BASE;EQ 10MG BASE | N022545 004 | Aug 26, 2010 | Aug | NEWA | |

ALPRAZOLAMTABLET; ORALALPRAZOLAM

| | | | | | | |
|----|-------------------|--------|-------------|--------------|-----|------|
| AB | SUN PHARMA GLOBAL | 0.25MG | A090082 001 | Jun 17, 2010 | May | NEWA |
| AB | | 0.5MG | A090082 002 | Jun 17, 2010 | May | NEWA |
| AB | | 1MG | A090082 003 | Jun 17, 2010 | May | NEWA |
| AB | | 2MG | A090082 004 | Jun 17, 2010 | May | NEWA |

TABLET, EXTENDED RELEASE; ORAL

ALPRAZOLAM

| | | | | | | |
|----|---------------------|-------|-------------|--------------|-----|------|
| AB | WATSON LABS FLORIDA | 0.5MG | A077198 001 | May 13, 2010 | May | NEWA |
| AB | | 1MG | A077198 002 | May 13, 2010 | May | NEWA |
| AB | | 2MG | A077198 003 | May 13, 2010 | May | NEWA |
| AB | | 3MG | A077198 004 | May 13, 2010 | May | NEWA |

TABLET, ORALLY DISINTEGRATING; ORAL

ALPRAZOLAM

| | | | | | | |
|----|-------------------|--------|-------------|--------------|-----|------|
| AB | ACTAVIS ELIZABETH | 0.25MG | A078561 001 | Mar 16, 2010 | Feb | NEWA |
| AB | | 0.5MG | A078561 002 | Mar 16, 2010 | Feb | NEWA |
| AB | | 1MG | A078561 003 | Mar 16, 2010 | Feb | NEWA |
| AB | | 2MG | A078561 004 | Mar 16, 2010 | Feb | NEWA |

AMANTADINE HYDROCHLORIDE

TABLET; ORAL

AMANTADINE HYDROCHLORIDE

| | | | | | |
|---------------|-------|-------------|--------------|-----|------|
| + USL PHARMA | 100MG | A076186 001 | Dec 16, 2002 | May | CRLD |
| SYMMETREL | | | | | |
| @ ENDO PHARMS | 100MG | N018101 001 | | May | DISC |

AMIFOSTINE

INJECTABLE; INJECTION

AMIFOSTINE

| | | | | | | |
|----|-------------------|------------|-------------|--------------|-----|------|
| AP | SUN PHARMA GLOBAL | 500MG/VIAL | A077126 001 | Mar 14, 2008 | Jun | CAHN |
|----|-------------------|------------|-------------|--------------|-----|------|

AMIODARONE HYDROCHLORIDE

INJECTABLE; INJECTION

AMIODARONE HYDROCHLORIDE

| | | | | | |
|--------------------------|---------|-------------|--------------|-----|------|
| AP + CLARIS LIFESCIENCES | 50MG/ML | A076394 001 | Apr 25, 2003 | Jun | CAHN |
|--------------------------|---------|-------------|--------------|-----|------|

AMLODIPINE BESYLATE

TABLET; ORAL

AMLODIPINE BESYLATE

| | | | | | | |
|--------|-----------------|---------------|-------------|--------------|-----|------|
| >D> AB | SYNTTHON PHARMS | EQ 2.5MG BASE | A077080 001 | Jun 27, 2007 | Aug | DISC |
| >A> | @ | EQ 2.5MG BASE | A077080 001 | Jun 27, 2007 | Aug | DISC |
| >D> AB | | EQ 5MG BASE | A077080 002 | Jun 27, 2007 | Aug | DISC |
| >A> | @ | EQ 5MG BASE | A077080 002 | Jun 27, 2007 | Aug | DISC |
| >D> AB | | EQ 10MG BASE | A077080 003 | Jun 27, 2007 | Aug | DISC |
| >A> | @ | EQ 10MG BASE | A077080 003 | Jun 27, 2007 | Aug | DISC |
| AB | VINTAGE | EQ 2.5MG BASE | A078414 001 | Apr 07, 2010 | Mar | NEWA |
| AB | | EQ 5MG BASE | A078414 002 | Apr 07, 2010 | Mar | NEWA |
| AB | | EQ 10MG BASE | A078414 003 | Apr 07, 2010 | Mar | NEWA |
| AB | WATSON LABS | EQ 2.5MG BASE | A077671 001 | Jul 19, 2007 | Jun | CAHN |
| AB | | EQ 5MG BASE | A077671 002 | Jul 19, 2007 | Jun | CAHN |
| AB | | EQ 10MG BASE | A077671 003 | Jul 19, 2007 | Jun | CAHN |
| AB | WORLD GEN | EQ 2.5MG BASE | A077516 001 | Jul 11, 2007 | Mar | CAHN |
| AB | | EQ 5MG BASE | A077516 002 | Jul 11, 2007 | Mar | CAHN |
| AB | | EQ 10MG BASE | A077516 003 | Jul 11, 2007 | Mar | CAHN |

AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE

CAPSULE; ORAL

AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE

| | | | | | | |
|----|--------------------|--------------------|-------------|--------------|-----|------|
| AB | DR REDDYS LABS INC | EQ 2.5MG BASE;10MG | A077183 001 | Apr 15, 2010 | Mar | NEWA |
| AB | | EQ 5MG BASE;10MG | A077183 002 | Apr 15, 2010 | Mar | NEWA |
| AB | | EQ 5MG BASE;20MG | A077183 003 | Apr 15, 2010 | Mar | NEWA |
| AB | | EQ 10MG BASE;20MG | A077183 004 | Apr 15, 2010 | Mar | NEWA |

CAPSULE; ORAL

| | | | | | | | |
|----|--|--------------------|---------|-----|--------------|-----|------|
| | AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE | | | | | | |
| AB | LUPIN PHARMS | EQ 2.5MG BASE;10MG | A078466 | 001 | Feb 05, 2010 | Jan | NEWA |
| AB | | EQ 5MG BASE;10MG | A078466 | 002 | Feb 05, 2010 | Jan | NEWA |
| AB | | EQ 5MG BASE;20MG | A078466 | 003 | Feb 05, 2010 | Jan | NEWA |
| AB | | EQ 10MG BASE;20MG | A078466 | 004 | Feb 05, 2010 | Jan | NEWA |
| AB | MYLAN | EQ 2.5MG BASE;10MG | A077375 | 001 | May 21, 2010 | May | NEWA |
| AB | | EQ 5MG BASE;10MG | A077375 | 002 | May 21, 2010 | May | NEWA |
| AB | | EQ 5MG BASE;20MG | A077375 | 003 | May 21, 2010 | May | NEWA |
| AB | | EQ 10MG BASE;20MG | A077375 | 004 | May 21, 2010 | May | NEWA |
| AB | PAR PHARM | EQ 2.5MG BASE;10MG | A078381 | 001 | Jul 29, 2010 | Jul | NEWA |
| AB | | EQ 5MG BASE;10MG | A078381 | 002 | Jul 29, 2010 | Jul | NEWA |
| AB | | EQ 5MG BASE;20MG | A078381 | 003 | Jul 29, 2010 | Jul | NEWA |
| AB | | EQ 5MG BASE;40MG | A078381 | 005 | Jul 29, 2010 | Jul | NEWA |
| AB | | EQ 10MG BASE;20MG | A078381 | 004 | Jul 29, 2010 | Jul | NEWA |
| AB | | EQ 10MG BASE;40MG | A078381 | 006 | Jul 29, 2010 | Jul | NEWA |

AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

TABLET; ORAL

TRIBENZOR

| | | | | | | | |
|---|----------------|--------------------------|---------|-----|--------------|-----|------|
| | DAIICHI SANKYO | EQ 5MG BASE;12.5MG;20MG | N200175 | 001 | Jul 23, 2010 | Jul | NEWA |
| | | EQ 5MG BASE;12.5MG;40MG | N200175 | 002 | Jul 23, 2010 | Jul | NEWA |
| | | EQ 5MG BASE;25MG;40MG | N200175 | 003 | Jul 23, 2010 | Jul | NEWA |
| | | EQ 10MG BASE;12.5MG;40MG | N200175 | 004 | Jul 23, 2010 | Jul | NEWA |
| + | | EQ 10MG BASE;25MG;40MG | N200175 | 005 | Jul 23, 2010 | Jul | NEWA |

>A> AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN

>A> TABLET; ORAL

>A> EXFORGE HCT

| | | | | | | | |
|-------|----------|-------------------|---------|-----|--------------|-----|------|
| >A> | NOVARTIS | 5MG;12.5MG;160MG | N022314 | 001 | Apr 30, 2009 | Aug | CAIN |
| >A> | | 5MG;25MG;160MG | N022314 | 002 | Apr 30, 2009 | Aug | CAIN |
| >A> | | 10MG;12.5MG;160MG | N022314 | 003 | Apr 30, 2009 | Aug | CAIN |
| >A> | | 10MG;25MG;160MG | N022314 | 004 | Apr 30, 2009 | Aug | CAIN |
| >A> + | | 10MG;25MG;320MG | N022314 | 005 | Apr 30, 2009 | Aug | CAIN |

>D> AMLODIPINE; HYDROCHLOROTHIAZIDE; VALSARTAN

>D> TABLET; ORAL

>D> EXFORGE HCT

| | | | | | | | |
|-------|----------|-------------------|---------|-----|--------------|-----|------|
| >D> | NOVARTIS | 5MG;12.5MG;160MG | N022314 | 001 | Apr 30, 2009 | Aug | CAIN |
| >D> | | 5MG;25MG;160MG | N022314 | 002 | Apr 30, 2009 | Aug | CAIN |
| >D> | | 10MG;12.5MG;160MG | N022314 | 003 | Apr 30, 2009 | Aug | CAIN |
| >D> | | 10MG;25MG;160MG | N022314 | 004 | Apr 30, 2009 | Aug | CAIN |
| >D> + | | 10MG;25MG;320MG | N022314 | 005 | Apr 30, 2009 | Aug | CAIN |

AMOXICILLIN

FOR SUSPENSION; ORAL

TRIMOX

| | | | | | | | |
|---|-----------|-----------|---------|-----|--------------|-----|------|
| @ | APOTHECON | 50MG/ML | A061886 | 001 | | Feb | DISC |
| @ | | 125MG/5ML | A061886 | 002 | | Feb | DISC |
| @ | | 125MG/5ML | A062885 | 001 | Mar 08, 1988 | Feb | DISC |
| @ | | 250MG/5ML | A062885 | 002 | Mar 08, 1988 | Feb | DISC |
| @ | | 250MG/5ML | A061886 | 003 | | Feb | DISC |

TABLET, CHEWABLE; ORAL

AMOXICILLIN

| | | | | | | | |
|--------|------|-------|---------|-----|--------------|-----|------|
| >D> AB | TEVA | 250MG | A064013 | 001 | Dec 22, 1992 | Aug | CRLD |
| >A> AB | + | 250MG | A064013 | 001 | Dec 22, 1992 | Aug | CRLD |

TABLET, EXTENDED RELEASE; ORAL
MOXATAG

| | | | | | | |
|-----|----------------------|-------|-------------|--------------|-----|------|
| >D> | + MIDDLEBROOK PHARMS | 775MG | N050813 001 | Jan 23, 2008 | Aug | CAHN |
| >A> | + VICTORY PHARMA | 775MG | N050813 001 | Jan 23, 2008 | Aug | CAHN |

AMOXICILLIN; CLAVULANATE POTASSIUM

FOR SUSPENSION; ORAL

AUGMENTIN '125'

| | | | | | | |
|----|-----------------|-------------------------------|-------------|--------------|-----|------|
| AB | GLAXOSMITHKLINE | 125MG/5ML;EQ 31.25MG BASE/5ML | N050575 001 | Aug 06, 1984 | Feb | CMFD |
|----|-----------------|-------------------------------|-------------|--------------|-----|------|

AUGMENTIN '250'

| | | | | | | |
|----|-------------------|------------------------------|-------------|--------------|-----|------|
| AB | + GLAXOSMITHKLINE | 250MG/5ML;EQ 62.5MG BASE/5ML | N050575 002 | Aug 06, 1984 | Jun | CRLD |
|----|-------------------|------------------------------|-------------|--------------|-----|------|

| | | | | | | |
|----|--|------------------------------|-------------|--------------|-----|------|
| AB | | 250MG/5ML;EQ 62.5MG BASE/5ML | N050575 002 | Aug 06, 1984 | Feb | CMFD |
|----|--|------------------------------|-------------|--------------|-----|------|

TABLET; ORAL

AUGMENTIN '250'

| | | | | | | |
|----|-----------------|---------------------|-------------|--------------|-----|------|
| AB | GLAXOSMITHKLINE | 250MG;EQ 125MG BASE | N050564 001 | Aug 06, 1984 | Feb | CMFD |
|----|-----------------|---------------------|-------------|--------------|-----|------|

AUGMENTIN '500'

| | | | | | | |
|----|-----------------|---------------------|-------------|--------------|-----|------|
| AB | GLAXOSMITHKLINE | 500MG;EQ 125MG BASE | N050564 002 | Aug 06, 1984 | Feb | CMFD |
|----|-----------------|---------------------|-------------|--------------|-----|------|

AUGMENTIN '875'

| | | | | | | |
|----|-----------------|---------------------|-------------|--------------|-----|------|
| AB | GLAXOSMITHKLINE | 875MG;EQ 125MG BASE | N050720 001 | Feb 13, 1996 | Feb | CMFD |
|----|-----------------|---------------------|-------------|--------------|-----|------|

TABLET, EXTENDED RELEASE; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

| | | | | | | |
|----|--------|--------------------|-------------|--------------|-----|------|
| AB | SANDOZ | 1GM;EQ 62.5MG BASE | A090227 001 | Apr 21, 2010 | Apr | NEWA |
|----|--------|--------------------|-------------|--------------|-----|------|

AUGMENTIN XR

| | | | | | | |
|----|-------------------|--------------------|-------------|--------------|-----|------|
| AB | + GLAXOSMITHKLINE | 1GM;EQ 62.5MG BASE | N050785 001 | Sep 25, 2002 | Jul | CRLD |
|----|-------------------|--------------------|-------------|--------------|-----|------|

| | | | | | | |
|----|--|--------------------|-------------|--------------|-----|------|
| AB | | 1GM;EQ 62.5MG BASE | N050785 001 | Sep 25, 2002 | Feb | CMFD |
|----|--|--------------------|-------------|--------------|-----|------|

AMPHOTERICIN B

INJECTABLE, LIPID COMPLEX; INJECTION

ABELCET

| | | | | | |
|-------------|--------|-------------|--------------|-----|------|
| + SIGMA TAU | 5MG/ML | N050724 001 | Nov 20, 1995 | Feb | CAHN |
|-------------|--------|-------------|--------------|-----|------|

AMPICILLIN SODIUM

INJECTABLE; INJECTION

AMPICILLIN SODIUM

| | | | | | | |
|-----|---------------------|--------------------|-------------|--------------|-----|------|
| >A> | AP AUROBINDO PHARMA | EQ 125MG BASE/VIAL | A065499 001 | Aug 17, 2010 | Aug | NEWA |
| >A> | AP | EQ 250MG BASE/VIAL | A065499 002 | Aug 17, 2010 | Aug | NEWA |
| >A> | AP | EQ 500MG BASE/VIAL | A065499 003 | Aug 17, 2010 | Aug | NEWA |
| >A> | AP | EQ 1GM BASE/VIAL | A065499 004 | Aug 17, 2010 | Aug | NEWA |
| >A> | AP | EQ 2GM BASE/VIAL | A065499 005 | Aug 17, 2010 | Aug | NEWA |
| >A> | AP | EQ 10GM BASE/VIAL | A065493 001 | Aug 17, 2010 | Aug | NEWA |
| AP | HANFORD GC | EQ 250MG BASE/VIAL | A063145 001 | Apr 15, 1993 | Jun | CMFD |

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE; INJECTION

AMPICILLIN AND SULBACTAM

| | | | | | | |
|----|-----------------|--|-------------|--------------|-----|------|
| AP | BIONICHE PHARMA | EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL | A065316 001 | Jun 29, 2007 | Mar | CAHN |
| AP | | EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL | A065316 002 | Jun 29, 2007 | Mar | CAHN |

ANASTROZOLE

TABLET; ORAL

ANASTROZOLE

| | | | | | | |
|----|----------------------|-----|-------------|--------------|-----|------|
| AB | ACCORD HLTHCARE INC | 1MG | A090568 001 | Jun 28, 2010 | Jun | NEWA |
| AB | DR REDDYS LABS LTD | 1MG | A090732 001 | Jun 28, 2010 | Jun | NEWA |
| AB | FRESENIUS KABI ONCOL | 1MG | A090088 001 | Jun 28, 2010 | Jun | NEWA |
| AB | MYLAN | 1MG | A091051 001 | Jun 28, 2010 | Jun | NEWA |

TABLET; ORAL

ANASTROZOLE

| | | | | | | |
|----|----------------------|-----|-------------|--------------|-----|------|
| AB | NATCO PHARMA LTD | 1MG | A079220 001 | Jun 28, 2010 | Jun | NEWA |
| AB | ROXANE | 1MG | A078485 001 | Jun 28, 2010 | Jun | NEWA |
| AB | SANDOZ | 1MG | A079007 001 | Jun 28, 2010 | Jun | NEWA |
| AB | STASON PHARMS | 1MG | A078944 001 | Jun 28, 2010 | Jun | NEWA |
| AB | SYNTHON PHARMS | 1MG | A078322 001 | Jun 28, 2010 | Jun | NEWA |
| AB | TEVA PHARMS | 1MG | A078058 001 | Jun 28, 2010 | Jun | NEWA |
| AB | THREE RIVERS PHARMS | 1MG | A091164 001 | Jun 28, 2010 | Jun | NEWA |
| AB | WATSON LABS | 1MG | A078984 001 | Jun 28, 2010 | Jun | NEWA |
| AB | ZYDUS PHARMS USA INC | 1MG | A078921 001 | Jun 28, 2010 | Jun | NEWA |
| | ARIMIDEX | | | | | |
| AB | + ASTRAZENECA | 1MG | N020541 001 | Dec 27, 1995 | Jun | CFTG |

APOMORPHINE HYDROCHLORIDE

INJECTABLE; SUBCUTANEOUS

APOKYN

| | | | | | |
|----------------------|--------------------|-------------|--------------|-----|------|
| @ IPSEN BIOPHARM LTD | 20MG/2ML (10MG/ML) | N021264 001 | Apr 20, 2004 | May | CAHN |
| + | 30MG/3ML (10MG/ML) | N021264 002 | Apr 20, 2004 | May | CAHN |

ARMODAFINIL

TABLET; ORAL

NUVIGIL

| | | | | | |
|------------|-------|-------------|--------------|-----|------|
| @ CEPHALON | 100MG | N021875 002 | Mar 26, 2009 | Feb | DISC |
| @ | 200MG | N021875 005 | Mar 26, 2009 | Feb | DISC |

ARTEMETHER; LUMEFANTRINE

TABLET; ORAL

COARTEM

| | | | | | | |
|---|----------|------------|-------------|--------------|-----|------|
| + | NOVARTIS | 20MG;120MG | N022268 001 | Apr 07, 2009 | Mar | CRLD |
|---|----------|------------|-------------|--------------|-----|------|

ARTICAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE

INJECTABLE; INJECTION

ARTICAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE

| | | | | | | |
|----|---|--|-------------|--------------|-----|------|
| AP | HOSPIRA | 4%;EQ 0.017MG BASE/1.7ML (4%;EQ 0.01MG BASE/ML) | A079138 001 | Jun 18, 2010 | Jun | NEWA |
| | ARTICAINE HYDROCHLORIDE WITH EPINEPHRINE | | | | | |
| | PIERREL | 4%;EQ 0.009MG BASE/1.8ML (EQ 0.005MG BASE/ML) | N022466 001 | Feb 26, 2010 | Feb | NEWA |
| + | | 4%;EQ 0.018MG BASE/1.8ML (EQ 0.01MG BASE/ML) | N022466 002 | Feb 26, 2010 | Feb | NEWA |
| | SEPTOCAIN | | | | | |
| AP | + DEPROCO | 4%;EQ 0.017MG BASE/1.7ML (4%;EQ 0.01MG BASE/ML) | N020971 001 | Apr 03, 2000 | Jun | CFTG |

ASPIRIN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL

FIORINAL

| | | | | | | |
|----|-----------------|-----------------|-------------|--------------|-----|------|
| AA | + WATSON PHARMS | 325MG;50MG;40MG | N017534 005 | Apr 16, 1986 | Feb | CTEC |
|----|-----------------|-----------------|-------------|--------------|-----|------|

LANORINAL

| | | | | | | |
|----|---------|-----------------|-------------|--------------|-----|------|
| AA | LANNETT | 325MG;50MG;40MG | A086996 002 | Oct 11, 1985 | Feb | CTEC |
|----|---------|-----------------|-------------|--------------|-----|------|

TABLET; ORAL

BUTALBITAL, ASPIRIN AND CAFFEINE

| | | | | | | |
|----|-------------------|-----------------|-------------|--------------|-----|------|
| AA | ACTAVIS ELIZABETH | 325MG;50MG;40MG | A086710 002 | Aug 23, 1983 | Feb | CTEC |
|----|-------------------|-----------------|-------------|--------------|-----|------|

| | | | | | | |
|----|-------------|-----------------|-------------|--------------|-----|------|
| AA | + WEST WARD | 325MG;50MG;40MG | A086162 002 | Feb 16, 1984 | Feb | CTEC |
|----|-------------|-----------------|-------------|--------------|-----|------|

ASPIRIN; CARISOPRODOL

TABLET; ORAL

CARISOPRODOL AND ASPIRIN

| | | | |
|-----|----|---------------------|-------------|
| >A> | AB | HERITAGE PHARMS INC | 325MG;200MG |
| >D> | AB | PAR PHARM | 325MG;200MG |

| | | | | |
|---------|-----|--------------|-----|------|
| A089594 | 001 | Mar 31, 1989 | Aug | CAHN |
| A089594 | 001 | Mar 31, 1989 | Aug | CAHN |

ASPIRIN; METHOCARBAMOL

TABLET; ORAL

METHOCARBAMOL AND ASPIRIN

| | | |
|---|----------------------|-------------|
| @ | IVAX SUB TEVA PHARMS | 325MG;400MG |
| + | STEVENS J | 325MG;400MG |

| | | | | |
|---------|-----|--------------|-----|------|
| A087211 | 001 | Dec 22, 1982 | Apr | DISC |
| A081145 | 001 | Jan 31, 1995 | Apr | CRLD |

ASPIRIN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE

TABLET; ORAL

OXYCODONE AND ASPIRIN

| | |
|---------------|--------------------|
| WATSON LABS | 325MG;4.5MG;0.38MG |
| PERCODAN | |
| @ ENDO PHARMS | 325MG;4.5MG;0.38MG |

| | | | | |
|---------|-----|--------------|-----|------|
| A040255 | 001 | Feb 27, 1998 | May | CRLD |
| N007337 | 006 | | May | DISC |

ATOMOXETINE HYDROCHLORIDE

CAPSULE; ORAL

ATOMOXETINE HYDROCHLORIDE

| | | | |
|-----|----|-------------------|-------|
| >A> | AB | ACTAVIS ELIZABETH | 10MG |
| >A> | AB | | 18MG |
| >A> | AB | | 25MG |
| >A> | AB | | 40MG |
| >A> | AB | | 60MG |
| >A> | AB | | 80MG |
| >A> | AB | | 100MG |
| >A> | AB | AUROBINDO PHARM | 10MG |
| >A> | AB | | 18MG |
| >A> | AB | | 25MG |
| >A> | AB | | 40MG |
| >A> | AB | | 60MG |
| >A> | AB | | 80MG |
| >A> | AB | | 100MG |
| >A> | AB | MYLAN | 10MG |
| >A> | AB | | 18MG |
| >A> | AB | | 25MG |
| >A> | AB | | 40MG |
| >A> | AB | | 60MG |
| >A> | AB | | 80MG |
| >A> | AB | | 100MG |
| >A> | AB | SANDOZ | 10MG |
| >A> | AB | | 18MG |
| >A> | AB | | 25MG |
| >A> | AB | | 40MG |
| >A> | AB | | 60MG |
| >A> | AB | | 80MG |
| >A> | AB | | 100MG |
| >A> | AB | SUN PHARMA GLOBAL | 10MG |
| >A> | AB | | 18MG |
| >A> | AB | | 25MG |
| >A> | AB | | 40MG |
| >A> | AB | | 60MG |

| | | | | |
|---------|-----|--------------|-----|------|
| A078940 | 001 | Aug 30, 2010 | Aug | NEWA |
| A078940 | 002 | Aug 30, 2010 | Aug | NEWA |
| A078940 | 003 | Aug 30, 2010 | Aug | NEWA |
| A078940 | 004 | Aug 30, 2010 | Aug | NEWA |
| A078940 | 005 | Aug 30, 2010 | Aug | NEWA |
| A078940 | 006 | Aug 30, 2010 | Aug | NEWA |
| A078940 | 007 | Aug 30, 2010 | Aug | NEWA |
| A079016 | 001 | Sep 13, 2010 | Aug | NEWA |
| A079016 | 002 | Sep 13, 2010 | Aug | NEWA |
| A079016 | 003 | Sep 13, 2010 | Aug | NEWA |
| A079016 | 004 | Sep 13, 2010 | Aug | NEWA |
| A079016 | 005 | Sep 13, 2010 | Aug | NEWA |
| A079016 | 006 | Sep 13, 2010 | Aug | NEWA |
| A079016 | 007 | Sep 13, 2010 | Aug | NEWA |
| A079021 | 001 | Aug 30, 2010 | Aug | NEWA |
| A079021 | 002 | Aug 30, 2010 | Aug | NEWA |
| A079021 | 003 | Aug 30, 2010 | Aug | NEWA |
| A079021 | 004 | Aug 30, 2010 | Aug | NEWA |
| A079021 | 005 | Aug 30, 2010 | Aug | NEWA |
| A079021 | 006 | Aug 30, 2010 | Aug | NEWA |
| A079021 | 007 | Aug 30, 2010 | Aug | NEWA |
| A079018 | 001 | Sep 13, 2010 | Aug | NEWA |
| A079018 | 002 | Sep 13, 2010 | Aug | NEWA |
| A079018 | 003 | Sep 13, 2010 | Aug | NEWA |
| A079018 | 004 | Sep 13, 2010 | Aug | NEWA |
| A079018 | 005 | Sep 13, 2010 | Aug | NEWA |
| A079018 | 006 | Sep 13, 2010 | Aug | NEWA |
| A079018 | 007 | Sep 13, 2010 | Aug | NEWA |
| A079020 | 001 | Aug 30, 2010 | Aug | NEWA |
| A079020 | 002 | Aug 30, 2010 | Aug | NEWA |
| A079020 | 003 | Aug 30, 2010 | Aug | NEWA |
| A079020 | 004 | Aug 30, 2010 | Aug | NEWA |
| A079020 | 005 | Aug 30, 2010 | Aug | NEWA |

CAPSULE; ORAL

| | | | |
|-----------|---------------------------|-------|-----------------------------------|
| >A> | ATOMOXETINE HYDROCHLORIDE | | |
| >A> AB | SUN PHARMA GLOBAL | 80MG | A079020 006 Aug 30, 2010 Aug NEWA |
| >A> AB | | 100MG | A079020 007 Aug 30, 2010 Aug NEWA |
| STRATTERA | | | |
| >D> | LILLY | 10MG | N021411 002 Nov 26, 2002 Aug CFTG |
| >A> AB | | 10MG | N021411 002 Nov 26, 2002 Aug CFTG |
| >D> | | 18MG | N021411 003 Nov 26, 2002 Aug CFTG |
| >A> AB | | 18MG | N021411 003 Nov 26, 2002 Aug CFTG |
| >D> | | 25MG | N021411 004 Nov 26, 2002 Aug CFTG |
| >A> AB | | 25MG | N021411 004 Nov 26, 2002 Aug CFTG |
| >D> | | 40MG | N021411 005 Nov 26, 2002 Aug CFTG |
| >A> AB | | 40MG | N021411 005 Nov 26, 2002 Aug CFTG |
| >D> | + | 60MG | N021411 006 Nov 26, 2002 Aug CFTG |
| >A> AB | + | 60MG | N021411 006 Nov 26, 2002 Aug CFTG |
| >D> | | 80MG | N021411 007 Feb 14, 2005 Aug CFTG |
| >A> AB | | 80MG | N021411 007 Feb 14, 2005 Aug CFTG |
| >D> | | 100MG | N021411 008 Feb 14, 2005 Aug CFTG |
| >A> AB | | 100MG | N021411 008 Feb 14, 2005 Aug CFTG |

ATOVAQUONE

SUSPENSION; ORAL

MEPRON

| | | |
|-----------------------|-----------|--|
| + GLAXOSMITHKLINE LLC | 750MG/5ML | |
|-----------------------|-----------|--|

N020500 001 Feb 08, 1995 Jun CAHN

TABLET; ORAL

MEPRON

| | | |
|-----------------------|-------|--|
| @ GLAXOSMITHKLINE LLC | 250MG | |
|-----------------------|-------|--|

N020259 001 Nov 25, 1992 Jun CAHN

ATOVAQUONE; PROGUANIL HYDROCHLORIDE

TABLET; ORAL

MALARONE PEDIATRIC

| | | |
|-----------------|-------------|--|
| GLAXOSMITHKLINE | 62.5MG;25MG | |
|-----------------|-------------|--|

N021078 002 Jul 14, 2000 Apr CRLD

AZELASTINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

AZELASTINE HYDROCHLORIDE

| | | | |
|--------------------------|---------------------|-----------------------|-----------------------------------|
| >D> | @ SUN PHARMA GLOBAL | 0.05% | A078738 001 Jun 21, 2010 Aug CMFD |
| >A> AT | | 0.05% | A078738 001 Jun 21, 2010 Aug CMFD |
| | @ | 0.05% | A078738 001 Jun 21, 2010 Jun DISC |
| SPRAY, METERED; NASAL | | | |
| ASTELIN | | | |
| AB | + MEDA PHARMS | EQ 0.125MG BASE/SPRAY | N020114 001 Nov 01, 1996 Jan CTEC |
| AZELASTINE HYDROCHLORIDE | | | |
| AB | APOTEX INC | EQ 0.125MG BASE/SPRAY | A077954 001 Apr 30, 2009 Jan CMFD |

AZITHROMYCIN

INJECTABLE; INJECTION

AZITHROMYCIN

| | | | |
|----|------------------|--------------------|-----------------------------------|
| AP | GENERAMEDIX | EQ 500MG BASE/VIAL | A065501 001 Nov 09, 2009 Mar CAHN |
| AP | GLAND PHARMA LTD | EQ 500MG BASE/VIAL | A065501 001 Nov 09, 2009 May CAHN |
| AP | | EQ 500MG BASE/VIAL | A065501 001 Nov 09, 2009 Feb CAHN |

AZTREONAM

FOR SOLUTION; INHALATION

CAYSTON

| | | |
|----------|-----------|--|
| + GILEAD | 75MG/VIAL | |
|----------|-----------|--|

N050814 001 Feb 22, 2010 Feb NEWA

INJECTABLE; INJECTION

AZACTAM

| | | | | | | | | | |
|----|---|----------------------|------------|---------|-----|---------|------|-----|------|
| AP | + | BRISTOL MYERS SQUIBB | 1GM/VIAL | N050580 | 002 | Dec 31, | 1986 | Jun | CFTG |
| AP | + | | 2GM/VIAL | N050580 | 003 | Dec 31, | 1986 | Jun | CFTG |
| | | AZTREONAM | | | | | | | |
| | | APP PHARMS | 500MG/VIAL | A065439 | 001 | Jun 18, | 2010 | Jun | NEWA |
| AP | | | 1GM/VIAL | A065439 | 002 | Jun 18, | 2010 | Jun | NEWA |
| AP | | | 2GM/VIAL | A065439 | 003 | Jun 18, | 2010 | Jun | NEWA |

BACITRACIN

INJECTABLE; INJECTION

BACITRACIN

| | | | | | | | | | |
|----|--|---------------|-------------------|---------|-----|---------|------|-----|------|
| AP | | SAGENT PHARMS | 50,000 UNITS/VIAL | A090211 | 001 | May 11, | 2010 | May | NEWA |
|----|--|---------------|-------------------|---------|-----|---------|------|-----|------|

BACLOFEN

TABLET; ORAL

BACLOFEN

| | | | | | | | | | |
|----|---|---------------------------|------|---------|-----|---------|------|-----|------|
| AB | | MATRIX LABS LTD | 10MG | A090334 | 001 | Feb 18, | 2010 | Jan | NEWA |
| AB | | | 20MG | A090334 | 002 | Feb 18, | 2010 | Jan | NEWA |
| | | AIRWALK INTERNATIONAL INC | 10MG | | | | | | |
| | | KEMSTRO | | | | | | | |
| | @ | SCHWARZ PHARMA | 10MG | N021589 | 001 | Oct 30, | 2003 | Jan | DISC |
| | @ | | 20MG | N021589 | 002 | Oct 30, | 2003 | Jan | DISC |

BECLOMETHASONE DIPROPIONATE

AEROSOL, METERED; INHALATION

QVAR 40

| | | | | | | | | |
|---|--------------------|------------|---------|-----|---------|------|-----|------|
| + | TEVA BRANDED PHARM | 0.04MG/INH | N020911 | 002 | Sep 15, | 2000 | Feb | CAHN |
| | QVAR 80 | | | | | | | |
| + | TEVA BRANDED PHARM | 0.08MG/INH | N020911 | 001 | Sep 15, | 2000 | Feb | CAHN |

BENAZEPRIL HYDROCHLORIDE

TABLET; ORAL

BENAZEPRIL HYDROCHLORIDE

| | | | | | | | | | |
|----|--|---------------|------|---------|-----|---------|------|-----|------|
| AB | | HUAHAI US INC | 5MG | A076118 | 001 | Feb 11, | 2004 | Mar | CAHN |
| AB | | | 10MG | A076118 | 002 | Feb 11, | 2004 | Mar | CAHN |
| AB | | | 20MG | A076118 | 003 | Feb 11, | 2004 | Mar | CAHN |
| AB | | | 40MG | A076118 | 004 | Feb 11, | 2004 | Mar | CAHN |

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

GEL; TOPICAL

BENZACLIN

| | | | | | | | | | |
|-----|----|--|---------------|---------|-----|---------|------|-----|------|
| >D> | | @ SANOFI AVENTIS US | 5%;EQ 1% BASE | N050756 | 001 | Dec 21, | 2000 | Aug | CMFD |
| >A> | AB | | 5%;EQ 1% BASE | N050756 | 001 | Dec 21, | 2000 | Aug | CMFD |
| | | @ | 5%;EQ 1% BASE | N050756 | 001 | Dec 21, | 2000 | Jul | DISC |
| | | CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE | | | | | | | |
| >D> | BT | DOW PHARM SCIENCES | 5%;EQ 1% BASE | A065443 | 001 | Aug 11, | 2009 | Aug | CTEC |
| >A> | AB | | 5%;EQ 1% BASE | A065443 | 001 | Aug 11, | 2009 | Aug | CTEC |
| | BT | | 5%;EQ 1% BASE | A065443 | 001 | Aug 11, | 2009 | Jul | CTEC |

BENZPHETAMINE HYDROCHLORIDE

TABLET; ORAL

BENZPHETAMINE HYDROCHLORIDE

| | | | | | | | | | |
|-----|----|----------|------|---------|-----|---------|------|-----|------|
| AA | | KVK TECH | 50MG | A090968 | 001 | Jul 20, | 2010 | Jul | NEWA |
| >A> | AA | MIKART | 25MG | A090473 | 001 | Sep 15, | 2010 | Aug | NEWA |
| >A> | AA | | 50MG | A090473 | 002 | Sep 15, | 2010 | Aug | NEWA |

BENZTROPINE MESYLATE

INJECTABLE; INJECTION

BENZTROPINE MESYLATE

| | | | |
|---------------------|----------------------|--------|-----------------------------------|
| AP | PHARMAFORCE | 1MG/ML | A091152 001 Mar 29, 2010 Mar NEWA |
| <u>TABLET; ORAL</u> | | | |
| | BENZTROPINE MESYLATE | | |
| AA | INVAGEN PHARMS | 0.5MG | A090294 001 Mar 29, 2010 Mar NEWA |
| AA | | 1MG | A090294 002 Mar 29, 2010 Mar NEWA |
| AA | | 2MG | A090294 003 Mar 29, 2010 Mar NEWA |
| AA + | LANNETT | 0.5MG | A088877 001 Apr 11, 1985 Feb CAHN |
| AA + | | 1MG | A088894 001 Apr 11, 1985 Feb CAHN |
| AA + | | 2MG | A088895 001 Apr 11, 1985 Feb CAHN |

BETAMETHASONE ACETATE; BETAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE

| | | | |
|----|----------|------------------------|-----------------------------------|
| AB | LUITPOLD | 3MG/ML; EQ 3MG BASE/ML | A090747 001 Jul 31, 2009 Mar CAHN |
|----|----------|------------------------|-----------------------------------|

BETAXOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

BETAXOLOL HYDROCHLORIDE

| | | | |
|---------------------|-------------------------|--------------|-----------------------------------|
| AT | AKORN | EQ 0.5% BASE | A075386 001 Jun 30, 2000 Jan CTNA |
| AT | NOVEX | EQ 0.5% BASE | A075446 001 Sep 28, 2000 Jan CTNA |
| AT | WOCKHARDT | EQ 0.5% BASE | A078694 001 Nov 16, 2009 Jan CAIN |
| <u>TABLET; ORAL</u> | | | |
| | BETAXOLOL HYDROCHLORIDE | | |
| AB | EPIC PHARMA | 10MG | A075541 001 Oct 22, 1999 May CAHN |
| AB + | | 20MG | A075541 002 Oct 22, 1999 May CAHN |
| AB | MIKAH PHARMA | 10MG | A075541 001 Oct 22, 1999 Feb CAHN |
| AB + | | 20MG | A075541 002 Oct 22, 1999 Feb CAHN |

BETHANECHOL CHLORIDE

TABLET; ORAL

BETHANECHOL CHLORIDE

| | | | |
|----|------------|------|-----------------------------------|
| AA | EMCURE USA | 5MG | A091256 001 May 04, 2010 Apr NEWA |
| AA | | 10MG | A091256 002 May 04, 2010 Apr NEWA |
| AA | | 25MG | A091256 003 May 04, 2010 Apr NEWA |
| AA | | 50MG | A091256 004 May 04, 2010 Apr NEWA |

BICALUTAMIDE

TABLET; ORAL

BICALUTAMIDE

| | | | |
|----|----------------------|------|-----------------------------------|
| AB | FRESENIUS KABI ONCOL | 50MG | A079045 001 May 13, 2010 May NEWA |
|----|----------------------|------|-----------------------------------|

BIMATOPROST

SOLUTION/DROPS; OPHTHALMIC

LUMIGAN

| | | | |
|-----|------------|-------|-----------------------------------|
| >A> | + ALLERGAN | 0.01% | N022184 001 Aug 31, 2010 Aug NEWA |
|-----|------------|-------|-----------------------------------|

BISACODYL; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

TABLET, DELAYED RELEASE, FOR SOLUTION; ORAL

HALFLYTLY

| | | |
|-------------|--|-----------------------------------|
| + BRAINTREE | 5MG,N/A;N/A,210GM;N/A,0.74GM;N/A, 2.86GM;N/A,5.6GM | N021551 003 Jul 16, 2010 Jul NEWA |
|-------------|--|-----------------------------------|

BISACODYL; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

TABLET, DELAYED RELEASE, FOR SOLUTION; ORAL

>D> HALFLYTELY

>A> @ BRAINTREE N/A,2MG,3MG,N/A,N/A;3MG,2MG,2MG,1 N021551 002 Sep 24, 2007 Aug DISC
MG,N/ABISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE

| | | | | | | |
|----|---------|--------------|-------------|--------------|-----|------|
| AB | UNICHEM | 2.5MG;6.25MG | A079106 001 | Jul 28, 2010 | Jul | NEWA |
| AB | | 5MG;6.25MG | A079106 002 | Jul 28, 2010 | Jul | NEWA |
| AB | | 10MG;6.25MG | A079106 003 | Jul 28, 2010 | Jul | NEWA |

BLEOMYCIN SULFATE

INJECTABLE; INJECTION

BLENOXANE

| | | | | | |
|------------------------|-----------------------|-------------|--------------|------|------|
| @ BRISTOL MYERS SQUIBB | EQ 15 UNITS BASE/VIAL | N050443 001 | Jul | DISC | |
| @ | EQ 30 UNITS BASE/VIAL | N050443 002 | Sep 07, 1995 | Jul | DISC |

BLEOMYCIN SULFATE

| | | | | | | |
|--------|------------|-----------------------|-------------|--------------|-----|------|
| >D> AP | APP PHARMS | EQ 15 UNITS BASE/VIAL | A065185 001 | Jan 28, 2008 | Aug | CRLD |
| >A> AP | + | EQ 15 UNITS BASE/VIAL | A065185 001 | Jan 28, 2008 | Aug | CRLD |
| >D> AP | | EQ 30 UNITS BASE/VIAL | A065185 002 | Jan 28, 2008 | Aug | CRLD |
| >A> AP | + | EQ 30 UNITS BASE/VIAL | A065185 002 | Jan 28, 2008 | Aug | CRLD |

BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

SYRUP; ORAL

BROMFED-DM

| | | | | | | |
|-----|-------------|---------------------------|-------------|--------------|-----|------|
| >D> | @ WOCKHARDT | 2MG/5ML;10MG/5ML;30MG/5ML | A088811 001 | Jun 07, 1985 | Aug | CMFD |
| >A> | + | 2MG/5ML;10MG/5ML;30MG/5ML | A088811 001 | Jun 07, 1985 | Aug | CMFD |
| | @ | 2MG/5ML;10MG/5ML;30MG/5ML | A088811 001 | Jun 07, 1985 | Jul | DISC |

BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE

INJECTABLE; INJECTION

BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE

| | | | | | | |
|----|---------|-----------------|-------------|--------------|-----|------|
| AP | HOSPIRA | 0.5%;0.005MG/ML | A071170 001 | Jun 16, 1988 | Mar | CMFD |
| AP | + | 0.5%;0.005MG/ML | A071168 001 | Jun 16, 1988 | Mar | CTEC |

BUPRENORPHINE

FILM, EXTENDED RELEASE; TRANSDERMAL

BUTTRANS

| | | | | | |
|------------------|----------|-------------|--------------|-----|------|
| PURDUE PHARMA LP | 5MCG/HR | N021306 001 | Jun 30, 2010 | Jun | NEWA |
| | 10MCG/HR | N021306 002 | Jun 30, 2010 | Jun | NEWA |
| + | 20MCG/HR | N021306 003 | Jun 30, 2010 | Jun | NEWA |

BUPRENORPHINE HYDROCHLORIDE

TABLET; SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE

| | | | | | | |
|----|------|-------------|-------------|--------------|-----|------|
| AB | BARR | EQ 2MG BASE | A090360 001 | May 07, 2010 | Apr | NEWA |
| AB | | EQ 8MG BASE | A090360 002 | May 07, 2010 | Apr | NEWA |

BUPRENORPHINE; NALOXONE

| | | | | | | |
|-----|-------------------|-----------|-------------|--------------|-----|------|
| >A> | FILM; SUBLINGUAL | | | | | |
| >A> | SUBOXONE | | | | | |
| >A> | RECKITT BENCKISER | 2MG;0.5MG | N022410 001 | Aug 30, 2010 | Aug | NEWA |
| >A> | + | 8MG;2MG | N022410 002 | Aug 30, 2010 | Aug | NEWA |

BUPROPION HYDROBROMIDE

TABLET, EXTENDED RELEASE; ORAL
 APLENZIN
 BIOVAIL LABS INTL 174MG
 + 348MG

N022108 001 Apr 23, 2008 Jul CRLD
 N022108 002 Apr 23, 2008 Jul CRLD

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
 BUPROPION HYDROCHLORIDE
 AB1 ACTAVIS 100MG
 AB1 200MG
 AB1 MYLAN 100MG
 AB3 150MG
 AB2 150MG
 AB1 150MG
 AB1 200MG
 AB3 300MG
 AB1 SUN PHARMA GLOBAL 100MG
 AB1 150MG
 AB1 200MG
 WELLBUTRIN SR
 @ GLAXOSMITHKLINE 50MG

A077455 001 Jul 19, 2010 Jul NEWA
 A077455 003 Jul 19, 2010 Jul NEWA
 A090325 001 Apr 08, 2010 Mar NEWA
 A090942 001 Jul 14, 2010 Jul NEWA
 A090941 001 May 03, 2010 Apr NEWA
 A090325 002 Apr 08, 2010 Mar NEWA
 A090325 003 Apr 08, 2010 Mar NEWA
 A090942 002 Jul 14, 2010 Jul NEWA
 A078866 001 Apr 06, 2010 Mar NEWA
 A078866 002 Apr 06, 2010 Mar NEWA
 A078866 003 Apr 06, 2010 Mar NEWA
 N020358 001 Oct 04, 1996 Jul DISC

BUSPIRONE HYDROCHLORIDE

TABLET; ORAL
 BUSPAR
 @ BRISTOL MYERS SQUIBB 10MG
 @ 15MG
 BUSPIRONE HYDROCHLORIDE
 AB + IVAX SUB TEVA PHARMS 15MG
 AB TEVA 30MG
 AB + 30MG

N018731 002 Sep 29, 1986 Mar DISC
 N018731 003 Apr 22, 1996 Feb DISC
 A075385 003 Mar 01, 2002 Mar CRLD
 A075022 004 Mar 25, 2004 Mar CRLD
 A075022 004 Mar 25, 2004 Feb CRLD

BUTENAFINE HYDROCHLORIDE

CREAM; TOPICAL
 MENTAX
 + MYLAN 1%
 MENTAX-TC
 + MYLAN 1%

N020524 001 Oct 18, 1996 Jun CAHN
 N021408 001 Oct 17, 2002 Jun CAHN

BUTORPHANOL TARTRATE

INJECTABLE; INJECTION
 BUTORPHANOL TARTRATE
 AP CLARIS LIFESCIENCES 2MG/ML
 BUTORPHANOL TARTRATE PRESERVATIVE FREE
 AP CLARIS LIFESCIENCES 1MG/ML
 AP 2MG/ML

A075697 001 Oct 23, 2001 Jun CAHN
 A075695 001 Oct 23, 2001 Jun CAHN
 A075695 002 Oct 23, 2001 Jun CAHN

CABAZITAXEL

SOLUTION; IV (INFUSION)
 JEVATANA KIT
 + SANOFI AVENTIS US 60MG/1.5ML (40MG/ML)

N201023 001 Jun 17, 2010 Jun NEWA

CABERGOLINE

TABLET; ORAL
CABERGOLINE

| | | | |
|----|----------------|-------|-----------------------------------|
| AB | IMPAK LABS INC | 0.5MG | A077843 001 Jul 03, 2007 Mar CAHN |
| AB | WATSON LABS | 0.5MG | A078035 001 Apr 21, 2008 Jun CAHN |

CAFFEINE CITRATE

SOLUTION; ORAL
CAFFEINE CITRATE

| | | | |
|----|--------------|---------------------------------------|-----------------------------------|
| AA | PADDOCK LABS | EQ 30MG BASE/3ML (EQ 10MG BASE/ML) | A077304 001 Sep 21, 2006 Apr CAHN |
|----|--------------|---------------------------------------|-----------------------------------|

CALCIOPOTRIENE

OINTMENT; TOPICAL
CALCIOPOTRIENE

| | | | |
|---|-------------------|--------|-----------------------------------|
| + | GLENMARK GENERICS | 0.005% | A090633 001 Mar 24, 2010 Mar NEWA |
|---|-------------------|--------|-----------------------------------|

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE;
SODIUM CITRATE

SOLUTION; IRRIGATION
BALANCED SALT

| | | | |
|----|---------|---|-----------------------------------|
| AT | B BRAUN | 0.48MG/ML; 0.3MG/ML; 0.75MG/ML; 3.9M G/ML; 6.4MG/ML; 1.7MG/ML | A091387 001 Feb 03, 2010 Jan NEWA |
|----|---------|---|-----------------------------------|

CAPTOPRIL

TABLET; ORAL
CAPTOPRIL

| | | | |
|----|---------------|--------|-----------------------------------|
| AB | HUAHAI US INC | 12.5MG | A074477 001 Feb 13, 1996 Apr CAHN |
| AB | | 25MG | A074477 002 Feb 13, 1996 Apr CAHN |
| AB | | 50MG | A074477 003 Feb 13, 1996 Apr CAHN |
| AB | | 100MG | A074477 004 Feb 13, 1996 Apr CAHN |

CAPTOPRIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL
CAPTOPRIL AND HYDROCHLOROTHIAZIDE

| | | | |
|---|----------------------|-----------|-----------------------------------|
| @ | IVAX SUB TEVA PHARMS | 25MG;15MG | A075055 001 Jun 18, 1998 Apr DISC |
| @ | | 25MG;25MG | A075055 002 Jun 18, 1998 Apr DISC |
| @ | | 50MG;15MG | A075055 004 Jun 18, 1998 Apr DISC |
| @ | | 50MG;25MG | A075055 003 Jun 18, 1998 Apr DISC |

CARBAMAZEPINE

TABLET; ORAL
CARBAMAZEPINE

| | | | |
|---|-------------|-------|-----------------------------------|
| @ | INWOOD LABS | 200MG | A070231 001 Aug 14, 1986 Apr DISC |
|---|-------------|-------|-----------------------------------|

CARBIDOPA

TABLET; ORAL
LODOSYN

| | | | |
|---|------|------|----------------------|
| + | ATON | 25MG | N017830 001 Apr CAHN |
|---|------|------|----------------------|

CARBIDOPA; LEVODOPA

TABLET, ORALLY DISINTEGRATING; ORAL
CARBIDOPA AND LEVODOPA

| | | | |
|----|------------|------------|-----------------------------------|
| AB | IMPAK LABS | 10MG;100MG | A090631 001 Jun 08, 2010 May NEWA |
| AB | | 25MG;100MG | A090631 002 Jun 08, 2010 May NEWA |
| AB | | 25MG;250MG | A090631 003 Jun 08, 2010 May NEWA |

CARBINOXAMINE MALEATE

SOLUTION; ORAL
CARBINOXAMINE MALEATE
AA CYPRESS PHARM 4MG/5ML A090418 001 May 04, 2010 Apr NEWA
TABLET; ORAL
CARBINOXAMINE MALEATE
>A> AA CYPRESS PHARM 4MG A090417 001 Aug 23, 2010 Aug NEWA
AA INVAGEN PHARMS 4MG A090435 001 Apr 15, 2010 Mar NEWA

CARBOPLATIN

INJECTABLE; IV (INFUSION)

CARBOPLATIN

| | | |
|------------------------|----------------------|-----------------------------------|
| AP AKORN | 600MG/60ML (10MG/ML) | A091268 002 Jul 28, 2010 Jul NEWA |
| AP BIONICHE PHARMA USA | 50MG/5ML (10MG/ML) | A077998 001 Apr 24, 2007 Mar CAHN |
| AP | 150MG/15ML (10MG/ML) | A077998 002 Apr 24, 2007 Mar CAHN |
| AP | 450MG/45ML (10MG/ML) | A077998 003 Apr 24, 2007 Mar CAHN |
| AP SUN PHARMA GLOBAL | 50MG/5ML (10MG/ML) | A077926 001 Sep 19, 2008 Jun CAHN |
| AP | 150MG/15ML (10MG/ML) | A077926 002 Sep 19, 2008 Jun CAHN |
| AP | 450MG/45ML (10MG/ML) | A077926 003 Sep 19, 2008 Jun CAHN |
| PARAPLATIN | | |
| @ BRISTOL MYERS SQUIBB | 50MG/5ML (10MG/ML) | N020452 001 Jul 14, 2003 Jul DISC |
| @ | 150MG/15ML (10MG/ML) | N020452 002 Jul 14, 2003 Jul DISC |
| @ | 450MG/45ML (10MG/ML) | N020452 003 Jul 14, 2003 Jul DISC |
| @ | 600MG/60ML (10MG/ML) | N020452 004 Jan 15, 2004 Jul DISC |

CARGLUMIC ACID

TABLET; ORAL

CARBAGLU

+ ORPHAN EUROPE 200MG

N022562 001 Mar 18, 2010 Mar NEWA

CARVEDILOL PHOSPHATE

CAPSULE, EXTENDED RELEASE; ORAL

COREG CR

+ SB PHARMCO 40MG
80MGN022012 003 Oct 20, 2006 Feb CRLD
N022012 004 Oct 20, 2006 Feb CRLDCEFACLOR

CAPSULE; ORAL

CEFACLOR

| | | |
|----------------------|-------------------|-----------------------------------|
| AB + HIKMA | EQ 500MG BASE | A065350 002 Apr 03, 2007 Jun CRLD |
| AB RANBAXY | EQ 500MG BASE | A064156 002 Aug 28, 1997 Jun CRLD |
| FOR SUSPENSION; ORAL | | |
| CEFACLOR | | |
| @ ACS DOBFAR INFO SA | EQ 125MG BASE/5ML | A062206 001 Jun CAHN |
| @ | EQ 187MG BASE/5ML | A062206 003 Apr 20, 1988 Jun CAHN |
| @ | EQ 250MG BASE/5ML | A062206 002 Jun CAHN |
| @ | EQ 375MG BASE/5ML | A062206 004 Apr 20, 1988 Jun CAHN |

TABLET, EXTENDED RELEASE; ORAL

CEFACLOR

| | | |
|----------------|---------------|-----------------------------------|
| AB + WORLD GEN | EQ 500MG BASE | A065057 001 Jan 05, 2001 Mar CAHN |
|----------------|---------------|-----------------------------------|

CEFADROXIL/CEFADROXIL HEMIHYDRATE

CAPSULE; ORAL

CEFADROXIL

| | | |
|------------------|---------------|-----------------------------------|
| AB + TEVA PHARMS | EQ 500MG BASE | A065282 001 Jan 20, 2006 Mar CRLD |
|------------------|---------------|-----------------------------------|

FOR SUSPENSION; ORAL

CEFADROXIL

| | | | | |
|----|---|-----------------|-------------------|-----------------------------------|
| AB | + | LUPIN | EQ 500MG BASE/5ML | A065396 002 Feb 21, 2008 Jan CRLD |
| | | DURICEF | | |
| | @ | WARNER CHILCOTT | EQ 250MG BASE/5ML | N050527 003 Jan DISC |
| | @ | | EQ 500MG BASE/5ML | N050527 001 Jan DISC |

CEFAZOLIN SODIUM

INJECTABLE; INJECTION

CEFAZOLIN SODIUM

@ STERI PHARMA

@

| | | | | |
|----|--|--|--------------------|-----------------------------------|
| AP | | | EQ 500MG BASE/VIAL | A063216 001 Dec 27, 1991 May CAHN |
| AP | | | EQ 500MG BASE/VIAL | A063214 001 Dec 27, 1991 May CAHN |
| AP | | | EQ 1GM BASE/VIAL | A063208 001 Dec 27, 1991 May CAHN |
| AP | | | EQ 1GM BASE/VIAL | A063207 001 Dec 27, 1991 May CAHN |
| AP | | | EQ 10GM BASE/VIAL | A063209 001 Dec 27, 1991 May CAHN |
| AP | | | EQ 20GM BASE/VIAL | A063209 002 Apr 30, 1999 Jun NEWA |

CEFDINIR

CAPSULE; ORAL

CEFDINIR

| | | | | |
|-----|----|----------------------|-----------|-----------------------------------|
| >D> | AB | SANDOZ | 300MG | A065330 001 Apr 06, 2007 Aug CRLD |
| >A> | AB | + | 300MG | A065330 001 Apr 06, 2007 Aug CRLD |
| >D> | | OMNICEF | | |
| >D> | AB | + | 300MG | N050739 001 Dec 04, 1997 Aug DISC |
| >A> | | @ | 300MG | N050739 001 Dec 04, 1997 Aug DISC |
| | | FOR SUSPENSION; ORAL | | |
| | | CEFDINIR | | |
| >D> | AB | SANDOZ | 250MG/5ML | A065337 002 Apr 06, 2007 Aug CRLD |
| >A> | AB | + | 250MG/5ML | A065337 002 Apr 06, 2007 Aug CRLD |
| >D> | | OMNICEF | | |
| >D> | AB | ABBOTT | 125MG/5ML | N050749 001 Dec 04, 1997 Aug DISC |
| >A> | | @ | 125MG/5ML | N050749 001 Dec 04, 1997 Aug DISC |
| >D> | AB | + | 250MG/5ML | N050749 002 Jul 29, 2004 Aug DISC |
| >A> | | @ | 250MG/5ML | N050749 002 Jul 29, 2004 Aug DISC |

CEFEPIME HYDROCHLORIDE

INJECTABLE; INJECTION

CEFEPIME AND DEXTROSE IN DUPLEX CONTAINER

B BRAUN

EQ 1GM BASE/VIAL

EQ 2GM BASE/VIAL

| |
|-----------------------------------|
| N050821 001 May 06, 2010 May NEWA |
| N050821 002 May 06, 2010 May NEWA |

CEFOTAXIME SODIUM

INJECTABLE; INJECTION

CEFOTAXIME SODIUM

| | | | | |
|----|--|------------------|-------------------|-----------------------------------|
| AP | | CEPHAZONE PHARMA | EQ 10GM BASE/VIAL | A065348 001 Jan 25, 2010 Jan NEWA |
|----|--|------------------|-------------------|-----------------------------------|

CEFOXITIN SODIUM

INJECTABLE; INJECTION

CEFOXITIN

| | | | | |
|----|--|--------------------|-------------------|-----------------------------------|
| AP | | ACS DOBFAR | EQ 10GM BASE/VIAL | A065415 001 May 19, 2010 May NEWA |
| AP | | HIKMA FARMACEUTICA | EQ 1GM BASE/VIAL | A065238 001 Mar 12, 2010 Feb NEWA |
| AP | | | EQ 2GM BASE/VIAL | A065238 002 Mar 12, 2010 Feb NEWA |
| AP | | | EQ 10GM BASE/VIAL | A065239 001 Mar 02, 2010 Feb NEWA |

CEFPROZIL

FOR SUSPENSION; ORAL

CEFPROZIL

| | | | | |
|----|---|----------------------|-----------|-----------------------------------|
| AB | + | LUPIN | 250MG/5ML | A065261 002 Dec 19, 2005 Feb CTEC |
| | | CEFZIL | | |
| | @ | BRISTOL MYERS SQUIBB | 125MG/5ML | N050665 001 Dec 23, 1991 Jul DISC |
| | @ | | 250MG/5ML | N050665 002 Dec 23, 1991 Jul DISC |
| | | TABLET; ORAL | | |
| | | CEFPROZIL | | |
| AB | + | LUPIN | 500MG | A065276 002 Dec 08, 2005 Feb CRLD |
| | | CEFZIL | | |
| | @ | BRISTOL MYERS SQUIBB | 250MG | N050664 001 Dec 23, 1991 Jul DISC |
| | @ | | 500MG | N050664 002 Dec 23, 1991 Jul DISC |

CEFTAZIDIME

INJECTABLE; INJECTION

CEFTAZIDIME

| | | | | |
|----|--|------------------|------------|-----------------------------------|
| AP | | AUROBINDO PHARMA | 500MG/VIAL | A065481 001 May 28, 2010 May NEWA |
| AP | | | 1GM/VIAL | A065481 002 May 28, 2010 May NEWA |
| AP | | | 2GM/VIAL | A065481 003 May 28, 2010 May NEWA |
| AP | | | 6GM/VIAL | A065482 001 May 28, 2010 May NEWA |

CEFTIBUTEN DIHYDRATE

CAPSULE; ORAL

CEDAX

+ PERNIX THERAP

EQ 400MG BASE

N050685 002 Dec 20, 1995 May CAHN

FOR SUSPENSION; ORAL

CEDAX

+ PERNIX THERAP

EQ 90MG BASE/5ML

N050686 001 Dec 20, 1995 May CAHN

@

EQ 180MG BASE/5ML

N050686 002 Dec 20, 1995 May CAHN

CEFTRIAXONE SODIUM

INJECTABLE; IM-IV

CEFTRIAXONE

| | | | | |
|----|--|-----------------------|-------------------|-----------------------------------|
| AP | | STERI PHARMA | EQ 1GM BASE/VIAL | A065268 001 Feb 28, 2007 May CAHN |
| AP | | | EQ 2GM BASE/VIAL | A065268 002 Feb 28, 2007 May CAHN |
| | | INJECTABLE; INJECTION | | |
| | | CEFTRIAXONE | | |
| AP | | STERI PHARMA | EQ 10GM BASE/VIAL | A065269 001 Feb 28, 2007 May CAHN |

CEFUROXIME AXETIL

TABLET; ORAL

CEFUROXIME AXETIL

| | | | | |
|-----|----|--------|---------------|-----------------------------------|
| AB | | ALKEM | EQ 250MG BASE | A065496 001 Jun 07, 2010 May NEWA |
| AB | | | EQ 500MG BASE | A065496 002 Jun 07, 2010 May NEWA |
| >D> | AB | SANDOZ | EQ 250MG BASE | A065126 001 Oct 28, 2003 Aug DISC |
| >A> | | @ | EQ 250MG BASE | A065126 001 Oct 28, 2003 Aug DISC |
| >D> | AB | | EQ 500MG BASE | A065126 002 Oct 28, 2003 Aug DISC |
| >A> | | @ | EQ 500MG BASE | A065126 002 Oct 28, 2003 Aug DISC |

CEFUROXIME SODIUM

INJECTABLE; IM-IV

CEFUROXIME SODIUM

| | | | | |
|----|--|--------------|--------------------|-----------------------------------|
| AB | | STERI PHARMA | EQ 750MG BASE/VIAL | A064125 001 May 30, 1997 May CAHN |
|----|--|--------------|--------------------|-----------------------------------|

INJECTABLE; INJECTION

CEFUROXIME SODIUM

| | | | |
|----|--------------|--------------------|-----------------------------------|
| AP | STERI PHARMA | EQ 1.5GM BASE/VIAL | A064125 002 May 30, 1997 May CAHN |
| AP | | EQ 7.5GM BASE/VIAL | A064124 001 May 30, 1997 May CAHN |

CEPHALEXIN

CAPSULE; ORAL

CEPHALEXIN

| | | | |
|-----|------------------------|-------------------|-----------------------------------|
| AB | ACS DOBFAR INFO SA | EQ 250MG BASE | A062118 001 Jun CAHN |
| AB | | EQ 500MG BASE | A062118 002 Jun CAHN |
| | @ IVAX SUB TEVA PHARMS | EQ 250MG BASE | A061969 001 Apr DISC |
| | @ | EQ 500MG BASE | A061969 002 Apr DISC |
| | KEFLEX | | |
| >D> | AB MIDDLEBROOK PHARMS | EQ 250MG BASE | N050405 002 Aug CAHN |
| >D> | @ | EQ 333MG BASE | N050405 004 May 12, 2006 Aug CAHN |
| >D> | AB | EQ 500MG BASE | N050405 003 Aug CAHN |
| >D> | + | EQ 750MG BASE | N050405 005 May 12, 2006 Aug CAHN |
| >A> | AB VICTORY PHARMA | EQ 250MG BASE | N050405 002 Aug CAHN |
| >A> | @ | EQ 333MG BASE | N050405 004 May 12, 2006 Aug CAHN |
| >A> | AB | EQ 500MG BASE | N050405 003 Aug CAHN |
| >A> | + | EQ 750MG BASE | N050405 005 May 12, 2006 Aug CAHN |
| | FOR SUSPENSION; ORAL | | |
| | CEPHALEXIN | | |
| | @ ACS DOBFAR INFO SA | EQ 100MG BASE/ML | A062117 001 Jun CAHN |
| AB | | EQ 125MG BASE/5ML | A062117 002 Jun CAHN |
| AB | + | EQ 250MG BASE/5ML | A062117 003 Jun CAHN |

CETIRIZINE HYDROCHLORIDE

SYRUP; ORAL

CETIRIZINE HYDROCHLORIDE

| | | | |
|----|----------------------|---------|-----------------------------------|
| AA | ACTAVIS MID ATLANTIC | 5MG/5ML | A078617 001 Feb 02, 2010 Jan NEWA |
|----|----------------------|---------|-----------------------------------|

CHLOROQUINE PHOSPHATE

TABLET; ORAL

CHLOROQUINE PHOSPHATE

| | | | |
|----|---------------|---------------|-----------------------------------|
| AA | IPCA LABS LTD | EQ 150MG BASE | A090610 001 Dec 03, 2009 May CAHN |
| AA | | EQ 300MG BASE | A090249 001 Dec 03, 2009 Apr CAHN |

CHLORZOXAZONE

TABLET; ORAL

CHLORZOXAZONE

MIKART

375MG

A040861 001 Jun 01, 2010 May NEWA

750MG

A040861 002 Jun 01, 2010 May NEWA

CICLOPIROX

SHAMPOO; TOPICAL

CICLOPIROX

| | | | |
|----|------------|----|-----------------------------------|
| AT | NYCOMED US | 1% | A090146 001 May 25, 2010 May NEWA |
| AT | PERRIGO | 1% | A078594 001 Feb 16, 2010 Jan NEWA |

SOLUTION; TOPICAL

CICLOPIROX

| | | | |
|----|------------|----|-----------------------------------|
| AT | VERSAPHARM | 8% | A078975 001 Feb 17, 2010 Jan NEWA |
|----|------------|----|-----------------------------------|

CILOSTAZOL

TABLET; ORAL
CILOSTAZOL
@ IVAX SUB TEVA PHARMS 100MG

A077020 002 Mar 01, 2005 Apr DISC

CIPROFLOXACIN HYDROCHLORIDE

TABLET; ORAL
CIPRO
AB + BAYER HLTHCARE EQ 500MG BASE
AB EQ 750MG BASE
CIPROFLOXACIN HYDROCHLORIDE
AB WATSON LABS EQ 100MG BASE
AB EQ 250MG BASE
AB EQ 500MG BASE
AB EQ 750MG BASE

N019537 003 Oct 22, 1987 Feb CRLD
N019537 004 Oct 22, 1987 Feb CRLD
A076794 001 Feb 10, 2005 Jun CAHN
A076794 002 Jun 09, 2004 Jun CAHN
A076794 003 Jun 09, 2004 Jun CAHN
A076794 004 Jun 09, 2004 Jun CAHN

CISPLATIN

INJECTABLE; INJECTION
CISPLATIN
>D> AP APP PHARMS 1MG/ML A074735 001 Jul 16, 1999 Aug CRLD
>A> AP + 1MG/ML A074735 001 Jul 16, 1999 Aug CRLD
PLATINOL
@ BRISTOL MYERS 10MG/VIAL N018057 001 Jul DISC
PLATINOL-AQ
@ BRISTOL MYERS 1MG/ML N018057 004 Nov 08, 1988 Jul DISC

CITALOPRAM HYDROBROMIDE

TABLET; ORAL
CITALOPRAM HYDROBROMIDE
AB EPIC PHARMA EQ 10MG BASE A077045 003 Apr 29, 2005 May CMFD
AB EQ 20MG BASE A077045 002 Apr 29, 2005 May CMFD
AB EQ 40MG BASE A077045 001 Apr 29, 2005 May CMFD
AB WATSON LABS EQ 10MG BASE A077034 001 Jun 30, 2005 Jun CAHN
AB EQ 20MG BASE A077034 002 Jun 30, 2005 Jun CAHN
AB EQ 40MG BASE A077034 003 Jun 30, 2005 Jun CAHN

CLARITHROMYCIN

TABLET; ORAL
CLARITHROMYCIN
@ IVAX SUB TEVA PHARMS 250MG A065137 001 May 31, 2005 Apr DISC
@ 500MG A065137 002 May 31, 2005 Apr DISC

CLINDAMYCIN PALMITATE HYDROCHLORIDE

FOR SOLUTION; ORAL
CLEOCIN
AA + PHARMACIA AND UPJOHN EQ 75MG BASE/5ML A062644 001 Apr 07, 1986 Jul CFTG
CLINDAMYCIN PALMITATE HYDROCHLORIDE
AA PADDOCK LABS EQ 75MG BASE/5ML A090902 001 Jul 07, 2010 Jul NEWA

CLINDAMYCIN PHOSPHATE

AEROSOL, FOAM; TOPICAL
CLINDAMYCIN PHOSPHATE
AT COBREK PHARMS 1% A090785 001 Mar 31, 2010 Mar NEWA
AT PERRIGO 1% A090785 001 Mar 31, 2010 Jun CAHN
AT PERRIGO UK FINCO 1% A090785 001 Mar 31, 2010 Jul CAHN

AEROSOL, FOAM; TOPICAL

EVOCLIN

| | | | | | | | |
|----|---|-----------------------|------------|-------------|--------------|-----|------|
| AT | + | STIEFEL LABS INC | 1% | N050801 001 | Oct 22, 2004 | Mar | CFTG |
| | | CREAM; VAGINAL | | | | | |
| AB | | NYCOMED US | EQ 2% BASE | A065139 001 | Dec 27, 2004 | Mar | CAHN |
| | | SOLUTION; TOPICAL | | | | | |
| | | CLINDAMYCIN PHOSPHATE | | | | | |
| AT | | VERSAPHARM | EQ 1% BASE | A065513 001 | Jun 17, 2010 | May | NEWA |

CLINDAMYCIN PHOSPHATE; TRETINOIN

GEL; TOPICAL

VELTIN

| | | | | | | | |
|----|---|-------------|-------------|-------------|--------------|-----|------|
| BX | | STIEFEL GSK | 1.2%;0.025% | N050803 001 | Jul 16, 2010 | Jul | NEWA |
| BX | + | MEDICIS | 1.2%;0.025% | N050802 001 | Nov 07, 2006 | Jul | CTEC |

CLOBETASOL PROPIONATE

OINTMENT; TOPICAL

CLOBETASOL PROPIONATE

| | | | | | | | |
|----|--|------------|-------|-------------|--------------|-----|------|
| AB | | NYCOMED US | 0.05% | A074407 001 | Feb 23, 1996 | Mar | CAHN |
|----|--|------------|-------|-------------|--------------|-----|------|

CLONIDINE

FILM, EXTENDED RELEASE; TRANSDERMAL

CLONIDINE

| | | | | | | | |
|----|--|--------------------|------------|-------------|--------------|-----|------|
| AB | | MYLAN TECHNOLOGIES | 0.1MG/24HR | A076166 001 | Jul 16, 2010 | Jul | NEWA |
| AB | | | 0.2MG/24HR | A076166 002 | Jul 16, 2010 | Jul | NEWA |
| AB | | | 0.3MG/24HR | A076166 003 | Jul 16, 2010 | Jul | NEWA |

PATCH; TRANSDERMAL

CLONIDINE

| | | | | | | | |
|-----|----|------|------------|-------------|--------------|-----|------|
| >A> | AB | BARR | 0.1MG/24HR | A079090 001 | Aug 20, 2010 | Aug | NEWA |
| >A> | AB | | 0.2MG/24HR | A079090 002 | Aug 20, 2010 | Aug | NEWA |
| >A> | AB | | 0.3MG/24HR | A079090 003 | Aug 20, 2010 | Aug | NEWA |

CLONIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

DURACLON

| | | | | | | | |
|----|---|---------------------|------------------------|-------------|--------------|-----|------|
| AP | | BIONICHE PHARMA USA | 1 MG/10 ML (0.1 MG/ML) | N020615 001 | Oct 02, 1996 | Mar | CAHN |
| AP | + | | 5 MG/10 ML (0.5 MG/ML) | N020615 002 | Apr 27, 1999 | Mar | CAHN |

TABLET; ORAL

CLONIDINE HYDROCHLORIDE

| | | | | | | |
|---|------------|-------|-------------|--------------|-----|------|
| @ | INTERPHARM | 0.1MG | A071252 001 | Oct 01, 1986 | May | CAHN |
| @ | | 0.2MG | A071253 001 | Oct 01, 1986 | May | CAHN |
| @ | | 0.3MG | A071254 001 | Oct 01, 1986 | May | CAHN |

JENLOGA

| | | | | | | | |
|----|--|-----------------|-------|-------------|--------------|-----|------|
| BX | | SHIONOGI PHARMA | 0.2MG | N022331 002 | May 25, 2010 | Jun | NEWA |
|----|--|-----------------|-------|-------------|--------------|-----|------|

CLOTRIMAZOLE

CREAM; TOPICAL

CLOTRIMAZOLE

| | | | | | | | |
|----|--|-----------------|----|-------------|--------------|-----|------|
| AB | | GLENMARK PHARMS | 1% | A090219 001 | Aug 03, 2010 | Jul | NEWA |
|----|--|-----------------|----|-------------|--------------|-----|------|

CLOZAPINE

TABLET, ORALLY DISINTEGRATING; ORAL

FAZACLO ODT

| | | | | | | |
|--|------------------|-------|-------------|--------------|-----|------|
| | AZUR PHARMA INTL | 150MG | N021590 005 | Jul 09, 2010 | Jul | NEWA |
|--|------------------|-------|-------------|--------------|-----|------|

TABLET, ORALLY DISINTEGRATING; ORAL

FAZACLO ODT

AZUR PHARMA INTL 200MG

N021590 006 Jul 09, 2010 Jul NEWA

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE

AA SUN PHARM INDS INC 10MG/5ML;6.25MG/5ML

A090180 001 Mar 17, 2010 Mar NEWA

COLCHICINE; PROBENECID

TABLET; ORAL

PROBENECID AND COLCHICINE

@ IVAX SUB TEVA PHARMS 0.5MG;500MG

A083734 001 Apr DISC

COSYNTROPIN

INJECTABLE; INJECTION

COSYNTROPIN

AP BIONICHE PHARMA 0.25MG/VIAL

A090574 001 Dec 17, 2009 Mar CAHN

CROMOLYN SODIUM

CONCENTRATE; ORAL

CROMOLYN SODIUM

@ GENERA PHARMS 100MG/5ML

A090954 001 Dec 18, 2009 Apr DISC

GASTROCROM

+ AZUR PHARMA 100MG/5ML

N020479 001 Feb 29, 1996 Apr CTEC

SOLUTION; INHALATION

CROMOLYN SODIUM

AN WATSON LABS 10MG/ML

A076469 001 Jun 17, 2005 Jun CAHN

CYANOCOBALAMIN

SPRAY, METERED; NASAL

CALOMIST

@ FLEMING 25MCG/SPRAY

N022102 001 Jul 27, 2007 Jan DISC

@ PAR PHARM 25MCG/SPRAY

N022102 001 Jul 27, 2007 Jul CAHN

CYCLOBENZAPRINE HYDROCHLORIDE

TABLET; ORAL

CYCLOBENZAPRINE HYDROCHLORIDE

AB INVAGEN PHARMS 5MG

A090478 001 Jul 23, 2010 Jul NEWA

AB 10MG

A090478 002 Jul 23, 2010 Jul NEWA

CYCLOPHOSPHAMIDE

INJECTABLE; INJECTION

CYTOXAN

AP + BAXTER HLTHCARE 500MG/VIAL

N012142 003 Feb CMFD

AP + 1GM/VIAL

N012142 004 Aug 30, 1982 Feb CMFD

AP + 2GM/VIAL

N012142 005 Aug 30, 1982 Feb CMFD

LYOPHILIZED CYTOXAN

@ BAXTER HLTHCARE 100MG/VIAL

N012142 006 Dec 05, 1985 Feb DISC

@ 200MG/VIAL

N012142 007 Dec 10, 1985 Feb DISC

@ 500MG/VIAL

N012142 008 Jan 04, 1984 Feb DISC

@ 1GM/VIAL

N012142 010 Sep 24, 1985 Feb DISC

@ 2GM/VIAL

N012142 009 Dec 10, 1985 Feb DISC

CYPROHEPTADINE HYDROCHLORIDE

TABLET; ORAL

CYPROHEPTADINE HYDROCHLORIDE
@ PLIVA 4MG

A088205 001 Jul 26, 1983 May DISC

CYTARABINE

INJECTABLE; INJECTION

CYTARABINE

AP + HOSPIRA 20MG/ML
AP + 20MG/MLA071868 001 Jun 04, 1990 Apr CRLD
A072168 001 Aug 31, 1990 Mar CRLDDACTINOMYCIN

INJECTABLE; INJECTION

COSMEGEN

AP + LUNDBECK INC 0.5MG/VIAL
DACTINOMYCIN
AP BEDFORD 0.5MG/VIALN050682 001 Mar CFTG
A090304 001 Mar 16, 2010 Mar NEWADALFAMPRIDINE

TABLET, EXTENDED RELEASE; ORAL

AMPYRA

+ ACORDA 10MG

N022250 001 Jan 22, 2010 Jan NEWA

DARUNAVIR ETHANOLATE

TABLET; ORAL

PREZISTA

TIBOTEC EQ 75MG BASE
EQ 150MG BASE
EQ 300MG BASE
EQ 400MG BASE
+ EQ 600MG BASEN021976 004 Dec 18, 2008 May CAHN
N021976 005 Dec 18, 2008 May CAHN
N021976 001 Jun 23, 2006 May CAHN
N021976 003 Oct 21, 2008 May CAHN
N021976 002 Feb 25, 2008 May CAHNDAUNORUBICIN CITRATE

INJECTABLE, LIPOSOMAL; INJECTION

DAUNOXOME

+ GILEAD EQ 2MG BASE/ML

N050704 002 Apr 08, 1996 Jul CMFD

DESLORATADINE

TABLET; ORAL

CLARINEX

AB + SCHERING PLOUGH 5MG
DESLORATADINE
AB ORCHID HLTHCARE 5MG
TABLET, ORALLY DISINTEGRATING; ORAL
CLARINEX
AB SCHERING 2.5MG
AB + 5MG
DESLORATADINE
AB REDDYS 2.5MG
AB 5MGN021165 001 Dec 21, 2001 Jan CFTG
A078357 001 Feb 19, 2010 Jan NEWA
N021312 002 Jul 14, 2005 Jun CFTG
N021312 001 Jun 26, 2002 Jun CFTG
A078367 001 Jul 12, 2010 Jun NEWA
A078367 002 Jul 12, 2010 Jun NEWADESMOPRESSIN ACETATE

SPRAY, METERED; NASAL

STIMATE (NEEDS NO REFRIGERATION)

+ CSL BEHRING 1.5MG/SPRAY

N020355 002 Oct 24, 2007 Jun CMFD

SPRAY, METERED; NASAL
 STIMATE (NEEDS NO REFRIGERATION)
 @ CSL BEHRING 1.5MG/SPRAY

N020355 002 Oct 24, 2007 Jan DISC

DESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-28
 MIRCETTE
 AB + TEVA WOMENS 0.15MG,N/A;0.02MG,0.01MG

N020713 001 Apr 22, 1998 Apr CAHN

DESOXIMETASONE

CREAM; TOPICAL
 DESOXIMETASONE
 AB NYCOMED US 0.25%

A078369 001 Jun 29, 2010 Jun NEWA

DEXLANSOPRAZOLE

CAPSULE, DELAYED RELEASE; ORAL
 DEXILANT
 TAKEDA PHARMS 30MG
 + 60MG

N022287 001 Jan 30, 2009 Mar CTNA

N022287 002 Jan 30, 2009 Mar CTNA

DEXMEDETOMIDINE HYDROCHLORIDE

INJECTABLE; INJECTION
 PRECEDEX
 + HOSPIRA EQ 100MCG BASE/ML (EQ100MCG
 BASE/ML)

N021038 001 Dec 17, 1999 Jan CAIN

DEXMETHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
 FOCALIN XR
 >D> + NOVARTIS 30MG
 >A> 30MG
 >A> + 40MG

N021802 005 Oct 23, 2009 Aug CRLD

N021802 005 Oct 23, 2009 Aug CRLD

N021802 006 Aug 11, 2010 Aug NEWA

DIATRIZOATE SODIUM

FOR SOLUTION; ORAL, RECTAL
 HYPAQUE
 @ GE HEALTHCARE 100%

N011386 001 May DISC

DIAZEPAM

TABLET; ORAL
 DIAZEPAM
 >D> AB BARR 5MG
 >A> @ TEVA PHARMS 5MG

A070153 001 Nov 01, 1985 Aug DISC

A070153 001 Nov 01, 1985 Aug DISC

DIAZOXIDE

CAPSULE; ORAL
 PROGLYCEM
 @ TEVA BRANDED PHARM 50MG
 @ 100MG

N017425 001 Feb CAHN

N017425 002 Feb CAHN

DICLOFENAC POTASSIUM

FOR SOLUTION; ORAL
 CAMBIA
 + NAUTILUS NEUROSCIENC 50MG

N022165 001 Jun 17, 2009 Mar CAHN

TABLET; ORAL

DICLOFENAC POTASSIUM

| | | | | | |
|---------------|------|-------------|--------------|-----|------|
| @ SANDOZ | 50MG | A075582 001 | Feb 23, 2001 | Jan | DISC |
| @ WATSON LABS | 50MG | A075152 001 | Nov 27, 1998 | Apr | DISC |

DICLOFENAC SODIUM

SOLUTION; TOPICAL

PENNSAID

| | | | | | |
|----------------|------|-------------|--------------|-----|------|
| + MALLINCKRODT | 1.5% | N020947 001 | Nov 04, 2009 | May | CAHN |
|----------------|------|-------------|--------------|-----|------|

TABLET, DELAYED RELEASE; ORAL

DICLOFENAC SODIUM

| | | | | | |
|----------------|------|-------------|--------------|-----|------|
| @ NOSTRUM LABS | 50MG | A074986 001 | Feb 26, 1999 | Apr | DISC |
|----------------|------|-------------|--------------|-----|------|

| | | | | | |
|---|------|-------------|--------------|-----|------|
| @ | 75MG | A074986 002 | Feb 26, 1999 | Apr | DISC |
|---|------|-------------|--------------|-----|------|

| | | | | | |
|-------------|------|-------------|--------------|-----|------|
| AB + SANDOZ | 75MG | A074394 001 | Nov 30, 1995 | Jul | CRLD |
|-------------|------|-------------|--------------|-----|------|

VOLTAREN

| | | | | | |
|------------|------|-------------|--------------|-----|------|
| @ NOVARTIS | 75MG | N019201 003 | Jul 28, 1988 | Jul | DISC |
|------------|------|-------------|--------------|-----|------|

DIDANOSINE

CAPSULE, DELAYED REL PELLETS; ORAL

DIDANOSINE

| | | | | | |
|--------------------|-------|-------------|--------------|-----|------|
| AB MATRIX LABS LTD | 125MG | A090788 001 | Apr 08, 2010 | Mar | NEWA |
| AB | 200MG | A090788 002 | Apr 08, 2010 | Mar | NEWA |
| AB | 250MG | A090788 003 | Apr 08, 2010 | Mar | NEWA |
| AB | 400MG | A090788 004 | Apr 08, 2010 | Mar | NEWA |

DIENOGEST; ESTRADIOL VALERATE

TABLET; ORAL-28

NATAZIA

| | | | | | |
|------------------|---|-------------|--------------|-----|------|
| + BAYER HLTHCARE | N/A, 2MG, 3MG, N/A, N/A; 3MG, 2MG, 2MG, 1 MG, N/A | N022252 001 | May 06, 2010 | Jun | CRLD |
| | N/A, 2MG, 3MG, N/A, N/A; 3MG, 2MG, 2MG, 1 MG, N/A | N022252 001 | May 06, 2010 | May | NEWA |

DIFLORASONE DIACETATE

CREAM; TOPICAL

DIFLORASONE DIACETATE

| | | | | | |
|---------------------|-------|-------------|--------------|-----|------|
| AB1 + ALTANA | 0.05% | A075187 001 | Mar 30, 1998 | Mar | CRLD |
| PSORCON | | | | | |
| @ SANOFI AVENTIS US | 0.05% | N020205 001 | Nov 20, 1992 | Feb | DISC |

DIFLUPREDNATE

EMULSION; OPHTHALMIC

DUREZOL

| | | | | | |
|-------------|-------|-------------|--------------|-----|------|
| + ALCON RES | 0.05% | N022212 001 | Jun 23, 2008 | Jun | CAHN |
|-------------|-------|-------------|--------------|-----|------|

DIGOXIN

CAPSULE; ORAL

LANOXICAPS

| | | | | | |
|-----------------------|--------|-------------|--------------|-----|------|
| @ GLAXOSMITHKLINE LLC | 0.05MG | N018118 002 | Jul 26, 1982 | Jul | DISC |
| | 0.05MG | N018118 002 | Jul 26, 1982 | Jun | CAHN |
| @ | 0.1MG | N018118 003 | Jul 26, 1982 | Jul | DISC |
| | 0.1MG | N018118 003 | Jul 26, 1982 | Jun | CAHN |
| @ | 0.15MG | N018118 004 | Sep 24, 1984 | Jun | CAHN |
| @ | 0.2MG | N018118 001 | Jul 26, 1982 | Jul | DISC |
| + | 0.2MG | N018118 001 | Jul 26, 1982 | Jun | CAHN |

INJECTABLE; INJECTION

LANOXIN

| | | | | | | |
|----|---|---------------------|-----------|-------------|-----|------|
| AP | + | GLAXOSMITHKLINE LLC | 0.25MG/ML | N009330 002 | Jun | CAHN |
| | + | GLAXOSMITHKLINE LLC | 0.1MG/ML | N009330 004 | Jun | CAHN |

DILTIAZEM HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

CARDIZEM LA

| | | | | | | |
|----|-------------------------|-------|-------------|--------------|-----|------|
| AB | BIOVAIL LABS INTL | 120MG | N021392 001 | Feb 06, 2003 | Feb | CFTG |
| AB | | 180MG | N021392 002 | Feb 06, 2003 | Feb | CFTG |
| AB | | 240MG | N021392 003 | Feb 06, 2003 | Feb | CFTG |
| AB | | 300MG | N021392 004 | Feb 06, 2003 | Feb | CFTG |
| AB | | 360MG | N021392 005 | Feb 06, 2003 | Feb | CFTG |
| AB | + | 420MG | N021392 006 | Feb 06, 2003 | Feb | CFTG |
| | DILTIAZEM HYDROCHLORIDE | | | | | |
| AB | WATSON LABS FLORIDA | 120MG | A077686 006 | Mar 15, 2010 | Feb | NEWA |
| AB | | 180MG | A077686 005 | Mar 15, 2010 | Feb | NEWA |
| AB | | 240MG | A077686 004 | Mar 15, 2010 | Feb | NEWA |
| AB | | 300MG | A077686 003 | Mar 15, 2010 | Feb | NEWA |
| AB | | 360MG | A077686 002 | Mar 15, 2010 | Feb | NEWA |
| AB | | 420MG | A077686 001 | Mar 15, 2010 | Feb | NEWA |

DIPYRIDAMOLE

INJECTABLE; INJECTION

DIPYRIDAMOLE

| | | | | | | |
|----|---------------------|--------|-------------|--------------|-----|------|
| AP | CLARIS LIFESCIENCES | 5MG/ML | A075769 001 | Nov 27, 2002 | Jun | CAHN |
|----|---------------------|--------|-------------|--------------|-----|------|

DISOPYRAMIDE PHOSPHATE

CAPSULE; ORAL

DISOPYRAMIDE PHOSPHATE

| | | | | | | |
|---|------------|---------------|-------------|--------------|-----|------|
| @ | INTERPHARM | EQ 100MG BASE | A071190 001 | Jan 15, 1987 | May | CAHN |
| @ | | EQ 150MG BASE | A071191 001 | Jan 15, 1987 | May | CAHN |

DOCETAXEL

INJECTABLE; INJECTION

TAXOTERE

| | | | | | | | |
|-----|---|-------------------|--------------------|-------------|--------------|-----|------|
| >A> | + | SANOFI AVENTIS US | 20MG/ML (20MG/ML) | N020449 003 | Aug 03, 2010 | Aug | NEWA |
| >A> | + | | 80MG/4ML (20MG/ML) | N020449 004 | Aug 02, 2010 | Aug | NEWA |

DONEPEZIL HYDROCHLORIDE

TABLET; ORAL

ARICEPT

| | | | | | | | |
|-----|----|-----------|------|-------------|--------------|-----|------|
| >D> | AB | EISAI INC | 5MG | N020690 002 | Nov 25, 1996 | Aug | CTEC |
| >A> | | | 5MG | N020690 002 | Nov 25, 1996 | Aug | CTEC |
| >D> | AB | + | 10MG | N020690 001 | Nov 25, 1996 | Aug | CTEC |
| >A> | | + | 10MG | N020690 001 | Nov 25, 1996 | Aug | CTEC |
| | | + | 23MG | N022568 001 | Jul 23, 2010 | Jul | NEWA |

DOXAZOSIN MESYLATE

TABLET; ORAL

DOXAZOSIN MESYLATE

| | | | | | | |
|---|----------------------|-------------|-------------|--------------|-----|------|
| @ | IVAX SUB TEVA PHARMS | EQ 1MG BASE | A075453 001 | Oct 18, 2000 | Apr | DISC |
| @ | | EQ 2MG BASE | A075453 002 | Oct 18, 2000 | Apr | DISC |
| @ | | EQ 4MG BASE | A075453 003 | Oct 18, 2000 | Apr | DISC |
| @ | | EQ 8MG BASE | A075453 004 | Oct 18, 2000 | Apr | DISC |

TABLET; ORAL

DOXAZOSIN MESYLATE

| | | | | | | | |
|-----|----|--------|-------------|-------------|--------------|-----|------|
| >D> | AB | SANDOZ | EQ 1MG BASE | A075432 001 | Oct 18, 2000 | Aug | DISC |
| >A> | | @ | EQ 1MG BASE | A075432 001 | Oct 18, 2000 | Aug | DISC |
| >D> | AB | | EQ 2MG BASE | A075432 002 | Oct 18, 2000 | Aug | DISC |
| >A> | | @ | EQ 2MG BASE | A075432 002 | Oct 18, 2000 | Aug | DISC |
| >D> | AB | | EQ 4MG BASE | A075432 003 | Oct 18, 2000 | Aug | DISC |
| >A> | | @ | EQ 4MG BASE | A075432 003 | Oct 18, 2000 | Aug | DISC |
| >D> | AB | | EQ 8MG BASE | A075432 004 | Oct 18, 2000 | Aug | DISC |
| >A> | | @ | EQ 8MG BASE | A075432 004 | Oct 18, 2000 | Aug | DISC |

DOXEPIN HYDROCHLORIDE

TABLET; ORAL

SILENOR

SOMAXON

+

EQ 3MG BASE

N022036 001 Mar 17, 2010 Mar NEWA

EQ 6MG BASE

N022036 002 Mar 17, 2010 Mar NEWA

DOXYCYCLINE

CAPSULE; ORAL

DOXYCYCLINE

| | | | | | | | |
|----|---|--------------------------------|------|-------------|--------------|-----|------|
| AB | | MYLAN | 40MG | A090855 001 | Jul 01, 2010 | Jun | NEWA |
| | | ORACEA | | | | | |
| AB | + | GALDERMA LABS LP | 40MG | N050805 001 | May 26, 2006 | Jun | CFTG |
| | | CAPSULE, DELAYED RELEASE; ORAL | | | | | |
| | | DOXYCYCLINE | | | | | |
| AB | | MYLAN | 40MG | A090855 001 | Jul 01, 2010 | Jul | NEWA |

DOXYCYCLINE HYCLATE

CAPSULE; ORAL

DOXYCYCLINE HYCLATE

@ INTERPHARM

EQ 50MG BASE

A062763 001 Sep 02, 1988 May CAHN

@

EQ 100MG BASE

A062763 002 Sep 02, 1988 May CAHN

CAPSULE, DELAYED RELEASE; ORAL

DOXYCYCLINE HYCLATE

MEDICIS

EQ 75MG BASE

A065281 001 Dec 21, 2005 Jun CAHN

+

EQ 100MG BASE

A065281 002 Dec 21, 2005 Jun CAHN

TABLET; ORAL

DOXYCYCLINE HYCLATE

@ INTERPHARM

EQ 100MG BASE

A062764 001 Sep 02, 1988 May CAHN

@ LARKEN LABS

EQ 20MG BASE

A065287 001 Feb 28, 2006 Apr CAHN

DRONABINOL

CAPSULE; ORAL

MARINOL

| | | | | | | | |
|----|---|--------------|-------|-------------|--------------|-----|------|
| AB | | ABBOTT PRODS | 2.5MG | N018651 001 | May 31, 1985 | May | CAHN |
| AB | + | | 5MG | N018651 002 | May 31, 1985 | May | CAHN |
| AB | | | 10MG | N018651 003 | May 31, 1985 | May | CAHN |

DROSPIRENONE; ETHINYLMESTRADIOL

TABLET; ORAL-28

DROSPIRENONE AND ETHINYLMESTRADIOL

| | | | | | | | |
|-----|----|-------------|------------|-------------|--------------|-----|------|
| >A> | AB | WATSON LABS | 3MG;0.03MG | A090081 001 | Sep 07, 2010 | Aug | NEWA |
|-----|----|-------------|------------|-------------|--------------|-----|------|

DUTASTERIDE; TAMSULOSIN HYDROCHLORIDE

CAPSULE; ORAL
 JALYN
 + GLAXOSMITHKLINE 0.5MG;0.4MG N022460 001 Jun 14, 2010 Jun NEWA

ELTROMBOPAG OLAMINE

TABLET; ORAL
 PROMACTA
 GLAXOSMITHKLINE EQ 75MG ACID N022291 003 Sep 08, 2009 Mar NEWA

ENALAPRIL MALEATE

TABLET; ORAL
 ENALAPRIL MALEATE
 >D> AB KRKA DD NOVO MESTO 2.5MG A075370 001 Aug 22, 2000 Aug DISC
 >A> @ 2.5MG A075370 001 Aug 22, 2000 Aug DISC
 >D> AB 5MG A075370 002 Aug 22, 2000 Aug DISC
 >A> @ 5MG A075370 002 Aug 22, 2000 Aug DISC
 >D> AB 10MG A075369 001 Aug 22, 2000 Aug DISC
 >A> @ 10MG A075369 001 Aug 22, 2000 Aug DISC
 >D> AB 20MG A075369 002 Aug 22, 2000 Aug DISC
 >A> @ 20MG A075369 002 Aug 22, 2000 Aug DISC
 AB MYLAN 2.5MG A075472 001 Aug 22, 2000 Apr CAHN
 AB 5MG A075472 002 Aug 22, 2000 Apr CAHN
 AB 10MG A075472 003 Aug 22, 2000 Apr CAHN
 AB 20MG A075472 004 Aug 22, 2000 Apr CAHN
 >D> AB RANBAXY 2.5MG A075556 001 Aug 22, 2000 Aug DISC
 >A> @ 2.5MG A075556 001 Aug 22, 2000 Aug DISC
 >D> AB 5MG A075556 002 Aug 22, 2000 Aug DISC
 >A> @ 5MG A075556 002 Aug 22, 2000 Aug DISC
 >D> AB 10MG A075556 003 Aug 22, 2000 Aug DISC
 >A> @ 10MG A075556 003 Aug 22, 2000 Aug DISC
 >D> AB 20MG A075556 004 Aug 22, 2000 Aug DISC
 >A> @ 20MG A075556 004 Aug 22, 2000 Aug DISC

ENALAPRIL MALEATE; FELODIPINE

TABLET, EXTENDED RELEASE; ORAL
 LEXCEL
 @ ASTRAZENECA 5MG;5MG N020668 001 Dec 27, 1996 Mar DISC

ENOXAPARIN SODIUM

INJECTABLE; SUBCUTANEOUS
 ENOXAPARIN SODIUM (PRESERVATIVE FREE)
 AP SANDOZ 30MG/0.3ML (100MG/ML) A077857 002 Jul 23, 2010 Jul NEWA
 AP 40MG/0.4ML (100MG/ML) A077857 003 Jul 23, 2010 Jul NEWA
 AP 60MG/0.6ML (100MG/ML) A077857 004 Jul 23, 2010 Jul NEWA
 AP 80MG/0.8ML (100MG/ML) A077857 005 Jul 23, 2010 Jul NEWA
 AP 100MG/ML (100MG/ML) A077857 001 Jul 23, 2010 Jul NEWA
 AP 120MG/0.8ML (150MG/ML) A077857 006 Jul 23, 2010 Jul NEWA
 AP 150MG/ML (150MG/ML) A077857 007 Jul 23, 2010 Jul NEWA
 LOVENOX (PRESERVATIVE FREE)
 AP SANOFI AVENTIS US 30MG/0.3ML (100MG/ML) N020164 001 Mar 29, 1993 Jul CFTG
 AP 40MG/0.4ML (100MG/ML) N020164 002 Jan 30, 1998 Jul CFTG
 AP 60MG/0.6ML (100MG/ML) N020164 003 Mar 27, 1998 Jul CFTG
 AP 80MG/0.8ML (100MG/ML) N020164 004 Mar 27, 1998 Jul CFTG
 AP + 100MG/ML (100MG/ML) N020164 005 Mar 27, 1998 Jul CFTG

INJECTABLE; SUBCUTANEOUS

LOVENOX (PRESERVATIVE FREE)

| | | | | | | |
|----|-------------------|------------------------|-------------|--------------|-----|------|
| AP | SANOFI AVENTIS US | 120MG/0.8ML (150MG/ML) | N020164 007 | Jun 02, 2000 | Jul | CFTG |
| AP | | 150MG/ML (150MG/ML) | N020164 008 | Jun 02, 2000 | Jul | CFTG |

EPINEPHRINE

INJECTABLE; IM-SC

ADRENACCLICK

| | | | | | | |
|----|------------------------|---------------------|-------------|--------------|-----|------|
| BX | + SHIONOGI PHARMA | EQ 0.15MG /DELIVERY | N020800 003 | Nov 25, 2009 | Apr | CTEC |
| | + | EQ 0.15MG /DELIVERY | N020800 003 | Nov 25, 2009 | Mar | NEWA |
| BX | + | EQ 0.3MG /DELIVERY | N020800 004 | Nov 25, 2009 | Apr | CTEC |
| | + | EQ 0.3MG /DELIVERY | N020800 004 | Nov 25, 2009 | Mar | NEWA |
| | EPIPEN | | | | | |
| BX | + MERIDIAN MEDCL TECHN | 0.3MG/DELIVERY | N019430 001 | Dec 22, 1987 | Apr | CDFR |
| | EPIPEN JR. | | | | | |
| BX | + MERIDIAN MEDCL TECHN | 0.15MG/DELIVERY | N019430 002 | Dec 22, 1987 | Apr | CDFR |
| | TWINJECT 0.15 | | | | | |
| BX | + SHIONOGI PHARMA | EQ 0.15MG /DELIVERY | N020800 002 | May 28, 2004 | Apr | CTEC |
| | + | EQ 0.15MG /DELIVERY | N020800 002 | May 28, 2004 | Jan | CAHN |
| | TWINJECT 0.3 | | | | | |
| BX | + SHIONOGI PHARMA | EQ 0.3MG /DELIVERY | N020800 001 | May 30, 2003 | Apr | CTEC |
| | + | EQ 0.3MG /DELIVERY | N020800 001 | May 30, 2003 | Jan | CAHN |

EPIRUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

EPIRUBICIN HYDROCHLORIDE

| | | | | | | |
|----|---------------------|----------------------|-------------|--------------|-----|------|
| AP | BIONICHE PHARMA USA | 50MG/25ML (2MG/ML) | A065371 001 | Nov 28, 2007 | Mar | CAHN |
| AP | | 200MG/100ML (2MG/ML) | A065371 002 | Nov 28, 2007 | Mar | CAHN |
| AP | X GEN PHARMS | 50MG/25ML (2MG/ML) | A090075 001 | Mar 25, 2010 | Mar | NEWA |
| AP | | 200MG/100ML (2MG/ML) | A090075 002 | Mar 25, 2010 | Mar | NEWA |

EPOPROSTENOL SODIUM

INJECTABLE; INJECTION

FLOLAN

| | | | | | | |
|----|-----------------------|--------------------|-------------|--------------|-----|------|
| AP | + GLAXOSMITHKLINE LLC | EQ 0.5MG BASE/VIAL | N020444 001 | Sep 20, 1995 | Jun | CAHN |
| AP | + | EQ 1.5MG BASE/VIAL | N020444 002 | Sep 20, 1995 | Jun | CAHN |

ERGOCALCIFEROL

CAPSULE; ORAL

ERGOCALCIFEROL

| | | | | | | |
|----|---------------------|-----------|-------------|--------------|-----|------|
| AA | SIGMAPHARM LABS LLC | 50,000 IU | A091004 001 | Jul 14, 2010 | Jul | NEWA |
| AA | STRIDES ARCOLAB LTD | 50,000 IU | A090455 001 | Aug 03, 2010 | Jul | NEWA |

ERYTHROMYCIN

OINTMENT; OPHTHALMIC

ERYTHROMYCIN

| | | | | | | |
|----|---------------|------|-------------|--------------|-----|------|
| AT | AKORN | 0.5% | A064030 001 | Jul 18, 1996 | Apr | CMFD |
| | SWAB; TOPICAL | | | | | |
| | ERYTHROMYCIN | | | | | |
| AT | VERSAPHARM | 2% | A090215 001 | May 12, 2010 | May | NEWA |

ERYTHROMYCIN ETHYLSUCCINATE

TABLET; ORAL

E.E.S. 400

| | | | | | | |
|----|----------|---------------|-------------|--------------|-----|------|
| BX | + ABBOTT | EQ 400MG BASE | A061905 002 | Aug 12, 1982 | Jul | CTEC |
|----|----------|---------------|-------------|--------------|-----|------|

TABLET; ORAL

ERYTHROMYCIN ETHYLSUCCINATE

BX + ABBOTT EQ 400MG BASE A061904 001 Jul NEWA

ESMOLOL HYDROCHLORIDE

INJECTABLE; INJECTION

BREVIBLOC

@ BAXTER HLTHCARE CORP 20MG/ML

N019386 007 May 28, 2003 Jun DISC

ESOMEPRAZOLE MAGNESIUM; NAPROXEN

TABLET, DELAYED RELEASE; ORAL

VIMOVO

ASTRAZENECA LP EQ 20MG BASE;375MG

N022511 002 Apr 30, 2010 Jun CAHN

+ EQ 20MG BASE;500MG

N022511 001 Apr 30, 2010 Jun CAHN

POZEN EQ 20MG BASE;375MG

N022511 002 Apr 30, 2010 Apr NEWA

+ EQ 20MG BASE;500MG

N022511 001 Apr 30, 2010 Apr NEWA

ESTRADIOL VALERATE

INJECTABLE; INJECTION

ESTRADIOL VALERATE

AO PHARMAFORCE 20MG/ML

A090920 001 Jan 19, 2010 Jan NEWA

AO 40MG/ML

A090920 002 Jan 19, 2010 Jan NEWA

ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL

ESTRADIOL AND NORETHINDRONE ACETATE

AB BARR 1MG;0.5MG

A079193 001 May 11, 2010 May NEWA

ESTROGENS, CONJUGATED SYNTHETIC A

CREAM; VAGINAL

SYNTHETIC CONJUGATED ESTROGENS A

>D> + DURAMED RES 0.625MG/GM

N021788 001 Nov 28, 2008 Aug CAHN

>A> + TEVA WOMENS 0.625MG/GM

N021788 001 Nov 28, 2008 Aug CAHN

TABLET; ORAL

CENESTIN

TEVA WOMENS 0.3MG

N020992 001 Jun 21, 2002 Apr CAHN

0.45MG

N020992 005 Feb 05, 2004 Apr CAHN

0.625MG

N020992 002 Mar 24, 1999 Apr CAHN

0.9MG

N020992 003 Mar 24, 1999 Apr CAHN

+ 1.25MG

N020992 004 Mar 13, 2000 Apr CAHN

ESTROGENS, CONJUGATED SYNTHETIC B

TABLET; ORAL

ENJUVIA

TEVA WOMENS 0.3MG

N021443 001 Dec 20, 2004 Apr CAHN

0.45MG

N021443 002 Dec 20, 2004 Apr CAHN

0.625MG

N021443 003 May 10, 2004 Apr CAHN

0.9MG

N021443 005 Apr 27, 2007 Apr CAHN

+ 1.25MG

N021443 004 May 10, 2004 Apr CAHN

ETHINYLL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL-28

ALTAVERA

AB SANDOZ 0.03MG;0.15MG

A079102 001 Aug 03, 2010 Jul NEWA

ETHINYLMESTRADIOL; NORETHINDRONE

TABLET; ORAL-21

NORETHINDRONE AND ETHINYLMESTRADIOL

WATSON LABS 0.035MG;0.4MG

A078379 001 Feb 23, 2010 Feb NEWA

TABLET; ORAL-28

NORETHINDRONE AND ETHINYLMESTRADIOL

AB WATSON LABS 0.035MG;0.4MG

A078323 001 Feb 04, 2010 Jan NEWA

AB 0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG A076393 001 Feb 04, 2010 Jan NEWA

TABLET, CHEWABLE; ORAL-28

FEMCON FE

AB + WARNER CHILCOTT 0.035MG;0.4MG

N021490 001 Nov 14, 2003 Jul CFTG

NORETHINDRONE AND ETHINYLMESTRADIOL AND FERROUS FUMARATE

AB BARR 0.035MG;0.4MG

A078965 001 Aug 05, 2010 Jul NEWA

ETHINYLMESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL

NORETHINDRONE ACETATE AND ETHINYLMESTRADIOL AND FERROUS FUMARATE

AB WATSON LABS 0.02MG;1MG

A078267 001 Sep 01, 2009 Jan CDFR

TABLET; ORAL-28

NORETHINDRONE ACETATE AND ETHINYLMESTRADIOL

AB WATSON LABS 0.02MG,0.03MG,0.035MG;1MG,1MG,1MG

A076629 001 Mar 18, 2010 Mar NEWA

NORETHINDRONE ACETATE AND ETHINYLMESTRADIOL AND FERROUS FUMARATE

AB VINTAGE 0.02MG;1MG

A077077 001 May 20, 2005 Feb CAHN

AB 0.03MG;1.5MG

A077075 001 Apr 28, 2005 Feb CAHN

ETHINYLMESTRADIOL; NORGESTIMATE

TABLET; ORAL-28

PREVIFEM

AB VINTAGE 0.035MG;0.25MG

A076334 001 Jan 09, 2004 Feb CAHN

TRI-PREVIFEM

AB VINTAGE 0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG

A076335 001 Mar 26, 2004 Feb CAHN

ETHIODIZED OIL

OIL; INTRALYMPHATIC, INTRAUTERINE

ETHIODOL

GUERBET 99%

N009190 001 May CAHN

ETOPOSIDE

INJECTABLE; INJECTION

ETOPOSIDE

>D> AP BEDFORD 20MG/ML

A074290 001 Jul 17, 1995 Aug CRLD

>A> AP + 20MG/ML

A074290 001 Jul 17, 1995 Aug CRLD

VEPESID

@ BRISTOL MYERS SQUIBB 20MG/ML

N018768 001 Nov 10, 1983 Jul DISC

EVEROLIMUS

TABLET; ORAL

AFINITOR

NOVARTIS 2.5MG

N022334 003 Jul 09, 2010 Jun NEWA

ZORTRESS

NOVARTIS 0.25MG

N021560 001 Apr 20, 2010 Apr NEWA

NOVARTIS 0.5MG

N021560 002 Apr 20, 2010 Apr NEWA

+ 0.75MG

N021560 003 Apr 20, 2010 Apr NEWA

FAMCICLOVIR

TABLET; ORAL
FAMCICLOVIR

| | | | | | | | |
|-----|----|-------------|-------|-------------|--------------|-----|------|
| >A> | AB | WATSON LABS | 125MG | A078278 001 | Sep 14, 2010 | Aug | NEWA |
| >A> | AB | | 250MG | A078278 002 | Sep 14, 2010 | Aug | NEWA |
| >A> | AB | | 500MG | A078278 003 | Sep 14, 2010 | Aug | NEWA |

FAMOTIDINE

FOR SUSPENSION; ORAL
FAMOTIDINE

| | | | | | | |
|----|-------------|----------|-------------|--------------|-----|------|
| AB | LUPIN LTD | 40MG/5ML | A090440 001 | Jun 29, 2010 | Jun | NEWA |
| AB | NAVINTA LLC | 40MG/5ML | A091020 001 | May 27, 2010 | May | NEWA |

PEPCID

| | | | | | | |
|----|----------------|----------|-------------|--------------|-----|------|
| AB | + SALIX PHARMS | 40MG/5ML | N019527 001 | Feb 02, 1987 | May | CFTG |
|----|----------------|----------|-------------|--------------|-----|------|

INJECTABLE; INJECTION
FAMOTIDINE

| | | | | | | |
|----|-------------------|---------|-------------|--------------|-----|------|
| AP | + BAXTER HLTHCARE | 10MG/ML | A075799 001 | Apr 30, 2002 | Feb | CRLD |
| AP | + BAXTER HLTHCARE | 10MG/ML | A075488 001 | Apr 16, 2001 | Feb | CRLD |

FAMOTIDINE PRESERVATIVE FREE

| | | | | | | |
|----|-------------------|---------|-------------|--------------|-----|------|
| AP | + BAXTER HLTHCARE | 10MG/ML | A075789 001 | Apr 30, 2002 | Feb | CRLD |
| AP | + BAXTER HLTHCARE | 10MG/ML | A075486 001 | Apr 16, 2001 | Feb | CRLD |

CLARIS LIFESCIENCES 10MG/ML

| | | | | | | |
|----|---------------------|---------|-------------|--------------|-----|------|
| AP | CLARIS LIFESCIENCES | 10MG/ML | A076324 001 | Nov 27, 2002 | Jun | CAHN |
|----|---------------------|---------|-------------|--------------|-----|------|

FAMOTIDINE PRESERVATIVE FREE (PHARMACY BULK)

| | | | | | | |
|----|---------------------|---------|-------------|--------------|-----|------|
| AP | CLARIS LIFESCIENCES | 10MG/ML | A076322 001 | Nov 27, 2002 | Jun | CAHN |
|----|---------------------|---------|-------------|--------------|-----|------|

FAMOTIDINE PRESERVATIVE FREE IN PLASTIC CONTAINER

| | | | | | | |
|----|-------------------|----------|-------------|--------------|-----|------|
| AP | + BAXTER HLTHCARE | 0.4MG/ML | A075591 001 | May 10, 2001 | Feb | CRLD |
|----|-------------------|----------|-------------|--------------|-----|------|

TABLET, ORALLY DISINTEGRATING; ORAL
FLUXID

| | | | | | | |
|---|----------------|------|-------------|--------------|-----|------|
| @ | SCHWARZ PHARMA | 20MG | N021712 001 | Sep 24, 2004 | Jan | DISC |
| @ | | 40MG | N021712 002 | Sep 24, 2004 | Jan | DISC |

FENOFIBRATE

CAPSULE; ORAL
ANTARA (MICRONIZED)

| | | | | | |
|----------------|-------|-------------|--------------|-----|------|
| LUPIN ATLANTIS | 43MG | N021695 001 | Nov 30, 2004 | Jan | CAHN |
| @ | 87MG | N021695 002 | Nov 30, 2004 | Jan | CAHN |
| + | 130MG | N021695 003 | Nov 30, 2004 | Jan | CAHN |

TABLET; ORAL
FENOGLIDE

| | | | | | |
|-----------------|-------|-------------|--------------|-----|------|
| SHIONOGI PHARMA | 40MG | N022118 001 | Aug 10, 2007 | Jan | CAHN |
| + | 120MG | N022118 002 | Aug 10, 2007 | Jan | CAHN |

FENTANYL HYDROCHLORIDE

SYSTEM; IONTOPHORESIS, TRANSDERMAL
IONSYS

| | | | | | |
|------------------|---------|-------------|--------------|-----|------|
| @ INCLINE THERAP | 10.8MCG | N021338 001 | May 22, 2006 | Jul | CAHN |
|------------------|---------|-------------|--------------|-----|------|

FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
ALLEGRA D 24 HOUR

| | | | | | | |
|----|---------------------|-------------|-------------|--------------|-----|------|
| AB | + SANOFI AVENTIS US | 180MG;240MG | N021704 001 | Oct 19, 2004 | Mar | CFTG |
|----|---------------------|-------------|-------------|--------------|-----|------|

FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

| | | | | | | |
|----|--------------------|-------------|-------------|--------------|-----|------|
| AB | DR REDDYS LABS LTD | 180MG;240MG | A079043 001 | Mar 17, 2010 | Mar | NEWA |
|----|--------------------|-------------|-------------|--------------|-----|------|

FINASTERIDE

TABLET; ORAL

FINASTERIDE

| | | | | | | |
|----|---------------------|-----|-------------|--------------|-----|------|
| AB | ACCORD HLTHCARE INC | 5MG | A090121 001 | Feb 23, 2010 | Feb | NEWA |
| AB | HETERO DRUGS LTD | 5MG | A090061 001 | Jun 07, 2010 | May | NEWA |

FLAVOXATE HYDROCHLORIDE

TABLET; ORAL

FLAVOXATE HYDROCHLORIDE

| | | | | | | |
|----|-------------|-------|-------------|--------------|-----|------|
| AB | EPIC PHARMA | 100MG | A076835 001 | Nov 30, 2005 | May | CAHN |
| | URISPAS | | N016769 001 | | Jul | DISC |

@ ORTHO MCNEIL JANSSEN 100MG

FLUCONAZOLE

INJECTABLE; INJECTION

FLUCONAZOLE IN SODIUM CHLORIDE 0.9%

| | | | | | | |
|----|--|----------------------|-------------|--------------|-----|------|
| | BEDFORD | 100MG/50ML (2MG/ML) | A076087 002 | Sep 26, 2008 | Jan | CTNA |
| AP | CLARIS LIFESCIENCES | 200MG/100ML (2MG/ML) | A077947 001 | May 26, 2010 | May | NEWA |
| AP | | 400MG/200ML (2MG/ML) | A077947 002 | May 26, 2010 | May | NEWA |
| | FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER | | | | | |
| AP | CLARIS LIFESCIENCES | 200MG/100ML (2MG/ML) | A077909 001 | May 26, 2010 | May | NEWA |
| AP | | 400MG/200ML (2MG/ML) | A077909 002 | May 26, 2010 | May | NEWA |
| | @ HOSPIRA | 200MG/100ML (2MG/ML) | A076617 001 | Jul 29, 2004 | Feb | DISC |
| | @ | 400MG/200ML (2MG/ML) | A076617 002 | Jul 29, 2004 | Feb | DISC |
| | FULCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER | | | | | |
| AP | CLARIS LIFESCIENCES | 200MG/100ML (2MG/ML) | A077988 001 | May 26, 2010 | May | NEWA |
| AP | | 400MG/200ML (2MG/ML) | A077988 002 | May 26, 2010 | May | NEWA |

FLUDARABINE PHOSPHATE

INJECTABLE; INJECTION

FLUDARABINE PHOSPHATE

| | | | | | | | |
|----|---|--------|--------------------|-------------|--------------|-----|------|
| AP | + | SANDOZ | 50MG/2ML (25MG/ML) | N022137 001 | Sep 21, 2007 | Jul | CAHN |
|----|---|--------|--------------------|-------------|--------------|-----|------|

FLUDEOXYGLUCOSE F-18

INJECTABLE; INTRAVENOUS

FLUDEOXYGLUCOSE F18

| | | | | | | |
|---|-----------|--------------|-------------|--------------|-----|------|
| + | FEINSTEIN | 20-200mCi/ML | N021870 001 | Aug 19, 2005 | Jul | CRLD |
| + | | 20-300mCi/ML | N021870 002 | Nov 21, 2008 | Jul | CRLD |
| | | 20-300mCi/ML | N021870 002 | Nov 21, 2008 | May | NEWA |

FLUMAZENIL

INJECTABLE; INJECTION

FLUMAZENIL

| | | | | | | |
|----|---------------------|----------------------|-------------|--------------|-----|------|
| AP | CLARIS LIFESCIENCES | 0.5MG/5ML (0.1MG/ML) | A076755 002 | Oct 12, 2004 | Jun | CAHN |
| AP | | 1MG/10ML (0.1MG/ML) | A076755 001 | Oct 12, 2004 | Jun | CAHN |

FLUNISOLIDE

AEROSOL, METERED; INHALATION

AEROSPAH HFA

| | | | | | | |
|---|--------------|-------------------|-------------|--------------|-----|------|
| + | ACTON PHARMS | EQ 78MCG BASE/INH | N021247 001 | Jan 27, 2006 | Feb | CAHN |
|---|--------------|-------------------|-------------|--------------|-----|------|

SPRAY, METERED; NASAL

FLUNISOLIDE

| | | | | | | |
|---|------------|---------------|-------------|--------------|-----|------|
| + | APOTEX INC | 0.029MG/SPRAY | A077436 001 | Aug 09, 2007 | Jun | CRLD |
| | NASAREL | | N020409 001 | Mar 08, 1995 | Jun | DISC |

@ TEVA BRANDED PHARM 0.029MG/SPRAY

SPRAY, METERED; NASAL
NASAREL

AB + TEVA BRANDED PHARM 0.029MG/SPRAY N020409 001 Mar 08, 1995 Feb CAHN

FLUORESCEIN SODIUM

INJECTABLE; INTRAVENOUS

>D> AK-FLUOR 25%
>D> AKORN EQ 500MG BASE/2ML (EQ 250MG
BASE/ML) N022186 002 Aug 08, 2008 Aug DISC
>A> @ EQ 500MG BASE/2ML (EQ 250MG
BASE/ML) N022186 002 Aug 08, 2008 Aug DISC

FLUOROURACILCREAM; TOPICAL
FLUOROURACIL

AB TARO 5% A090368 001 Mar 05, 2010 Feb NEWA
INJECTABLE; INJECTION
FLUOROURACIL
AP + BIONICHE PHARMA 500MG/10ML (50MG/ML) A040743 002 Apr 26, 2007 Mar CAHN
AP + 1GM/20ML (50MG/ML) A040743 001 Apr 26, 2007 Mar CAHN
AP + 2.5GM/50ML (50MG/ML) A040798 002 Apr 26, 2007 Mar CAHN
AP + 5GM/100ML (50MG/ML) A040798 001 Apr 26, 2007 Mar CAHN

FLUOXETINE HYDROCHLORIDECAPSULE, DELAYED REL PELLETS; ORAL
FLUOXETINE HYDROCHLORIDE

AB BARR EQ 90MG BASE A076237 001 Mar 24, 2010 Mar NEWA
AB DR REDDYS LABS LTD EQ 90MG BASE A078572 001 Mar 22, 2010 Mar NEWA
PROZAC WEEKLY
AB + LILLY EQ 90MG BASE N021235 001 Feb 26, 2001 Mar CFTG
SOLUTION; ORAL
FLUOXETINE HYDROCHLORIDE
AA LANNETT EQ 20MG BASE/5ML A076458 001 May 14, 2004 Feb CAHN

FLUPHENAZINE DECANOATEINJECTABLE; INJECTION
FLUPHENAZINE DECANOATE

AO CLARIS LIFESCIENCES 25MG/ML A075918 001 Aug 17, 2001 Jun CAHN

FLUVOXAMINE MALEATETABLET; ORAL
LUVOX

AB ANI PHARMS 25MG N021519 001 Dec 20, 2007 Jun CAHN
AB 50MG N021519 002 Dec 20, 2007 Jun CAHN
AB 100MG N021519 003 Dec 20, 2007 Jun CAHN

FOLIC ACIDTABLET; ORAL
FOLIC ACID

AA + PHARMAX 1MG A040625 001 Jul 21, 2005 Jan CRLD
AA VINTAGE 1MG A040756 001 Jun 04, 2010 May NEWA
AA + WATSON LABS 1MG A080680 001 Jan CMFD

FOMEPIZOLE

INJECTABLE; INJECTION

FOMEPIZOLE

AP BIONICHE PHARMA USA 1.5GM/1.5ML (1GM/ML)

A079033 001 Apr 07, 2009 Mar CAHN

FORMOTEROL FUMARATE

SOLUTION; INHALATION

PERFOROMIST

+ DEY PHARMA 0.02MG/2ML

N022007 001 May 11, 2007 Apr CAHN

FORMOTEROL FUMARATE; MOMETASONE FUROATE

AEROSOL, METERED; INHALATION

DULEREA

+ SCHERING 0.005MG/INH;0.1MG/INH
+ 0.005MG/INH;0.2MG/INHN022518 001 Jun 22, 2010 Jun NEWA
N022518 002 Jun 22, 2010 Jun NEWAFOSCARNET SODIUM

INJECTABLE; INJECTION

FOSCAVIR

AP + CLINIGEN HLTHCARE 2.4GM/100ML

N020068 001 Sep 27, 1991 Jun CAHN

FOSINOPRIL SODIUM

TABLET; ORAL

FOSINOPRIL SODIUM

AB WATSON LABS 10MG
AB 20MG
AB 40MGA077531 001 Aug 31, 2006 Jun CAHN
A077531 002 Aug 31, 2006 Jun CAHN
A077531 003 Aug 31, 2006 Jun CAHNFOSPHENYTOIN SODIUM

INJECTABLE; INJECTION

FOSPHENYTOIN SODIUM

AP LUITPOLD EQ 50MG PHENYTOIN NA/ML
AP PHARMAFORCE EQ 50MG PHENYTOIN NA/ML
AP STRIDES ARCOLAB EQ 50MG PHENYTOIN NA/ML
AP SUN PHARMA GLOBAL EQ 50MG PHENYTOIN NA/MLA090099 001 May 13, 2010 May NEWA
A078277 001 Aug 06, 2007 Feb CAHN
A078736 001 Jun 08, 2010 May NEWA
A078417 001 Mar 18, 2008 Jun CAHNGABAPENTIN

CAPSULE; ORAL

GABAPENTIN

@ SANDOZ 100MG
@ 300MG
@ 400MGA075539 001 Apr 06, 2005 May DISC
A075539 002 Apr 06, 2005 May DISC
A075539 003 Apr 06, 2005 May DISC

TABLET; ORAL

GABAPENTIN

AB MATRIX LABS LTD 600MG
AB 800MG
@ SANDOZ 600MG
@ 800MGA090335 001 Jun 01, 2010 May NEWA
A090335 002 Jun 01, 2010 May NEWA
A076877 001 Jul 06, 2006 May DISC
A076877 002 Jul 06, 2006 May DISCGADOVERSETAMIDE

INJECTABLE; INJECTION

OPTIMARK IN PLASTIC CONTAINER

+ MALLINCKRODT 9927MG/30ML (330.9MG/ML)

N020976 001 Dec 08, 1999 Mar CPOT

GANCICLOVIR

GEL; OPHTHALMIC
ZIRGAN
+ BAUSCH AND LOMB 0.15% N022211 001 Sep 15, 2009 Jun CAHN

GANCICLOVIR SODIUM

INJECTABLE; INJECTION
CYTOVENE
AP + ROCHE PALO EQ 500MG BASE/VIAL N019661 001 Jun 23, 1989 Jun CFTG
+ EQ 500MG BASE/VIAL N019661 001 Jun 23, 1989 Mar CMFD
GANCICLOVIR
AP APP PHARMS EQ 500MG BASE/VIAL A090658 001 Jun 21, 2010 Jun NEWA
GANCICLOVIR SODIUM
@ BEDFORD EQ 500MG BASE/VIAL A076222 001 Jul 16, 2003 Mar DISC

GATIFLOXACIN

SOLUTION/DROPS; OPHTHALMIC
ZYMAXID
+ ALLERGAN 0.5% N022548 001 May 18, 2010 May NEWA

GEMCITABINE HYDROCHLORIDE

INJECTABLE; INJECTION
GEMZAR
>D> AP + LILLY EQ 200MG BASE/VIAL N020509 001 May 15, 1996 Aug CTEC
>A> + EQ 200MG BASE/VIAL N020509 001 May 15, 1996 Aug CTEC
>D> AP + EQ 1GM BASE/VIAL N020509 002 May 15, 1996 Aug CTEC
>A> + EQ 1GM BASE/VIAL N020509 002 May 15, 1996 Aug CTEC

GEMFIBROZIL

TABLET; ORAL
GEMFIBROZIL
AB DAVA PHARMS INC 600MG A074270 001 Sep 27, 1993 Mar CMFD
>A> AB HIKMA PHARMS 600MG A078599 001 Aug 16, 2010 Aug NEWA

GEMIFLOXACIN MESYLATE

TABLET; ORAL
FACTIVE
+ CORNERSTONE THERAP EQ 320MG BASE N021158 001 Apr 04, 2003 May CAHN

GLIMEPIRIDE

TABLET; ORAL
GLIMEPIRIDE
AB WATSON LABS 1MG A077280 001 Feb 03, 2006 Jun CAHN
AB 2MG A077280 002 Feb 03, 2006 Jun CAHN
AB 4MG A077280 003 Feb 03, 2006 Jun CAHN
AB WATSON LABS FLORIDA 1MG A076995 001 Apr 27, 2010 Apr NEWA
AB 2MG A076995 002 Apr 27, 2010 Apr NEWA
AB 4MG A076995 003 Apr 27, 2010 Apr NEWA

GLIPIZIDE; METFORMIN HYDROCHLORIDE

TABLET; ORAL
GLIPIZIDE AND METFORMIN HYDROCHLORIDE
AB INDICUS PHARMA 2.5MG;250MG A078728 001 Jun 23, 2010 Jun NEWA
AB 2.5MG;500MG A078728 002 Jun 23, 2010 Jun NEWA
AB 5MG;500MG A078728 003 Jun 23, 2010 Jun NEWA

GLYBURIDE; METFORMIN HYDROCHLORIDE

TABLET; ORAL

GLYBURIDE AND METFORMIN HYDROCHLORIDE

| | | | | | |
|--------|--------------|-------------|--------------|-----|------|
| @ TEVA | 1.25MG;250MG | A076821 001 | Jan 27, 2005 | Jan | DISC |
| @ | 2.5MG;500MG | A076821 002 | Jan 27, 2005 | Jan | DISC |
| @ | 5MG;500MG | A076821 003 | Jan 27, 2005 | Jan | DISC |

GLYCOPYRROLATE

SOLUTION; ORAL

CUVPOSA

+ SHIONOGI PHARMA 1MG/5ML

N022571 001 Jul 28, 2010 Jul NEWA

TABLET; ORAL

ROBINUL

AA + SHIONOGI PHARMA 1MG

N012827 001 Jan CAHN

ROBINUL FORTE

AA + SHIONOGI PHARMA 2MG

N012827 002 Jan CAHN

GRANISETRON HYDROCHLORIDE

INJECTABLE; INJECTION

GRANISETRON HYDROCHLORIDE

| | | | | | |
|------------------------|--|-------------|--------------|-----|------|
| AP CLARIS LIFESCIENCES | EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML) | A078197 001 | Dec 31, 2007 | Jun | CAHN |
| AP | EQ 1MG BASE/ML (EQ 1MG BASE/ML) | A078198 001 | Jun 30, 2008 | Jun | CAHN |
| AP | EQ 4MG BASE/4ML (EQ 1MG BASE/ML) | A078198 002 | Jun 30, 2008 | Jun | CAHN |
| AP SAGENT STRIDES | EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML) | A091136 001 | Apr 09, 2010 | Mar | NEWA |
| AP | EQ 1MG BASE/ML (EQ 1MG BASE/ML) | A091136 002 | Apr 09, 2010 | Mar | NEWA |
| AP | EQ 4MG BASE/4ML (EQ 1MG BASE/ML) | A091137 002 | Apr 09, 2010 | Mar | NEWA |

TABLET; ORAL

GRANISETRON HYDROCHLORIDE

@ BARR EQ 1MG BASE

A078221 001 Dec 31, 2007 May DISC

AB TARO EQ 1MG BASE

A090817 001 May 28, 2010 May NEWA

GRISEOFULVIN, MICROCRYSTALLINE

TABLET; ORAL

FULVICIN-U/F

@ ELORAC 250MG

A060569 002 Feb CAHN

@ 500MG

A060569 001 Feb CAHN

GUANFACINE HYDROCHLORIDE

TABLET; ORAL

GUANFACINE HYDROCHLORIDE

| | | | | | |
|---------------------|-------------|-------------|--------------|-----|------|
| >A> AB EPIC PHARMA | EQ 1MG BASE | A074673 001 | Feb 28, 1997 | Aug | CAHN |
| >A> AB | EQ 2MG BASE | A074673 002 | Feb 28, 1997 | Aug | CAHN |
| >D> AB MIKAH PHARMA | EQ 1MG BASE | A074673 001 | Feb 28, 1997 | Aug | CAHN |
| AB | EQ 1MG BASE | A074673 001 | Feb 28, 1997 | Feb | CAHN |
| >D> AB | EQ 2MG BASE | A074673 002 | Feb 28, 1997 | Aug | CAHN |
| AB | EQ 2MG BASE | A074673 002 | Feb 28, 1997 | Feb | CAHN |

HALCINONIDE

SOLUTION; TOPICAL

HALOG

@ RANBAXY 0.1%

N017823 001 May DISC

HALOPERIDOL DECANOATE

INJECTABLE; INJECTION

HALOPERIDOL DECANOATE

| | | | | | | |
|----|---------------------|------------------|-------------|--------------|-----|------|
| AO | CLARIS LIFESCIENCES | EQ 50MG BASE/ML | A075440 001 | Feb 28, 2000 | Jun | CAHN |
| AO | | EQ 100MG BASE/ML | A075440 002 | Feb 28, 2000 | Jun | CAHN |

HALOPERIDOL LACTATE

INJECTABLE; INJECTION

HALDOL

| | | | | | | |
|--------|------------------------|-----------------|-------------|--------------|------|------|
| >D> | @ ORTHO MCNEIL JANSSEN | EQ 5MG BASE/ML | N015923 001 | Aug | CMFD | |
| >A> AP | + | EQ 5MG BASE/ML | N015923 001 | Aug | CMFD | |
| | @ | EQ 5MG BASE/ML | N015923 001 | Feb | DISC | |
| | HALOPERIDOL | | | | | |
| AP | CLARIS LIFESCIENCES | EQ 5MG BASE/ML | A076791 001 | Aug 25, 2004 | Jun | CAHN |
| AP | | EQ 5MG BASE/ML | A076828 001 | Aug 25, 2004 | Jun | CAHN |
| >D> AP | + | TEVA PARENTERAL | A076035 001 | Aug 29, 2001 | Aug | CRLD |
| >A> AP | | EQ 5MG BASE/ML | A076035 001 | Aug 29, 2001 | Aug | CRLD |
| AP | + | EQ 5MG BASE/ML | A076035 001 | Aug 29, 2001 | Feb | CRLD |

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM

| | | | | | | |
|----|----------------------------------|-----------------|-------------|--------------|-----|------|
| AP | SAGENT PHARMS | 1,000 UNITS/ML | A090808 001 | Jun 30, 2010 | Jun | NEWA |
| AP | | 5,000 UNITS/ML | A090808 002 | Jun 30, 2010 | Jun | NEWA |
| AP | | 10,000 UNITS/ML | A090808 003 | Jun 30, 2010 | Jun | NEWA |
| AP | | 20,000 UNITS/ML | A090809 001 | Jun 30, 2010 | Jun | NEWA |
| | HEPARIN SODIUM PRESERVATIVE FREE | | | | | |
| | @ HOSPIRA | 2,000 UNITS/ML | N005264 013 | Apr 07, 1986 | May | DISC |
| | @ | 2,500 UNITS/ML | N005264 014 | Apr 07, 1986 | May | DISC |
| AP | SAGENT PHARMS | 1,000 UNITS/ML | A090810 001 | Jun 30, 2010 | Jun | NEWA |

HEXAMINOLEVULINATE HYDROCHLORIDE

FOR SOLUTION; INTRAVESICAL

CYSVIEW KIT

+ PHOTOCURE ASA 100MG/VIAL

N022555 001 May 28, 2010 May NEWA

HYDRALAZINE HYDROCHLORIDE

TABLET; ORAL

HYDRALAZINE HYDROCHLORIDE

| | | | | | | |
|----|---------------------|-------|-------------|--------------|-----|------|
| AA | HERITAGE PHARMS INC | 10MG | A086242 001 | Feb 04, 2010 | Jan | NEWA |
| AA | | 100MG | A086242 004 | Feb 04, 2010 | Jan | NEWA |
| AA | ZYDUS PHARMS USA | 10MG | A040858 001 | Feb 26, 2010 | Feb | NEWA |
| AA | | 25MG | A040858 002 | Feb 26, 2010 | Feb | NEWA |
| AA | | 50MG | A040858 003 | Feb 26, 2010 | Feb | NEWA |
| AA | | 100MG | A040858 004 | Feb 26, 2010 | Feb | NEWA |

HYDROCHLOROTHIAZIDE

CAPSULE; ORAL

HYDROCHLOROTHIAZIDE

| | | | | | | |
|--------|---------------------|--------|-------------|--------------|-----|------|
| AB | UNICHEM | 12.5MG | A090510 001 | Jan 19, 2010 | Jan | NEWA |
| | TABLET; ORAL | | | | | |
| | HYDROCHLOROTHIAZIDE | | | | | |
| >D> AB | SANDOZ | 50MG | A085219 001 | | Aug | DISC |
| >A> | @ | 50MG | A085219 001 | | Aug | DISC |

HYDROCHLOROTHIAZIDE; LISINOPRIL

TABLET; ORAL

LISINOPRIL AND HYDROCHLOROTHIAZIDE

| | | | | | | | |
|-----|----|-------------------|-------------|-------------|--------------|-----|------|
| >D> | AB | ACTAVIS ELIZABETH | 12.5MG;10MG | A076230 001 | Jul 01, 2002 | Aug | CAHN |
| >D> | AB | | 12.5MG;20MG | A076230 002 | Jul 01, 2002 | Aug | CAHN |
| >D> | AB | | 25MG;20MG | A076230 003 | Jul 01, 2002 | Aug | CAHN |
| >A> | AB | HUAHAI US INC | 12.5MG;10MG | A076230 001 | Jul 01, 2002 | Aug | CAHN |
| >A> | AB | | 12.5MG;20MG | A076230 002 | Jul 01, 2002 | Aug | CAHN |
| >A> | AB | | 25MG;20MG | A076230 003 | Jul 01, 2002 | Aug | CAHN |
| | @ | TEVA | 12.5MG;10MG | A075869 001 | Jul 01, 2002 | Jan | DISC |
| | @ | | 12.5MG;20MG | A075869 002 | Jul 01, 2002 | Jan | DISC |
| | @ | | 25MG;20MG | A075869 003 | Jul 01, 2002 | Jan | DISC |

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

TABLET; ORAL

HYZAAR

| | | | | | | | |
|--|-------|----------------|--------------|--------------|--------------|------|------|
| AB | MERCK | 12.5MG;50MG | N020387 001 | Apr 28, 1995 | Mar | CFTG | |
| AB | | 12.5MG;100MG | N020387 003 | Oct 20, 2005 | Mar | CFTG | |
| AB | + | 25MG;100MG | N020387 002 | Nov 10, 1998 | Mar | CFTG | |
| LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE | | | | | | | |
| >A> | AB | APOTEX | 12.5MG;100MG | A090150 002 | Aug 11, 2010 | Aug | NEWA |
| | AB | LUPIN LTD | 12.5MG;100MG | A078245 002 | May 21, 2010 | May | NEWA |
| | AB | MYLAN | 12.5MG;100MG | A091652 002 | Apr 06, 2010 | Mar | NEWA |
| | AB | ROXANE | 12.5MG;100MG | A077732 001 | Apr 06, 2010 | Mar | NEWA |
| >A> | AB | SANDOZ | 12.5MG;100MG | A077948 003 | Aug 19, 2010 | Aug | NEWA |
| | AB | TEVA PHARMS | 12.5MG;50MG | A077157 001 | Apr 06, 2010 | Mar | NEWA |
| | AB | | 12.5MG;100MG | A077157 002 | Apr 06, 2010 | Mar | NEWA |
| | AB | | 25MG;100MG | A077157 003 | Apr 06, 2010 | Mar | NEWA |
| | AB | TORRENT PHARMS | 12.5MG;100MG | A090528 003 | Apr 06, 2010 | Mar | NEWA |

HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE

TABLET; ORAL

METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE

| | | | | | | |
|----|-------|------------|-------------|--------------|-----|------|
| AB | MYLAN | 25MG;100MG | A076792 002 | Aug 20, 2004 | Apr | CRLD |
| AB | + | 25MG;100MG | A076792 002 | Aug 20, 2004 | Jan | CRLD |
| | | 50MG;100MG | A076792 003 | Aug 20, 2004 | Jan | CTEC |

HYDROCHLOROTHIAZIDE; MOEXIPRIL HYDROCHLORIDE

TABLET; ORAL

MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

| | | | | | | |
|----|-----------------|--------------|-------------|--------------|-----|------|
| AB | GLENMARK PHARMS | 12.5MG;7.5MG | A090718 001 | Mar 17, 2010 | Mar | NEWA |
| AB | | 12.5MG;15MG | A090718 002 | Mar 17, 2010 | Mar | NEWA |
| AB | | 25MG;15MG | A090718 003 | Mar 17, 2010 | Mar | NEWA |

HYDROCHLOROTHIAZIDE; TRIAMTERENE

CAPSULE; ORAL

DYAZIDE

| | | | | | | | |
|----|---|---------------------|-------------|-------------|--------------|-----|------|
| AB | + | GLAXOSMITHKLINE LLC | 25MG;37.5MG | N016042 003 | Mar 03, 1994 | Jun | CAHN |
| | @ | | 25MG;50MG | N016042 002 | | Jun | CAHN |

HYDROCODONE BITARTRATE; IBUPROFEN

TABLET; ORAL

HYDROCODONE BITARTRATE AND IBUPROFEN

| | | | | | | |
|----|---------------------|-----------|-------------|--------------|-----|------|
| AB | WATSON LABS FLORIDA | 5MG;200MG | A077454 001 | Jun 23, 2010 | Jun | NEWA |
|----|---------------------|-----------|-------------|--------------|-----|------|

HYDROCORTISONE

CREAM; TOPICAL
HYDROCORTISONE

| | | | | | | | | |
|---------------------|----|---------|-------------|--------------|--------------|--------------|------|------|
| AT | + | FOUGERA | 1% | A080693 003 | Feb | CRLD | | |
| AT | + | | 2.5% | A089414 001 | Dec 16, 1986 | Feb | CRLD | |
| >A> | AT | LYNE | 2.5% | A040879 001 | Aug 20, 2010 | Aug | NEWA | |
| HYTONE | | | | | | | | |
| @ SANOFI AVENTIS US | | | | 1% | A080472 003 | Feb | DISC | |
| @ | | | | 2.5% | A080472 004 | Feb | DISC | |
| LOTION; TOPICAL | | | | | | | | |
| HYDROCORTISONE | | | | | | | | |
| AT | + | ALTANA | 2.5% | A040351 001 | Jul 25, 2000 | Jun | CRLD | |
| HYTONE | | | | | | | | |
| @ SANOFI AVENTIS US | | | | 1% | A080473 003 | Feb | DISC | |
| @ | | | | 2.5% | A080473 004 | Nov 30, 1982 | Feb | DISC |
| OINTMENT; TOPICAL | | | | | | | | |
| HYDROCORTISONE | | | | | | | | |
| AT | + | ALTANA | 1% | A080692 001 | | Jun | CRLD | |
| AT | + | FOUGERA | 2.5% | A081203 001 | May 28, 1993 | Jun | CRLD | |
| SOLUTION; TOPICAL | | | | | | | | |
| TEXACORT | | | | | | | | |
| + JSJ PHARMS | | 2.5% | A081271 001 | Apr 17, 1992 | Jul | CMFD | | |

HYDROMORPHONE HYDROCHLORIDE

INJECTABLE; INJECTION
HYDROMORPHONE HYDROCHLORIDE

| | | | | | | | | |
|--------------------------------|-------|---------|-------------|--------------|-------------|--------------|-----|------|
| AP | AKORN | 10MG/ML | A078228 001 | Apr 14, 2010 | Apr | NEWA | | |
| AP | | 10MG/ML | A078228 001 | Apr 14, 2010 | Mar | NEWA | | |
| AP | | 10MG/ML | A078261 001 | Apr 14, 2010 | Mar | NEWA | | |
| TABLET, EXTENDED RELEASE; ORAL | | | | | | | | |
| EXALGO | | | | | | | | |
| MALLINCKRODT INC | | | | 8MG | N021217 001 | Mar 01, 2010 | Mar | NEWA |
| | | | | 12MG | N021217 002 | Mar 01, 2010 | Mar | NEWA |
| + | | 16MG | N021217 003 | Mar 01, 2010 | Mar | NEWA | | |

HYDROXYZINE HYDROCHLORIDE

TABLET; ORAL
HYDROXYZINE HYDROCHLORIDE

| | | | | | | |
|----|---------------------|------|-------------|--------------|-----|------|
| AB | HERITAGE PHARMS INC | 10MG | A040804 001 | Jun 30, 2008 | May | CAHN |
| AB | | 25MG | A040804 002 | Jun 30, 2008 | May | CAHN |
| AB | | 50MG | A040804 003 | Jun 30, 2008 | May | CAHN |
| AB | MYLAN | 10MG | A091176 001 | Jun 07, 2010 | May | NEWA |
| AB | | 25MG | A091176 002 | Jun 07, 2010 | May | NEWA |
| AB | | 50MG | A091176 003 | Jun 07, 2010 | May | NEWA |

HYDROXYZINE PAMOATE

CAPSULE; ORAL
HYDROXYZINE PAMOATE

| | | | | | |
|------------------------|-------------|-------------|--------------|-----|------|
| @ IVAX SUB TEVA PHARMS | EQ 25MG HCL | A087761 001 | Mar 05, 1982 | Apr | DISC |
| @ | EQ 50MG HCL | A087760 001 | Mar 05, 1982 | Apr | DISC |

IBUPROFEN

TABLET; ORAL
IBUPROFEN

| | | | | | | |
|----|--------------------|-------|-------------|--------------|-----|------|
| AB | CONTRACT PHARMACAL | 400MG | A071267 001 | Oct 15, 1986 | Jan | CAHN |
|----|--------------------|-------|-------------|--------------|-----|------|

TABLET; ORAL

IBUPROFEN

| | | | |
|----|--------------------|-------|-----------------------------------|
| AB | CONTRACT PHARMACAL | 600MG | A071268 001 Oct 15, 1986 Jan CAHN |
| AB | | 800MG | A072300 001 Jul 01, 1988 Jan CAHN |

IBUTILIDE FUMARATE

INJECTABLE; INJECTION

IBUTILIDE FUMARATE

| | | | |
|----|---------------------|----------|-----------------------------------|
| AP | BIONICHE PHARMA USA | 0.1MG/ML | A090924 001 Jan 11, 2010 Mar CAHN |
|----|---------------------|----------|-----------------------------------|

IFOSFAMIDE

INJECTABLE; INJECTION

IFEX

| | | | |
|----|-------------------|--------------------|-----------------------------------|
| AP | BAXTER HLTHCARE | 1GM/VIAL | N019763 001 Dec 30, 1988 Feb CMFD |
| AP | | 3GM/VIAL | N019763 002 Dec 30, 1988 Feb CMFD |
| | IFOSFAMIDE | | |
| AP | + APP PHARMS | 1GM/VIAL | A076078 001 May 28, 2002 Feb CTEC |
| AP | + APP PHARMS | 1GM/VIAL | A076078 001 May 28, 2002 Feb CTEC |
| | + APP PHARMS | 1GM/VIAL | A076078 001 May 28, 2002 Jan CTEC |
| AP | | 1GM/20ML (50MG/ML) | A090181 001 Sep 22, 2009 Jan CPOT |
| | + APP PHARMS | 1GM/VIAL | A076078 001 May 28, 2002 Jan CTEC |
| AP | + APP PHARMS | 3GM/VIAL | A076078 002 May 28, 2002 Feb CTEC |
| AP | + APP PHARMS | 3GM/VIAL | A076078 002 May 28, 2002 Feb CTEC |
| AP | | 3GM/60ML (50MG/ML) | A090181 002 Sep 22, 2009 Jan CPOT |
| | + APP PHARMS | 3GM/VIAL | A076078 002 May 28, 2002 Jan CTEC |
| AP | + TEVA PARENTERAL | 1GM/20ML (50MG/ML) | A076657 001 Apr 04, 2007 Jan CTEC |
| AP | + TEVA PARENTERAL | 3GM/60ML (50MG/ML) | A076657 002 Apr 04, 2007 Jan CTEC |

IFOSFAMIDE; MESNA

INJECTABLE; INJECTION

IFEX/MESNEX KIT

| | | |
|-------------------|-------------------|-----------------------------------|
| @ BAXTER HLTHCARE | 1GM/VIAL;100MG/ML | N019763 003 Oct 10, 1992 Feb DISC |
| @ BAXTER HLTHCARE | 3GM/VIAL;100MG/ML | N019763 004 Oct 10, 1992 Feb DISC |

IMIPRAMINE HYDROCHLORIDE

TABLET; ORAL

IMIPRAMINE HYDROCHLORIDE

| | | | |
|----|-----------|------|-----------------------------------|
| AB | LUPIN LTD | 10MG | A090443 001 Mar 11, 2010 Feb NEWA |
| AB | | 25MG | A090442 001 Mar 11, 2010 Feb NEWA |
| AB | | 50MG | A090441 001 Mar 11, 2010 Feb NEWA |

IMIPRAMINE PAMOATE

CAPSULE; ORAL

IMIPRAMINE PAMOATE

| | | | |
|----|-----------------|--------------|-----------------------------------|
| AB | LUPIN LTD | EQ 75MG HCL | A090444 001 Apr 16, 2010 Apr NEWA |
| AB | | EQ 100MG HCL | A090444 002 Apr 16, 2010 Apr NEWA |
| AB | | EQ 125MG HCL | A090444 003 Apr 16, 2010 Apr NEWA |
| AB | | EQ 150MG HCL | A090444 004 Apr 16, 2010 Apr NEWA |
| AB | ROXANE | EQ 75MG HCL | A091099 001 Apr 16, 2010 Apr NEWA |
| AB | | EQ 100MG HCL | A091099 002 Apr 16, 2010 Apr NEWA |
| AB | | EQ 125MG HCL | A091099 003 Apr 16, 2010 Apr NEWA |
| AB | | EQ 150MG HCL | A091099 004 Apr 16, 2010 Apr NEWA |
| | TOFRANIL-PM | | |
| AB | + TYCO HLTHCARE | EQ 75MG HCL | N017090 001 Apr CFTG |
| AB | | EQ 100MG HCL | N017090 004 Apr CFTG |

CAPSULE; ORALTOFRANIL-PM

| | | | | | |
|----|---------------|--------------|-------------|-----|------|
| AB | TYCO HLTHCARE | EQ 125MG HCL | N017090 003 | Apr | CFTG |
| AB | | EQ 150MG HCL | N017090 002 | Apr | CFTG |

IMIQUIMODCREAM; TOPICALALDARA

| | | | | | | |
|-----|-------------------|-------|-------------|--------------|-----|------|
| AB | + GRACEWAY | 5% | N020723 001 | Feb 27, 1997 | Feb | CFTG |
| AB | IMIQUIMOD | | A078548 001 | Feb 25, 2010 | Feb | NEWA |
| AB | NYCOMED US | 5% | A078837 001 | Sep 07, 2010 | Aug | NEWA |
| >A> | AB PERRIGO ISRAEL | 5% | | | | |
| | ZYCLARA | | | | | |
| | + GRACEWAY | 3.75% | N022483 001 | Mar 25, 2010 | Mar | NEWA |

INAMRINONE LACTATEINJECTABLE; INJECTIONAMRINONE LACTATE

| | | | | | |
|------------------------|----------------|-------------|--------------|-----|------|
| @ BAXTER HLTHCARE CORP | EQ 5MG BASE/ML | A075542 001 | May 10, 2000 | Feb | DISC |
| + BEDFORD | EQ 5MG BASE/ML | A075513 001 | May 09, 2000 | Feb | CTEC |

INDOMETHACININJECTABLE; INJECTIONINDOMETHACIN

| | | | | | |
|--------------|------------------|-------------|--------------|-----|------|
| + APP PHARMS | EQ 1MG BASE/VIAL | N022536 001 | Mar 17, 2010 | Mar | NEWA |
|--------------|------------------|-------------|--------------|-----|------|

INSULIN LISPRO PROTAMINE RECOMBINANT; INSULIN LISPRO RECOMBINANTINJECTABLE; INJECTIONHUMALOG MIX 50/50 PEN

| | | | | | |
|-----------------------|-------------------------|-------------|--------------|-----|------|
| + LILLY | 50 UNITS/ML;50 UNITS/ML | N021018 003 | Dec 22, 1999 | Jul | NEWA |
| HUMALOG MIX 75/25 PEN | | | | | |
| + LILLY | 75 UNITS/ML;25 UNITS/ML | N021017 003 | Dec 22, 1999 | Jul | NEWA |

IOPAMIDOLINJECTABLE; INJECTIONSCANLUX-300

| | | | | | | |
|----|---------------------|-----|-------------|--------------|-----|------|
| AP | SANOCHEMIA CORP USA | 61% | A090394 001 | Jun 18, 2010 | Jun | NEWA |
| | SCANLUX-370 | | | | | |
| AP | SANOCHEMIA CORP USA | 76% | A090394 002 | Jun 18, 2010 | Jun | NEWA |

IOVERSOLINJECTABLE; INJECTIONOPTIRAY 160

| | | | | | |
|----------------|-----|-------------|--------------|-----|------|
| @ MALLINCKRODT | 34% | N019710 003 | Dec 30, 1988 | May | DISC |
|----------------|-----|-------------|--------------|-----|------|

IRINOTECAN HYDROCHLORIDEINJECTABLE; INJECTIONCAMPTOSAR

| | | | | | | |
|-----|--------------------------|----------------------|-------------|--------------|-----|------|
| >A> | + PFIZER INC | 300MG/15ML (20MG/ML) | N020571 003 | Aug 05, 2010 | Aug | NEWA |
| | IRINOTECAN HYDROCHLORIDE | | | | | |
| AP | DR REDDYS LABS LTD | 40MG/2ML (20MG/ML) | A078953 001 | Apr 15, 2010 | Apr | NEWA |
| AP | | 100MG/5ML (20MG/ML) | A078953 002 | Apr 15, 2010 | Apr | NEWA |
| | @ SANDOZ | 40MG/2ML (20MG/ML) | A077994 001 | Feb 27, 2008 | Mar | DISC |
| | @ | 100MG/5ML (20MG/ML) | A077994 002 | Feb 27, 2008 | Mar | DISC |

ISOSORBIDE DINITRATE

TABLET, EXTENDED RELEASE; ORAL
ISOSORBIDE DINITRATE

| | | | | |
|----|---|--------|------|-----------------------------------|
| AB | + | CARACO | 40MG | A040009 001 Dec 30, 1998 Mar CAHN |
|----|---|--------|------|-----------------------------------|

ISOSORBIDE MONONITRATE

TABLET; ORAL

| | | | | |
|--------------------------------|----|----------------|-------|-----------------------------------|
| >D> | | ISMO | | |
| >D> | AB | PROMIUS PHARMA | 20MG | N019091 001 Dec 30, 1991 Aug DISC |
| >A> | | @ | 20MG | N019091 001 Dec 30, 1991 Aug DISC |
| TABLET, EXTENDED RELEASE; ORAL | | | | |
| ISOSORBIDE MONONITRATE | | | | |
| AB | | VINTAGE PHARMS | 30MG | A090598 001 Aug 11, 2010 Jul NEWA |
| AB | | | 60MG | A090598 002 Aug 11, 2010 Jul NEWA |
| AB | | | 120MG | A090598 003 Aug 11, 2010 Jul NEWA |

ISOSULFAN BLUE

INJECTABLE; INJECTION

ISOSULFAN BLUE

| | | | | |
|-------------|---|----------|----|-----------------------------------|
| AP | | SYNERX | 1% | A090874 001 Jul 20, 2010 Jul NEWA |
| LYMPHAZURIN | | | | |
| AP | + | COVIDIEN | 1% | N018310 001 Jul CFTG |
| | + | | 1% | N018310 001 Jun CAHN |

ISOTRETINOIN

CAPSULE; ORAL

AMNESTEEM

| | | | | |
|-----|----|----------|------|-----------------------------------|
| >D> | AB | GENPHARM | 10MG | A075945 001 Nov 08, 2002 Aug CAHN |
| >D> | AB | + | 20MG | A075945 002 Nov 08, 2002 Aug CAHN |
| >D> | AB | + | 40MG | A075945 003 Nov 08, 2002 Aug CAHN |
| >A> | AB | MYLAN | 10MG | A075945 001 Nov 08, 2002 Aug CAHN |
| >A> | AB | + | 20MG | A075945 002 Nov 08, 2002 Aug CAHN |
| >A> | AB | + | 40MG | A075945 003 Nov 08, 2002 Aug CAHN |

ISRADIPINE

CAPSULE; ORAL

ISRADIPINE

| | | | | |
|--------------------------------|---|-------------|-------|-----------------------------------|
| AB | | WATSON LABS | 2.5MG | A077317 001 Jan 05, 2006 Jun CAHN |
| AB | + | | 5MG | A077317 002 Jan 05, 2006 Jun CAHN |
| TABLET, EXTENDED RELEASE; ORAL | | | | |
| DYNACIRC CR | | | | |
| GLAXOSMITHKLINE LLC 5MG | | | | |
| | + | | 10MG | N020336 001 Jun 01, 1994 Jun CAHN |
| | + | | | N020336 002 Jun 01, 1994 Jun CAHN |

ITRACONAZOLE

TABLET; ORAL

ITRACONAZOLE

| | | | |
|---|------------------|-------|-----------------------------------|
| + | STIEFEL LABS INC | 200MG | N022484 001 Apr 29, 2010 Apr NEWA |
|---|------------------|-------|-----------------------------------|

KETOROLAC TROMETHAMINE

INJECTABLE; INJECTION

KETOROLAC TROMETHAMINE

| | | | | |
|----|--|---------------------|---------|-----------------------------------|
| AP | | CLARIS LIFESCIENCES | 15MG/ML | A075631 002 Jun 29, 2001 Jun CAHN |
| AP | | | 30MG/ML | A075631 001 Jun 29, 2001 Jun CAHN |

SPRAY, METERED; NASAL

SPRIX

+ ROXRO PHARMA INC 15.75MG/SPRAY

N022382 001 May 14, 2010 May NEWA

LABETALOL HYDROCHLORIDE

INJECTABLE; INJECTION

LABETALOL HYDROCHLORIDE

AP CLARIS LIFESCIENCES 5MG/ML

A076051 001 Jul 05, 2002 Jun CAHN

LABETALOL HYDROCHLORIDE

AP SAGENT STRIDES 5MG/ML

A079134 001 Feb 03, 2010 Jan NEWA

TABLET; ORAL

TRANDATE

AB + PROMETHEUS LABS 200MG

N018716 002 Aug 01, 1984 Feb CRLD

@ 300MG

N018716 003 Aug 01, 1984 Apr DISC

AB 300MG

N018716 003 Aug 01, 1984 Feb CRLD

LACOSAMIDE

SOLUTION; ORAL

VIMPAT

+ SCHWARZ BIOSCIENCES 10MG/ML

N022255 001 Apr 20, 2010 Apr NEWA

LAMOTRIGINE

TABLET; ORAL

LAMOTRIGINE

AB LUPIN LTD 25MG

A078691 001 Jun 01, 2010 May NEWA

AB 100MG

A078691 002 Jun 01, 2010 May NEWA

AB 150MG

A078691 003 Jun 01, 2010 May NEWA

AB 200MG

A078691 004 Jun 01, 2010 May NEWA

@ WOCKHARDT 25MG

A078982 001 Jan 27, 2009 Jul DISC

@ 100MG

A078982 002 Jan 27, 2009 Jul DISC

@ 150MG

A078982 003 Jan 27, 2009 Jul DISC

@ 200MG

A078982 004 Jan 27, 2009 Jul DISC

TABLET, CHEWABLE; ORAL

LAMOTRIGINE

AB WATSON LABS 2MG

A076928 001 Jan 22, 2009 Jun CAHN

AB 5MG

A076928 002 Jan 22, 2009 Jun CAHN

AB 25MG

A076928 003 Jan 22, 2009 Jun CAHN

TABLET, EXTENDED RELEASE; ORAL

LAMICTAL XR

SMITHKLINE BEECHAM 300MG

N022115 005 Apr 14, 2010 Apr NEWA

LANSOPRAZOLE

CAPSULE, DELAYED RELEASE; ORAL

LANSOPRAZOLE

AB SANDOZ 15MG

A090331 001 Apr 23, 2010 Apr NEWA

AB 30MG

A090331 002 Apr 23, 2010 Apr NEWA

LENALIDOMIDE

CAPSULE; ORAL

REVLIMID

CELGENE 5MG

N021880 001 Dec 27, 2005 Jul CRLD

+ 5MG

N021880 001 Dec 27, 2005 Jan CRLD

+ 15MG

N021880 003 Jun 29, 2006 May CRLD

LEUCOVORIN CALCIUM

| | | | | | | |
|--------------------------------------|--------------------|--|---------|-----|--------------|----------|
| INJECTABLE; INJECTION | | | | | | |
| LEUCOVORIN CALCIUM | | | | | | |
| @ HOSPIRA | EQ 350MG BASE/VIAL | | N008107 | 005 | Apr 05, 1989 | Jun DISC |
| LEUCOVORIN CALCIUM PRESERVATIVE FREE | | | | | | |
| AP + BEDFORD | EQ 350MG BASE/VIAL | | A040335 | 001 | Apr 20, 2000 | Jun CRLD |
| TABLET; ORAL | | | | | | |
| LEUCOVORIN CALCIUM | | | | | | |
| >D> AB SANDOZ | EQ 15MG BASE | | A075327 | 001 | Mar 24, 1999 | Aug DISC |
| >A> @ | EQ 15MG BASE | | A075327 | 001 | Mar 24, 1999 | Aug DISC |

LEUPROLIDE ACETATE

| | | | | | | |
|-----------------------|--------------|--|---------|-----|--------------|----------|
| INJECTABLE; INJECTION | | | | | | |
| LEUPROLIDE ACETATE | | | | | | |
| AP OAKWOOD LABS | 1MG/0.2ML | | A074728 | 001 | Aug 04, 1998 | Apr CAHN |
| AP + SANDOZ | 1MG/0.2ML | | A074728 | 001 | Aug 04, 1998 | Jul CRLD |
| LUPRON | | | | | | |
| @ ABBOTT LABS | 1MG/0.2ML | | N019010 | 001 | Apr 09, 1985 | Jul DISC |
| >A> LUPRON DEPOT | | | | | | |
| >A> + ABBOTT LABS | 11.25MG/VIAL | | N020708 | 001 | Mar 07, 1997 | Aug CTNA |
| >A> + | 30MG/VIAL | | N020517 | 002 | May 30, 1997 | Aug CTNA |
| >D> LUPRON DEPOT-3 | | | | | | |
| >D> + ABBOTT LABS | 11.25MG/VIAL | | N020708 | 001 | Mar 07, 1997 | Aug CTNA |
| >D> LUPRON DEPOT-4 | | | | | | |
| >D> + ABBOTT LABS | 30MG/VIAL | | N020517 | 002 | May 30, 1997 | Aug CTNA |

LEVETIRACETAM

| | | | | | | |
|---------------------------|----------------------|--|---------|-----|--------------|----------|
| INJECTABLE; IV (INFUSION) | | | | | | |
| KEPPRA | | | | | | |
| AP + UCB INC | 500MG/5ML (100MG/ML) | | N021872 | 001 | Jul 31, 2006 | May CFTG |
| LEVETIRACETAM | | | | | | |
| AP NEXUS PHARMS | 500MG/5ML (100MG/ML) | | A090813 | 001 | May 26, 2010 | May NEWA |
| AP SUN PHARM IND'S LTD | 500MG/5ML (100MG/ML) | | A090754 | 001 | Jun 16, 2010 | May NEWA |
| SOLUTION; ORAL | | | | | | |
| LEVETIRACETAM | | | | | | |
| AA WOCKHARDT | 100MG/ML | | A090028 | 001 | Mar 03, 2010 | Feb NEWA |
| TABLET; ORAL | | | | | | |
| LEVETIRACETAM | | | | | | |
| AB METHAPHARM | 250MG | | A090767 | 001 | Jul 28, 2010 | Jul NEWA |
| AB | 500MG | | A090767 | 002 | Jul 28, 2010 | Jul NEWA |
| AB | 750MG | | A090767 | 003 | Jul 28, 2010 | Jul NEWA |
| AB | 1GM | | A090767 | 004 | Jul 28, 2010 | Jul NEWA |
| AB ORCHID HLTHCARE | 1GM | | A090484 | 001 | Aug 05, 2010 | Jul NEWA |
| AB TARO | 250MG | | A078960 | 004 | Feb 01, 2010 | Jan NEWA |
| AB | 500MG | | A078960 | 003 | Feb 01, 2010 | Jan NEWA |
| AB | 750MG | | A078960 | 002 | Feb 01, 2010 | Jan NEWA |
| AB | 1GM | | A078960 | 001 | Feb 01, 2010 | Jan NEWA |
| AB WATSON LABS | 1GM | | A078797 | 001 | Jan 15, 2009 | Jun CAHN |

LEVONORGESTREL

| | | | | | | |
|------------------|--------|--|---------|-----|--------------|----------|
| TABLET; ORAL | | | | | | |
| LEVONORGESTREL | | | | | | |
| AB + WATSON LABS | 0.75MG | | A078665 | 001 | Aug 28, 2009 | Apr CRLD |

LEVOTHYROXINE SODIUM

CAPSULE; ORAL

TIROSINT

| | | | | | |
|------------------------|---------|-------------|--------------|-----|------|
| INST BIOCHIMIQUE | 0.013MG | N022121 001 | Aug 01, 2007 | Feb | CMFD |
| | 0.025MG | N021924 002 | Oct 13, 2006 | Feb | CMFD |
| | 0.05MG | N021924 003 | Oct 13, 2006 | Feb | CMFD |
| | 0.075MG | N021924 004 | Oct 13, 2006 | Feb | CMFD |
| | 0.088MG | N021924 010 | Oct 02, 2009 | Feb | NEWA |
| | 0.1MG | N021924 005 | Oct 13, 2006 | Feb | CMFD |
| | 0.112MG | N021924 008 | Oct 02, 2009 | Feb | NEWA |
| | 0.125MG | N021924 006 | Oct 13, 2006 | Feb | CMFD |
| | 0.137MG | N021924 009 | Oct 02, 2009 | Feb | NEWA |
| | 0.15MG | N021924 007 | Oct 13, 2006 | Feb | CMFD |
| + INSTITUT BIOCHIMIQUE | 0.15MG | N021924 007 | Oct 13, 2006 | Jul | CRLD |

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIDOCAINE HYDROCHLORIDE

| | | | | | |
|-----------------------------|----|-------------|--------------|------|------|
| @ INTL MEDICATION | 1% | A083173 001 | Jul | DISC | |
| @ | 2% | A083173 002 | Jul | DISC | |
| XYLOCAINE PRESERVATIVE FREE | | | | | |
| >D> AP APP PHARMS | 1% | N016801 005 | Jan 19, 1988 | Aug | CRLD |
| >A> AP + | 1% | N016801 005 | Jan 19, 1988 | Aug | CRLD |
| >D> AP | 4% | N016801 002 | | Aug | CRLD |
| >A> AP + | 4% | N016801 002 | | Aug | CRLD |

LIDOCAINE; PRILOCAINE

CREAM; TOPICAL

LIDOCAINE AND PRILOCAINE

| | | | | | |
|---------------|-----------|-------------|--------------|-----|------|
| AB NYCOMED US | 2.5%;2.5% | A076453 001 | Aug 18, 2003 | Mar | CAHN |
|---------------|-----------|-------------|--------------|-----|------|

LIRAGLUTIDE RECOMBINANT

SOLUTION; SUBCUTANEOUS

VICTOZA

| | | | | | |
|--------------------|---------------------|-------------|--------------|-----|------|
| + NOVO NORDISK INC | 18MG/3ML (6MG/ML) | N022341 001 | Jan 25, 2010 | Jan | NEWA |
|--------------------|---------------------|-------------|--------------|-----|------|

LISINOPRIL

TABLET; ORAL

LISINOPRIL

| | | | | | |
|--------------------------|-------|-------------|--------------|-----|------|
| >D> AB ACTAVIS ELIZABETH | 2.5MG | A076180 001 | Jul 01, 2002 | Aug | CAHN |
| >D> AB | 5MG | A076180 002 | Jul 01, 2002 | Aug | CAHN |
| >D> AB | 10MG | A076180 003 | Jul 01, 2002 | Aug | CAHN |
| >D> AB | 20MG | A076164 001 | Jul 01, 2002 | Aug | CAHN |
| >D> AB | 30MG | A076164 002 | Jul 01, 2002 | Aug | CAHN |
| >D> AB | 40MG | A076164 003 | Jul 01, 2002 | Aug | CAHN |
| >A> AB HUAHAI US INC | 2.5MG | A076180 001 | Jul 01, 2002 | Aug | CAHN |
| >A> AB | 5MG | A076180 002 | Jul 01, 2002 | Aug | CAHN |
| >A> AB | 10MG | A076180 003 | Jul 01, 2002 | Aug | CAHN |
| >A> AB | 20MG | A076164 001 | Jul 01, 2002 | Aug | CAHN |
| >A> AB | 30MG | A076164 002 | Jul 01, 2002 | Aug | CAHN |
| >A> AB | 40MG | A076164 003 | Jul 01, 2002 | Aug | CAHN |
| @ TEVA | 2.5MG | A075783 001 | Jul 01, 2002 | Jan | DISC |
| @ | 5MG | A075783 002 | Jul 01, 2002 | Jan | DISC |
| @ | 10MG | A075783 003 | Jul 01, 2002 | Jan | DISC |
| @ | 20MG | A075783 004 | Jul 01, 2002 | Jan | DISC |

TABLET; ORAL

LISINOPRIL

| | | | | | |
|--------|------|-------------|--------------|-----|------|
| @ TEVA | 30MG | A075783 005 | Jul 01, 2002 | Jan | DISC |
| @ | 40MG | A075783 006 | Jul 01, 2002 | Jan | DISC |

LITHIUM CARBONATE

CAPSULE; ORAL

ESKALITH

| | | | | | |
|----------------|-------|-------------|--|-----|------|
| @ NOVEN THERAP | 300MG | N016860 001 | | Jan | DISC |
|----------------|-------|-------------|--|-----|------|

TABLET; ORAL

LITHIUM CARBONATE

| | | | | | |
|-----------------------|-------|-------------|--------------|-----|------|
| AB + ROXANE | 300MG | N018558 001 | Jan 29, 1982 | Jun | CTEC |
| AB SUN PHARM INDS INC | 300MG | A091027 001 | Jun 24, 2010 | Jun | NEWA |

LORAZEPAM

CONCENTRATE; ORAL

LORAZEPAM

| | | | | | |
|----------------|--------|-------------|--------------|-----|------|
| AA PHARM ASSOC | 2MG/ML | A090260 001 | Jun 15, 2010 | May | NEWA |
|----------------|--------|-------------|--------------|-----|------|

TABLET; ORAL

LORAZEPAM

| | | | | | |
|------------------|-------|-------------|--------------|-----|------|
| AB AMNEAL PHARMS | 0.5MG | A078826 001 | Jun 23, 2010 | Jun | NEWA |
| AB | 1MG | A078826 002 | Jun 23, 2010 | Jun | NEWA |
| AB | 2MG | A078826 003 | Jun 23, 2010 | Jun | NEWA |

LOSARTAN POTASSIUM

TABLET; ORAL

COZAAR

| | | | | | |
|----------|------|-------------|--------------|-----|------|
| AB MERCK | 25MG | N020386 001 | Apr 14, 1995 | Mar | CFTG |
|----------|------|-------------|--------------|-----|------|

| | | | | | |
|----|------|-------------|--------------|-----|------|
| AB | 50MG | N020386 002 | Apr 14, 1995 | Mar | CFTG |
|----|------|-------------|--------------|-----|------|

| | | | | | |
|------|-------|-------------|--------------|-----|------|
| AB + | 100MG | N020386 003 | Oct 13, 1998 | Mar | CFTG |
|------|-------|-------------|--------------|-----|------|

LOSARTAN POTASSIUM

| | | | | | |
|---------|------|-------------|--------------|-----|------|
| AB TEVA | 25MG | A076958 001 | Apr 06, 2010 | Mar | NEWA |
|---------|------|-------------|--------------|-----|------|

| | | | | | |
|----|------|-------------|--------------|-----|------|
| AB | 50MG | A076958 002 | Apr 06, 2010 | Mar | NEWA |
|----|------|-------------|--------------|-----|------|

| | | | | | |
|----|-------|-------------|--------------|-----|------|
| AB | 100MG | A076958 003 | Apr 06, 2010 | Mar | NEWA |
|----|-------|-------------|--------------|-----|------|

>A> MAGNESIUM SULFATE ANHYDROUS; POTASSIUM SULFATE; SODIUM SULFATE

>A> SOLUTION; ORAL

>A> SUPREP BOWEL PREP KIT

| | | | | | |
|----------------------|---------------------------------|-------------|--------------|-----|------|
| >A> + BRAINTREE LABS | 1.6GM/BOT;3.13GM/BOT;17.5GM/BOT | N022372 001 | Aug 05, 2010 | Aug | NEWA |
|----------------------|---------------------------------|-------------|--------------|-----|------|

MECLIZINE HYDROCHLORIDE

TABLET; ORAL

ANTIVERT

| | | | | | |
|-------------|------|-------------|--------------|-----|------|
| AA + PFIZER | 50MG | N010721 001 | Jan 20, 1982 | Jan | CMFD |
|-------------|------|-------------|--------------|-----|------|

MECLIZINE HYDROCHLORIDE

| | | | | | |
|-------------------|--------|-------------|--------------|-----|------|
| AA CADISTA PHARMS | 12.5MG | A040659 001 | Jun 04, 2010 | May | NEWA |
|-------------------|--------|-------------|--------------|-----|------|

| | | | | | |
|----|------|-------------|--------------|-----|------|
| AA | 25MG | A040659 002 | Jun 04, 2010 | May | NEWA |
|----|------|-------------|--------------|-----|------|

TABLET, CHEWABLE; ORAL

ANTIVERT

| | | | | | |
|----------|------|-------------|--|-----|------|
| @ PFIZER | 25MG | N010721 005 | | Jan | DISC |
|----------|------|-------------|--|-----|------|

MEFLOQUINE HYDROCHLORIDE

TABLET; ORAL

MEFLOQUINE HYDROCHLORIDE

| | | | | | |
|--------------|-------|-------------|--------------|-----|------|
| AB WEST WARD | 250MG | A077699 001 | Apr 21, 2010 | Apr | NEWA |
|--------------|-------|-------------|--------------|-----|------|

MEGESTROL ACETATE

TABLET; ORAL
 MEGACE
 @ BRISTOL MYERS SQUIBB 20MG N016979 001 Jul DISC
 @ 40MG N016979 002 Jul DISC
 MEGESTROL ACETATE
 >D> AB PAR PHARM 40MG A072423 001 Aug 08, 1988 Aug CRLD
 >A> AB + 40MG A072423 001 Aug 08, 1988 Aug CRLD

MELPHALAN HYDROCHLORIDE

INJECTABLE; INJECTION
 MELPHALAN HYDROCHLORIDE
 AP BIONICHE PHARMA USA EQ 50MG BASE/VIAL A090299 001 Oct 27, 2009 Mar CAHN

MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
 NAMENDA XR
 FOREST LABS 7MG N022525 001 Jun 21, 2010 Jun NEWA
 14MG N022525 002 Jun 21, 2010 Jun NEWA
 21MG N022525 003 Jun 21, 2010 Jun NEWA
 + 28MG N022525 004 Jun 21, 2010 Jun NEWA
 TABLET; ORAL
 MEMANTINE
 @ SUN PHARM IND (IN) 5MG A090058 001 May 05, 2010 Apr DISC
 @ 10MG A090058 002 May 05, 2010 Apr DISC
 MEMANTINE HYDROCHLORIDE
 @ DR REDDYS LABS LTD 5MG A090048 001 Apr 14, 2010 Apr DISC
 AB 5MG A090048 001 Apr 14, 2010 Mar NEWA
 @ 10MG A090048 002 Apr 14, 2010 Apr DISC
 AB 10MG A090048 002 Apr 14, 2010 Mar NEWA
 NAMENDA
 FOREST LABS 5MG N021487 001 Oct 16, 2003 Apr CTEC
 AB 5MG N021487 001 Oct 16, 2003 Mar CFTG
 + 10MG N021487 002 Oct 16, 2003 Apr CTEC
 AB + 10MG N021487 002 Oct 16, 2003 Mar CFTG

MEPERIDINE HYDROCHLORIDE

SYRUP; ORAL
 DEMEROL
 @ SANOFI AVENTIS US 50MG/5ML N005010 005 May DISC
 MEPERIDINE HYDROCHLORIDE
 + ROXANE 50MG/5ML A088744 001 Jan 30, 1985 Feb CRLD
 TABLET; ORAL
 DEMEROL
 AA + SANOFI AVENTIS US 50MG N005010 001 May CMFD
 @ 50MG N005010 001 Feb DISC
 MEPERIDINE HYDROCHLORIDE
 >A> AA EPIC PHARMA 50MG A040331 001 May 28, 1999 Aug CAHN
 >A> AA 100MG A040331 002 May 28, 1999 Aug CAHN
 >D> AA MIKAH PHARMA 50MG A040331 001 May 28, 1999 Aug CAHN
 AA 50MG A040331 001 May 28, 1999 Feb CAHN
 >D> AA 100MG A040331 002 May 28, 1999 Aug CAHN
 AA 100MG A040331 002 May 28, 1999 Feb CAHN

MEROPENEM

INJECTABLE; INJECTION

MEROPENEM

| | | | | | | |
|----|---------------|------------|-------------|--------------|-----|------|
| AP | HOSPIRA INC | 500MG/VIAL | A090940 001 | Jun 22, 2010 | Jun | NEWA |
| AP | | 1GM/VIAL | A090940 002 | Jun 22, 2010 | Jun | NEWA |
| | MERREM I.V. | | | | | |
| AP | + ASTRazeneca | 500MG/VIAL | N050706 003 | Jun 21, 1996 | Jun | CFTG |
| AP | + | 1GM/VIAL | N050706 001 | Jun 21, 1996 | Jun | CFTG |

MESALAMINE

SUPPOSITORY; RECTAL

CANASA

| | | | | | | |
|---|-------|-------|-------------|--------------|-----|------|
| @ | AXCAN | 500MG | N021252 001 | Jan 05, 2001 | May | CAHN |
| + | | 1GM | N021252 002 | Nov 05, 2004 | May | CAHN |

TABLET, DELAYED RELEASE; ORAL

ASACOL

| | | | | | | |
|---|---------------------|-------|-------------|--------------|-----|------|
| + | WARNER CHILCOTT INC | 400MG | N019651 001 | Jan 31, 1992 | Feb | CAHN |
| | ASACOL HD | | | | | |
| + | WARNER CHILCOTT INC | 800MG | N021830 001 | May 29, 2008 | Feb | CAHN |

MESNA

INJECTABLE; INTRAVENOUS

MESNA

| | | | | | | |
|----|----------------|----------|-------------|--------------|-----|------|
| AP | SAGENT STRIDES | 100MG/ML | A090913 001 | Apr 13, 2010 | Mar | NEWA |
|----|----------------|----------|-------------|--------------|-----|------|

METAXALONE

TABLET; ORAL

METAXALONE

| | | | | | | |
|----|---------------|-------|-------------|--------------|-----|------|
| AB | SANDOZ | 800MG | A040445 001 | Mar 31, 2010 | Mar | NEWA |
| AB | + KING PHARMS | 800MG | N013217 003 | Aug 30, 2002 | Mar | CFTG |

METFORMIN HYDROCHLORIDE

TABLET; ORAL

METFORMIN HYDROCHLORIDE

| | | | | | | |
|----|------------------------|-------|-------------|--------------|-----|------|
| AB | GRANULES INDIA | 500MG | A090564 001 | Apr 22, 2010 | Apr | NEWA |
| AB | | 850MG | A090564 002 | Apr 22, 2010 | Apr | NEWA |
| AB | | 1GM | A090564 003 | Apr 22, 2010 | Apr | NEWA |
| | @ IPCA LABS LTD | 500MG | A078422 001 | Aug 06, 2007 | Mar | DISC |
| | @ | 850MG | A078422 002 | Aug 06, 2007 | Mar | DISC |
| | @ | 1GM | A078422 003 | Aug 06, 2007 | Mar | DISC |
| | @ IVAX SUB TEVA PHARMS | 500MG | A075975 001 | Jan 24, 2002 | Apr | DISC |
| | | 625MG | A075972 005 | Jan 24, 2002 | Apr | CTEC |
| | @ | 625MG | A075975 004 | Jan 24, 2002 | Apr | DISC |
| | | 750MG | A075972 004 | Jan 24, 2002 | Apr | CTEC |
| | @ | 750MG | A075975 005 | Jan 24, 2002 | Apr | DISC |
| | @ | 850MG | A075975 002 | Jan 24, 2002 | Apr | DISC |
| | @ | 1GM | A075975 003 | Jan 24, 2002 | Apr | DISC |

TABLET, EXTENDED RELEASE; ORAL

METFORMIN HYDROCHLORIDE

| | | | | | | |
|----|----------------------|-------|-------------|--------------|-----|------|
| @ | IVAX SUB TEVA PHARMS | 500MG | A076545 001 | Dec 01, 2003 | Apr | DISC |
| AB | TORRENT PHARMS | 750MG | A079226 001 | Feb 18, 2010 | Jan | NEWA |
| AB | WATSON LABS | 500MG | A076818 001 | Dec 14, 2004 | Jun | CAHN |

METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE

TABLET; ORAL
 AVANDAMET
 @ SB PHARMCO 500MG;EQ 1MG BASE N021410 001 Oct 10, 2002 Jul DISC

METHADONE HYDROCHLORIDE

INJECTABLE; INJECTION
 DOLOPHINE HYDROCHLORIDE
 + BIONICHE PHARMA 10MG/ML N021624 001 Mar CAHN
 SOLUTION; ORAL
 METHADONE HYDROCHLORIDE
 AA + ROXANE 5MG/5ML A087393 001 Jun CTEC
 AA + 10MG/5ML A087997 001 Aug 30, 1982 Jun CTEC
 AA VISTAPHARM 5MG/5ML A090707 001 Jun 30, 2010 Jun NEWA
 AA 10MG/5ML A090707 002 Jun 30, 2010 Jun NEWA

METHAMPHETAMINE HYDROCHLORIDE

TABLET; ORAL
 DESOXYN
 AA + LUNDBECK INC 5MG N005378 002 Apr CTEC
 METHAMPHETAMINE HYDROCHLORIDE
 AA COASTAL PHARMS 5MG A091189 001 Apr 21, 2010 Apr NEWA

METHENAMINE HIPPURATE

TABLET; ORAL
 UREX
 AB CNTY LINE PHARMS 1GM N016151 001 Feb CAHN

METHOTREXATE SODIUM

INJECTABLE; INJECTION
 METHOTREXATE SODIUM PRESERVATIVE FREE
 AP + BIONICHE PHARMA EQ 50MG BASE/2ML (EQ 25MG
 BASE/ML) A040767 001 Apr 30, 2007 Mar CAHN
 AP + BIONICHE PHARMA USA EQ 250MG BASE/10ML (EQ 25MG
 BASE/ML) A040768 001 Apr 30, 2007 Mar CAHN
 AP + EQ 1GM BASE/40ML (EQ 25MG
 BASE/ML) A040716 001 Apr 30, 2007 Mar CAHN

METHYLERGONOVINE MALEATE

INJECTABLE; INJECTION
 METHYLERGONOVINE MALEATE
 >A> AP ERGOJECT 0.2MG/ML A040889 001 Sep 13, 2010 Aug NEWA

METHYLPHENIDATE HYDROCHLORIDE

SOLUTION; ORAL
 METHYLIN
 AA + MALLINCKRODT 5MG/5ML N021419 001 Dec 19, 2002 Jul CFTG
 AA + 10MG/5ML N021419 002 Dec 19, 2002 Jul CFTG
 METHYLPHENIDATE HYDROCHLORIDE
 AA TRIS PHARMA INC 5MG/5ML A091601 001 Jul 23, 2010 Jul NEWA
 AA 10MG/5ML A091601 002 Jul 23, 2010 Jul NEWA

METOCLOPRAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION
 METOCLOPRAMIDE HYDROCHLORIDE
 @ HOSPIRA EQ 5MG BASE/ML A074147 001 Aug 02, 1996 Feb DISC

TABLET; ORAL

METOCLOPRAMIDE HYDROCHLORIDE

| | |
|---------------|--------------|
| @ INTERPHARM | EQ 10MG BASE |
| @ SANDOZ | EQ 10MG BASE |
| @ WATSON LABS | EQ 10MG BASE |

| | | | |
|-------------|--------------|-----|------|
| A071213 001 | Sep 24, 1986 | May | CAHN |
| A074478 002 | Oct 05, 1995 | Jan | DISC |
| A070511 001 | Jan 22, 1986 | Jan | DISC |

TABLET, ORALLY DISINTEGRATING; ORAL

METOZOLV ODT

| | |
|----------------|--------------|
| + SALIX PHARMS | EQ 10MG BASE |
|----------------|--------------|

| | | | |
|-------------|--------------|-----|------|
| N022246 002 | Sep 04, 2009 | Jul | CRLD |
|-------------|--------------|-----|------|

METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE; ORAL

METOPROLOL SUCCINATE

| | |
|------------------------|-------------------|
| AB WATSON LABS FLORIDA | EQ 100MG TARTRATE |
| AB | EQ 200MG TARTRATE |
| AB WOCKHARDT | EQ 25MG TARTRATE |
| AB | EQ 50MG TARTRATE |
| AB | EQ 100MG TARTRATE |
| AB | EQ 200MG TARTRATE |

| | | | |
|-------------|--------------|-----|------|
| A077298 001 | Apr 15, 2010 | Apr | NEWA |
| A077298 002 | Apr 15, 2010 | Apr | NEWA |
| A090615 001 | Jul 22, 2010 | Jul | NEWA |
| A090615 002 | Jul 22, 2010 | Jul | NEWA |
| A090615 003 | Jul 22, 2010 | Jul | NEWA |
| A090615 004 | Jul 22, 2010 | Jul | NEWA |

METOPROLOL TARTRATE

INJECTABLE; INJECTION

METOPROLOL TARTRATE

| | |
|-------------------|--------|
| AP SAGENT STRIDES | 1MG/ML |
|-------------------|--------|

| | | | |
|-------------|--------------|-----|------|
| A090317 001 | Apr 19, 2010 | Apr | NEWA |
|-------------|--------------|-----|------|

METRONIDAZOLE

TABLET; ORAL

METRONIDAZOLE

| | |
|------------------------|-------|
| @ IVAX SUB TEVA PHARMS | 250MG |
| @ | 500MG |
| >D> AB SANDOZ | 250MG |
| >A> | 250MG |
| >D> AB | 500MG |
| >A> | 500MG |
| @ WORLD GEN | 250MG |
| @ | 500MG |

| | | | |
|-------------|--------------|-----|------|
| N018517 001 | | Apr | DISC |
| N018517 002 | May 05, 1982 | Apr | DISC |
| N018620 001 | Mar 04, 1982 | Aug | DISC |
| N018620 001 | Mar 04, 1982 | Aug | DISC |
| N018620 002 | Jun 02, 1983 | Aug | DISC |
| N018620 002 | Jun 02, 1983 | Aug | DISC |
| A070040 001 | Jan 29, 1985 | Mar | CAHN |
| A070039 001 | Jan 29, 1985 | May | CAHN |

TABLET, EXTENDED RELEASE; ORAL

FLAGYL ER

| | |
|--------------------|-------|
| AB + GD SEARLE LLC | 750MG |
| AB METRONIDAZOLE | |
| AB ALEMBIC LTD | 750MG |

| | | | |
|-------------|--------------|-----|------|
| N020868 001 | Nov 26, 1997 | Apr | CFTG |
| A090222 001 | May 05, 2010 | Apr | NEWA |

MICONAZOLE

TABLET; BUCCAL

ORAVIG

| | |
|----------------------|------|
| + BIOALLIANCE PHARMA | 50MG |
|----------------------|------|

| | | | |
|-------------|--------------|-----|------|
| N022404 001 | Apr 16, 2010 | Apr | NEWA |
|-------------|--------------|-----|------|

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION

MIDAZOLAM HYDROCHLORIDE

| | |
|------------------------|----------------|
| AP CLARIS LIFESCIENCES | EQ 1MG BASE/ML |
| AP | EQ 5MG BASE/ML |

| | | | |
|-------------|--------------|-----|------|
| A075637 001 | Oct 31, 2000 | Jun | CAHN |
| A075637 002 | Oct 31, 2000 | Jun | CAHN |

MILRINONE LACTATE

INJECTABLE; INJECTION

MILRINONE LACTATE

| | |
|------------------------|----------------|
| AP CLARIS LIFESCIENCES | EQ 1MG BASE/ML |
|------------------------|----------------|

| | | | |
|-------------|--------------|-----|------|
| A076427 001 | Sep 21, 2004 | Jun | CAHN |
|-------------|--------------|-----|------|

INJECTABLE; INJECTION

MILRINONE LACTATE IN DEXTROSE 5%

| | | | |
|---------------------|---------------------|---|-----------------------------------|
| AP | CLARIS LIFESCIENCES | EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML) | A077151 002 Jul 20, 2005 Jun CAHN |
| AP | + BAXTER HLTHCARE | MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML) | A075834 001 May 28, 2002 Feb CTEC |
| AP | + | EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML) | A075834 002 May 28, 2002 Feb CRLD |
| AP | CLARIS LIFESCIENCES | EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML) | A077151 001 Jul 20, 2005 Jun CAHN |
| | | MILRINONE LACTATE IN PLASTIC CONTAINER | |
| AP | HIKMA FARMACEUTICA | EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML) | A090038 001 Jan 21, 2010 Jan NEWA |
| AP | | EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML) | A090038 002 Jan 21, 2010 Jan NEWA |
| | | PRIMACOR IN DEXTROSE 5% IN PLASTIC CONTAINER | |
| @ SANOFI AVENTIS US | | EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML) | N020343 003 Aug 09, 1994 Feb DISC |
| @ | | EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML) | N020343 004 Aug 09, 1994 Feb DISC |

MINOCYCLINE HYDROCHLORIDETABLET, EXTENDED RELEASE; ORAL
MINOCYCLINE HYDROCHLORIDE

| | | | |
|-----|-----------------|---------------|-----------------------------------|
| AB | MATRIX LABS LTD | EQ 45MG BASE | A090911 001 Jul 20, 2010 Jul NEWA |
| AB | | EQ 90MG BASE | A090911 002 Jul 20, 2010 Jul NEWA |
| AB | | EQ 135MG BASE | A090911 003 Jul 20, 2010 Jul NEWA |
| | | SOLODYN | |
| >A> | MEDICIS | EQ 55MG BASE | N050808 008 Aug 27, 2010 Aug NEWA |
| >A> | | EQ 80MG BASE | N050808 007 Aug 27, 2010 Aug NEWA |
| >A> | | EQ 105MG BASE | N050808 006 Aug 27, 2010 Aug NEWA |

MITOMYCININJECTABLE; INJECTION
MITOMYCIN

| | | | |
|-----------------|-------------------|-----------|-----------------------------------|
| AP | + ACCORD HLTHCARE | 5MG/VIAL | A064144 001 Apr 30, 1998 Jul CRLD |
| AP | + | 20MG/VIAL | A064144 002 Apr 30, 1998 Jul CRLD |
| AP | + | 40MG/VIAL | A064144 003 Aug 11, 2009 Jul CRLD |
| | | MUTAMYCIN | |
| @ BRISTOL MYERS | | 5MG/VIAL | A062336 001 Jul DISC |
| @ | | 20MG/VIAL | A062336 002 Jul DISC |
| @ | | 40MG/VIAL | A062336 003 Mar 10, 1988 Jul DISC |

MITOXANTRONE HYDROCHLORIDEINJECTABLE; INJECTION
MITOXANTRONE HYDROCHLORIDE

| | | | |
|----|---------------------|---------------------------------------|-----------------------------------|
| AP | BIONICHE PHARMA USA | EQ 20MG BASE/10ML (EQ 2MG BASE/ML) | A078980 001 Apr 13, 2009 Mar CAHN |
| AP | | EQ 30MG BASE/15ML (EQ 2MG BASE/ML) | A078980 002 Apr 13, 2009 Mar CAHN |

MIVACURIUM CHLORIDEINJECTABLE; INJECTION
MIVACURIUM CHLORIDE

| | | | |
|---------------|--|----------------|-----------------------------------|
| + PISGAH LABS | | EQ 2MG BASE/ML | A078562 001 Apr 30, 2009 May CAHN |
|---------------|--|----------------|-----------------------------------|

MOEXIPRIL HYDROCHLORIDE

TABLET; ORAL

MOEXIPRIL HYDROCHLORIDE

| | | | | | | |
|----|-------------------|-------|-------------|--------------|-----|------|
| AB | GLENMARK GENERICS | 7.5MG | A090416 001 | Mar 30, 2010 | Mar | NEWA |
| AB | | 15MG | A090416 002 | Mar 30, 2010 | Mar | NEWA |

MOLINDONE HYDROCHLORIDE

TABLET; ORAL

MOBAN

| | | | | |
|---------------|------|-------------|-----|------|
| @ ENDO PHARMS | 5MG | N017111 004 | May | DISC |
| @ | 10MG | N017111 005 | May | DISC |
| @ | 25MG | N017111 006 | May | DISC |
| @ | 50MG | N017111 007 | May | DISC |

MOMETASONE FUROATE

LOTION; TOPICAL

MOMETASONE FUROATE

| | | | | | | | |
|-----|----|-------------------|------|-------------|--------------|-----|------|
| >A> | AB | GLENMARK GENERICS | 0.1% | A090506 001 | Aug 09, 2010 | Aug | NEWA |
|-----|----|-------------------|------|-------------|--------------|-----|------|

MORPHINE SULFATE

INJECTABLE, LIPOSOMAL; EPIDURAL

DEPODUR

| | | | | | |
|------------|----------------------|-------------|--------------|-----|------|
| EKR THERAP | 10MG/ML (10MG/ML) | N021671 001 | May 18, 2004 | Jun | CAHN |
| + | 15MG/1.5ML (10MG/ML) | N021671 002 | May 18, 2004 | Jun | CAHN |
| @ | 20MG/2ML (10MG/ML) | N021671 003 | May 18, 2004 | Jun | CAHN |

SOLUTION; ORAL

MORPHINE SULFATE

| | | | | | |
|--------|-----------|-------------|--------------|-----|------|
| ROXANE | 20MG/5ML | N022195 002 | Mar 17, 2008 | Jan | CRLD |
| + | 100MG/5ML | N022195 003 | Jan 25, 2010 | Jan | NEWA |

TABLET, EXTENDED RELEASE; ORAL

MORPHINE SULFATE

| | | | | | | |
|----|------------------|-------|-------------|--------------|-----|------|
| AB | CLONMEL HLTHCARE | 15MG | A075407 001 | Jan 28, 2000 | Jul | CMFD |
| AB | PURDUE PHARMA LP | 15MG | A074862 001 | Jul 07, 1998 | Jul | CMFD |
| | @ | 15MG | A074862 001 | Jul 07, 1998 | Feb | CAHN |
| AB | | 30MG | A074862 002 | Jul 07, 1998 | Jul | CMFD |
| | @ | 30MG | A074862 002 | Jul 07, 1998 | Feb | CAHN |
| AB | | 60MG | A074862 003 | Jul 07, 1998 | Jul | CMFD |
| | @ | 60MG | A074862 003 | Jul 07, 1998 | Feb | CAHN |
| AB | | 100MG | A074769 001 | Jul 02, 1998 | Jul | CMFD |
| | @ | 100MG | A074769 001 | Jul 02, 1998 | Feb | CAHN |
| AB | | 200MG | A074769 002 | Jul 02, 1998 | Jul | CMFD |
| | @ | 200MG | A074769 002 | Jul 02, 1998 | Feb | CAHN |

MYCOPHENOLATE MOFETIL

CAPSULE; ORAL

MYCOPHENOLATE MOFETIL

| | | | | | | |
|----|---------------------|-------|-------------|--------------|-----|------|
| AB | STRIDES ARCOLAB LTD | 250MG | A090055 001 | Jun 10, 2010 | May | NEWA |
|----|---------------------|-------|-------------|--------------|-----|------|

TABLET; ORAL

MYCOPHENOLATE MOFETIL

| | | | | | | | |
|-----|----|---------------------|-------|-------------|--------------|-----|------|
| >A> | AB | DR REDDYS LABS LTD | 500MG | A090464 001 | Sep 13, 2010 | Aug | NEWA |
| | AB | ENDO PHARMS | 500MG | A090606 001 | Jul 16, 2010 | Jul | NEWA |
| | AB | STRIDES ARCOLAB LTD | 500MG | A090456 001 | Jun 10, 2010 | May | NEWA |

NABUMETONE

TABLET; ORAL
NABUMETONE

| | | | |
|----|-----------------|-------|-----------------------------------|
| AB | MATRIX LABS LTD | 500MG | A090516 001 Jul 12, 2010 Jun NEWA |
| AB | | 750MG | A090516 002 Jul 12, 2010 Jun NEWA |

NALIDIXIC ACID

TABLET; ORAL
NEGRAM

| | | |
|---------------------|-------|----------------------|
| @ SANOFI AVENTIS US | 250MG | N014214 002 Feb DISC |
| @ | 500MG | N014214 004 Feb DISC |
| @ | 1GM | N014214 005 Feb DISC |

NALOXONE HYDROCHLORIDE; PENTAZOCINE HYDROCHLORIDE

TABLET; ORAL
PENTAZOCINE AND NALOXONE HYDROCHLORIDES

| | | | |
|----|---------------------|----------------------------|-----------------------------------|
| AB | + WATSON LABS | EQ 0.5MG BASE;EQ 50MG BASE | A074736 001 Jan 21, 1997 Feb CRLD |
| | TALWIN NX | | |
| | @ SANOFI AVENTIS US | EQ 0.5MG BASE;EQ 50MG BASE | N018733 001 Dec 16, 1982 Feb DISC |

NANDROLONE DECANOATE

INJECTABLE; INJECTION
NANDROLONE DECANOATE

| | | | |
|-----|---------------|----------|-----------------------------------|
| >A> | + PHARMAFORCE | 200MG/ML | A091252 001 Aug 30, 2010 Aug NEWA |
|-----|---------------|----------|-----------------------------------|

NAPROXEN

TABLET; ORAL
NAPROXEN

| | | | |
|-----|-------------------|-------|-----------------------------------|
| >D> | @ BAXTER HLTHCARE | 250MG | A074105 001 Dec 21, 1993 Aug CAHN |
| >D> | @ | 375MG | A074105 002 Dec 21, 1993 Aug CAHN |
| >D> | @ | 500MG | A074105 003 Dec 21, 1993 Aug CAHN |
| >A> | @ DAVA PHARMS INC | 250MG | A074105 001 Dec 21, 1993 Aug CAHN |
| >A> | @ | 375MG | A074105 002 Dec 21, 1993 Aug CAHN |
| >A> | @ | 500MG | A074105 003 Dec 21, 1993 Aug CAHN |

NAPROXEN SODIUM

TABLET; ORAL
NAPROXEN SODIUM

| | | | |
|-----|-----------|---------------|-----------------------------------|
| >D> | AB SANDOZ | EQ 250MG BASE | A074162 001 Dec 21, 1993 Aug DISC |
| >D> | AB | EQ 250MG BASE | A074495 001 Dec 05, 1994 Aug DISC |
| >A> | @ | EQ 250MG BASE | A074162 001 Dec 21, 1993 Aug DISC |
| >A> | @ | EQ 250MG BASE | A074495 001 Dec 05, 1994 Aug DISC |
| >D> | AB | EQ 500MG BASE | A074162 002 Dec 21, 1993 Aug DISC |
| >D> | AB | EQ 500MG BASE | A074495 002 Dec 05, 1994 Aug DISC |
| >A> | @ | EQ 500MG BASE | A074495 002 Dec 05, 1994 Aug DISC |
| >A> | @ | EQ 500MG BASE | A074162 002 Dec 21, 1993 Aug DISC |

NARATRIPTAN HYDROCHLORIDE

TABLET; ORAL
AMERGE

| | | | |
|----|-----------------|---------------|-----------------------------------|
| AB | GLAXOSMITHKLINE | EQ 1MG BASE | N020763 002 Feb 10, 1998 Jun CFTG |
| AB | + | EQ 2.5MG BASE | N020763 001 Feb 10, 1998 Jun CFTG |

NARATRIPTAN

| | | | |
|----|--------------|---------------|-----------------------------------|
| AB | PADDICK LABS | EQ 1MG BASE | A091326 001 Jul 08, 2010 Jun NEWA |
| AB | | EQ 2.5MG BASE | A091326 002 Jul 08, 2010 Jun NEWA |

TABLET; ORALNARatriptan

| | | | | | | |
|----|-------------|---------------|-------------|--------------|-----|------|
| AB | ROXANE | EQ 1MG BASE | A090381 001 | Jul 07, 2010 | Jun | NEWA |
| AB | | EQ 2.5MG BASE | A090381 002 | Jul 07, 2010 | Jun | NEWA |
| AB | SANDOZ | EQ 1MG BASE | A090288 001 | Jul 07, 2010 | Jun | NEWA |
| AB | | EQ 2.5MG BASE | A090288 002 | Jul 07, 2010 | Jun | NEWA |
| AB | TEVA PHARMS | EQ 1MG BASE | A078751 001 | Jul 07, 2010 | Jun | NEWA |
| AB | | EQ 2.5MG BASE | A078751 002 | Jul 07, 2010 | Jun | NEWA |

NEFAZODONE HYDROCHLORIDETABLET; ORALNEFAZODONE HYDROCHLORIDE

| | | | | | | | |
|-----|----------------------|--------|-------------|--------------|--------------|------|------|
| @ | IVAX SUB TEVA PHARMS | 50MG | A075763 001 | Sep 16, 2003 | Apr | DISC | |
| @ | | 100MG | A075763 002 | Sep 16, 2003 | Apr | DISC | |
| @ | | 150MG | A075763 003 | Sep 16, 2003 | Apr | DISC | |
| @ | | 200MG | A075763 004 | Sep 16, 2003 | Apr | DISC | |
| @ | | 250MG | A075763 005 | Sep 16, 2003 | Apr | DISC | |
| >D> | AB | SANDOZ | 50MG | A076302 001 | Sep 16, 2003 | Aug | DISC |
| >A> | | @ | 50MG | A076302 001 | Sep 16, 2003 | Aug | DISC |
| >D> | AB | | 100MG | A076302 002 | Sep 16, 2003 | Aug | DISC |
| >A> | | @ | 100MG | A076302 002 | Sep 16, 2003 | Aug | DISC |
| >D> | AB | | 150MG | A076302 003 | Sep 16, 2003 | Aug | DISC |
| >A> | | @ | 150MG | A076302 003 | Sep 16, 2003 | Aug | DISC |
| >D> | AB | | 200MG | A076302 004 | Sep 16, 2003 | Aug | DISC |
| >A> | | @ | 200MG | A076302 004 | Sep 16, 2003 | Aug | DISC |
| >D> | AB | | 250MG | A076302 005 | Sep 16, 2003 | Aug | DISC |
| >A> | | @ | 250MG | A076302 005 | Sep 16, 2003 | Aug | DISC |

NEOMYCIN SULFATETABLET; ORALNEOMYCIN SULFATE

| | | | | | | |
|----|---------------------|-------|-------------|--------------|-----|------|
| AA | OMAN PHARM PRODUCTS | 500MG | A065468 001 | Mar 29, 2010 | Mar | NEWA |
|----|---------------------|-------|-------------|--------------|-----|------|

NIACIN; SIMVASTATINTABLET, EXTENDED RELEASE; ORALSIMCOR

| | | | | | | |
|---|--------|------------|-------------|--------------|-----|------|
| + | ABBOTT | 500MG;40MG | N022078 004 | Jul 28, 2010 | Jul | NEWA |
| + | | 1GM;40MG | N022078 005 | Jul 28, 2010 | Jul | NEWA |

NICARDIPIINE HYDROCHLORIDECAPSULE; ORALNICARDIPIINE HYDROCHLORIDE

| | | | | | | | |
|-----|----|--------------|------|-------------|--------------|-----|------|
| >D> | AB | AMNEAL PHARM | 20MG | A074928 001 | Mar 19, 1998 | Aug | CAHN |
| >D> | AB | | 30MG | A074928 002 | Mar 19, 1998 | Aug | CAHN |
| >A> | AB | EPIC PHARMA | 20MG | A074928 001 | Mar 19, 1998 | Aug | CAHN |
| >A> | AB | | 30MG | A074928 002 | Mar 19, 1998 | Aug | CAHN |

INJECTABLE; INJECTIONNICARDIPIINE HYDROCHLORIDE

| | | | | | | |
|----|----------------------|----------------------|-------------|--------------|-----|------|
| AP | BIONICHE PHARMA USA | 25MG/10ML (2.5MG/ML) | A090664 001 | Nov 17, 2009 | Mar | CAHN |
| AP | EXELA PHARMA SCIENCE | 25MG/10ML (2.5MG/ML) | N022276 001 | Jul 24, 2008 | Jun | CAHN |
| AP | SUN PHARMA GLOBAL | 25MG/10ML (2.5MG/ML) | A078405 001 | Nov 17, 2009 | Jun | CAHN |

NIFEDIPINECAPSULE; ORALNIFEDIPINE

| | | | | | | |
|----|----------------|------|-------------|--------------|-----|------|
| AB | INTERGEL PHARM | 10MG | A072781 001 | Jul 30, 1993 | Mar | CAHN |
|----|----------------|------|-------------|--------------|-----|------|

TABLET, EXTENDED RELEASE; ORAL
NIFEDIPINE

| | | | | | | | |
|-----|-----|-----------------|------|-------------|--------------|-----|------|
| >A> | AB2 | MATRIX LABS LTD | 30MG | A090602 001 | Sep 13, 2010 | Aug | NEWA |
| >A> | AB2 | | 60MG | A090602 002 | Sep 13, 2010 | Aug | NEWA |
| >A> | AB2 | | 90MG | A090602 003 | Sep 13, 2010 | Aug | NEWA |
| | AB2 | MYLAN | 30MG | A090649 001 | Jun 21, 2010 | Jun | NEWA |
| | AB2 | | 60MG | A090649 002 | Jun 21, 2010 | Jun | NEWA |
| | AB2 | | 90MG | A090649 003 | Jun 21, 2010 | Jun | NEWA |

NISOLDIPINE

TABLET, EXTENDED RELEASE; ORAL
SULAR

| | | | | | | |
|---|-----------------|--------|-------------|--------------|-----|------|
| + | SHIONOGI PHARMA | 8.5MG | N020356 008 | Jan 02, 2008 | Jan | CAHN |
| @ | | 10MG | N020356 001 | Feb 02, 1995 | Jan | CAHN |
| + | | 17MG | N020356 007 | Jan 02, 2008 | Jan | CAHN |
| @ | | 20MG | N020356 002 | Feb 02, 1995 | Jan | CAHN |
| | | 25.5MG | N020356 006 | Jan 02, 2008 | Jan | CAHN |
| @ | | 30MG | N020356 003 | Feb 02, 1995 | Jan | CAHN |
| + | | 34MG | N020356 005 | Jan 02, 2008 | Jan | CAHN |
| @ | | 40MG | N020356 004 | Feb 02, 1995 | Jan | CAHN |

NITROFURANTOIN

SUSPENSION; ORAL
FURADANTIN

| | | | | | |
|---|-----------------|----------|-------------|-----|------|
| + | SHIONOGI PHARMA | 25MG/5ML | N009175 001 | Jan | CAHN |
|---|-----------------|----------|-------------|-----|------|

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL
MACRODANTIN

| | | | | | |
|----|---------|-------|-------------|-----|------|
| AB | ALVOGEN | 25MG | N016620 003 | Jul | CAHN |
| AB | | 50MG | N016620 001 | Jul | CAHN |
| AB | + | 100MG | N016620 002 | Jul | CAHN |

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL
MACROBID

| | | | | | | | |
|----|---|---------|-----------|-------------|--------------|-----|------|
| AB | + | ALVOGEN | 75MG;25MG | N020064 001 | Dec 24, 1991 | Jul | CAHN |
|----|---|---------|-----------|-------------|--------------|-----|------|

NITROGLYCERIN

AEROSOL; SUBLINGUAL
NITROLINGUAL

| | | | | | | |
|---|-----------------|-------------|-------------|--------------|-----|------|
| @ | POHL BOSKAMP | 0.4MG/SPRAY | N018705 001 | Oct 31, 1985 | Mar | CAHN |
| @ | SHIONOGI PHARMA | 0.4MG/SPRAY | N018705 001 | Oct 31, 1985 | Jan | CAHN |

AEROSOL, METERED; SUBLINGUAL
NITROMIST

| | | | | | | |
|---|---------|-------------|-------------|--------------|-----|------|
| + | NOVADEL | 0.4MG/SPRAY | N021780 001 | Nov 02, 2006 | Jun | CAHN |
|---|---------|-------------|-------------|--------------|-----|------|

SPRAY, METERED; SUBLINGUAL
NITROLINGUAL PUMPSPRAY

| | | | | | | |
|---|-----------------|-------------|-------------|--------------|-----|------|
| + | POHL BOSKAMP | 0.4MG/SPRAY | N018705 002 | Jan 10, 1997 | Mar | CAHN |
| + | SHIONOGI PHARMA | 0.4MG/SPRAY | N018705 002 | Jan 10, 1997 | Jan | CAHN |

NORETHINDRONE

TABLET; ORAL-28

HEATHER

| | | | | | | |
|-----|-------------------|--------|-------------|--------------|-----|------|
| AB1 | GLENMARK GENERICS | 0.35MG | A090454 001 | Apr 23, 2010 | Apr | NEWA |
|-----|-------------------|--------|-------------|--------------|-----|------|

TABLET; ORAL-28

NORETHIDRONE

AB2 GLENMARK GENERICS 0.35MG A091209 001 Jul 21, 2010 Jul NEWA

NORETHINDRONE ACETATE

TABLET; ORAL

NORETHINDRONE ACETATE

AB GLENMARK GENERICS 5MG A091090 001 Jul 21, 2010 Jul NEWA

OFLOXACIN

TABLET; ORAL

OFLOXACIN

@ LARKEN LABS 200MG
@ 300MG
@ 400MGA076093 001 Sep 02, 2003 Jan CAHN
A076093 002 Sep 02, 2003 Jan CAHN
A076093 003 Sep 02, 2003 Jan CAHNOMEPPRAZOLE; SODIUM BICARBONATE

CAPSULE; ORAL

OMEPPRAZOLE AND SODIUM BICARBONATE

AB PAR PHARM 20MG;1.1GM A078966 001 May 25, 2010 May NEWA
AB 40MG;1.1GM A078966 002 May 25, 2010 May NEWA

ZEGERID

AB SANTARUS 20MG;1.1GM N021849 001 Feb 27, 2006 May CFTG
AB + 40MG;1.1GM N021849 002 Feb 27, 2006 May CFTGONDANSETRON

FILM; ORAL

ZUPLENZ

PAR PHARM 4MG N022524 001 Jul 02, 2010 Jul NEWA
+ 8MG N022524 002 Jul 02, 2010 Jul NEWA

TABLET, ORALLY DISINTEGRATING; ORAL

ONDANSETRON

AB AUROBINDO PHARMA 4MG A090469 001 Apr 12, 2010 Mar NEWA
AB 8MG A090469 002 Apr 12, 2010 Mar NEWAONDANSETRON HYDROCHLORIDE

INJECTABLE; INJECTION

ONDANSETRON HYDROCHLORIDE

AP EMCURE PHARMS EQ 2MG BASE/ML A090424 001 Apr 16, 2010 Apr NEWA
AP LANNETT EQ 2MG BASE/ML A090883 001 Aug 05, 2010 Jul NEWA
AP EQ 2MG BASE/ML A090116 001 Apr 14, 2010 Mar NEWAORPHENADRINE CITRATE

TABLET, EXTENDED RELEASE; ORAL

ORPHENADRINE CITRATE

AB GAVIS PHARMS 100MG A040284 001 Jun 19, 1998 Feb CAHN

OXALIPLATIN

INJECTABLE; INJECTION

OXALIPLATIN

AP + HOSPIRA INC 50MG/VIAL A078815 001 Sep 30, 2009 Jan CRLD
AP + 100MG/VIAL A078815 002 Sep 30, 2009 Jan CRLD

INJECTABLE; IV (INFUSION)

OXALIPLATIN

AP APP PHARMS 50MG/VIAL A078819 001 Jun 02, 2010 May NEWA
AP 100MG/VIAL A078819 002 Jun 02, 2010 May NEWA

INJECTABLE; IV (INFUSION)OXALIPLATIN

| | | | | | | |
|----|----------------------|---------------------|-------------|--------------|-----|------|
| AP | FRESENIUS KABI ONCOL | 100MG/20ML (5MG/ML) | A078811 002 | Jun 10, 2010 | May | NEWA |
| AP | | 50MG/10ML (5MG/ML) | A078811 001 | Jun 10, 2010 | May | NEWA |
| AP | + | HOSPIRA INC | A078815 001 | Sep 30, 2009 | Apr | CDFR |
| AP | + | | A078815 002 | Sep 30, 2009 | Apr | CDFR |
| AP | SUN PHARMA GLOBAL | 50MG/VIAL | A078818 001 | Aug 07, 2009 | Jun | CAHN |
| AP | | 100MG/VIAL | A078818 002 | Aug 07, 2009 | Jun | CAHN |

OXCARBAZEPINETABLET; ORALOXCARBAZEPINE

| | | | | | | |
|----|----------------|-------|-------------|--------------|-----|------|
| AB | CADISTA PHARMS | 150MG | A090239 001 | Jan 25, 2010 | Jan | NEWA |
| AB | | 300MG | A090239 002 | Jan 25, 2010 | Jan | NEWA |
| AB | | 600MG | A090239 003 | Jan 25, 2010 | Jan | NEWA |

OXYCODONE HYDROCHLORIDETABLET, EXTENDED RELEASE; ORALOXYCODONE HYDROCHLORIDE

| | | | | | |
|----------------|------|-------------|--------------|-----|------|
| @ MALLINCKRODT | 10MG | A077822 001 | Jul 24, 2008 | Apr | DISC |
| @ | 20MG | A077822 002 | Jul 24, 2008 | Apr | DISC |
| @ | 40MG | A077822 003 | Jul 24, 2008 | Apr | DISC |
| @ | 80MG | A077822 004 | Jul 24, 2008 | Apr | DISC |

OXYCONTIN

| | | | | | |
|-------------------|------|-------------|--------------|-----|------|
| PURDUE PHARMA INC | 10MG | N022272 001 | Apr 05, 2010 | May | NEWA |
| | 15MG | N022272 002 | Apr 05, 2010 | May | NEWA |
| | 20MG | N022272 003 | Apr 05, 2010 | May | NEWA |
| | 30MG | N022272 004 | Apr 05, 2010 | May | NEWA |
| | 40MG | N022272 005 | Apr 05, 2010 | May | NEWA |
| | 60MG | N022272 006 | Apr 05, 2010 | May | NEWA |
| | 80MG | N022272 007 | Apr 05, 2010 | May | NEWA |

| | | | | | | |
|-----|------------------|------|-------------|--------------|-----|------|
| >D> | PURDUE PHARMA LP | 10MG | N020553 001 | Dec 12, 1995 | Aug | DISC |
| >D> | | 10MG | N020553 001 | Dec 12, 1995 | Aug | DISC |
| >D> | @ | 10MG | N022272 001 | Apr 05, 2010 | Aug | CMFD |
| >A> | | 10MG | N022272 001 | Apr 05, 2010 | Aug | CMFD |
| >A> | @ | 10MG | N020553 001 | Dec 12, 1995 | Aug | DISC |
| >A> | @ | 10MG | N020553 001 | Dec 12, 1995 | Aug | DISC |
| | @ | 10MG | N022272 001 | Apr 05, 2010 | Jun | DISC |
| | | 10MG | N020553 001 | Dec 12, 1995 | Apr | CTEC |
| | | 10MG | N020553 001 | Dec 12, 1995 | Apr | CTEC |
| >D> | | 15MG | N020553 006 | Sep 18, 2006 | Aug | DISC |
| >D> | @ | 15MG | N022272 002 | Apr 05, 2010 | Aug | CMFD |
| >A> | @ | 15MG | N020553 006 | Sep 18, 2006 | Aug | DISC |
| >A> | | 15MG | N022272 002 | Apr 05, 2010 | Aug | CMFD |
| | @ | 15MG | N022272 002 | Apr 05, 2010 | Jun | DISC |
| >D> | @ | 20MG | N022272 003 | Apr 05, 2010 | Aug | CMFD |
| >D> | | 20MG | N020553 002 | Dec 12, 1995 | Aug | DISC |
| >D> | | 20MG | N020553 002 | Dec 12, 1995 | Aug | DISC |
| >A> | @ | 20MG | N020553 002 | Dec 12, 1995 | Aug | DISC |
| >A> | | 20MG | N022272 003 | Apr 05, 2010 | Aug | CMFD |
| >A> | @ | 20MG | N020553 002 | Dec 12, 1995 | Aug | DISC |
| | @ | 20MG | N022272 003 | Apr 05, 2010 | Jun | DISC |
| | | 20MG | N020553 002 | Dec 12, 1995 | Apr | CTEC |
| | | 20MG | N020553 002 | Dec 12, 1995 | Apr | CTEC |
| >D> | | 30MG | N020553 007 | Sep 18, 2006 | Aug | DISC |
| >D> | @ | 30MG | N022272 004 | Apr 05, 2010 | Aug | CMFD |

TABLET, EXTENDED RELEASE; ORAL
OXYCONTIN

| | | | | | | |
|-----|------------------|------|-------------|--------------|-----|------|
| >A> | PURDUE PHARMA LP | 30MG | N022272 004 | Apr 05, 2010 | Aug | CMFD |
| >A> | @ | 30MG | N020553 007 | Sep 18, 2006 | Aug | DISC |
| | @ | 30MG | N022272 004 | Apr 05, 2010 | Jun | DISC |
| >D> | @ | 40MG | N022272 005 | Apr 05, 2010 | Aug | CMFD |
| >D> | + | 40MG | N020553 003 | Dec 12, 1995 | Aug | DISC |
| >D> | + | 40MG | N020553 003 | Dec 12, 1995 | Aug | DISC |
| >A> | @ | 40MG | N020553 003 | Dec 12, 1995 | Aug | DISC |
| >A> | @ | 40MG | N020553 003 | Dec 12, 1995 | Aug | DISC |
| >A> | | 40MG | N022272 005 | Apr 05, 2010 | Aug | CMFD |
| | @ | 40MG | N022272 005 | Apr 05, 2010 | Jun | DISC |
| | + | 40MG | N020553 003 | Dec 12, 1995 | Apr | CTEC |
| | + | 40MG | N020553 003 | Dec 12, 1995 | Apr | CTEC |
| >D> | | 60MG | N020553 008 | Sep 18, 2006 | Aug | DISC |
| >D> | @ | 60MG | N022272 006 | Apr 05, 2010 | Aug | CMFD |
| >A> | | 60MG | N022272 006 | Apr 05, 2010 | Aug | CMFD |
| >A> | @ | 60MG | N020553 008 | Sep 18, 2006 | Aug | DISC |
| | @ | 60MG | N022272 006 | Apr 05, 2010 | Jun | DISC |
| >D> | | 80MG | N020553 004 | Jan 06, 1997 | Aug | DISC |
| >D> | | 80MG | N020553 004 | Jan 06, 1997 | Aug | DISC |
| >D> | @ | 80MG | N022272 007 | Apr 05, 2010 | Aug | CMFD |
| >A> | @ | 80MG | N020553 004 | Jan 06, 1997 | Aug | DISC |
| >A> | | 80MG | N022272 007 | Apr 05, 2010 | Aug | CMFD |
| >A> | @ | 80MG | N020553 004 | Jan 06, 1997 | Aug | DISC |
| | @ | 80MG | N022272 007 | Apr 05, 2010 | Jun | DISC |
| | | 80MG | N020553 004 | Jan 06, 1997 | Apr | CTEC |
| | | 80MG | N020553 004 | Jan 06, 1997 | Apr | CTEC |

OXYMORPHONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
OPANA ER

| | | | | | | |
|----|-------------|------|-------------|--------------|-----|------|
| AB | ENDO PHARMS | 5MG | N021610 001 | Jun 22, 2006 | May | CFTG |
| AB | | 10MG | N021610 002 | Jun 22, 2006 | May | CFTG |
| AB | | 20MG | N021610 003 | Jun 22, 2006 | May | CFTG |
| AB | | 30MG | N021610 007 | Feb 29, 2008 | Jul | CFTG |
| AB | + | 40MG | N021610 004 | Jun 22, 2006 | May | CFTG |

OXYMORPHONE HYDROCHLORIDE

| | | | | | | |
|----|------------|------|-------------|--------------|-----|------|
| AB | IMPAX LABS | 5MG | A079087 001 | Jun 14, 2010 | May | NEWA |
| AB | | 10MG | A079087 003 | Jun 14, 2010 | May | NEWA |
| AB | | 20MG | A079087 005 | Jun 14, 2010 | May | NEWA |
| AB | | 30MG | A079087 006 | Jul 22, 2010 | Jul | NEWA |
| AB | | 40MG | A079087 007 | Jun 14, 2010 | May | NEWA |

PACLITAXEL

INJECTABLE; INJECTION

PACLITAXEL

| | | | | | | | |
|-----|----|------------------------|--------|-------------|--------------|-----|------|
| >D> | AP | HOSPIRA | 6MG/ML | A076131 001 | May 08, 2002 | Aug | CRLD |
| >A> | AP | + | 6MG/ML | A076131 001 | May 08, 2002 | Aug | CRLD |
| | | @ PLIVA LACHEMA | 6MG/ML | A077413 001 | Mar 12, 2008 | Apr | DISC |
| | | TAXOL | | | | | |
| | | @ BRISTOL MYERS SQUIBB | 6MG/ML | N020262 001 | Dec 29, 1992 | Jul | DISC |

PALIPERIDONE PALMITATE

SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR
INVEGA SUSTENNA
+ JOHNSON AND JOHNSON 234MG/1.5ML (156MG/ML)

N022264 005 Jul 31, 2009 Jan CRLD

PAMIDRONATE DISODIUM

INJECTABLE; INJECTION
PAMIDRONATE DISODIUM

| | | | | | | |
|----|-------------------|-----------|-------------|--------------|-----|------|
| AP | MN PHARMS | 30MG/VIAL | A078300 001 | Mar 10, 2009 | Feb | CAHN |
| AP | | 90MG/VIAL | A078300 002 | Mar 10, 2009 | Feb | CAHN |
| AP | SUN PHARMA GLOBAL | 30MG/VIAL | A077703 001 | Dec 24, 2008 | Jun | CAHN |
| AP | | 90MG/VIAL | A077703 002 | Dec 24, 2008 | Jun | CAHN |

PANCRELIPASE (AMYLASE;LIPASE;PROTEASE)

CAPSULE, DELAYED RELEASE; ORAL
CREON

| | | | | | |
|----------------------|--|-------------|--------------|-----|------|
| ABBOTT PRODS | 30,000USP UNITS;6,000USP UNITS;19,000USP UNITS | N020725 001 | Apr 30, 2009 | Mar | CAHN |
| | 60,000USP UNITS;12,000USP UNITS;38,000USP UNITS | N020725 002 | Apr 30, 2009 | Mar | CAHN |
| + | 120,000USP UNITS;24,000USP UNITS;76,000USP UNITS | N020725 003 | Apr 30, 2009 | Mar | CAHN |
| PANCREAZE | | | | | |
| ORTHO MCNEIL JANSSEN | 17,500USP/ UNITS;4,200USP/ UNITS;10,000USP/ UNITS | N022523 001 | Apr 12, 2010 | Apr | NEWA |
| | 43,750USP/ UNITS;10,500USP/ UNITS;25,000USP/ UNITS | N022523 002 | Apr 12, 2010 | Apr | NEWA |
| | 70,000USP/ UNITS;16,800USP/ UNITS;40,000USP/ UNITS | N022523 004 | Apr 12, 2010 | Apr | NEWA |
| + | 61,000USP/ UNITS;21,000USP/ UNITS;37,000USP/ UNITS | N022523 003 | Apr 12, 2010 | Apr | NEWA |

PANCURONIUM BROMIDE

INJECTABLE; INJECTION

| | | | | | |
|---------------------|--------|-------------|--------------|-----|------|
| PANCURONIUM BROMIDE | | | | | |
| @ ELKINS SINK | 1MG/ML | A072058 001 | Mar 23, 1988 | Jul | DISC |
| @ | 2MG/ML | A072060 001 | Mar 23, 1988 | Jul | DISC |
| @ | 2MG/ML | A072059 001 | Mar 23, 1988 | Jul | DISC |

PANTOPRAZOLE SODIUM

TABLET, DELAYED RELEASE; ORAL

| | | | | | |
|----------------------|--------------|-------------|--------------|-----|------|
| PANTOPRAZOLE SODIUM | | | | | |
| AB SUN PHARMA GLOBAL | EQ 20MG BASE | A077058 001 | Sep 10, 2007 | Jun | CAHN |
| AB | EQ 40MG BASE | A077058 002 | Sep 10, 2007 | Jun | CAHN |

PAROXETINE HYDROCHLORIDE

TABLET; ORAL

| | | | | | |
|--------------------------|--------------|-------------|--------------|-----|------|
| PAROXETINE HYDROCHLORIDE | | | | | |
| AB ACTAVIS ELIZABETH | EQ 10MG BASE | A076968 001 | Jun 21, 2010 | Jun | NEWA |
| AB | EQ 20MG BASE | A076968 002 | Jun 21, 2010 | Jun | NEWA |
| AB | EQ 30MG BASE | A076968 003 | Jun 21, 2010 | Jun | NEWA |
| AB | EQ 40MG BASE | A076968 004 | Jun 21, 2010 | Jun | NEWA |

PEGADEMASE BOVINE

INJECTABLE; INJECTION

| | | | | | |
|-------------|--------------|-------------|--------------|-----|------|
| ADAGEN | | | | | |
| + SIGMA TAU | 250 UNITS/ML | N019818 001 | Mar 21, 1990 | Feb | CAHN |

PENTETATE CALCIUM TRISODIUM

SOLUTION; INHALATION, INTRAVENOUS

PENTETATE CALCIUM TRISODIUM

@ HAMELN PHARMS EQ 1GM BASE/5ML (EQ 200MG
BASE/ML) N021749 001 Aug 11, 2004 Jun DISCPENTETATE ZINC TRISODIUM

SOLUTION; INHALATION, INTRAVENOUS

PENTETATE ZINC TRISODIUM

@ HAMELN PHARMS EQ 1GM BASE/5ML (EQ 200MG
BASE/ML) N021751 001 Aug 11, 2004 Jun DISCPERINDOPRIL ERBUMINE

TABLET; ORAL

ACEON

| | | | |
|----------------------|--------------|-----|-----------------------------------|
| AB | ABBOTT PRODS | 2MG | N020184 001 Dec 30, 1993 May CAHN |
| AB | | 4MG | N020184 002 Dec 30, 1993 May CAHN |
| AB | + | 8MG | N020184 003 Dec 30, 1993 May CAHN |
| PERINDOPRIL ERBUMINE | | | |
| >A> | AB APOTEX | 2MG | A090463 001 Aug 30, 2010 Aug NEWA |
| >A> | AB | 4MG | A090463 002 Aug 30, 2010 Aug NEWA |
| >A> | AB | 8MG | A090463 003 Aug 30, 2010 Aug NEWA |
| | LUPIN LTD | 2MG | A078263 001 Jan 27, 2010 Jan NEWA |
| | | 4MG | A078263 002 Jan 27, 2010 Jan NEWA |
| | | 8MG | A078263 003 Jan 27, 2010 Jan NEWA |

PHENDIMETRAZINE TARTRATE

CAPSULE, EXTENDED RELEASE; ORAL

BONTRIL

| | | | |
|----|---------|-------|-----------------------------------|
| BC | VALEANT | 105MG | A088021 001 Sep 21, 1982 Feb CAHN |
|----|---------|-------|-----------------------------------|

TABLET; ORAL

PHENDIMETRAZINE TARTRATE

| | | | |
|-----|-------------|------|-----------------------------------|
| >A> | AA KVK TECH | 35MG | A091042 001 Aug 31, 2010 Aug NEWA |
|-----|-------------|------|-----------------------------------|

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL

PHENTERMINE HYDROCHLORIDE

| | | | |
|----|---------|------|-----------------------------------|
| AA | BARR | 15MG | A090591 001 Mar 18, 2010 Mar NEWA |
| AA | | 30MG | A090591 002 Mar 18, 2010 Mar NEWA |
| AA | LANNETT | 30MG | A091359 001 Jul 16, 2010 Jul NEWA |

PILOCARPINE HYDROCHLORIDE

SOLUTION; OPHTHALMIC

CARPINE

| | | |
|-------|----|-----------------------------------|
| ALCON | 1% | N200890 001 Jun 22, 2010 Jun NEWA |
| | 2% | N200890 002 Jun 22, 2010 Jun NEWA |
| + | 4% | N200890 003 Jun 22, 2010 Jun NEWA |

PODOFILOX

SOLUTION; TOPICAL

PODOFILOX

| | | | |
|----|-----------------|------|-----------------------------------|
| AT | COLLEGIUM PHARM | 0.5% | A090184 001 Jul 21, 2010 Jul NEWA |
|----|-----------------|------|-----------------------------------|

POLIDOCANOL

SOLUTION; INTRAVENOUS

ASCLERA

| | | | | | |
|----------------------|--------------------|-------------|--------------|-----|------|
| CHEMISCH FBRK KRSSLR | 10MG/2ML (5MG/ML) | N021201 001 | Mar 30, 2010 | Mar | NEWA |
| + | 20MG/2ML (10MG/ML) | N021201 002 | Mar 30, 2010 | Mar | NEWA |

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

FOR SOLUTION; ORAL

LAX-LYTE WITH FLAVOR PACKS

| | | | | | |
|--|--|-------------|--------------|-----|------|
| AA PADDOCK | 420GM/BOT;1.48GM/BOT;5.72GM/BOT;1 1.2GM/BOT | A079232 001 | Feb 25, 2010 | Feb | NEWA |
| PEG-3350;POTASSIUM CHLORIDE;SODIUM BICARBONATE;SODIUM CHLORIDE | | | | | |
| AA MYLAN | 420GM/BOT;1.48GM/BOT;5.72GM/BOT;1 1.2GM/BOT | A090409 001 | Apr 02, 2010 | Mar | NEWA |

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE

FOR SOLUTION; ORAL

CLENZ-LYTE

| | | | | | |
|-----------------|--|-------------|--------------|-----|------|
| AA PADDOCK LABS | 236GM/BOT;2.97GM/BOT;6.74GM/BOT;5 .86GM/BOT;22.74GM/BOT | A090769 001 | Jun 07, 2010 | May | NEWA |
|-----------------|--|-------------|--------------|-----|------|

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE ANHYDROUS

FOR SOLUTION; ORAL

PEG 3350 AND ELECTROLYTES

| | | | | | |
|---|--|-------------|--------------|-----|------|
| AA MYLAN | 236GM;2.97GM;6.74GM;5.86GM;22.74G M | A090928 001 | Jan 28, 2010 | Jan | NEWA |
| POLYETHYLENE GLYCOL 3350 AND ELECTROLYTES | | | | | |
| AA PADDOCK LABS | 240GM/BOT;2.98GM/BOT;6.72GM/BOT;5 .84GM/BOT;22.72GM/BOT | A090712 001 | Feb 25, 2010 | Feb | NEWA |

POTASSIUM CHLORIDE

TABLET, EXTENDED RELEASE; ORAL

KLOR-CON

| | | | | | |
|-------------------|------|-------------|--------------|-----|------|
| BC + UPSHER SMITH | 8MEQ | N019123 001 | Apr 17, 1986 | Apr | CTEC |
|-------------------|------|-------------|--------------|-----|------|

POTASSIUM CITRATE

TABLET, EXTENDED RELEASE; ORAL

UROCIT-K

| | | | | | |
|-------------------------|-------|-------------|--------------|-----|------|
| >D> AB + MISSION PHARMA | 10MEQ | N019071 002 | Aug 31, 1992 | Aug | CRLD |
| >A> AB | 10MEQ | N019071 002 | Aug 31, 1992 | Aug | CRLD |
| >D> | 15MEQ | N019071 003 | Dec 30, 2009 | Aug | CRLD |
| >A> + | 15MEQ | N019071 003 | Dec 30, 2009 | Aug | CRLD |
| | 15MEQ | N019071 003 | Dec 30, 2009 | Feb | NEWA |

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET; ORAL

MIRAPEX

| | | | | | |
|-----------------------------|---------|-------------|--------------|-----|------|
| AB BOEHRINGER INGELHEIM | 0.75MG | N020667 007 | Jul 30, 2007 | Mar | CFTG |
| PRAMIPEXOLE DIHYDROCHLORIDE | | | | | |
| AB MYLAN | 0.75MG | A090764 001 | Apr 09, 2010 | Mar | NEWA |
| AB SANDOZ | 0.125MG | A090190 001 | Jul 06, 2010 | Jun | NEWA |
| AB | 0.25MG | A090190 002 | Jul 06, 2010 | Jun | NEWA |
| AB | 0.5MG | A090190 003 | Jul 06, 2010 | Jun | NEWA |
| AB | 1MG | A090190 004 | Jul 06, 2010 | Jun | NEWA |
| AB | 1.5MG | A090190 005 | Jul 06, 2010 | Jun | NEWA |
| AB ZYDUS PHARMS USA INC | 0.125MG | A078920 001 | Jul 06, 2010 | Jun | NEWA |

TABLET; ORAL

PRAMIPEXOLE DIHYDROCHLORIDE

| | | | | | | |
|----|----------------------|--------|-------------|--------------|-----|------|
| AB | ZYDUS PHARMS USA INC | 0.25MG | A078920 002 | Jul 06, 2010 | Jun | NEWA |
| AB | | 0.5MG | A078920 003 | Jul 06, 2010 | Jun | NEWA |
| AB | | 1MG | A078920 004 | Jul 06, 2010 | Jun | NEWA |
| AB | | 1.5MG | A078920 005 | Jul 06, 2010 | Jun | NEWA |

TABLET, EXTENDED RELEASE; ORAL

MIRAPEX ER

| | | | | | | |
|---|----------------------|---------|-------------|--------------|-----|------|
| | BOEHRINGER INGELHEIM | 0.375MG | N022421 001 | Feb 19, 2010 | Feb | NEWA |
| | | 0.75MG | N022421 002 | Feb 19, 2010 | Feb | NEWA |
| | | 1.5MG | N022421 003 | Feb 19, 2010 | Feb | NEWA |
| | | 3MG | N022421 004 | Feb 19, 2010 | Feb | NEWA |
| + | | 4.5MG | N022421 005 | Feb 19, 2010 | Feb | NEWA |

PRAVASTATIN SODIUMTABLET; ORAL

PRAVASTATIN SODIUM

| | | | | | | |
|----|-----------------|------|-------------|--------------|-----|------|
| AB | MATRIX LABS LTD | 10MG | A079187 001 | May 27, 2010 | May | NEWA |
| AB | | 20MG | A079187 002 | May 27, 2010 | May | NEWA |
| AB | | 40MG | A079187 003 | May 27, 2010 | May | NEWA |
| AB | | 80MG | A079187 004 | May 27, 2010 | May | NEWA |
| AB | WATSON LABS | 10MG | A076939 004 | Oct 23, 2006 | Jun | CAHN |
| AB | | 20MG | A076939 003 | Oct 23, 2006 | Jun | CAHN |
| AB | | 40MG | A076939 002 | Oct 23, 2006 | Jun | CAHN |
| AB | | 80MG | A076939 001 | Dec 28, 2007 | Jun | CAHN |

PRAZOSIN HYDROCHLORIDECAPSULE; ORAL

PRAZOSIN HYDROCHLORIDE

| | | | | | |
|---------------|-------------|-------------|--------------|-----|------|
| @ WATSON LABS | EQ 1MG BASE | A072352 001 | May 16, 1989 | Jan | DISC |
| @ | EQ 2MG BASE | A072333 001 | May 16, 1989 | Jan | DISC |

PREDNISOLONESYRUP; ORAL

PREDNISOLONE

| | | | | | |
|------------------------|----------|-------------|--------------|-----|------|
| @ IVAX SUB TEVA PHARMS | 15MG/5ML | A040287 001 | May 28, 1999 | Apr | DISC |
|------------------------|----------|-------------|--------------|-----|------|

PREDNISOLONE SODIUM PHOSPHATESOLUTION; ORAL

PREDNOSOLONE SODIUM PHOSPHATE

| | | | | | | |
|-----|---------------|------------------|-------------|--------------|-----|------|
| >A> | + PHARM ASSOC | EQ 25MG BASE/5ML | A091396 001 | Sep 13, 2010 | Aug | NEWA |
|-----|---------------|------------------|-------------|--------------|-----|------|

PREDNISONETABLET; ORAL

PREDNISONE

| | | | | | | |
|----|--------------------|-----|-------------|--|-----|------|
| AB | CONTRACT PHARMACAL | 5MG | A080209 001 | | Jan | CAHN |
|----|--------------------|-----|-------------|--|-----|------|

PREGABALINSOLUTION; ORAL

LYRICA

| | | | | | |
|----------|---------|-------------|--------------|-----|------|
| + PFIZER | 20MG/ML | N022488 001 | Jan 04, 2010 | Jan | NEWA |
|----------|---------|-------------|--------------|-----|------|

PROCAINE HYDROCHLORIDEINJECTABLE; INJECTION

PROCAINE HYDROCHLORIDE

| | | | | | |
|---------------|----|-------------|--|-----|------|
| @ WATSON LABS | 1% | A080658 001 | | Jan | DISC |
|---------------|----|-------------|--|-----|------|

PROCHLORPERAZINE MALEATE

TABLET; ORAL

PROCHLORPERAZINE MALEATE

| | |
|-----------------------|--------------|
| @ DURAMED PHARMS BARR | EQ 5MG BASE |
| @ | EQ 10MG BASE |
| PROCOMP | |
| AB CADISTA PHARMS | EQ 5MG BASE |
| AB | EQ 10MG BASE |

| | | | |
|-------------|--------------|-----|------|
| A040207 001 | May 01, 1997 | Jan | DISC |
| A040207 002 | May 01, 1997 | Jan | DISC |
| A040268 001 | Feb 27, 1998 | Jan | CTNA |
| A040268 002 | Feb 27, 1998 | Jan | CTNA |

PROGESTERONE

CAPSULE; ORAL

PROMETRIUM

| | | | | | |
|-----------------------|-------|-------------|--------------|-----|------|
| >A> ABBOTT PRODS | 100MG | N019781 001 | May 14, 1998 | Aug | CAHN |
| >A> + | 200MG | N019781 002 | Oct 15, 1999 | Aug | CAHN |
| >A> @ | 300MG | N019781 003 | Oct 15, 1999 | Aug | CAHN |
| >D> UNIMED PHARMS LLC | 100MG | N019781 001 | May 14, 1998 | Aug | CAHN |
| >D> + | 200MG | N019781 002 | Oct 15, 1999 | Aug | CAHN |
| >D> @ | 300MG | N019781 003 | Oct 15, 1999 | Aug | CAHN |
| GEL; VAGINAL | | | | | |
| CRINONE | | | | | |
| WATSON LABS | 4% | N020701 001 | Jul 31, 1997 | Jul | CAHN |
| + 8% | | N020701 002 | Jul 31, 1997 | Jul | CAHN |

PROPAFENONE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

RYTHMOL SR

| | | | | | |
|---------------------|-------|-------------|--------------|-----|------|
| GLAXOSMITHKLINE LLC | 225MG | N021416 001 | Sep 04, 2003 | Jun | CAHN |
| | 325MG | N021416 002 | Sep 04, 2003 | Jun | CAHN |
| + 425MG | | N021416 003 | Sep 04, 2003 | Jun | CAHN |

TABLET; ORAL

RYTHMOL

| | | | | | |
|------------------------|-------|-------------|--------------|-----|------|
| AB GLAXOSMITHKLINE LLC | 150MG | N019151 001 | Nov 27, 1989 | Jun | CAHN |
| AB 225MG | | N019151 003 | Nov 20, 1992 | Jun | CAHN |
| AB + 300MG | | N019151 002 | Nov 27, 1989 | Jun | CAHN |

PROPOFOL

INJECTABLE; INJECTION

PROPOFOL

| | | | | | |
|------------------------|---------|-------------|--------------|-----|------|
| >D> AB TEVA PARENTERAL | 10MG/ML | A075392 001 | Sep 19, 2000 | Aug | DISC |
| >A> @ | 10MG/ML | A075392 001 | Sep 19, 2000 | Aug | DISC |

PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL

PROPOXYPHENE HYDROCHLORIDE

| | | | | | |
|-------------|------|-------------|--|-----|------|
| @ PAR PHARM | 65MG | A080269 001 | | Jan | DISC |
|-------------|------|-------------|--|-----|------|

PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

INNOPRAN XL

| | | | | | |
|------------------------|-------|-------------|--------------|-----|------|
| BX GLAXOSMITHKLINE LLC | 80MG | N021438 001 | Mar 12, 2003 | Jun | CAHN |
| BX | 120MG | N021438 002 | Mar 12, 2003 | Jun | CAHN |

TABLET; ORAL

PROPRANOLOL HYDROCHLORIDE

| | | | | | |
|--------------|------|-------------|--------------|-----|------|
| @ INTERPHARM | 10MG | A071368 001 | May 05, 1987 | May | CAHN |
| @ | 20MG | A071369 001 | May 05, 1987 | May | CAHN |

TABLET; ORAL

PROPRANOLOL HYDROCHLORIDE

| | | | | | | |
|-------------------|------|---------|-----|--------------|-----|------|
| @ INTERPHARM | 40MG | A071370 | 001 | May 05, 1987 | May | CAHN |
| @ | 80MG | A071371 | 001 | May 05, 1987 | May | CAHN |
| AB PAR PHARM | 10MG | A070217 | 001 | Aug 01, 1986 | Jun | CMFD |
| AB | 20MG | A070218 | 001 | Aug 01, 1986 | Jun | CMFD |
| AB | 40MG | A070219 | 001 | Aug 01, 1986 | Jun | CMFD |
| AB | 60MG | A070220 | 001 | Sep 24, 1986 | Jun | CMFD |
| AB | 80MG | A070221 | 001 | Apr 14, 1986 | Jun | CMFD |
| AB VINTAGE PHARMS | 10MG | A070217 | 001 | Aug 01, 1986 | Jul | CAHN |
| AB | 20MG | A070218 | 001 | Aug 01, 1986 | Jul | CAHN |
| AB | 40MG | A070219 | 001 | Aug 01, 1986 | Jul | CAHN |
| AB | 60MG | A070220 | 001 | Sep 24, 1986 | Jul | CAHN |
| AB | 80MG | A070221 | 001 | Apr 14, 1986 | Jul | CAHN |

PROTRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

PROTRIPTYLINE HYDROCHLORIDE

| | | | | | | |
|------------------------|------|---------|-----|--------------|-----|------|
| AB SIGMAPHARM LABS LLC | 5MG | A090462 | 001 | May 03, 2010 | Apr | NEWA |
| AB | 10MG | A090462 | 002 | May 03, 2010 | Apr | NEWA |

PYRIMETHAMINE

TABLET; ORAL

DARAPRIM

| | |
|-----------------------|------|
| + GLAXOSMITHKLINE LLC | 25MG |
|-----------------------|------|

N008578 001 Jun CAHN

QUINIDINE SULFATE

TABLET; ORAL

QUINIDINE SULFATE

| | |
|----------------------|-------|
| @ CONTRACT PHARMACAL | 200MG |
|----------------------|-------|

A083808 001 Jan CAHN

RAMIPRIL

CAPSULE; ORAL

RAMIPRIL

| | | | | | | |
|----------------|--------|---------|-----|--------------|-----|------|
| AB WATSON LABS | 1.25MG | A076549 | 001 | Oct 24, 2005 | Jun | CAHN |
| AB | 2.5MG | A076549 | 002 | Oct 24, 2005 | Jun | CAHN |
| AB | 5MG | A076549 | 003 | Oct 24, 2005 | Jun | CAHN |
| AB | 10MG | A076549 | 004 | Oct 24, 2005 | Jun | CAHN |

RANITIDINE HYDROCHLORIDE

SYRUP; ORAL

RANITIDINE HYDROCHLORIDE

| | | | | | | |
|--------------------|-----------------|---------|-----|--------------|-----|------|
| AA AUROBINDO PHARM | EQ 15MG BASE/ML | A090623 | 001 | Jul 28, 2010 | Jul | NEWA |
| AA VINTAGE PHARMS | EQ 15MG BASE/ML | A078890 | 001 | Jul 01, 2010 | Jun | NEWA |

TABLET; ORAL

RANITIDINE HYDROCHLORIDE

| | | | | | | |
|----------------|---------------|---------|-----|--------------|-----|------|
| AB WATSON LABS | EQ 150MG BASE | A077426 | 001 | Dec 19, 2005 | Jun | CAHN |
| AB | EQ 300MG BASE | A077426 | 002 | Dec 19, 2005 | Jun | CAHN |

RIFAXIMIN

TABLET; ORAL

XIFAXAN

| | |
|--------------|-------|
| SALIX PHARMS | 550MG |
|--------------|-------|

N021361 002 Mar 24, 2010 Mar NEWA

RISPERIDONE

INJECTABLE; INTRAMUSCULAR

RISPERDAL CONSTA

| | |
|------------------------|-----------|
| + ORTHO MCNEIL JANSSEN | 25MG/VIAL |
| | 50MG/VIAL |

| | | | |
|-------------|--------------|-----|------|
| N021346 001 | Oct 29, 2003 | Jan | CRLD |
| N021346 003 | Oct 29, 2003 | Jan | CRLD |

SOLUTION; ORAL

RISPERIDONE

| | |
|-------------------|--------|
| AA PRECISION DOSE | 1MG/ML |
|-------------------|--------|

| | | | |
|-------------|--------------|-----|------|
| A076797 001 | Jun 28, 2010 | Jun | NEWA |
|-------------|--------------|-----|------|

TABLET; ORAL

RISPERIDONE

| | |
|---------------|--------|
| AB RATIOPHARM | 0.25MG |
|---------------|--------|

| | | | |
|-------------|--------------|-----|------|
| A077784 001 | Jun 08, 2010 | May | NEWA |
|-------------|--------------|-----|------|

| | |
|----|-------|
| AB | 0.5MG |
|----|-------|

| | | | |
|-------------|--------------|-----|------|
| A077784 002 | Jun 08, 2010 | May | NEWA |
|-------------|--------------|-----|------|

| | |
|----|-----|
| AB | 1MG |
|----|-----|

| | | | |
|-------------|--------------|-----|------|
| A077784 003 | Jun 08, 2010 | May | NEWA |
|-------------|--------------|-----|------|

| | |
|----|-----|
| AB | 2MG |
|----|-----|

| | | | |
|-------------|--------------|-----|------|
| A077784 004 | Jun 08, 2010 | May | NEWA |
|-------------|--------------|-----|------|

| | |
|----|-----|
| AB | 3MG |
|----|-----|

| | | | |
|-------------|--------------|-----|------|
| A077784 005 | Jun 08, 2010 | May | NEWA |
|-------------|--------------|-----|------|

| | |
|----|-----|
| AB | 4MG |
|----|-----|

| | | | |
|-------------|--------------|-----|------|
| A077784 006 | Jun 08, 2010 | May | NEWA |
|-------------|--------------|-----|------|

| | |
|------------------|--------|
| @ SYNTHON PHARMS | 0.25MG |
|------------------|--------|

| | | | |
|-------------|--------------|-----|------|
| A078187 001 | Oct 22, 2009 | Feb | DISC |
|-------------|--------------|-----|------|

| | |
|---|-------|
| @ | 0.5MG |
|---|-------|

| | | | |
|-------------|--------------|-----|------|
| A078187 002 | Oct 22, 2009 | Feb | DISC |
|-------------|--------------|-----|------|

| | |
|---|-----|
| @ | 1MG |
|---|-----|

| | | | |
|-------------|--------------|-----|------|
| A078187 003 | Oct 22, 2009 | Feb | DISC |
|-------------|--------------|-----|------|

| | |
|---|-----|
| @ | 2MG |
|---|-----|

| | | | |
|-------------|--------------|-----|------|
| A078187 004 | Oct 22, 2009 | Feb | DISC |
|-------------|--------------|-----|------|

| | |
|---|-----|
| @ | 3MG |
|---|-----|

| | | | |
|-------------|--------------|-----|------|
| A078187 005 | Oct 22, 2009 | Feb | DISC |
|-------------|--------------|-----|------|

| | |
|---|-----|
| @ | 4MG |
|---|-----|

| | | | |
|-------------|--------------|-----|------|
| A078187 006 | Oct 22, 2009 | Feb | DISC |
|-------------|--------------|-----|------|

| | |
|----------------|--------|
| AB WATSON LABS | 0.25MG |
|----------------|--------|

| | | | |
|-------------|--------------|-----|------|
| A077860 001 | Dec 05, 2008 | Jun | CAHN |
|-------------|--------------|-----|------|

| | |
|----|-------|
| AB | 0.5MG |
|----|-------|

| | | | |
|-------------|--------------|-----|------|
| A077860 002 | Dec 05, 2008 | Jun | CAHN |
|-------------|--------------|-----|------|

| | |
|----|-----|
| AB | 1MG |
|----|-----|

| | | | |
|-------------|--------------|-----|------|
| A077860 003 | Dec 05, 2008 | Jun | CAHN |
|-------------|--------------|-----|------|

| | |
|----|-----|
| AB | 2MG |
|----|-----|

| | | | |
|-------------|--------------|-----|------|
| A077860 004 | Dec 05, 2008 | Jun | CAHN |
|-------------|--------------|-----|------|

| | |
|----|-----|
| AB | 3MG |
|----|-----|

| | | | |
|-------------|--------------|-----|------|
| A077860 005 | Dec 05, 2008 | Jun | CAHN |
|-------------|--------------|-----|------|

| | |
|----|-----|
| AB | 4MG |
|----|-----|

| | | | |
|-------------|--------------|-----|------|
| A077860 006 | Dec 05, 2008 | Jun | CAHN |
|-------------|--------------|-----|------|

TABLET, ORALLY DISINTEGRATING; ORAL

RISPERIDONE

| | |
|------------|-------|
| AB RANBAXY | 0.5MG |
|------------|-------|

| | | | |
|-------------|--------------|-----|------|
| A077542 001 | Aug 06, 2010 | Jul | NEWA |
|-------------|--------------|-----|------|

| | |
|----|-----|
| AB | 1MG |
|----|-----|

| | | | |
|-------------|--------------|-----|------|
| A077542 002 | Aug 06, 2010 | Jul | NEWA |
|-------------|--------------|-----|------|

| | |
|----|-----|
| AB | 2MG |
|----|-----|

| | | | |
|-------------|--------------|-----|------|
| A077542 003 | Aug 06, 2010 | Jul | NEWA |
|-------------|--------------|-----|------|

| | |
|--------|-----|
| >A> AB | 3MG |
|--------|-----|

| | | | |
|-------------|--------------|-----|------|
| A078474 001 | Aug 06, 2010 | Aug | NEWA |
|-------------|--------------|-----|------|

| | |
|--------|-----|
| >A> AB | 4MG |
|--------|-----|

| | | | |
|-------------|--------------|-----|------|
| A078474 002 | Aug 06, 2010 | Aug | NEWA |
|-------------|--------------|-----|------|

RITONAVIR

TABLET; ORAL

NORVIR

| | |
|---------------|-------|
| + ABBOTT LABS | 100MG |
|---------------|-------|

| | | | |
|-------------|--------------|-----|------|
| N022417 001 | Feb 10, 2010 | May | CTNA |
|-------------|--------------|-----|------|

| | |
|---------------|-------|
| + ABBOTT LABS | 100MG |
|---------------|-------|

| | | | |
|-------------|--------------|-----|------|
| N022417 001 | Feb 10, 2010 | Feb | NEWA |
|-------------|--------------|-----|------|

RIVASTIGMINE TARTRATE

CAPSULE; ORAL

EXELON

| | |
|-------------|-------------|
| AB NOVARTIS | EQ 6MG BASE |
|-------------|-------------|

| | | | |
|-------------|--------------|-----|------|
| N020823 006 | Apr 21, 2000 | Feb | CRLD |
|-------------|--------------|-----|------|

ROCURONIUM BROMIDE

INJECTABLE; INJECTION

ROCURONIUM BROMIDE

| | |
|------------------------|----------------------|
| AP BIONICHE PHARMA USA | 50MG/5ML (10MG/ML) |
| | 100MG/10ML (10MG/ML) |
| AP SAGENT PHARMS | 50MG/5ML (10MG/ML) |
| | 100MG/10ML (10MG/ML) |

| | | | |
|-------------|--------------|-----|------|
| A079199 001 | Nov 26, 2008 | Mar | CAHN |
| A079199 002 | Nov 26, 2008 | Mar | CAHN |
| A091458 001 | Jul 28, 2010 | Jul | NEWA |
| A091458 002 | Jul 28, 2010 | Jul | NEWA |

ROMIDEPSIN

POWDER; IV (INFUSION)

ISTODAX

+ CELGENE

10MG/VIAL

N022393 001 Nov 05, 2009 Jul CAHN

ROPINIROLE HYDROCHLORIDE

TABLET; ORAL

ROPINIROLE HYDROCHLORIDE

| | | | | | | |
|----|-------------------|----------------|-------------|--------------|-----|------|
| AB | ALEMBIC LTD | EQ 0.25MG BASE | A090429 001 | Mar 24, 2010 | Mar | NEWA |
| AB | | EQ 0.5MG BASE | A090429 002 | Mar 24, 2010 | Mar | NEWA |
| AB | | EQ 1MG BASE | A090429 003 | Mar 24, 2010 | Mar | NEWA |
| AB | | EQ 2MG BASE | A090429 004 | Mar 24, 2010 | Mar | NEWA |
| AB | | EQ 3MG BASE | A090429 005 | Mar 24, 2010 | Mar | NEWA |
| AB | | EQ 4MG BASE | A090429 006 | Mar 24, 2010 | Mar | NEWA |
| AB | | EQ 5MG BASE | A090429 007 | Mar 24, 2010 | Mar | NEWA |
| AB | GLENMARK GENERICS | EQ 0.25MG BASE | A090135 001 | Feb 25, 2010 | Feb | NEWA |
| AB | | EQ 0.5MG BASE | A090135 002 | Feb 25, 2010 | Feb | NEWA |
| AB | | EQ 1MG BASE | A090135 003 | Feb 25, 2010 | Feb | NEWA |
| AB | | EQ 2MG BASE | A090135 004 | Feb 25, 2010 | Feb | NEWA |
| AB | | EQ 3MG BASE | A090135 005 | Feb 25, 2010 | Feb | NEWA |
| AB | | EQ 4MG BASE | A090135 006 | Feb 25, 2010 | Feb | NEWA |
| AB | | EQ 5MG BASE | A090135 007 | Feb 25, 2010 | Feb | NEWA |

SELEGILINE HYDROCHLORIDE

TABLET; ORAL

SELEGILINE HYDROCHLORIDE

| | | | | | | |
|----|-------|-----|-------------|--------------|-----|------|
| AB | MYLAN | 5MG | A074866 001 | Nov 26, 1997 | Mar | CAHN |
|----|-------|-----|-------------|--------------|-----|------|

SERTRALINE HYDROCHLORIDE

TABLET; ORAL

SERTRALINE HYDROCHLORIDE

| | | | | | | |
|----|----------------|---------------|-------------|--------------|-----|------|
| AB | ACTAVIS TOTOWA | EQ 25MG BASE | A078175 001 | Jul 21, 2010 | Jul | NEWA |
| AB | | EQ 50MG BASE | A078175 002 | Jul 21, 2010 | Jul | NEWA |
| AB | | EQ 100MG BASE | A078175 003 | Jul 21, 2010 | Jul | NEWA |
| | @ SANDOZ | EQ 25MG BASE | A077713 001 | Feb 06, 2007 | May | DISC |
| | @ | EQ 50MG BASE | A077713 002 | Feb 06, 2007 | May | DISC |
| | @ | EQ 100MG BASE | A077713 003 | Feb 06, 2007 | May | DISC |
| AB | WATSON LABS | EQ 25MG BASE | A077663 001 | Feb 06, 2007 | Jun | CAHN |
| AB | | EQ 50MG BASE | A077663 002 | Feb 06, 2007 | Jun | CAHN |
| AB | | EQ 100MG BASE | A077663 003 | Feb 06, 2007 | Jun | CAHN |

SILVER SULFADIAZINE

CREAM; TOPICAL

THERMAZENE

| | | | | | | | |
|-----|----|------------|----|-------------|--------------|-----|------|
| >A> | AB | COVIDIEN | 1% | N018810 001 | Dec 23, 1985 | Aug | CAHN |
| >D> | AB | KENDALL LP | 1% | N018810 001 | Dec 23, 1985 | Aug | CAHN |

SIMVASTATIN

TABLET; ORAL

SIMVASTATIN

| | | | | | | | |
|-----|----|----------------|------|-------------|--------------|-----|------|
| >A> | AB | ACTAVIS TOTOWA | 5MG | A078735 001 | Aug 30, 2010 | Aug | NEWA |
| >A> | AB | | 10MG | A078735 002 | Aug 30, 2010 | Aug | NEWA |
| >A> | AB | | 20MG | A078735 003 | Aug 30, 2010 | Aug | NEWA |
| >A> | AB | | 40MG | A078735 004 | Aug 30, 2010 | Aug | NEWA |
| >A> | AB | | 80MG | A078735 005 | Aug 30, 2010 | Aug | NEWA |

TABLET; ORALSIMVASTATIN

| | | | | | | |
|----|-----------------|------|-------------|--------------|-----|------|
| AB | MATRIX LABS LTD | 5MG | A090868 001 | Jun 08, 2010 | May | NEWA |
| AB | | 10MG | A090868 002 | Jun 08, 2010 | May | NEWA |
| AB | | 20MG | A090868 003 | Jun 08, 2010 | May | NEWA |
| AB | | 40MG | A090868 004 | Jun 08, 2010 | May | NEWA |
| AB | | 80MG | A090868 005 | Jun 08, 2010 | May | NEWA |
| AB | WATSON LABS | 5MG | A076685 001 | Dec 20, 2006 | Jun | CAHN |
| AB | | 10MG | A076685 002 | Dec 20, 2006 | Jun | CAHN |
| AB | | 20MG | A076685 003 | Dec 20, 2006 | Jun | CAHN |
| AB | | 40MG | A076685 004 | Dec 20, 2006 | Jun | CAHN |
| AB | | 80MG | A076685 005 | Dec 20, 2006 | Jun | CAHN |

SIROLIMUSTABLET; ORALRAPAMUNE

WYETH PHARMS INC

0.5MG

N021110 004 Jan 25, 2010 Jun NEWA

SODIUM BICARBONATEINJECTABLE; INJECTIONSODIUM BICARBONATE

+ HOSPIRA

0.9MEQ/ML

A077394 001 Nov 09, 2005 Feb CRLD

SODIUM IODIDE I-131CAPSULE; ORALHICON

+ DRAXIMAGE

1-1,000UCI/1ML

N021305 005 Apr 04, 2006 Jul NEWA

SOMATROPIN RECOMBINANTINJECTABLE; INJECTIONNORDITROPIN FLEXPRO

BX NOVO NORDISK INC

5MG/1.5ML

N021148 008 Mar 01, 2010 Mar NEWA

BX

10MG/1.5ML

N021148 009 Mar 01, 2010 Mar NEWA

15MG/1.5ML

N021148 010 Mar 01, 2010 Mar NEWA

SPIRONOLACTONETABLET; ORALSPIRONOLACTONE

AB AMNEAL PHARMS

25MG

A091426 001 Jun 08, 2010 Jun NEWA

AB

50MG

A091426 002 Jun 08, 2010 Jun NEWA

AB

100MG

A091426 003 Jun 08, 2010 Jun NEWA

STAVUDINECAPSULE; ORALSTAVUDINE

AB MYLAN

15MG

A079069 001 Dec 29, 2008 Feb CAHN

AB

20MG

A079069 002 Dec 29, 2008 Feb CAHN

AB

30MG

A079069 003 Dec 29, 2008 Feb CAHN

AB

40MG

A079069 004 Dec 29, 2008 Feb CAHN

SUCRALFATETABLET; ORALSUCRALFATE

AB NOSTRUM LABS

1GM

A074415 001 Jun 08, 1998 Mar CAHN

SULFAMETHOXAZOLE; TRIMETHOPRIM

SUSPENSION; ORAL

SULFAMETHOXAZOLE AND TRIMETHOPRIM

| | | | | | | |
|----|------------------|--------------------|-------------|--------------|-----|------|
| AB | AUROBINDO PHARMA | 200MG/5ML;40MG/5ML | A091348 001 | Jun 08, 2010 | May | NEWA |
| AB | + HI TECH PHARMA | 200MG/5ML;40MG/5ML | A074650 001 | Dec 29, 1997 | May | CRLD |
| | @ TEVA PHARMS | 200MG/5ML;40MG/5ML | A077612 001 | Nov 13, 2006 | May | DISC |

TABLET; ORAL

SULFAMETHOXAZOLE AND TRIMETHOPRIM

| | | | | | | |
|----|------------------|-------------|-------------|--------------|-----|------|
| AB | AUROBINDO PHARMA | 400MG;80MG | A090624 001 | Feb 16, 2010 | Jan | NEWA |
| AB | | 800MG;160MG | A090624 002 | Feb 16, 2010 | Jan | NEWA |
| | @ INTERPHARM | 400MG;80MG | A071299 001 | Oct 27, 1987 | May | CAHN |
| | @ | 800MG;160MG | A071300 001 | Oct 27, 1987 | May | CAHN |

SULFISOXAZOLE

TABLET; ORAL

SULFISOXAZOLE

@ IVAX SUB TEVA PHARMS 500MG

A080142 001 Apr DISC

SUMATRIPTAN

SPRAY; NASAL

IMITREX

@ GLAXOSMITHKLINE 10MG/SPRAY

N020626 002 Aug 26, 1997 Jul DISC

SUMATRIPTAN SUCCINATE

INJECTABLE; SUBCUTANEOUS

ALSUMA

| | | | | | |
|---------------|--|-------------|--------------|-----|------|
| + KING PHARMS | EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) | N022377 001 | Jun 29, 2010 | Jun | NEWA |
|---------------|--|-------------|--------------|-----|------|

SUMATRIPTAN SUCCINATE

| | | | | | |
|-------------------|--|-------------|--------------|-----|------|
| AP BEDFORD LABS | EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) | A090310 001 | Aug 11, 2010 | Jul | NEWA |
| AP SAGENT STRIDES | EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) | A090641 001 | Jul 28, 2010 | Jul | NEWA |
| AP | EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) | A090314 001 | Jun 10, 2010 | May | NEWA |

SUMAVEL DOSEPRO

| | | | | | |
|---------------|--|-------------|--------------|-----|------|
| + ZOGENIX INC | EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) | N022239 001 | Jul 15, 2009 | Jun | CPOT |
|---------------|--|-------------|--------------|-----|------|

TABLET; ORAL

SUMATRIPTAN SUCCINATE

| | | | | | |
|----------------|---------------|-------------|--------------|-----|------|
| AB WATSON LABS | EQ 25MG BASE | A076933 001 | Aug 10, 2009 | Jun | CAHN |
| AB | EQ 50MG BASE | A076933 002 | Aug 10, 2009 | Jun | CAHN |
| AB | EQ 100MG BASE | A076933 003 | Aug 10, 2009 | Jun | CAHN |

TACROLIMUS

CAPSULE; ORAL

TACROLIMUS

| | | | | | |
|-----------------------|---------------|-------------|--------------|-----|------|
| AB DR REDDYS LABS LTD | EQ 0.5MG BASE | A090509 001 | May 12, 2010 | May | NEWA |
| AB | EQ 1MG BASE | A090509 002 | May 12, 2010 | May | NEWA |
| AB | EQ 5MG BASE | A090509 003 | May 12, 2010 | May | NEWA |
| AB WATSON LABS | EQ 5MG BASE | A090402 001 | Jul 01, 2010 | Jun | NEWA |

TAMSULOSIN HYDROCHLORIDE

CAPSULE; ORAL

FLOMAX

| | | | | | |
|---------------------------|-------|-------------|--------------|-----|------|
| AB + BOEHRINGER INGELHEIM | 0.4MG | N020579 001 | Apr 15, 1997 | Feb | CFTG |
|---------------------------|-------|-------------|--------------|-----|------|

CAPSULE; ORAL

TAMSULOSIN HYDROCHLORIDE

| | | | | | | |
|----|----------------------|-------|-------------|--------------|-----|------|
| AB | IMPAK LABS | 0.4MG | A090377 001 | Mar 02, 2010 | Feb | NEWA |
| AB | MYLAN | 0.4MG | A090408 001 | Apr 27, 2010 | Apr | NEWA |
| AB | SANDOZ | 0.4MG | A078015 001 | Apr 27, 2010 | Apr | NEWA |
| AB | SUN PHARM INDS LTD | 0.4MG | A090931 001 | Jul 15, 2010 | Jul | NEWA |
| AB | SYNTHON PHARMS | 0.4MG | A078801 001 | Apr 27, 2010 | Apr | NEWA |
| AB | TEVA PHARMS | 0.4MG | A077630 001 | Apr 27, 2010 | Apr | NEWA |
| AB | WOCKHARDT | 0.4MG | A078938 001 | Apr 27, 2010 | Apr | NEWA |
| AB | ZYDUS PHARMS USA INC | 0.4MG | A078225 001 | Apr 27, 2010 | Apr | NEWA |

TECHNETIUM TC-99M MEDRONATE

INJECTABLE; INJECTION

DRAXIMAGE MDP-10

| | | | | | |
|---|------------------|-----|-------------|--------------|----------|
| @ | DRAXIMAGE | N/A | N018035 001 | Jul | DISC |
| | DRAXIMAGE MDP-25 | | | | |
| + | DRAXIMAGE | N/A | N018035 002 | Feb 27, 2004 | Jul CMFD |

TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR

SOLUTION; INJECTION, ORAL

TECHNELITE

| | | | | | |
|---|--------------------|-------------------------|-------------|-----|------|
| + | LANTHEUS MEDCL | 0.0083-2.7 CI/GENERATOR | N017771 001 | Feb | CRLD |
| | ULTRA-TECHNEKOW FM | | | | |
| + | MALLINCKRODT | 0.25-3 CI/GENERATOR | N017243 002 | Feb | CRLD |

TEMAZEPMAM

CAPSULE; ORAL

TEMAZEPMAM

| | | | | | | |
|----|-------|-------|-------------|--------------|-----|------|
| AB | MYLAN | 7.5MG | A070920 002 | May 21, 2010 | May | NEWA |
|----|-------|-------|-------------|--------------|-----|------|

TEMOZOLOMIDE

CAPSULE; ORAL

TEMODAR

| | | | | | | |
|----|----------|-------|-------------|--------------|-----|------|
| AB | SCHERING | 5MG | N021029 001 | Aug 11, 1999 | Feb | CFTG |
| AB | | 20MG | N021029 002 | Aug 11, 1999 | Feb | CFTG |
| AB | | 100MG | N021029 003 | Aug 11, 1999 | Feb | CFTG |
| AB | | 140MG | N021029 005 | Oct 19, 2006 | Feb | CFTG |
| AB | | 180MG | N021029 006 | Oct 19, 2006 | Feb | CFTG |
| AB | + | 250MG | N021029 004 | Aug 11, 1999 | Feb | CFTG |

TEMOZOLOMIDE

| | | | | | | |
|----|------|-------|-------------|--------------|-----|------|
| AB | BARR | 5MG | A078879 001 | Mar 01, 2010 | Feb | NEWA |
| AB | | 20MG | A078879 002 | Mar 01, 2010 | Feb | NEWA |
| AB | | 100MG | A078879 003 | Mar 01, 2010 | Feb | NEWA |
| AB | | 140MG | A078879 005 | Mar 01, 2010 | Feb | NEWA |
| AB | | 180MG | A078879 006 | Mar 01, 2010 | Feb | NEWA |
| AB | | 250MG | A078879 004 | Mar 01, 2010 | Feb | NEWA |

TERBINAFINE

GEL; TOPICAL

LAMISIL

@ NOVARTIS

1%

N020846 001 Apr 29, 1998 Jun DISC

TERBINAFINE HYDROCHLORIDE

SOLUTION; TOPICAL

LAMISIL

@ NOVARTIS

1%

N020749 001 Oct 17, 1997 Jun DISC

TABLET; ORAL

TERBINAFINE HYDROCHLORIDE

| | | | |
|----|----------------------|---------------|-----------------------------------|
| AB | BRECKENRIDGE PHARM | EQ 250MG BASE | A077714 001 Jun 04, 2010 May NEWA |
| | @ GEDEON RICHTER USA | EQ 250MG BASE | A077065 001 Jul 02, 2007 Jun DISC |

TERCONAZOLE

CREAM; VAGINAL

TERCONAZOLE

| | | | | |
|----|---|------------|------|-----------------------------------|
| BX | + | NYCOMED US | 0.8% | N021735 001 Oct 01, 2004 Jan CAHN |
|----|---|------------|------|-----------------------------------|

TERIPARATIDE RECOMBINANT HUMAN

INJECTABLE; SUBCUTANEOUS

FORTEO

| | | | |
|-----|---------|-------------------------|-----------------------------------|
| >D> | @ LILLY | 0.6MG/2.4ML (0.25MG/ML) | N021318 002 Jun 25, 2008 Aug CMFD |
| >A> | + | 0.6MG/2.4ML (0.25MG/ML) | N021318 002 Jun 25, 2008 Aug CMFD |
| | @ | 0.6MG/2.4ML (0.25MG/ML) | N021318 002 Jun 25, 2008 Jul DISC |
| | + | 0.6MG/2.4ML (0.25MG/ML) | N021318 002 Jun 25, 2008 Jun CRLD |
| | @ | 0.75MG/3ML (0.25MG/ML) | N021318 001 Nov 26, 2002 Jun DISC |

TESTOSTERONE

GEL; TRANSDERMAL

ANDROGEL

| | | | | | |
|-----|----|---|---------------------------|------------------------|-----------------------------------|
| >A> | BX | + | ABBOTT PRODS | 1% (5GM/PACKET) | N021015 002 Feb 28, 2000 Aug CAHN |
| >A> | | | | 1% (2.5GM/PACKET) | N021015 001 Feb 28, 2000 Aug CAHN |
| >D> | | | UNIMED PHARMS | 1% (2.5GM/PACKET) | N021015 001 Feb 28, 2000 Aug CAHN |
| >D> | BX | + | | 1% (5GM/PACKET) | N021015 002 Feb 28, 2000 Aug CAHN |
| | | | GEL, METERED; TRANSDERMAL | | |
| | | | ANDROGEL | | |
| >A> | | + | ABBOTT PRODS | 1% (1.25GM/ACTIVATION) | N021015 003 Sep 26, 2003 Aug CAHN |
| >D> | | + | UNIMED PHARMS | 1% (1.25GM/ACTIVATION) | N021015 003 Sep 26, 2003 Aug CAHN |

TESTOSTERONE CYPIONATE

INJECTABLE; INJECTION

TESTOSTERONE CYPIONATE

| | | | |
|----|---------|----------|-----------------------------------|
| AO | BEDFORD | 100MG/ML | A090387 001 Jul 15, 2010 Jul NEWA |
| AO | | 200MG/ML | A090387 002 Jul 15, 2010 Jul NEWA |

THEOPHYLLINE

ELIXIR; ORAL

ELIXOPHYLLIN

| | | | |
|---|--------|-----------|----------------------|
| + | CARACO | 80MG/15ML | A085186 001 Mar CAHN |
|---|--------|-----------|----------------------|

TABLET, EXTENDED RELEASE; ORAL

THEOCHRON

| | | | |
|----|--------|-------|-----------------------------------|
| AB | CARACO | 100MG | A088320 001 Feb 21, 1985 Mar CAHN |
| AB | | 200MG | A088321 001 Feb 21, 1985 Mar CAHN |
| AB | | 300MG | A087400 002 Jan 11, 1983 Mar CAHN |

THEOPHYLLINE

| | | | |
|----|-------------------|-------|-----------------------------------|
| AB | GLENMARK GENERICS | 400MG | A090355 001 Jul 13, 2010 Jun NEWA |
| AB | | 600MG | A090355 002 Jul 13, 2010 Jun NEWA |

| | | | |
|----|---------|-------|-----------------------------------|
| AB | NOSTRUM | 400MG | A040595 001 Apr 21, 2006 Jul CTEC |
| | | 400MG | A040595 001 Apr 21, 2006 Jun CTEC |

| | | | |
|----|---|-------|-----------------------------------|
| AB | + | 600MG | A040560 002 Apr 21, 2006 Jul CTEC |
| | + | 600MG | A040560 002 Apr 21, 2006 Jun CRLD |

UNIPHYL

| | | |
|----------------------|-------|-----------------------------------|
| @ PURDUE PHARM PRODS | 400MG | A087571 001 Sep 01, 1982 Jun DISC |
|----------------------|-------|-----------------------------------|

| | | |
|---|-------|-----------------------------------|
| @ | 600MG | A040086 001 Apr 15, 1996 Jun DISC |
|---|-------|-----------------------------------|

THIORIDAZINE HYDROCHLORIDE

TABLET; ORAL

THIORIDAZINE HYDROCHLORIDE

| | | | | | | | |
|-----|----|--------------|------|-------------|--------------|-----|------|
| >A> | AB | MUTUAL PHARM | 10MG | A089953 004 | Aug 01, 1986 | Aug | NEWA |
| >A> | AB | | 25MG | A089953 003 | Aug 01, 1986 | Aug | NEWA |
| >A> | AB | | 50MG | A089953 002 | Aug 01, 1986 | Aug | NEWA |

TINZAPARIN SODIUM

INJECTABLE; INJECTION

INNOHEP

+ LEO PHARMA AS 20,000 IU/ML

N020484 001 Jul 14, 2000 Feb CAHN

TOLAZAMIDE

TABLET; ORAL

TOLAZAMIDE

@ INTERPHARM 250MG
@ 500MGA071270 001 Sep 23, 1986 May CAHN
A071271 001 Sep 23, 1986 May CAHNTOLMETIN SODIUM

TABLET; ORAL

TOLMETIN SODIUM

@ IVAX SUB TEVA PHARMS EQ 600MG BASE

A074399 001 Mar 28, 1996 Apr DISC

TOPIRAMATE

CAPSULE; ORAL

TOPIRAMATE

| | | | | | | |
|----|-------------|------|-------------|--------------|-----|------|
| AB | WATSON LABS | 15MG | A077868 001 | Apr 15, 2009 | Jun | CAHN |
| AB | | 25MG | A077868 002 | Apr 15, 2009 | Jun | CAHN |

TABLET; ORAL

TOPIRAMATE

@ PLIVA HRVATSKA DOO 25MG
@ 50MG
@ 100MG
@ 200MGA077905 001 Mar 30, 2009 Jan DISC
A077905 002 Mar 30, 2009 Jan DISC
A077905 003 Mar 30, 2009 Jan DISC
A077905 004 Mar 30, 2009 Jan DISC

| | | | | | | | |
|-----|----|---------------|-------|-------------|--------------|-----|------|
| >D> | AB | ROXANE | 25MG | A076306 001 | Mar 27, 2009 | Aug | DISC |
| >A> | | @ | 25MG | A076306 001 | Mar 27, 2009 | Aug | DISC |
| >D> | AB | | 50MG | A076306 002 | Mar 27, 2009 | Aug | DISC |
| >A> | | @ | 50MG | A076306 002 | Mar 27, 2009 | Aug | DISC |
| >D> | AB | | 100MG | A076306 003 | Mar 27, 2009 | Aug | DISC |
| >A> | | @ | 100MG | A076306 003 | Mar 27, 2009 | Aug | DISC |
| >D> | AB | | 200MG | A076306 004 | Mar 27, 2009 | Aug | DISC |
| >A> | | @ | 200MG | A076306 004 | Mar 27, 2009 | Aug | DISC |
| | AB | WATSON LABS | 25MG | A077643 001 | Mar 27, 2009 | Jun | CAHN |
| | AB | | 50MG | A077643 002 | Mar 27, 2009 | Jun | CAHN |
| | AB | | 100MG | A077643 003 | Mar 27, 2009 | Jun | CAHN |
| | AB | | 200MG | A077643 004 | Mar 27, 2009 | Jun | CAHN |
| >A> | AB | WOCKHARDT USA | 25MG | A090353 001 | Sep 01, 2010 | Aug | NEWA |
| >A> | AB | | 50MG | A090353 002 | Sep 01, 2010 | Aug | NEWA |
| >A> | AB | | 100MG | A090353 003 | Sep 01, 2010 | Aug | NEWA |
| >A> | AB | | 200MG | A090353 004 | Sep 01, 2010 | Aug | NEWA |

TORSEMIDE

INJECTABLE; INJECTION

TORSEMIDE

| | | | | | | | |
|----|---|--------------|--------------------|-------------|--------------|-----|------|
| AP | + | BEDFORD LABS | 20MG/2ML (10MG/ML) | A078007 001 | Jun 11, 2008 | Apr | CTEC |
|----|---|--------------|--------------------|-------------|--------------|-----|------|

INJECTABLE; INJECTION

TORSEMIDE

| | | | | | | | |
|----|---|--------------|--------------------|-------------|--------------|-----|------|
| AP | + | BEDFORD LABS | 50MG/5ML (10MG/ML) | A078007 002 | Jun 11, 2008 | Apr | CTEC |
| AP | | LUITPOLD | 20MG/2ML (10MG/ML) | A090656 001 | Apr 21, 2010 | Jun | CAHN |
| AP | | | 50MG/5ML (10MG/ML) | A090656 002 | Apr 21, 2010 | Jun | CAHN |
| AP | | PHARMAFORCE | 20MG/2ML (10MG/ML) | A090656 001 | Apr 21, 2010 | Apr | NEWA |
| AP | | | 50MG/5ML (10MG/ML) | A090656 002 | Apr 21, 2010 | Apr | NEWA |

TRAMADOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

TRAMADOL HYDROCHLORIDE

| | | | | | | |
|---|-------------------|-------|-------------|--------------|-----|------|
| + | CIPHER PHARMS INC | 100MG | N022370 001 | May 07, 2010 | May | NEWA |
| | | 200MG | N022370 002 | May 07, 2010 | May | NEWA |
| | | 300MG | N022370 003 | May 07, 2010 | May | NEWA |

TABLET; ORAL

TRAMADOL HYDROCHLORIDE

| | | | | | | | |
|----|--|--------------------|------|-------------|--------------|-----|------|
| AB | | NORTHSTAR HLTHCARE | 50MG | A078935 001 | May 26, 2010 | May | NEWA |
|----|--|--------------------|------|-------------|--------------|-----|------|

TABLET, ORALLY DISINTEGRATING; ORAL

TRAMADOL HYDROCHLORIDE

| | | | | | | |
|---|----------------|------|-------------|--------------|-----|------|
| + | VICTORY PHARMA | 50MG | N021693 001 | May 05, 2005 | Mar | CMFD |
|---|----------------|------|-------------|--------------|-----|------|

TRANDOLAPRIL

TABLET; ORAL

TRANDOLAPRIL

| | | | | | | | |
|----|--|-------------|-----|-------------|--------------|-----|------|
| AB | | EPIC PHARMA | 1MG | A078508 003 | Jun 18, 2008 | Feb | CAHN |
| AB | | | 2MG | A078508 001 | Jun 18, 2008 | Feb | CAHN |
| AB | | | 4MG | A078508 002 | Jun 18, 2008 | Feb | CAHN |
| AB | | WATSON LABS | 1MG | A077805 001 | Jun 12, 2007 | Jun | CAHN |
| AB | | | 2MG | A077805 002 | Jun 12, 2007 | Jun | CAHN |
| AB | | | 4MG | A077805 003 | Jun 12, 2007 | Jun | CAHN |

TRANDOLAPRIL; VERAPAMIL HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

TARKA

| | | | | | | | |
|-----|----|--|-----------|-------------|--------------|-----|------|
| >D> | | ABBOTT | 1MG;240MG | N020591 003 | Oct 22, 1996 | Aug | CFTG |
| >A> | AB | | 1MG;240MG | N020591 003 | Oct 22, 1996 | Aug | CFTG |
| | AB | | 2MG;180MG | N020591 001 | Oct 22, 1996 | May | CFTG |
| | AB | | 2MG;240MG | N020591 004 | Oct 22, 1996 | May | CFTG |
| >A> | AB | + | 4MG;240MG | N020591 002 | Oct 22, 1996 | Apr | CFTG |
| >A> | | TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE | | | | | |
| >A> | AB | GLENMARK GENERICS | 1MG;240MG | A079135 004 | Aug 30, 2010 | Aug | NEWA |
| | AB | | 2MG;180MG | A079135 001 | May 26, 2010 | May | NEWA |
| | AB | | 2MG;240MG | A079135 002 | May 26, 2010 | May | NEWA |
| | AB | | 4MG;240MG | A079135 003 | May 05, 2010 | Apr | NEWA |

TRANEXAMIC ACID

TABLET; ORAL

LYSTEDA

| | | | | | | |
|---|-------------------|-------|-------------|--------------|-----|------|
| + | FERRING PHARMS AS | 650MG | N022430 001 | Nov 13, 2009 | May | CAHN |
|---|-------------------|-------|-------------|--------------|-----|------|

TRAZODONE HYDROCHLORIDE

TABLET; ORAL

TRAZODONE HYDROCHLORIDE

| | | | | | | | |
|----|--|---------|-------|-------------|--------------|-----|------|
| AB | | VINTAGE | 50MG | A072192 001 | Feb 02, 1989 | Feb | CAHN |
| AB | | | 100MG | A072193 001 | Feb 02, 1989 | Feb | CAHN |

TABLET, EXTENDED RELEASE; ORAL

OLEPTRO

LABOPHARM 150MG
+ 300MGN022411 001 Feb 02, 2010 Feb NEWA
N022411 002 Feb 02, 2010 Feb NEWATRETINOIN

CAPSULE; ORAL

TRETINOIN

+ BARR 10MG
VESANOID 10MG
@ ROCHE
CREAM; TOPICAL
TRETINOIN
+ TRIAX PHARMS LLC 0.0375%
GEL; TOPICAL
AVITA
BT MYLAN 0.025%A077684 001 Jun 22, 2007 Feb CRLD
N020438 001 Nov 22, 1995 Feb DISC
A090098 001 Mar 22, 2010 Mar NEWA
N020400 001 Jan 29, 1998 Jul CAHNTRIAMCINOLONE ACETONIDE

PASTE; DENTAL

ORACORT

AT + TARO 0.1%
TRIAMCINOLONE ACETONIDE
AT LYNE 0.1%A070730 001 Oct 01, 1986 Jun CFTG
A040771 001 Jul 01, 2010 Jun NEWATRIPTORELIN FAMOATE

INJECTABLE; INTRAMUSCULAR

TRELSTAR

+ WATSON LABS EQ 22.5MG BASE/VIAL

N022437 001 Mar 10, 2010 Mar NEWA

TROSPiUM CHLORIDE

TABLET; ORAL

SANCTURA

>D> + ALLERGAN 20MG
>A> AB + 20MG
>A> TROSPiUM CHLORIDE
>A> AB GLENMARK GENERICS 20MGN021595 001 May 28, 2004 Aug CFTG
N021595 001 May 28, 2004 Aug CFTG
A091575 001 Aug 13, 2010 Aug NEWAULIPRISTAL ACETATE

>A> TABLET; ORAL

ELLA

>A> + LAB HRA PHARMA 30MG

N022474 001 Aug 13, 2010 Aug NEWA

UNOPROSTONE ISOPROPYL

SOLUTION/DROPS; OPHTHALMIC

RESCULA

@ SUCAMPO PHARMS 0.15%

N021214 001 Aug 03, 2000 Jan DISC

UREA, C-14

CAPSULE; ORAL

PYTEST

+ AVENT 1uCi
PYTEST KIT
+ AVENT 1uCiN020617 001 May 09, 1997 Feb CAHN
N020617 002 May 09, 1997 Feb CAHN

URSODIOL

CAPSULE; ORAL

URSODIOL

| | | | |
|----|--------------|-------|-----------------------------------|
| AB | EPIC PHARMA | 300MG | A075517 001 Mar 14, 2000 May CAHN |
| AB | MIKAH PHARMA | 300MG | A075517 001 Mar 14, 2000 Feb CAHN |
| AB | MYLAN | 300MG | A090530 001 Feb 17, 2010 Jan NEWA |

VALACYCLOVIR HYDROCHLORIDE

TABLET; ORAL

VALACYCLOVIR HYDROCHLORIDE

| | | | |
|----|--------------------|---------------|-----------------------------------|
| AB | AUROBINDO PHARMA | EQ 500MG BASE | A090682 001 May 24, 2010 May NEWA |
| AB | | EQ 1GM BASE | A090682 002 May 24, 2010 May NEWA |
| AB | DR REDDYS LABS LTD | EQ 500MG BASE | A079012 001 May 24, 2010 May NEWA |
| AB | | EQ 1GM BASE | A079012 002 May 24, 2010 May NEWA |
| AB | MATRIX LABS LTD | EQ 500MG BASE | A078518 001 May 24, 2010 May NEWA |
| AB | | EQ 1GM BASE | A078518 002 May 24, 2010 May NEWA |
| AB | MYLAN | EQ 500MG BASE | A078070 001 May 24, 2010 May NEWA |
| AB | | EQ 1GM BASE | A078070 002 May 24, 2010 May NEWA |
| AB | ROXANE | EQ 500MG BASE | A078656 001 May 24, 2010 May NEWA |
| AB | | EQ 1GM BASE | A078656 002 May 24, 2010 May NEWA |
| AB | SANDOZ | EQ 500MG BASE | A077478 001 May 24, 2010 May NEWA |
| AB | | EQ 1GM BASE | A077478 002 May 24, 2010 May NEWA |
| AB | TEVA PHARMS | EQ 500MG BASE | A077655 001 May 24, 2010 May NEWA |
| AB | | EQ 1GM BASE | A077655 002 May 24, 2010 May NEWA |
| AB | WATSON LABS | EQ 500MG BASE | A077135 001 May 24, 2010 May NEWA |
| AB | | EQ 1GM BASE | A077135 002 May 24, 2010 May NEWA |
| AB | WOCKHARDT | EQ 500MG BASE | A090216 001 May 24, 2010 May NEWA |
| AB | | EQ 1GM BASE | A090216 002 May 24, 2010 May NEWA |

VALPROATE SODIUM

INJECTABLE; INJECTION

VALPROATE SODIUM

| | | | |
|----|--------------------|------------------|-----------------------------------|
| AP | HIKMA FARMACEUTICA | EQ 100MG BASE/ML | A078523 001 Feb 17, 2010 Jan NEWA |
|----|--------------------|------------------|-----------------------------------|

VALPROIC ACID

SYRUP; ORAL

VALPROIC ACID

| | | | |
|----|--------------------|-----------|-----------------------------------|
| @ | APOTEX INC | 250MG/5ML | A077105 001 Jul 29, 2005 May DISC |
| AA | SUN PHARM INDs INC | 250MG/5ML | A090517 001 May 28, 2010 May NEWA |

VANCOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION

VANCOMYCIN HYDROCHLORIDE

| | | | |
|----|---------------------|--------------------|-----------------------------------|
| AP | BIONICHE PHARMA USA | EQ 500MG BASE/VIAL | A065401 001 Jun 30, 2008 Mar CAHN |
| AP | | EQ 1GM BASE/VIAL | A065401 002 Jun 30, 2008 Mar CAHN |
| AP | SANDOZ | EQ 500MG BASE/VIAL | A090250 001 Apr 27, 2010 Apr NEWA |
| AP | | EQ 1GM BASE/VIAL | A090250 002 Apr 27, 2010 Apr NEWA |

VARDENAFIL HYDROCHLORIDE

TABLET, ORALLY DISINTEGRATING; ORAL

STAXYN

+ BAYER HLTHCARE

10MG

N200179 001 Jun 17, 2010 Jun NEWA

VECURONIUM BROMIDE

INJECTABLE; INJECTION

VECURONIUM BROMIDE

| | | | | | | |
|----|----------------|-----------|-------------|--------------|-----|------|
| AP | AKORN STRIDES | 10MG/VIAL | A090243 001 | May 11, 2010 | May | NEWA |
| AP | | 20MG/VIAL | A090243 002 | May 11, 2010 | May | NEWA |
| AP | MUSTAFA NEVZAT | 10MG/VIAL | A078274 001 | Dec 29, 2008 | Mar | CAHN |
| AP | | 20MG/VIAL | A078274 002 | Dec 29, 2008 | Mar | CAHN |

VELAGLUCERASE ALFA

INJECTABLE; IV (INFUSION)

VPRIIV

SHIRE HUMAN GENETIC 400 UNITS/VIAL

N022575 001 Feb 26, 2010 Feb NEWA

POWDER; IV (INFUSION)

VPRIIV

+ SHIRE HUMAN GENETIC 200 UNITS/VIAL

N022575 002 Feb 26, 2010 Feb NEWA

VENLAFAKINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

EFFEXOR XR

| | | | | | | |
|----|---------------------------|----------------|-------------|--------------|-----|------|
| AB | WYETH PHARMS INC | EQ 37.5MG BASE | N020699 001 | Oct 20, 1997 | Jun | CFTG |
| AB | | EQ 75MG BASE | N020699 002 | Oct 20, 1997 | Jun | CFTG |
| AB | + | EQ 150MG BASE | N020699 004 | Oct 20, 1997 | Jun | CFTG |
| | VENLAFAKINE HYDROCHLORIDE | | | | | |
| AB | TEVA | EQ 37.5MG BASE | A076565 001 | Jun 28, 2010 | Jun | NEWA |
| AB | | EQ 75MG BASE | A076565 002 | Jun 28, 2010 | Jun | NEWA |
| AB | | EQ 150MG BASE | A076565 003 | Jun 28, 2010 | Jun | NEWA |

TABLET; ORAL

VENLAFAKINE HYDROCHLORIDE

| | | | | | | |
|----|------------------|----------------|-------------|--------------|-----|------|
| AB | AMNEAL PHARMS | EQ 25MG BASE | A079098 001 | May 11, 2010 | Jun | CAHN |
| AB | | EQ 37.5MG BASE | A079098 002 | May 11, 2010 | Jun | CAHN |
| AB | | EQ 50MG BASE | A079098 003 | May 11, 2010 | Jun | CAHN |
| AB | | EQ 75MG BASE | A079098 004 | May 11, 2010 | Jun | CAHN |
| AB | | EQ 100MG BASE | A079098 005 | May 11, 2010 | Jun | CAHN |
| AB | AUROBINDO PHARMA | EQ 25MG BASE | A090555 001 | Apr 07, 2010 | Mar | NEWA |
| AB | | EQ 37.5MG BASE | A090555 002 | Apr 07, 2010 | Mar | NEWA |
| AB | | EQ 50MG BASE | A090555 003 | Apr 07, 2010 | Mar | NEWA |
| AB | | EQ 75MG BASE | A090555 004 | Apr 07, 2010 | Mar | NEWA |
| AB | | EQ 100MG BASE | A090555 005 | Apr 07, 2010 | Mar | NEWA |
| AB | INTERPHARM | EQ 25MG BASE | A079098 001 | May 11, 2010 | Apr | NEWA |
| AB | | EQ 37.5MG BASE | A079098 002 | May 11, 2010 | Apr | NEWA |
| AB | | EQ 50MG BASE | A079098 003 | May 11, 2010 | Apr | NEWA |
| AB | | EQ 75MG BASE | A079098 004 | May 11, 2010 | Apr | NEWA |
| AB | | EQ 100MG BASE | A079098 005 | May 11, 2010 | Apr | NEWA |
| AB | VINTAGE | EQ 25MG BASE | A090027 001 | Aug 04, 2010 | Jul | NEWA |
| AB | | EQ 37.5MG BASE | A090027 002 | Aug 04, 2010 | Jul | NEWA |
| AB | | EQ 50MG BASE | A090027 003 | Aug 04, 2010 | Jul | NEWA |
| AB | | EQ 75MG BASE | A090027 004 | Aug 04, 2010 | Jul | NEWA |
| AB | | EQ 100MG BASE | A090027 005 | Aug 04, 2010 | Jul | NEWA |

TABLET, EXTENDED RELEASE; ORAL

VENLAFAKINE HYDROCHLORIDE

| | | | | | | |
|-----|----------------|----------------|-------------|--------------|-----|------|
| >D> | OSMOTICA PHARM | EQ 37.5MG BASE | N022104 001 | May 20, 2008 | Aug | CFTG |
| >A> | AB | EQ 37.5MG BASE | N022104 001 | May 20, 2008 | Aug | CFTG |
| >D> | | EQ 75MG BASE | N022104 002 | May 20, 2008 | Aug | CFTG |
| >A> | AB | EQ 75MG BASE | N022104 002 | May 20, 2008 | Aug | CFTG |
| >D> | + | EQ 150MG BASE | N022104 003 | May 20, 2008 | Aug | CFTG |

TABLET, EXTENDED RELEASE; ORAL
VENLAFAXINE HYDROCHLORIDE

| | | | | | | | | |
|-----|----|---|-------------------|----------------|-------------|--------------|-----|------|
| >A> | AB | + | OSMOTICA PHARM | EQ 150MG BASE | N022104 003 | May 20, 2008 | Aug | CFTG |
| >A> | AB | | SUN PHARMA GLOBAL | EQ 37.5MG BASE | A091272 001 | Aug 18, 2010 | Aug | NEWA |
| >A> | AB | | | EQ 75MG BASE | A091272 002 | Aug 18, 2010 | Aug | NEWA |
| >A> | AB | | | EQ 150MG BASE | A091272 003 | Aug 18, 2010 | Aug | NEWA |

VORICONAZOLE

TABLET; ORAL
VFEND

| | | | | | | | |
|----|---|-----------------|-------|-------------|--------------|-----|------|
| AB | | PFIZER | 50MG | N021266 001 | May 24, 2002 | Apr | CFTG |
| AB | + | | 200MG | N021266 002 | May 24, 2002 | Apr | CFTG |
| | | VORICONAZOLE | | | | | |
| AB | | MATRIX LABS LTD | 50MG | A090547 001 | Apr 22, 2010 | Apr | NEWA |
| AB | | | 200MG | A090547 002 | Apr 22, 2010 | Apr | NEWA |

WARFARIN SODIUM

TABLET; ORAL
WARFARIN SODIUM

| | | | | | | | |
|-----|----|--------|-------|-------------|--------------|-----|------|
| >D> | AB | SANDOZ | 1MG | A040196 001 | Sep 30, 1997 | Aug | DISC |
| >A> | | @ | 1MG | A040196 001 | Sep 30, 1997 | Aug | DISC |
| >D> | AB | | 2MG | A040196 002 | Sep 30, 1997 | Aug | DISC |
| >A> | | @ | 2MG | A040196 002 | Sep 30, 1997 | Aug | DISC |
| >D> | AB | | 2.5MG | A040196 003 | Sep 30, 1997 | Aug | DISC |
| >A> | | @ | 2.5MG | A040196 003 | Sep 30, 1997 | Aug | DISC |
| >D> | AB | | 3MG | A040196 008 | Jul 26, 2000 | Aug | DISC |
| >A> | | @ | 3MG | A040196 008 | Jul 26, 2000 | Aug | DISC |
| >D> | AB | | 4MG | A040196 004 | Sep 30, 1997 | Aug | DISC |
| >A> | | @ | 4MG | A040196 004 | Sep 30, 1997 | Aug | DISC |
| >D> | AB | | 5MG | A040196 005 | Sep 30, 1997 | Aug | DISC |
| >A> | | @ | 5MG | A040196 005 | Sep 30, 1997 | Aug | DISC |
| >D> | AB | | 6MG | A040196 009 | Jul 26, 2000 | Aug | DISC |
| >A> | | @ | 6MG | A040196 009 | Jul 26, 2000 | Aug | DISC |
| >D> | AB | | 7.5MG | A040196 006 | Sep 30, 1997 | Aug | DISC |
| >A> | | @ | 7.5MG | A040196 006 | Sep 30, 1997 | Aug | DISC |
| >D> | AB | | 10MG | A040196 007 | Sep 30, 1997 | Aug | DISC |
| >A> | | @ | 10MG | A040196 007 | Sep 30, 1997 | Aug | DISC |

ZICONOTIDE

INJECTABLE; INTRATHECAL
PRIALT

| | | | | | | |
|---|----------------|------------------------|-------------|--------------|-----|------|
| + | AZUR PHARMA II | 100MCG/1ML (100MCG/ML) | N021060 002 | Dec 28, 2004 | May | CAHN |
| | @ | 200MCG/2ML (100MCG/ML) | N021060 003 | Dec 28, 2004 | May | CAHN |
| + | | 500MCG/20ML (25MCG/ML) | N021060 001 | Dec 28, 2004 | May | CAHN |
| + | | 500MCG/5ML (100MCG/ML) | N021060 004 | Dec 28, 2004 | May | CAHN |

ZIDOVUDINE

INJECTABLE; INJECTION
RETROVIR

| | | | | | | | |
|----|---|---------------|---------|-------------|--------------|-----|------|
| AP | + | VIIV HLTHCARE | 10MG/ML | N019951 001 | Feb 02, 1990 | Apr | CFTG |
| | | ZIDOVUDINE | | | | | |
| AP | | PHARMAFORCE | 10MG/ML | A091457 001 | May 06, 2010 | Apr | NEWA |

ZILEUTON

| | | | | |
|--------------------------------|-------|-------------|--------------|----------|
| TABLET; ORAL | | | | |
| ZYFLO | | | | |
| @ CORNERSTONE THERAP | 300MG | N020471 001 | Dec 09, 1996 | May CAHN |
| + | 600MG | N020471 003 | Dec 09, 1996 | May CAHN |
| TABLET, EXTENDED RELEASE; ORAL | | | | |
| ZYFLO CR | | | | |
| + CORNERSTONE THERAP | 600MG | N022052 001 | May 30, 2007 | May CAHN |

ZOLPIDEM TARTRATE

| | | | | |
|-------------------|------|-------------|--------------|----------|
| TABLET; ORAL | | | | |
| ZOLPIDEM TARTRATE | | | | |
| @ WORLD GEN | 5MG | A076062 001 | Apr 23, 2007 | Mar CAHN |
| @ | 10MG | A076062 002 | Apr 23, 2007 | Mar CAHN |

OTC DRUG PRODUCT LIST - 30TH EDITION

OTC DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2010

2-1

ACETAMINOPHEN

SUPPOSITORY; RECTAL

ACETAMINOPHEN

PERRIGO NEW YORK

120MG

A070607 001 Apr 06, 1987 May CAHN

650MG

A070608 001 Dec 01, 1986 May CAHN

ANTAZOLINE PHOSPHATE; NAPHAZOLINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

VASOCON-A

@ NOVARTIS

0.5%;0.05%

N018746 002 Jul 11, 1994 Jul DISC

CALCIUM CARBONATE; FAMOTIDINE; MAGNESIUM HYDROXIDE

TABLET, CHEWABLE; ORAL

PEPCID COMPLETE

>D>

+ MERCK

800MG;10MG;165MG

N020958 001 Oct 16, 2000 Aug CAHN

>A>

+ MERCK SHARP DOHME

800MG;10MG;165MG

N020958 001 Oct 16, 2000 Aug CAHN

CETIRIZINE HYDROCHLORIDE

SYRUP; ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

AUROBINDO PHARMA 5MG/5ML

A090750 002 Feb 02, 2010 Jan NEWA

CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF

AUROBINDO PHARMA 5MG/5ML

A090750 001 Feb 02, 2010 Jan NEWA

TABLET; ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

AMNEAL PHARMS NY 5MG

A078780 001 Jan 21, 2010 Jan NEWA

10MG

A078780 004 Jan 21, 2010 Jan NEWA

CADISTA PHARMS 5MG

A078933 001 Jun 15, 2010 May NEWA

10MG

A078933 002 Jun 15, 2010 May NEWA

TORRENT PHARMS LLC 5MG

A079191 001 Apr 15, 2010 Mar NEWA

10MG

A079191 004 Apr 15, 2010 Mar NEWA

CETIRIZINE HYDROCHLORIDE HIVES

CADISTA PHARMS 5MG

A078933 003 Jun 15, 2010 May NEWA

10MG

A078933 004 Jun 15, 2010 May NEWA

CETIRIZINE HYDROCHLORIDE HIVES RELIEF

AMNEAL PHARMS NY 5MG

A078780 003 Jan 21, 2010 Jan NEWA

10MG

A078780 002 Jan 21, 2010 Jan NEWA

TORRENT PHARMS LLC 5MG

A079191 003 Apr 15, 2010 Mar NEWA

10MG

A079191 002 Apr 15, 2010 Mar NEWA

CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL

SPONGE; TOPICAL

CHLORAPREP ONE-STEP

>A>

+ CAREFUSION 2%;70% (3ML)

N020832 001 Jul 14, 2000 Aug CAHN

>A>

+ 2%;70% (26ML)

N020832 006 Nov 21, 2006 Aug CAHN

>A>

+ 2%;70% (10.5ML)

N020832 004 Aug 20, 2003 Aug CAHN

>D>

+ ENTURIA INC 2%;70% (26ML)

N020832 006 Nov 21, 2006 Aug CAHN

>D>

+ 2%;70% (3ML)

N020832 001 Jul 14, 2000 Aug CAHN

>D>

+ 2%;70% (10.5ML)

N020832 004 Aug 20, 2003 Aug CAHN

CHLORAPREP ONE-STEP FREPP

>A>

+ CAREFUSION 2%;70% (1.5ML)

N020832 003 Apr 26, 2002 Aug CAHN

>D>

+ ENTURIA INC 2%;70% (1.5ML)

N020832 003 Apr 26, 2002 Aug CAHN

SPONGE; TOPICAL

CHLORAPREP WITH TINT

| | | | | | | | |
|-----|---|-------------|-----------------|-------------|--------------|-----|------|
| >A> | + | CAREFUSION | 2%;70% (10.5ML) | N020832 005 | Apr 03, 2006 | Aug | CAHN |
| >A> | + | | 2%;70% (26ML) | N020832 002 | May 03, 2005 | Aug | CAHN |
| >A> | + | | 2%;70% (3ML) | N020832 007 | Oct 10, 2006 | Aug | CAHN |
| >D> | + | ENTURIA INC | 2%;70% (3ML) | N020832 007 | Oct 10, 2006 | Aug | CAHN |
| >D> | + | | 2%;70% (10.5ML) | N020832 005 | Apr 03, 2006 | Aug | CAHN |
| >D> | + | | 2%;70% (26ML) | N020832 002 | May 03, 2005 | Aug | CAHN |

SWAB; TOPICAL

CHLORAPREP ONE-STEP SEPP

| | | | | | | | |
|-----|---|-----------------------------|-----------------|-------------|--------------|-----|------|
| >A> | + | CAREFUSION | 2%;70% (0.67ML) | N021555 001 | Oct 07, 2002 | Aug | CAHN |
| >D> | + | ENTURIA INC | 2%;70% (0.67ML) | N021555 001 | Oct 07, 2002 | Aug | CAHN |
| | | CHLORAPREP SINGLE SWABSTICK | | | | | |
| >A> | + | CAREFUSION | 2%;70% (1.75ML) | N021555 002 | May 10, 2005 | Aug | CAHN |
| >D> | + | ENTURIA INC | 2%;70% (1.75ML) | N021555 002 | May 10, 2005 | Aug | CAHN |

CIMETIDINE

TABLET; ORAL

CIMETIDINE

| | | | | | |
|--------------------|-------|-------------|--------------|-----|------|
| CONTRACT PHARMACAL | 200MG | A074961 001 | Jun 19, 1998 | Jan | CAHN |
| | 200MG | A074963 001 | Jun 19, 1998 | Jan | CAHN |

FAMOTIDINE

TABLET, CHEWABLE; ORAL

FAMOTIDINE

| | | | | | | |
|-----------|---------------------|-------------|--------------|--------------|------|------|
| PERRIGO | 10MG | A075715 001 | Aug 22, 2003 | Apr | CRLD | |
| PEPCID AC | | | | | | |
| >D> | @ MERCK | 10MG | N020801 001 | Sep 24, 1998 | Aug | CAHN |
| >D> | + | 20MG | N020801 002 | Dec 17, 2007 | Aug | CAHN |
| | + | 20MG | N020801 002 | Dec 17, 2007 | Apr | CRLD |
| >A> | @ MERCK SHARP DOHME | 10MG | N020801 001 | Sep 24, 1998 | Aug | CAHN |
| >A> | + | 20MG | N020801 002 | Dec 17, 2007 | Aug | CAHN |

TABLET; ORAL

FAMOTIDINE

| | | | | | | |
|-----------|--------------------|-------------|--------------|--------------|------|------|
| WOCKHARDT | 20MG | A090837 001 | Aug 04, 2010 | Jul | NEWA | |
| PEPCID AC | | | | | | |
| >D> | MERCK | 10MG | N020325 001 | Apr 28, 1995 | Aug | CAHN |
| >D> | + | 20MG | N020325 002 | Sep 23, 2003 | Aug | CAHN |
| >A> | MERCK SHARP DOHME | 10MG | N020325 001 | Apr 28, 1995 | Aug | CAHN |
| >A> | + | 20MG | N020325 002 | Sep 23, 2003 | Aug | CAHN |
| | PEPCID AC (GELTAB) | | | | | |
| >D> | MERCK | 10MG | N020902 001 | Aug 05, 1999 | Aug | CAHN |
| >A> | MERCK SHARP DOHME | 10MG | N020902 001 | Aug 05, 1999 | Aug | CAHN |

IBUPROFEN

CAPSULE; ORAL

IBUPROFEN

| | | | | | |
|----------------------|-------|-------------|--------------|-----|------|
| + CONTRACT PHARMACAL | 200MG | A074782 001 | Jul 06, 1998 | Jan | CAHN |
|----------------------|-------|-------------|--------------|-----|------|

TABLET; ORAL

IBUPROFEN

| | | | | | | |
|--------------------|--------|-------------|--------------|--------------|------|------|
| CONTRACT PHARMACAL | 200MG | A071732 001 | Sep 10, 1987 | Jan | CAHN | |
| | 200MG | A071735 001 | Sep 10, 1987 | Jan | CAHN | |
| | 200MG | A072299 001 | Jul 01, 1988 | Jan | CAHN | |
| | 200MG | A073691 001 | Feb 25, 1994 | Jan | CAHN | |
| >D> | SANDOZ | 200MG | A071807 001 | Feb 25, 1988 | Aug | DISC |
| >A> | @ | 200MG | A071807 001 | Feb 25, 1988 | Aug | DISC |

TABLET; ORAL

IBUPROFEN

| | | | |
|-----|--------------------|-------|-----------------------------------|
| >D> | SANDOZ | 200MG | A074525 001 Dec 15, 1995 Aug DISC |
| >A> | @ | 200MG | A074525 001 Dec 15, 1995 Aug DISC |
| >D> | | 200MG | A074533 001 Dec 15, 1995 Aug DISC |
| >A> | @ | 200MG | A074533 001 Dec 15, 1995 Aug DISC |
| | PROFEN | | |
| | CONTRACT PHARMACAL | 200MG | A071265 001 Oct 15, 1986 Jan CAHN |

IBUPROFEN; PHENYLEPHRINE HYDROCHLORIDE

TABLET; ORAL

ADVIL CONGESTION RELIEF

| | | |
|--------------|------------|-----------------------------------|
| + WYETH CONS | 200MG;10MG | N022565 001 May 27, 2010 May NEWA |
|--------------|------------|-----------------------------------|

IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET; ORAL

IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE

CONTRACT PHARMACAL 200MG;30MG

A075588 001 Apr 08, 2002 Jan CAHN

LEVONORGESTREL

TABLET; ORAL

LEVONORGESTREL

| | | |
|---------------|--------|-----------------------------------|
| + WATSON LABS | 0.75MG | A078665 001 Aug 28, 2009 Apr CRLD |
|---------------|--------|-----------------------------------|

LOPERAMIDE HYDROCHLORIDE

TABLET; ORAL

LOPERAMIDE HYDROCHLORIDE

CONTRACT PHARMACAL 2MG

A073254 001 Jul 30, 1993 Jan CAHN

LORATADINE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

CLARITIN-D

| | | |
|-------------------|-----------|-----------------------------------|
| + SCHERING PLOUGH | 5MG;120MG | N019670 002 Nov 27, 2002 Mar CMFD |
|-------------------|-----------|-----------------------------------|

LORATADINE AND PSEUDOEPHEDRINE SULFATE

IMPAX LABS 5MG;120MG

A076050 001 Jan 30, 2003 Mar CRLD

MICONAZOLE NITRATE

CREAM, SUPPOSITORY; TOPICAL, VAGINAL

MICONAZOLE NITRATE

PERRIGO R AND D 2%,1.2GM

A079114 001 Jun 02, 2010 May NEWA

MONISTAT 1 COMBINATION PACK

| | | |
|-----------------------|----------|-----------------------------------|
| + JOHNSON AND JOHNSON | 2%,1.2GM | N021308 001 Jun 29, 2001 Mar CPOT |
|-----------------------|----------|-----------------------------------|

CREAM; VAGINAL

MICONAZOLE NITRATE

PERRIGO R AND D 4%

A091366 001 Jan 15, 2010 Jan NEWA

MINOXIDIL

SOLUTION; TOPICAL

MINOXIDIL EXTRA STRENGTH (FOR MEN)

AVACOR PRODS 5%

A075619 001 Nov 17, 2000 Jun CMFD

NAPHAZOLINE HYDROCHLORIDE; PHENIRAMINE MALEATE

SOLUTION/DROPS; OPHTHALMIC

VISINE-A

| | | |
|-----------------------|-------------|-----------------------------------|
| + JOHNSON AND JOHNSON | 0.025%;0.3% | N020485 001 Jan 31, 1996 Jan CRLD |
|-----------------------|-------------|-----------------------------------|

NONOXYNOL-9

SPONGE; VAGINAL
TODAY
+ AZTIQ PHARMA 1GM N018683 001 Apr 01, 1983 May CAHN

PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
SUDAFED 24 HOUR
+ MCNEIL CONS 240MG N020021 002 Dec 15, 1992 Feb CAHN

RANITIDINE HYDROCHLORIDE

TABLET; ORAL
RANITIDINE HYDROCHLORIDE
CONTRACT PHARMACAL EQ 75MG BASE A075094 001 Jun 21, 1999 Jan CAHN

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 08 AUGUST 2010

NO AUGUST 2010 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of List of Orphan Designations and Approvals is available at:

<http://www.fda.gov/orphan/designat/list.htm>

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO AUGUST 2010 ADDITIONS

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2010

See List footnote for information regarding List content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|-----------------|------------------------------|-----------------|-------------------------------|------------------------|-----------------------------------|
| <u>ADAPALENE - DIFFERIN</u> | | | | | | |
| N021753 001 | 7737181 | Aug 29, 2024 | DP | | | |
| <u>ADAPALENE - DIFFERIN</u> | | | | | | |
| N022502 001 | | | | | NDF | Mar 17, 2013 |
| <u>ALCAFTADINE - LASTACAF</u> | | | | | | |
| N022134 001 | >A> 5468743 | Nov 21, 2012 | DS DP | | NCE | Jul 28, 2015 |
| <u>ALENDRONATE SODIUM - FOSAMAX</u> | | | | | | |
| N021575 001 | 5994329 | Jul 17, 2018 | | Y | | |
| | 6015801 | Jul 17, 2018 | | Y | | |
| | 6225294 | Jul 17, 2018 | | Y | | |
| <u>ALFUZOSIN HYDROCHLORIDE - UROXATRAL</u> | | | | | | |
| N021287 001 | >A> 4661491 | Jan 18, 2011 | U-706 | | | |
| | >A> 4661491*PED | Jul 18, 2011 | | | | |
| | >A> 6149940 | Aug 22, 2017 | | | | |
| | >A> 6149940*PED | Feb 22, 2018 | | | | |
| <u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO</u> | | | | | | |
| N022545 001 | | | | >A> NCE | Mar 15, 2012 | |
| | | | | >A> NC | Aug 26, 2013 | |
| <u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO</u> | | | | | | |
| N022545 002 | | | | >A> NCE | Mar 15, 2012 | |
| | | | | >A> NC | Aug 26, 2013 | |
| <u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO</u> | | | | | | |
| N022545 003 | | | | >A> NCE | Mar 15, 2012 | |
| | | | | >A> NC | Aug 26, 2013 | |
| <u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO</u> | | | | | | |
| N022545 004 | | | | >A> NCE | Mar 15, 2012 | |
| | | | | >A> NC | Aug 26, 2013 | |
| <u>ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTURN A HCT</u> | | | | | | |
| N022107 001 | >A> 5559111 | Jul 21, 2018 | DS DP U-3 | | | |
| <u>ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTURN A HCT</u> | | | | | | |
| N022107 002 | >A> 5559111 | Jul 21, 2018 | DS DP U-3 | | | |
| <u>ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTURN A HCT</u> | | | | | | |
| N022107 003 | >A> 5559111 | Jul 21, 2018 | DS DP U-3 | | | |
| <u>ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTURN A HCT</u> | | | | | | |
| N022107 004 | >A> 5559111 | Jul 21, 2018 | DS DP U-3 | | | |
| <u>ALISKIREN HEMIFUMARATE; VALSARTAN - VALTURN A</u> | | | | | | |
| N022217 001 | | | | NCE | Mar 05, 2012 | |
| <u>ALISKIREN HEMIFUMARATE; VALSARTAN - VALTURN A</u> | | | | | | |
| N022217 002 | | | | NCE | Mar 05, 2012 | |
| <u>AMINOLEVULINIC ACID HYDROCHLORIDE - LEVULAN</u> | | | | | | |
| N020965 001 | 7723910 | Jun 17, 2019 | U-289 | M-82 | Mar 12, 2013 | |
| <u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL - TRIBENZOR</u> | | | | | | |
| N200175 001 | >A> 5616599 | Apr 25, 2016 | DS DP U-3 | NC | Jul 23, 2013 | |
| | >A> 5616599*PED | Oct 25, 2016 | | | | |

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2010

See List footnote for information regarding List content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|-----------------|------------------------------|-----------------|-------------------------------|------------------------|-----------------------------------|
| <u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL - TRIBENZOR</u> | | | | | | |
| N200175 002 | >A> 5616599 | Apr 25, 2016 | DS DP U-3 | | NC | Jul 23, 2013 |
| | >A> 5616599*PED | Oct 25, 2016 | | | | |
| <u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL - TRIBENZOR</u> | | | | | | |
| N200175 003 | >A> 5616599 | Apr 25, 2016 | DS DP U-3 | | NC | Jul 23, 2013 |
| | >A> 5616599*PED | Oct 25, 2016 | | | | |
| <u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL - TRIBENZOR</u> | | | | | | |
| N200175 004 | >A> 5616599 | Apr 25, 2016 | DS DP U-3 | | NC | Jul 23, 2013 |
| | >A> 5616599*PED | Oct 25, 2016 | | | | |
| <u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL - TRIBENZOR</u> | | | | | | |
| N200175 005 | >A> 5616599 | Apr 25, 2016 | DS DP U-3 | | NC | Jul 23, 2013 |
| | >A> 5616599*PED | Oct 25, 2016 | | | | |
| <u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 10</u> | | | | | | |
| N021303 001 | RE41148 | Oct 21, 2018 | DP | | | |
| | RE41148*PED | Apr 21, 2019 | | | | |
| <u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 15</u> | | | | | | |
| N021303 006 | RE41148 | Oct 21, 2018 | DP | | | |
| | RE41148*PED | Apr 21, 2019 | | | | |
| <u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 20</u> | | | | | | |
| N021303 002 | RE41148 | Oct 21, 2018 | DP | | | |
| | RE41148*PED | Apr 21, 2019 | | | | |
| <u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 25</u> | | | | | | |
| N021303 004 | RE41148 | Oct 21, 2018 | DP | | | |
| | RE41148*PED | Apr 21, 2019 | | | | |
| <u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 30</u> | | | | | | |
| N021303 003 | RE41148 | Oct 21, 2018 | DP | | | |
| | RE41148*PED | Apr 21, 2019 | | | | |
| <u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 5</u> | | | | | | |
| N021303 005 | RE41148 | Oct 21, 2018 | DP | | | |
| | RE41148*PED | Apr 21, 2019 | | | | |
| <u>ANIDULAFUNGIN - ERAXIS</u> | | | | | | |
| N021632 001 | 7709444 | Apr 12, 2021 | DP U-540 | | | |
| <u>ANIDULAFUNGIN - ERAXIS</u> | | | | | | |
| N021632 002 | 7709444 | Apr 12, 2021 | DP U-540 | | | |
| <u>APREPITANT - EMEND</u> | | | | | | |
| N021549 001 | | | | M-82 | Mar 19, 2013 | |
| <u>APREPITANT - EMEND</u> | | | | | | |
| N021549 002 | 5719147 | Apr 17, 2015 | DS DP U-853 | M-82 | Mar 19, 2013 | |
| <u>APREPITANT - EMEND</u> | | | | | | |
| N021549 003 | 5719147 | Apr 17, 2015 | DS DP U-853 | M-82 | Mar 19, 2013 | |

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2010

See List footnote for information regarding List content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|--|-----------------|------------------------------|-----------------|-------------------------------|------------------------------|-----------------------------------|
| <u>ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE - MOVIPREP</u> | | | | | | |
| N021881 001 | 7658914 | Sep 01, 2024 | DS DP | | | |
| <u>ASENAPINE MALEATE - SAPHRIS</u> | | | | | | |
| N022117 001 | 7741358 | Apr 06, 2026 | DS DP U-1064 | >A> I-629 >A> I-628 | Sep 03, 2013 Sep 03, 2013 | |
| <u>ASENAPINE MALEATE - SAPHRIS</u> | | | | | | |
| N022117 002 | 7741358 | Apr 06, 2026 | DS DP U-1064 | >A> I-629 >A> I-628 | Sep 03, 2013 Sep 03, 2013 | |
| <u>AZTREONAM - CAYSTON</u> | | | | | | |
| N050814 001 | 7208141 | Dec 20, 2021 | DP U-1031 | | | |
| | 7214364 | Dec 20, 2021 | DP | | | |
| | 7427633 | Dec 20, 2021 | DP U-1031 | | | |
| <u>BALSALAZIDE DISODIUM - COLAZAL</u> | | | | | | |
| N020610 001 | 7452872 | Aug 24, 2026 | U-141 | | | |
| | 7452872*PED | Feb 24, 2027 | | | | |
| | 7625884 | Aug 24, 2026 | U-141 | | | |
| | 7625884*PED | Feb 24, 2027 | | | | |
| <u>BEPOTASTINE BESILATE - BEPREVE</u> | | | | | | |
| N022288 001 | 6780877 | Dec 25, 2017 | DS DP | | | |
| <u>BEXAROTENE - TARGRETIN</u> | | | | | | |
| N021055 001 | 7655699 | Apr 22, 2012 | DS DP U-509 | | | |
| <u>BEXAROTENE - TARGRETIN</u> | | | | | | |
| N021056 001 | 7655699 | Apr 22, 2012 | DS DP U-510 | | | |
| <u>BIMATOPROST - LUMIGAN</u> | | | | | | |
| N022184 001 | | | | >A> NP | | Aug 31, 2013 |
| <u>BISACODYL; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE - HALFLYTLEY</u> | | | | | | |
| N021551 003 | >A> 7291324 | Oct 22, 2022 | U-837 | | NP | Jul 16, 2013 |
| <u>BIVALIRUDIN - ANGIOMAX</u> | | | | | | |
| N020873 001 | >A> 5196404 | Aug 13, 2011 | DS DP U-1040 | | | |
| | >A> 5196404*PED | Feb 13, 2012 | | | | |
| <u>BUDESONIDE - RHINOCORT</u> | | | | | | |
| N020746 001 | 6686346 | Apr 29, 2017 | DP U-557 | Y | | |
| | 6686346*PED | Oct 29, 2017 | | | | |
| | 6986904 | Apr 29, 2017 | DP U-699 | Y | | |
| | 6986904*PED | Oct 29, 2017 | | | | |
| <u>BUDESONIDE - RHINOCORT</u> | | | | | | |
| N020746 002 | 6686346 | Apr 29, 2017 | DP U-557 | | | |
| | 6686346*PED | Oct 29, 2017 | | | | |
| | 6986904 | Apr 29, 2017 | DP U-699 | | | |
| | 6986904*PED | Oct 29, 2017 | | | | |
| <u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u> | | | | | | |
| N021929 001 | 5349945 | Nov 12, 2011 | DP | | | |
| | 5674860 | Oct 07, 2014 | DP U-1075 | | | |
| | 5972919 | Dec 17, 2012 | DP U-1075 | | | |
| | 7759328 | Jan 29, 2023 | DP U-1073 | | | |

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2010

See List footnote for information regarding List content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|--|-------------|------------------------------|-----------------|-------------------------------|------------------------|-----------------------------------|
| <u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u> | | | | | | |
| N021929 002 | 5349945 | Nov 12, 2011 | DP | | | |
| | 5674860 | Oct 07, 2014 | DP U-1075 | | | |
| | 5972919 | Dec 17, 2012 | DP U-1075 | | | |
| | 7759328 | Jan 29, 2023 | DP U-1073 | | | |
| <u>BUPRENORPHINE - BUTRANS</u> | | | | | | |
| N021306 001 | 5240711 | Nov 28, 2010 | DP | | NDF | Jun 30, 2013 |
| | 5968547 | Sep 29, 2017 | U-1072 | | | |
| | 6264980 | Dec 18, 2015 | DP | | | |
| | 6344211 | Dec 18, 2015 | U-1072 | | | |
| | RE41408 | Sep 29, 2017 | U-1072 | | | |
| | >A> RE41489 | Sep 29, 2017 | U-1072 | | | |
| <u>BUPRENORPHINE - BUTRANS</u> | | | | | | |
| N021306 002 | 5240711 | Nov 28, 2010 | DP | | NDF | Jun 30, 2013 |
| | 5968547 | Sep 29, 2017 | U-1072 | | | |
| | 6264980 | Dec 18, 2015 | DP | | | |
| | 6344211 | Dec 18, 2015 | U-1072 | | | |
| | RE41408 | Sep 29, 2017 | U-1072 | | | |
| | >A> RE41489 | Sep 29, 2017 | U-1072 | | | |
| <u>BUPRENORPHINE - BUTRANS</u> | | | | | | |
| N021306 003 | 5240711 | Nov 28, 2010 | DP | | NDF | Jun 30, 2013 |
| | 5968547 | Sep 29, 2017 | U-1072 | | | |
| | 6264980 | Dec 18, 2015 | DP | | | |
| | 6344211 | Dec 18, 2015 | U-1072 | | | |
| | RE41408 | Sep 29, 2017 | U-1072 | | | |
| | >A> RE41489 | Sep 29, 2017 | U-1072 | | | |
| <u>BUPRENORPHINE; NALOXONE - SUBOXONE</u> | | | | | | |
| N022410 001 | | | | >A> NDF | | Aug 30, 2013 |
| <u>BUPRENORPHINE; NALOXONE - SUBOXONE</u> | | | | | | |
| N022410 002 | | | | >A> NDF | | Aug 30, 2013 |
| <u>BUPROPION HYDROBROMIDE - APLENZIN</u> | | | | | | |
| N022108 001 | 7645802 | Jun 27, 2026 | DP | | | |
| | 7649019 | Jun 27, 2026 | DP | | | |
| | 7662407 | Jun 27, 2026 | DP | | | |
| | 7671094 | Jun 27, 2026 | DP | | | |
| <u>BUPROPION HYDROBROMIDE - APLENZIN</u> | | | | | | |
| N022108 002 | 7645802 | Jun 27, 2026 | DP | | | |
| | 7649019 | Jun 27, 2026 | DP | | | |
| | 7662407 | Jun 27, 2026 | DP | | | |
| | 7671094 | Jun 27, 2026 | DP | | | |
| <u>BUPROPION HYDROBROMIDE - APLENZIN</u> | | | | | | |
| N022108 003 | 7645802 | Jun 27, 2026 | DP | | | |
| | 7649019 | Jun 27, 2026 | DP | | | |
| | 7662407 | Jun 27, 2026 | DP | | | |
| | 7671094 | Jun 27, 2026 | DP | | | |

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2010

See List footnote for information regarding List content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|--|-------------|------------------------------|-----------------|-------------------------------|------------------------|-----------------------------------|
| <u>CABAZITAXEL - JEVTANA KIT</u> | | | | | | |
| N201023 001 | 5438072 | Nov 22, 2013 | DP | | NCE | Jun 17, 2015 |
| | 5698582 | Jul 03, 2012 | DP | | | |
| | 5847170 | Mar 26, 2016 | DS DP | | | |
| | 6331635 | Mar 26, 2016 | DS DP | | | |
| | 6372780 | Mar 26, 2016 | U-1067 | | | |
| | 6387946 | Mar 26, 2016 | U-1067 | | | |
| | 7241907 | Dec 10, 2025 | DS | | | |
| <u>CAPSAICIN - QUTENZA</u> | | | | | | |
| N022395 001 | | | | | ODE | Nov 16, 2016 |
| <u>CARGLUMIC ACID - CARBAGLU</u> | | | | | | |
| N022562 001 | | | | | NCE | Mar 18, 2015 |
| <u>CEFTIBUTEN DIHYDRATE - CEDAX</u> | | | | | | |
| N050686 001 | 5599557 | Feb 04, 2014 | DP U-578 | | | |
| | 5599557 | Feb 04, 2014 | DP U-282 | | | |
| <u>CEFTIBUTEN DIHYDRATE - CEDAX</u> | | | | | | |
| N050686 002 | 5599557 | Feb 04, 2014 | DP U-578 | | | |
| | 5599557 | Feb 04, 2014 | DP U-282 | | | |
| <u>CICLESONIDE - ALVESCO</u> | | | | | | |
| N021658 002 | 6264923 | May 13, 2018 | DP | | | |
| <u>CICLESONIDE - ALVESCO</u> | | | | | | |
| N021658 003 | 6264923 | May 13, 2018 | DP | | | |
| <u>CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE - CIPRO XR</u> | | | | | | |
| N021473 001 | 7709022 | Jun 23, 2021 | DP | | | |
| | 7709022*PED | Dec 23, 2021 | | | | |
| <u>CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE - CIPRO XR</u> | | | | | | |
| N021473 002 | 7709022 | Jun 23, 2021 | DP | | | |
| | 7709022*PED | Dec 23, 2021 | | | | |
| <u>CLINDAMYCIN PHOSPHATE - CLINDAMYCIN PHOSPHATE</u> | | | | | | |
| A090785 001 | | | | | PC | Sep 27, 2010 |
| <u>CLINDAMYCIN PHOSPHATE; TRETINOIN - VELTIN</u> | | | | | | |
| N050803 001 | >A> 5690923 | Nov 25, 2014 | DP | | | |
| <u>CLINDAMYCIN PHOSPHATE; TRETINOIN - ZIANA</u> | | | | | | |
| N050802 001 | RE41134 | Feb 24, 2015 | DP U-1033 | | | |
| <u>CLOBETASOL PROPIONATE - CLOBEX</u> | | | | | | |
| N021644 001 | 7700081 | Jan 03, 2022 | U-1044 | | | |
| <u>CLOFARABINE - CLOLAR</u> | | | | | | |
| N021673 001 | 5661136 | Jan 14, 2018 | U-626 | | | |
| | 5661136*PED | Jul 14, 2018 | | | | |
| <u>CLONIDINE HYDROCHLORIDE - JENLOGA</u> | | | | | | |
| N022331 001 | 5869100 | Oct 13, 2013 | DP | | | |
| <u>CLONIDINE HYDROCHLORIDE - JENLOGA</u> | | | | | | |
| N022331 002 | 5869100 | Oct 13, 2013 | DP | | | |

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2010

See List footnote for information regarding List content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|--|-------------|------------------------------|-----------------|-------------------------------|------------------------|-----------------------------------|
| <u>CLOZAPINE - FAZACLO ODT</u> | | | | | | |
| N021590 005 | >A> 6024981 | Apr 09, 2018 | DP | | | |
| | >A> 6106861 | Dec 05, 2017 | DP | | | |
| | >A> 6221392 | Apr 09, 2018 | DP | | | |
| <u>CLOZAPINE - FAZACLO ODT</u> | | | | | | |
| N021590 006 | >A> 6024981 | Apr 09, 2018 | DP | | | |
| | >A> 6106861 | Dec 05, 2017 | DP | | | |
| | >A> 6221392 | Apr 09, 2018 | DP | | | |
| <u>COLESEVELAM HYDROCHLORIDE - WELCHOL</u> | | | | | | |
| N022362 001 | 5607669 | Jun 10, 2014 | U-757 | | | |
| | 5607669*PED | Dec 10, 2014 | | | | |
| | 5679717 | Apr 29, 2014 | U-757 | | | |
| | 5679717*PED | Oct 29, 2014 | | | | |
| | 5693675 | Dec 02, 2014 | DS | | | |
| | 5693675*PED | Jun 02, 2015 | | | | |
| | 5917007 | Apr 29, 2014 | DS | U-757 | | |
| | 5917007*PED | Oct 29, 2014 | | | | |
| | 5919832 | Apr 29, 2014 | DS | | | |
| | 5919832*PED | Oct 29, 2014 | | | | |
| | 6066678 | Apr 29, 2014 | DS | U-757 | | |
| | 6066678*PED | Oct 29, 2014 | | | | |
| | 6433026 | Apr 29, 2014 | DS | | | |
| | 6433026*PED | Oct 29, 2014 | | | | |
| | 6784254 | Apr 29, 2014 | DS DP | | | |
| | 6784254*PED | Oct 29, 2014 | | | | |
| | 7101960 | Apr 29, 2014 | DS DP | U-757 | | |
| | 7101960*PED | Oct 29, 2014 | | | | |
| | 7229613 | Apr 17, 2022 | | U-493 | | |
| | 7229613*PED | Oct 17, 2022 | | | | |
| <u>COLESEVELAM HYDROCHLORIDE - WELCHOL</u> | | | | | | |
| N022362 002 | 5607669 | Jun 10, 2014 | U-757 | | | |
| | 5607669*PED | Dec 10, 2014 | | | | |
| | 5679717 | Apr 29, 2014 | U-757 | | | |
| | 5679717*PED | Oct 29, 2014 | | | | |
| | 5693675 | Dec 02, 2014 | DS | | | |
| | 5693675*PED | Jun 02, 2015 | | | | |
| | 5917007 | Apr 29, 2014 | DS | U-757 | | |
| | 5917007*PED | Oct 29, 2014 | | | | |
| | 5919832 | Apr 29, 2014 | DS | | | |
| | 5919832*PED | Oct 29, 2014 | | | | |
| | 6066678 | Apr 29, 2014 | DS | U-757 | | |
| | 6066678*PED | Oct 29, 2014 | | | | |
| | 6433026 | Apr 29, 2014 | DS | | | |
| | 6433026*PED | Oct 29, 2014 | | | | |
| | 6784254 | Apr 29, 2014 | DS DP | | | |
| | 6784254*PED | Oct 29, 2014 | | | | |
| | 7101960 | Apr 29, 2014 | DS DP | U-757 | | |
| | 7101960*PED | Oct 29, 2014 | | | | |
| | 7229613 | Apr 17, 2022 | | U-493 | | |
| | 7229613*PED | Oct 17, 2022 | | | | |

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2010

See List footnote for information regarding List content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|--|-------------|------------------------------|-----------------|-------------------------------|------------------------|-----------------------------------|
| <u>CYCLOBENZAPRINE HYDROCHLORIDE - AMRIX</u> | | | | | | |
| N021777 001 | >A> 7790199 | Nov 14, 2023 | DP | | | |
| <u>CYCLOBENZAPRINE HYDROCHLORIDE - AMRIX</u> | | | | | | |
| N021777 002 | >A> 7790199 | Nov 14, 2023 | DP | | | |
| <u>DALFAMPRIDINE - AMPYRA</u> | | | | | | |
| N022250 001 | 5370879 | Dec 06, 2011 | DP | | NCE | Jan 22, 2015 |
| | 5540938 | Jul 30, 2013 | U-1030 | | ODE | Jan 22, 2017 |
| <u>DARUNAVIR ETHANOLATE - PREZISTA</u> | | | | | | |
| N021976 001 | 6037157 | Jun 26, 2016 | U-935 | | | |
| | 6703403 | Jun 26, 2016 | U-935 | | | |
| | 7470506 | Jun 23, 2019 | U-935 | | | |
| | 7700645 | Dec 26, 2026 | DS DP | | | |
| <u>DARUNAVIR ETHANOLATE - PREZISTA</u> | | | | | | |
| N021976 002 | 6037157 | Jun 26, 2016 | U-935 | | | |
| | 6703403 | Jun 26, 2016 | U-935 | | | |
| | 7470506 | Jun 23, 2019 | U-935 | | | |
| | 7700645 | Dec 26, 2026 | DS DP | | | |
| <u>DARUNAVIR ETHANOLATE - PREZISTA</u> | | | | | | |
| N021976 003 | 6037157 | Jun 26, 2016 | U-935 | | | |
| | 6703403 | Jun 26, 2016 | U-935 | | | |
| | 7470506 | Jun 23, 2019 | U-935 | | | |
| | 7700645 | Dec 26, 2026 | DS DP | | | |
| <u>DARUNAVIR ETHANOLATE - PREZISTA</u> | | | | | | |
| N021976 004 | 6037157 | Jun 26, 2016 | U-935 | | | |
| | 6703403 | Jun 26, 2016 | U-935 | | | |
| | 7470506 | Jun 23, 2019 | U-935 | | | |
| | 7700645 | Dec 26, 2026 | DS DP | | | |
| <u>DARUNAVIR ETHANOLATE - PREZISTA</u> | | | | | | |
| N021976 005 | 6037157 | Jun 26, 2016 | U-935 | | | |
| | 6703403 | Jun 26, 2016 | U-935 | | | |
| | 7470506 | Jun 23, 2019 | U-935 | | | |
| | 7700645 | Dec 26, 2026 | DS DP | | | |
| <u>DECITABINE - DACOGEN</u> | | | | | | |
| N021790 001 | | | | | D-123 | Mar 11, 2013 |
| <u>DEXAMETHASONE - OZURDEX</u> | | | | | | |
| N022315 001 | >A> 7767223 | Jul 11, 2025 | DP | | | |
| <u>DEXMETHYLPHENIDATE HYDROCHLORIDE - FOCALIN XR</u> | | | | | | |
| N021802 006 | | | | | >A> D-121 | Oct 23, 2012 |
| | | | | | >A> M-80 | Oct 17, 2011 |
| <u>DICLOFENAC POTASSIUM - CAMBIA</u> | | | | | | |
| N022165 001 | 7482377 | May 15, 2017 | DS DP U-436 | | NDF | Jun 17, 2012 |
| | >A> 7759394 | Jun 16, 2026 | DS DP U-436 | | | |
| <u>DICLOFENAC POTASSIUM - ZIPSOR</u> | | | | | | |
| N022202 001 | 6365180 | Jul 15, 2019 | DP U-980 | | | |
| | 7662858 | Feb 24, 2029 | U-1035 | | | |

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2010

See List footnote for information regarding List content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|--|-----------------|------------------------------|-----------------|-------------------------------|------------------------|-----------------------------------|
| <u>DIENOGEST; ESTRADIOL VALERATE - NATAZIA</u> | | | | | | |
| N022252 001 | 6133251 | Oct 25, 2016 | DP U-828 | | NP | May 06, 2013 |
| | 6133251 | Oct 25, 2016 | DP U-112 | | | |
| | 6133251 | Oct 25, 2016 | DP U-1 | | | |
| | 6884793 | Oct 25, 2016 | DP | | | |
| <u>DOCETAXEL - TAXOTERE</u> | | | | | | |
| N020449 001 | 4814470 | May 14, 2010 | DS DP | | I-543 | Sep 28, 2010 |
| | 4814470*PED | Nov 14, 2010 | | | I-542 | Sep 28, 2010 |
| | 5438072 | Nov 22, 2013 | DP | | M-61 | May 13, 2013 |
| | 5438072*PED | May 22, 2014 | | | PED | Nov 13, 2013 |
| | 5698582 | Jul 03, 2012 | DP | | PED | Mar 28, 2011 |
| | 5698582*PED | Jan 03, 2013 | | | | |
| | 5714512 | Jul 03, 2012 | DP | | | |
| | 5714512*PED | Jan 03, 2013 | | | | |
| | 5750561 | Jul 03, 2012 | DP | | | |
| | 5750561*PED | Jan 03, 2013 | | | | |
| <u>DOCETAXEL - TAXOTERE</u> | | | | | | |
| N020449 003 | 4814470 | May 14, 2010 | DS DP | | >A> I-543 | Sep 28, 2010 |
| | >A> 4814470*PED | Nov 14, 2010 | | | >A> I-542 | Sep 28, 2010 |
| | >A> 5698582 | Jul 03, 2012 | DP | | >A> M-61 | May 13, 2013 |
| | >A> 5698582*PED | Jan 03, 2013 | | | >A> PED | Nov 13, 2013 |
| | >A> 5714512 | Jul 03, 2012 | DP | | >A> PED | Mar 28, 2011 |
| | >A> 5714512*PED | Jan 03, 2013 | | | | |
| | >A> 5750561 | Jul 03, 2012 | DP | | | |
| | >A> 5750561*PED | Jan 03, 2013 | | | | |
| <u>DONEPEZIL HYDROCHLORIDE - ARICEPT</u> | | | | | | |
| N022568 001 | >A> 4895841 | Nov 25, 2010 | DS DP U-322 | | >A> NP | Jul 23, 2013 |
| <u>DONEPEZIL HYDROCHLORIDE - ARICEPT ODT</u> | | | | | | |
| N021720 001 | 7727548 | Jun 23, 2022 | DP U-1062 | | | |
| | 7727552 | Mar 26, 2018 | DP | | | |
| <u>DONEPEZIL HYDROCHLORIDE - ARICEPT ODT</u> | | | | | | |
| N021720 002 | 7727548 | Jun 23, 2022 | DP U-1062 | | | |
| | 7727552 | Mar 26, 2018 | DP | | | |

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2010

See List footnote for information regarding List content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|--|-------------|------------------------------|-----------------|-------------------------------|------------------------|-----------------------------------|
| <u>DOXEPIN HYDROCHLORIDE - SILENOR</u> | | | | | | |
| N022036 001 | 5502047 | Mar 26, 2013 | U-620 | | NP | Mar 17, 2013 |
| | 5585115 | Jan 09, 2015 | DP | | | |
| | 5725884 | Jan 09, 2015 | DP | | | |
| | 5866166 | Jan 09, 2015 | DP | | | |
| | 5948438 | Jan 09, 2015 | DP | | | |
| | 6103219 | Jan 09, 2015 | DP | | | |
| | 6211229 | Feb 17, 2020 | U-620 | | | |
| | 6217909 | Jan 09, 2015 | DP | | | |
| <u>DOXEPIN HYDROCHLORIDE - SILENOR</u> | | | | | | |
| N022036 002 | 5502047 | Mar 26, 2013 | U-620 | | NP | Mar 17, 2013 |
| | 5585115 | Jan 09, 2015 | DP | | | |
| | 5725884 | Jan 09, 2015 | DP | | | |
| | 5866166 | Jan 09, 2015 | DP | | | |
| | 5948438 | Jan 09, 2015 | DP | | | |
| | 6103219 | Jan 09, 2015 | DP | | | |
| | 6211229 | Feb 17, 2020 | U-620 | | | |
| | 6217909 | Jan 09, 2015 | DP | | | |
| <u>DOXYCYCLINE - ORACEA</u> | | | | | | |
| N050805 001 | 7749532 | Dec 19, 2027 | DP U-1063 | | | |
| <u>DUTASTERIDE; TAMSULOSIN HYDROCHLORIDE - JALYN</u> | | | | | | |
| N022460 001 | 5565467 | Nov 20, 2015 | DS DP | | | |
| | 5846976 | Sep 17, 2013 | U-1065 | | | |
| | 5998427 | Sep 17, 2013 | DS DP U-1066 | | | |
| <u>ELTROMBOPAG OLAMINE - PROMACTA</u> | | | | | | |
| N022291 003 | 6280959 | Oct 30, 2018 | DS DP U-930 | | NCE | Nov 20, 2013 |
| | 7160870 | Dec 08, 2021 | DS DP U-930 | | ODE | Nov 20, 2015 |
| | 7332481 | May 24, 2021 | U-930 | | | |
| | 7452874 | May 24, 2021 | DS DP | | | |
| | 7473686 | May 24, 2021 | DS DP U-930 | | | |
| | 7547719 | Mar 04, 2024 | DS DP U-930 | | | |
| <u>EPINEPHRINE - ADRENAClick</u> | | | | | | |
| N020800 003 | 5665071 | May 27, 2013 | DP | | | |
| <u>EPINEPHRINE - ADRENAClick</u> | | | | | | |
| N020800 004 | 5665071 | May 27, 2013 | DP | | | |
| <u>EPINEPHRINE - EPIPEN</u> | | | | | | |
| N019430 001 | >A> 7794432 | Sep 11, 2025 | DP | | | |
| <u>EPINEPHRINE - EPIPEN JR.</u> | | | | | | |
| N019430 002 | >A> 7794432 | Sep 11, 2025 | DP | | | |
| <u>ERLOTINIB HYDROCHLORIDE - TARCEVA</u> | | | | | | |
| N021743 001 | 6900221 | Nov 09, 2020 | DS DP U-875 | I-624 | Apr 16, 2013 | |
| | 6900221 | Nov 09, 2020 | DS DP U-659 | | | |
| | 6900221 | Nov 09, 2020 | DS DP U-1046 | | | |
| | 7087613 | Nov 09, 2020 | U-659 | | | |
| | 7087613 | Nov 09, 2020 | U-1045 | | | |

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2010

See List footnote for information regarding List content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|-------------|------------------------------|-----------------|-------------------------------|------------------------|-----------------------------------|
| <u>ERLOTINIB HYDROCHLORIDE - TARCEVA</u> | | | | | | |
| N021743 002 | 6900221 | Nov 09, 2020 | DS DP U-875 | | I-624 | Apr 16, 2013 |
| | 6900221 | Nov 09, 2020 | DS DP U-659 | | | |
| | 6900221 | Nov 09, 2020 | DS DP U-1046 | | | |
| | 7087613 | Nov 09, 2020 | U-659 | | | |
| | 7087613 | Nov 09, 2020 | U-1045 | | | |
| <u>ERLOTINIB HYDROCHLORIDE - TARCEVA</u> | | | | | | |
| N021743 003 | 6900221 | Nov 09, 2020 | DS DP U-875 | | I-624 | Apr 16, 2013 |
| | 6900221 | Nov 09, 2020 | DS DP U-659 | | | |
| | 6900221 | Nov 09, 2020 | DS DP U-1046 | | | |
| | 7087613 | Nov 09, 2020 | U-659 | | | |
| | 7087613 | Nov 09, 2020 | U-1045 | | | |
| <u>ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO</u> | | | | | | |
| N022511 001 | 5714504 | Feb 03, 2015 | DP U-1053 | | NC | Apr 30, 2013 |
| | 5900424 | May 04, 2016 | DS U-1053 | | | |
| | 6369085 | May 25, 2018 | DS DP U-1053 | | | |
| | 6875872 | May 27, 2014 | DS | | | |
| | 6926907 | Feb 28, 2023 | DP U-1052 | | | |
| | 7411070 | May 25, 2018 | DS U-1053 | | | |
| | 7745466 | Oct 13, 2018 | DP U-1053 | | | |
| <u>ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO</u> | | | | | | |
| N022511 002 | 5714504 | Feb 03, 2015 | DP U-1053 | | NC | Apr 30, 2013 |
| | 5900424 | May 04, 2016 | DS U-1053 | | | |
| | 6369085 | May 25, 2018 | DS DP U-1053 | | | |
| | 6875872 | May 27, 2014 | DS | | | |
| | 6926907 | Feb 28, 2023 | DP U-1052 | | | |
| | 7411070 | May 25, 2018 | DS U-1053 | | | |
| | 7745466 | Oct 13, 2018 | DP U-1053 | | | |
| <u>ESTRADIOL ACETATE - FEMTRACE</u> | | | | | | |
| N021633 001 | >A> 7572779 | Oct 02, 2025 | U-904 | | | |
| <u>ESTRADIOL ACETATE - FEMTRACE</u> | | | | | | |
| N021633 002 | >A> 7572779 | Oct 02, 2025 | U-904 | | | |
| <u>ESTRADIOL ACETATE - FEMTRACE</u> | | | | | | |
| N021633 003 | >A> 7572779 | Oct 02, 2025 | U-904 | | | |
| <u>ESZOPICLONE - LUNESTA</u> | | | | | | |
| N021476 001 | 6444673 | Feb 14, 2014 | DS DP | | | |
| <u>ESZOPICLONE - LUNESTA</u> | | | | | | |
| N021476 002 | 6444673 | Feb 14, 2014 | DS DP | | | |
| <u>ESZOPICLONE - LUNESTA</u> | | | | | | |
| N021476 003 | 6444673 | Feb 14, 2014 | DS DP | | | |
| <u>ETHINYLM ESTRADIOL; LEVONORGESTREL - SEASONIQUE</u> | | | | | | |
| N021840 001 | 7615545 | Jun 15, 2023 | U-1 | | | |

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2010

See List footnote for information regarding List content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|-------------------------------------|-------------|------------------------------|-----------------|-------------------------------|------------------------|-----------------------------------|
| <u>EVEROLIMUS - ZORTRESS</u> | | | | | | |
| N021560 001 | 5665772 | Sep 09, 2014 | DS DP U-1049 | | NP | Apr 20, 2013 |
| | 6004973 | Jul 12, 2016 | DP U-1049 | | NCE | Mar 30, 2014 |
| | 6239124 | Aug 11, 2017 | U-1049 | | | |
| | 6440990 | Sep 24, 2013 | DP U-1049 | | | |
| | 6455518 | Jul 29, 2017 | U-1049 | | | |
| <u>EVEROLIMUS - ZORTRESS</u> | | | | | | |
| N021560 002 | 5665772 | Sep 09, 2014 | DS DP U-1049 | | NP | Apr 20, 2013 |
| | 6004973 | Jul 12, 2016 | DP U-1049 | | NCE | Mar 30, 2014 |
| | 6239124 | Aug 11, 2017 | U-1049 | | | |
| | 6440990 | Sep 24, 2013 | DP U-1049 | | | |
| | 6455518 | Jul 29, 2017 | U-1049 | | | |
| <u>EVEROLIMUS - ZORTRESS</u> | | | | | | |
| N021560 003 | 5665772 | Sep 09, 2014 | DS DP U-1049 | | NP | Apr 20, 2013 |
| | 6004973 | Jul 12, 2016 | DP U-1049 | | NCE | Mar 30, 2014 |
| | 6239124 | Aug 11, 2017 | U-1049 | | | |
| | 6440990 | Sep 24, 2013 | DP U-1049 | | | |
| | 6455518 | Jul 29, 2017 | U-1049 | | | |
| <u>EXENATIDE SYNTHETIC - BYETTA</u> | | | | | | |
| N021773 001 | 7741269 | Jan 07, 2018 | | U-1074 | | |
| <u>EXENATIDE SYNTHETIC - BYETTA</u> | | | | | | |
| N021773 002 | 7741269 | Jan 07, 2018 | | U-1074 | | |
| <u>EZETIMIBE - ZETIA</u> | | | | | | |
| N021445 001 | 7612058 | Jan 25, 2022 | | U-1027 | | |
| | 7612058*PED | Jul 25, 2022 | | | | |
| <u>FENOFIBRATE - FENOGLIDE</u> | | | | | | |
| N022118 001 | 7658944 | Dec 09, 2024 | | DP | | |
| <u>FENOFIBRATE - FENOGLIDE</u> | | | | | | |
| N022118 002 | 7658944 | Dec 09, 2024 | | DP | | |
| <u>FENOFIBRIC ACID - FIBRICOR</u> | | | | | | |
| N022418 001 | 7741373 | Aug 20, 2027 | | U-1059 | | |
| | 7741374 | Aug 20, 2027 | | U-1061 | | |
| | 7741374 | Aug 20, 2027 | | U-1060 | | |
| <u>FENOFIBRIC ACID - FIBRICOR</u> | | | | | | |
| N022418 002 | 7741373 | Aug 20, 2027 | | U-1059 | | |
| | 7741374 | Aug 20, 2027 | | U-1061 | | |
| | 7741374 | Aug 20, 2027 | | U-1060 | | |
| <u>FENTANYL CITRATE - ONSOLIS</u> | | | | | | |
| N022266 001 | 7579019 | Jan 31, 2019 | | U-767 | | |
| <u>FENTANYL CITRATE - ONSOLIS</u> | | | | | | |
| N022266 002 | 7579019 | Jan 31, 2019 | | U-767 | | |
| <u>FENTANYL CITRATE - ONSOLIS</u> | | | | | | |
| N022266 003 | 7579019 | Jan 31, 2019 | | U-767 | | |

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2010

See List footnote for information regarding List content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|--|-------------|------------------------------|-----------------|-------------------------------|------------------------|-----------------------------------|
| <u>FENTANYL CITRATE - ONSOLIS</u> | | | | | | |
| N022266 004 | 7579019 | Jan 31, 2019 | | U-767 | | |
| <u>FENTANYL CITRATE - ONSOLIS</u> | | | | | | |
| N022266 005 | 7579019 | Jan 31, 2019 | | U-767 | | |
| <u>FEXOFENADINE HYDROCHLORIDE - ALLEGRA</u> | | | | | | |
| N020872 001 | 7662835 | May 18, 2014 | | U-139 | | |
| | 7662835*PED | Nov 18, 2014 | | | | |
| | 7666881 | May 18, 2014 | | U-139 | | |
| | 7666881*PED | Nov 18, 2014 | | | | |
| <u>FEXOFENADINE HYDROCHLORIDE - ALLEGRA</u> | | | | | | |
| N020872 002 | 7662835 | May 18, 2014 | | U-139 | | |
| | 7662835*PED | Nov 18, 2014 | | | | |
| | 7666881 | May 18, 2014 | | U-139 | | |
| | 7666881*PED | Nov 18, 2014 | | | | |
| <u>FEXOFENADINE HYDROCHLORIDE - ALLEGRA</u> | | | | | | |
| N020872 004 | 7662835 | May 18, 2014 | | U-139 | | |
| | 7662835*PED | Nov 18, 2014 | | | | |
| | 7666881 | May 18, 2014 | | U-139 | | |
| | 7666881*PED | Nov 18, 2014 | | | | |
| <u>FEXOFENADINE HYDROCHLORIDE - ALLEGRA</u> | | | | | | |
| N021909 001 | 7662835 | May 18, 2014 | | U-139 | | |
| | 7662835*PED | Nov 18, 2014 | | | | |
| <u>FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE - ALLEGRA D 24 HOUR</u> | | | | | | |
| N021704 001 | 7662835 | May 18, 2014 | | U-139 | | |
| | 7662835*PED | Nov 18, 2014 | | | | |
| <u>FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE - ALLEGRA-D 12 HOUR</u> | | | | | | |
| N020786 001 | 7662835 | May 18, 2014 | | U-139 | | |
| | 7662835*PED | Nov 18, 2014 | | | | |
| | 7666881 | May 18, 2014 | | U-139 | | |
| | 7666881*PED | Nov 18, 2014 | | | | |
| <u>FOLLITROPIN ALFA/BETA - FOLLISTIM AQ</u> | | | | | | |
| N021211 001 | | | | >A> I-306 | | Jun 28, 2013 |
| <u>FOLLITROPIN ALFA/BETA - FOLLISTIM AQ</u> | | | | | | |
| N021211 002 | | | | >A> I-306 | | Jun 28, 2013 |
| <u>FOLLITROPIN ALFA/BETA - FOLLISTIM AQ</u> | | | | | | |
| N021211 004 | | | | >A> I-306 | | Jun 28, 2013 |
| <u>FOLLITROPIN ALFA/BETA - FOLLISTIM AQ</u> | | | | | | |
| N021273 001 | | | | >A> I-306 | | Jun 28, 2013 |
| <u>FOLLITROPIN ALFA/BETA - FOLLISTIM AQ</u> | | | | | | |
| N021273 002 | | | | >A> I-306 | | Jun 28, 2013 |
| <u>FOLLITROPIN ALFA/BETA - GONAL-F RFF PEN</u> | | | | | | |
| N021684 001 | 7741268 | Apr 02, 2024 | DP | | | |
| <u>FOLLITROPIN ALFA/BETA - GONAL-F RFF PEN</u> | | | | | | |
| N021684 002 | 7741268 | Apr 02, 2024 | DP | | | |

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2010

See List footnote for information regarding List content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|--|-------------|------------------------------|-----------------|-------------------------------|------------------------|-----------------------------------|
| <u>FOLLITROPIN ALFA/BETA - GONAL-F RFF PEN</u> | | | | | | |
| N021684 003 | 7741268 | Apr 02, 2024 | DP | | | |
| <u>FORMOTEROL FUMARATE; MOMETASONE FUROATE - DULERA</u> | | | | | | |
| N022518 001 | 5889015 | Jan 27, 2014 | U-1068 | | NC | Jun 22, 2013 |
| | 5889015*PED | Jul 27, 2014 | | | | |
| | 6057307 | Jan 27, 2014 | DP U-1068 | | | |
| | 6057307*PED | Jul 27, 2014 | | | | |
| | 6068832 | Aug 27, 2017 | DP U-1068 | | | |
| | 6677323 | Jan 27, 2014 | U-1068 | | | |
| | 7067502 | May 21, 2020 | DP U-1068 | | | |
| | 7566705 | May 08, 2020 | DP U-1068 | | | |
| <u>FORMOTEROL FUMARATE; MOMETASONE FUROATE - DULERA</u> | | | | | | |
| N022518 002 | 5889015 | Jan 27, 2014 | U-1068 | | NC | Jun 22, 2013 |
| | 5889015*PED | Jul 27, 2014 | | | | |
| | 6057307 | Jan 27, 2014 | DP U-1068 | | | |
| | 6057307*PED | Jul 27, 2014 | | | | |
| | 6068832 | Aug 27, 2017 | DP U-1068 | | | |
| | 6677323 | Jan 27, 2014 | U-1068 | | | |
| | 7067502 | May 21, 2020 | DP U-1068 | | | |
| | 7566705 | May 08, 2020 | DP U-1068 | | | |
| <u>FULVESTRANT - FASLODEX</u> | | | | | | |
| N021344 001 | | | | >A> D-126 | | Sep 09, 2013 |
| <u>GADOBENATE DIMEGLUMINE - MULTIHANCE</u> | | | | | | |
| N021357 001 | | | | | NPP | Mar 17, 2013 |
| <u>GADOBENATE DIMEGLUMINE - MULTIHANCE</u> | | | | | | |
| N021357 002 | | | | | NPP | Mar 17, 2013 |
| <u>GADOBENATE DIMEGLUMINE - MULTIHANCE</u> | | | | | | |
| N021357 003 | | | | | NPP | Mar 17, 2013 |
| <u>GADOBENATE DIMEGLUMINE - MULTIHANCE</u> | | | | | | |
| N021357 004 | | | | | NPP | Mar 17, 2013 |
| <u>GATIFLOXACIN - ZYMAXID</u> | | | | | | |
| N022548 001 | 5880283 | Dec 05, 2015 | DS | | NP | May 18, 2013 |
| | 5880283*PED | Jun 05, 2016 | | | | |
| | 6333045 | Aug 20, 2019 | DS DP | | | |
| | 6333045*PED | Feb 20, 2020 | | | | |
| <u>GLIMEPIRIDE; PIOGLITAZONE HYDROCHLORIDE - DUETACT</u> | | | | | | |
| N021925 001 | >A> 7700128 | Jan 30, 2027 | DP | | | |
| <u>GLIMEPIRIDE; PIOGLITAZONE HYDROCHLORIDE - DUETACT</u> | | | | | | |
| N021925 002 | >A> 7700128 | Jan 30, 2027 | DP | | | |
| <u>GLYCOPYRROLATE - CUVPOSA</u> | | | | | | |
| N022571 001 | >A> 7638552 | Aug 20, 2023 | U-1076 | | NP | Jul 28, 2013 |
| <u>HEXAMINOLEVULINATE HYDROCHLORIDE - CYSVIEW KIT</u> | | | | | | |
| N022555 001 | | | | | NP | May 28, 2013 |
| <u>HYALURONIDASE RECOMBINANT HUMAN - HYLENEX RECOMBINANT</u> | | | | | | |
| N021859 001 | >A> 7767429 | Sep 23, 2027 | DS DP | | | |

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2010

See List footnote for information regarding List content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|-------------|------------------------------|-----------------|-------------------------------|------------------------|-----------------------------------|
| <u>HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM - HYZAAR</u> | | | | | | |
| N020387 001 | 5608075**** | Mar 04, 2009 | | | Y | |
| | 5608075*PED | Sep 04, 2009 | | | | |
| <u>HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM - HYZAAR</u> | | | | | | |
| N020387 002 | 5608075**** | Mar 04, 2009 | | | Y | |
| | 5608075*PED | Sep 04, 2009 | | | | |
| <u>HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM - LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE</u> | | | | | | |
| A077157 001 | | | | | PC | Oct 03, 2010 |
| <u>HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM - LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE</u> | | | | | | |
| A077157 003 | | | | | PC | Oct 03, 2010 |
| <u>HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL - BENICAR HCT</u> | | | | | | |
| N021532 002 | 6878703 | Nov 19, 2021 | U-3 | | Y | |
| <u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID</u> | | | | | | |
| N019034 003 | 6589960 | Nov 09, 2020 | DP | | | |
| <u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID</u> | | | | | | |
| N019034 004 | 6589960 | Nov 09, 2020 | DP | | | |
| <u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID</u> | | | | | | |
| N019034 005 | 6589960 | Nov 09, 2020 | DP | | | |
| <u>HYDROMORPHONE HYDROCHLORIDE - EXALGO</u> | | | | | | |
| N021217 001 | 5702725 | Jul 07, 2014 | DP U-1043 | | NDF | Mar 01, 2013 |
| | 5914131 | Jul 07, 2014 | DP U-1043 | | | |
| <u>HYDROMORPHONE HYDROCHLORIDE - EXALGO</u> | | | | | | |
| N021217 002 | 5702725 | Jul 07, 2014 | DP U-1043 | | NDF | Mar 01, 2013 |
| | 5914131 | Jul 07, 2014 | DP U-1043 | | | |
| <u>HYDROMORPHONE HYDROCHLORIDE - EXALGO</u> | | | | | | |
| N021217 003 | 5702725 | Jul 07, 2014 | DP U-1043 | | NDF | Mar 01, 2013 |
| | 5914131 | Jul 07, 2014 | DP U-1043 | | | |
| <u>IBANDRONATE SODIUM - BONIVA</u> | | | | | | |
| N021455 002 | 7718634 | May 06, 2023 | U-642 | | | |
| <u>IBUPROFEN; PHENYLEPHRINE HYDROCHLORIDE - ADVIL CONGESTION RELIEF</u> | | | | | | |
| N022565 001 | 5087454 | Jul 30, 2010 | DP | | | |
| <u>IMIQUIMOD - ALDARA</u> | | | | | | |
| N020723 001 | 7696159 | Apr 01, 2024 | DS | U-1048 | | |
| | 7696159 | Apr 01, 2024 | DS | U-1047 | | |
| | 7696159*PED | Oct 01, 2024 | | | | |
| <u>IMIQUIMOD - IMIQUIMOD</u> | | | | | | |
| A078548 001 | | | | | PC | Aug 24, 2010 |
| <u>IMIQUIMOD - ZYCLARA</u> | | | | | | |
| N022483 001 | | | | | NP | Mar 25, 2013 |
| <u>INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT - NOVOLOG MIX 70/30</u> | | | | | | |
| N021172 001 | 5547930 | Sep 28, 2013 | DS DP | | | |
| | 5834422 | Sep 28, 2013 | DP U-471 | | | |
| | 5840680 | Sep 28, 2013 | DS DP U-471 | | | |

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2010

See List footnote for information regarding List content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|--|-------------|------------------------------|-----------------|-------------------------------|------------------------|-----------------------------------|
| <u>INSULIN GLARGINE RECOMBINANT - LANTUS</u> | | | | | | |
| N021081 001 | 7713930 | Jun 13, 2023 | DP | | | |
| | 7713930*PED | Dec 13, 2023 | | | | |
| <u>INSULIN GLULISINE RECOMBINANT - APIDRA</u> | | | | | | |
| N021629 001 | 7696162 | Mar 22, 2022 | DP U-471 | | | |
| <u>INSULIN GLULISINE RECOMBINANT - APIDRA</u> | | | | | | |
| N021629 002 | 7696162 | Mar 22, 2022 | DP U-471 | | | |
| <u>INSULIN GLULISINE RECOMBINANT - APIDRA SOLOSTAR</u> | | | | | | |
| N021629 003 | 6221633 | Jun 18, 2018 | DS DP U-471 | | | |
| | 6960561 | Jan 25, 2023 | DP U-471 | | | |
| | 7452860 | Mar 22, 2022 | DP | | | |
| | 7696162 | Mar 22, 2022 | DP U-471 | | | |
| <u>ITRACONAZOLE - ITRACONAZOLE</u> | | | | | | |
| N022484 001 | 6509038 | May 12, 2017 | DP U-1054 | | NP | Apr 29, 2013 |
| | 7081255 | May 12, 2017 | DP U-1054 | | | |
| <u>KETOROLAC TROMETHAMINE - SPRIX</u> | | | | | | |
| N022382 001 | 6333044 | Dec 25, 2018 | DP U-1057 | | NDF | May 14, 2013 |
| | 7476689 | Oct 11, 2012 | DP U-1056 | | | |
| <u>LACOSAMIDE - VIMPAT</u> | | | | | | |
| N022255 001 | 5654301 | Aug 05, 2014 | DS DP U-914 | | NCE | Oct 28, 2013 |
| | RE38551 | Mar 17, 2017 | DS DP U-914 | | | |
| <u>LAMOTRIGINE - LAMICTAL XR</u> | | | | | | |
| N022115 001 | | | | I-622 | Jan 29, 2013 | |
| | | | | NDF | May 29, 2012 | |
| | | | | PED | Nov 29, 2012 | |
| <u>LAMOTRIGINE - LAMICTAL XR</u> | | | | | | |
| N022115 002 | | | | I-622 | Jan 29, 2013 | |
| | | | | NDF | May 29, 2012 | |
| | | | | PED | Nov 29, 2012 | |
| <u>LAMOTRIGINE - LAMICTAL XR</u> | | | | | | |
| N022115 003 | | | | I-622 | Jan 29, 2013 | |
| | | | | NDF | May 29, 2012 | |
| | | | | PED | Nov 29, 2012 | |
| <u>LAMOTRIGINE - LAMICTAL XR</u> | | | | | | |
| N022115 004 | | | | I-622 | Jan 29, 2013 | |
| | | | | NDF | May 29, 2012 | |
| | | | | PED | Nov 29, 2012 | |
| <u>LAMOTRIGINE - LAMICTAL XR</u> | | | | | | |
| N022115 005 | | | | I-622 | Jan 29, 2013 | |
| | | | | NDF | May 29, 2012 | |
| | | | | PED | Nov 29, 2012 | |
| <u>LAPATINIB DITOSYLATE - TYKERB</u> | | | | | | |
| N022059 001 | 6713485 | Sep 29, 2020 | DS DP U-800 | | I-620 | Jan 29, 2013 |
| <u>LEVALBUTEROL TARTRATE - XOPENEX HFA</u> | | | | | | |
| N021730 001 | 5836299 | Nov 17, 2015 | DP | | | |
| <u>LEVETIRACETAM - KEPPTRA</u> | | | | | | |
| N021872 001 | | | | I-563 | Mar 19, 2010 | |
| | | | | PED | Sep 19, 2010 | |

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2010

See List footnote for information regarding List content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|--|-----------|------------------------------|-----------------|-------------------------------|------------------------|-----------------------------------|
| <u>LEVOTHYROXINE SODIUM - TIROSINT</u> | | | | | | |
| N021924 002 | 7723390 | Mar 14, 2024 | DP | | | |
| <u>LEVOTHYROXINE SODIUM - TIROSINT</u> | | | | | | |
| N021924 003 | 7723390 | Mar 14, 2024 | DP | | | |
| <u>LEVOTHYROXINE SODIUM - TIROSINT</u> | | | | | | |
| N021924 004 | 7723390 | Mar 14, 2024 | DP | | | |
| <u>LEVOTHYROXINE SODIUM - TIROSINT</u> | | | | | | |
| N021924 005 | 7723390 | Mar 14, 2024 | DP | | | |
| <u>LEVOTHYROXINE SODIUM - TIROSINT</u> | | | | | | |
| N021924 006 | 7723390 | Mar 14, 2024 | DP | | | |
| <u>LEVOTHYROXINE SODIUM - TIROSINT</u> | | | | | | |
| N021924 007 | 7723390 | Mar 14, 2024 | DP | | | |
| <u>LEVOTHYROXINE SODIUM - TIROSINT</u> | | | | | | |
| N021924 008 | 7723390 | Mar 14, 2024 | DP | | | |
| <u>LEVOTHYROXINE SODIUM - TIROSINT</u> | | | | | | |
| N021924 009 | 7723390 | Mar 14, 2024 | DP | | | |
| <u>LEVOTHYROXINE SODIUM - TIROSINT</u> | | | | | | |
| N021924 010 | 7723390 | Mar 14, 2024 | DP | | | |
| <u>LEVOTHYROXINE SODIUM - TIROSINT</u> | | | | | | |
| N022121 001 | 7723390 | Mar 14, 2024 | DP | | | |
| <u>LIRAGLUTIDE RECOMBINANT - VICTOZA</u> | | | | | | |
| N022341 001 | 6268343 | Aug 22, 2017 | DS DP U-968 | | NCE | Jan 25, 2015 |
| | 6458924 | Aug 22, 2017 | DS DP U-968 | | | |
| | 7235627 | Aug 22, 2017 | DS DP | | | |
| <u>LISDEXAMFETAMINE Dimesylate - VYVANSE</u> | | | | | | |
| N021977 001 | 7655630 | Feb 24, 2023 | DS | | M-82 | Apr 05, 2013 |
| | 7659253 | Feb 24, 2023 | DS DP U-727 | | | |
| | 7659254 | Feb 24, 2023 | | U-1034 | | |
| | 7662787 | Feb 24, 2023 | DS | | | |
| | 7671030 | Feb 24, 2023 | | DP U-727 | | |
| | 7671031 | Feb 28, 2023 | | U-727 | | |
| | 7674774 | Mar 18, 2023 | DP | U-842 | | |
| | 7678770 | Mar 25, 2023 | | U-842 | | |
| | 7678771 | Mar 25, 2023 | DP | U-842 | | |
| | 7687466 | Feb 24, 2023 | | DP | | |
| | 7687467 | Apr 08, 2023 | DP | U-842 | | |
| | 7700561 | Jun 29, 2023 | DP | | | |
| | 7718619 | Feb 24, 2023 | DP | U-842 | | |
| | 7723305 | Feb 24, 2023 | DP | U-842 | | |

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2010

See List footnote for information regarding List content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|--|-----------|------------------------------|-----------------|-------------------------------|------------------------|-----------------------------------|
| <u>LISDEXAMFETAMINE Dimesylate - Vyvanse</u> | | | | | | |
| N021977 002 | 7655630 | Feb 24, 2023 | DS | | M-82 | Apr 05, 2013 |
| | 7659253 | Feb 24, 2023 | DS DP U-727 | | | |
| | 7659254 | Feb 24, 2023 | | U-1034 | | |
| | 7662787 | Feb 24, 2023 | DS | | | |
| | 7671030 | Feb 24, 2023 | | DP U-727 | | |
| | 7671031 | Feb 28, 2023 | | U-727 | | |
| | 7674774 | Mar 18, 2023 | | DP U-842 | | |
| | 7678770 | Mar 25, 2023 | | U-842 | | |
| | 7678771 | Mar 25, 2023 | | DP U-842 | | |
| | 7687466 | Feb 24, 2023 | | DP | | |
| | 7687467 | Apr 08, 2023 | | DP U-842 | | |
| | 7700561 | Jun 29, 2023 | | DP | | |
| | 7718619 | Feb 24, 2023 | | DP U-842 | | |
| | 7723305 | Feb 24, 2023 | | DP U-842 | | |
| <u>LISDEXAMFETAMINE Dimesylate - Vyvanse</u> | | | | | | |
| N021977 003 | 7655630 | Feb 24, 2023 | DS | | M-82 | Apr 05, 2013 |
| | 7659253 | Feb 24, 2023 | DS DP U-727 | | | |
| | 7659254 | Feb 24, 2023 | | U-1034 | | |
| | 7662787 | Feb 24, 2023 | DS | | | |
| | 7671030 | Feb 24, 2023 | | DP U-727 | | |
| | 7671031 | Feb 28, 2023 | | U-727 | | |
| | 7674774 | Mar 18, 2023 | | DP U-842 | | |
| | 7678770 | Mar 25, 2023 | | U-842 | | |
| | 7678771 | Mar 25, 2023 | | DP U-842 | | |
| | 7687466 | Feb 24, 2023 | | DP | | |
| | 7687467 | Apr 08, 2023 | | DP U-842 | | |
| | 7700561 | Jun 29, 2023 | | DP | | |
| | 7718619 | Feb 24, 2023 | | DP U-842 | | |
| | 7723305 | Feb 24, 2023 | | DP U-842 | | |
| <u>LISDEXAMFETAMINE Dimesylate - Vyvanse</u> | | | | | | |
| N021977 004 | 7655630 | Feb 24, 2023 | DS | | M-82 | Apr 05, 2013 |
| | 7659253 | Feb 24, 2023 | DS DP U-727 | | | |
| | 7659254 | Feb 24, 2023 | | U-1034 | | |
| | 7662787 | Feb 24, 2023 | DS | | | |
| | 7671031 | Feb 28, 2023 | | U-727 | | |
| | 7678770 | Mar 25, 2023 | | U-842 | | |
| | 7687466 | Feb 24, 2023 | | DP | | |
| | 7700561 | Jun 29, 2023 | | DP | | |

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2010

See List footnote for information regarding List content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|--|-------------|------------------------------|-----------------|-------------------------------|------------------------|-----------------------------------|
| <u>LISDEXAMFETAMINE Dimesylate - Vyvanse</u> | | | | | | |
| N021977 005 | 7655630 | Feb 24, 2023 | DS | | M-82 | Apr 05, 2013 |
| | 7659253 | Feb 24, 2023 | DS DP U-727 | | | |
| | 7659254 | Feb 24, 2023 | | U-1034 | | |
| | 7662787 | Feb 24, 2023 | DS | | | |
| | 7671030 | Feb 24, 2023 | | DP U-727 | | |
| | 7671031 | Feb 28, 2023 | | U-727 | | |
| | 7674774 | Mar 18, 2023 | | DP U-842 | | |
| | 7678770 | Mar 25, 2023 | | U-842 | | |
| | 7678771 | Mar 25, 2023 | | DP U-842 | | |
| | 7687466 | Feb 24, 2023 | | DP | | |
| | 7687467 | Apr 08, 2023 | | DP U-842 | | |
| | 7700561 | Jun 29, 2023 | | DP | | |
| | 7718619 | Feb 24, 2023 | | DP U-842 | | |
| | 7723305 | Feb 24, 2023 | | DP U-842 | | |
| <u>LISDEXAMFETAMINE Dimesylate - Vyvanse</u> | | | | | | |
| N021977 006 | 7655630 | Feb 24, 2023 | DS | | M-82 | Apr 05, 2013 |
| | 7659253 | Feb 24, 2023 | DS DP U-727 | | | |
| | 7659254 | Feb 24, 2023 | | U-1034 | | |
| | 7662787 | Feb 24, 2023 | DS | | | |
| | 7671030 | Feb 24, 2023 | | DP U-727 | | |
| | 7671031 | Feb 28, 2023 | | U-727 | | |
| | 7674774 | Mar 18, 2023 | | DP U-842 | | |
| | 7678770 | Mar 25, 2023 | | U-842 | | |
| | 7678771 | Mar 25, 2023 | | DP U-842 | | |
| | 7687466 | Feb 24, 2023 | | DP | | |
| | 7687467 | Apr 08, 2023 | | DP U-842 | | |
| | 7700561 | Jun 29, 2023 | | DP | | |
| | 7718619 | Feb 24, 2023 | | DP U-842 | | |
| | 7723305 | Feb 24, 2023 | | DP U-842 | | |
| <u>LOPINAVIR; RITONAVIR - Kaletra</u> | | | | | | |
| N021251 001 | 5541206 | Jul 30, 2013 | DS DP U-895 | | D-124 | Apr 27, 2013 |
| | 5541206 | Jul 30, 2013 | DS DP U-348 | | | |
| | 5635523 | Jun 03, 2014 | | U-895 | | |
| | 5635523 | Jun 03, 2014 | | U-352 | | |
| | 5886036 | Nov 19, 2013 | DS DP U-895 | | | |
| | 6037157 | Jun 26, 2016 | | U-895 | | |
| | 6037157 | Jun 26, 2016 | | U-346 | | |
| | 6703403 | Jun 26, 2016 | | U-895 | | |
| | 6703403 | Jun 26, 2016 | | U-257 | | |
| | 6911214 | Nov 28, 2021 | | DP U-895 | | |
| <u>LOPINAVIR; Ritonavir - Kaletra</u> | | | | | | |
| N021906 001 | 5886036 | Nov 19, 2013 | DS DP U-895 | | D-124 | Apr 27, 2013 |
| <u>LOPINAVIR; RITONAVIR - Kaletra</u> | | | | | | |
| N021906 002 | 5886036 | Nov 19, 2013 | DS DP U-895 | | D-124 | Apr 27, 2013 |
| <u>Losartan Potassium - Cozaar</u> | | | | | | |
| N020386 001 | 5608075**** | Mar 04, 2009 | | Y | | |
| | 5608075*PED | Sep 04, 2009 | | | | |

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2010

See List footnote for information regarding List content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|-------------|------------------------------|-----------------|-------------------------------|------------------------|-----------------------------------|
| <u>LOSARTAN POTASSIUM - COZAAR</u> | | | | | | |
| N020386 002 | 5608075**** | Mar 04, 2009 | | | Y | |
| | 5608075*PED | Sep 04, 2009 | | | | |
| <u>LOSARTAN POTASSIUM - COZAAR</u> | | | | | | |
| N020386 003 | 5608075**** | Mar 04, 2009 | | | Y | |
| | 5608075*PED | Sep 04, 2009 | | | | |
| <u>LOSARTAN POTASSIUM - LOSARTAN POTASSIUM</u> | | | | | | |
| A076958 001 | | | | | PC | Oct 03, 2010 |
| <u>LOSARTAN POTASSIUM - LOSARTAN POTASSIUM</u> | | | | | | |
| A076958 002 | | | | | PC | Oct 03, 2010 |
| <u>LOSARTAN POTASSIUM - LOSARTAN POTASSIUM</u> | | | | | | |
| A076958 003 | | | | | PC | Oct 03, 2010 |
| <u>MAGNESIUM SULFATE ANHYDROUS; POTASSIUM SULFATE; SODIUM SULFATE - SUPREP BOWEL PREP KIT</u> | | | | | | |
| N022372 001 | >A> 6946149 | Apr 30, 2022 | DP U-837 | >A> NC | | Aug 05, 2013 |
| <u>MARAVIROC - SELZENTRY</u> | | | | | | |
| N022128 001 | | | | | NPP | May 28, 2013 |
| <u>MARAVIROC - SELZENTRY</u> | | | | | | |
| N022128 002 | | | | | NPP | May 28, 2013 |
| <u>MEMANTINE HYDROCHLORIDE - NAMENDA XR</u> | | | | | | |
| N022525 001 | 5061703 | Apr 11, 2015 | U-539 | | NDF | Jun 21, 2013 |
| <u>MEMANTINE HYDROCHLORIDE - NAMENDA XR</u> | | | | | | |
| N022525 002 | 5061703 | Apr 11, 2015 | U-539 | | NDF | Jun 21, 2013 |
| <u>MEMANTINE HYDROCHLORIDE - NAMENDA XR</u> | | | | | | |
| N022525 003 | 5061703 | Apr 11, 2015 | U-539 | | NDF | Jun 21, 2013 |
| <u>MEMANTINE HYDROCHLORIDE - NAMENDA XR</u> | | | | | | |
| N022525 004 | 5061703 | Apr 11, 2015 | U-539 | | NDF | Jun 21, 2013 |
| <u>MESALAMINE - SFROWASA</u> | | | | | | |
| N019618 002 | 7645801 | Jul 24, 2027 | DS DP | | | |
| <u>METAXALONE - SKELAXIN</u> | | | | | | |
| N013217 003 | 7714006 | Dec 03, 2021 | | U-1050 | | |
| <u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET</u> | | | | | | |
| N021842 001 | 5965584 | Jun 19, 2016 | DP U-1055 | | | |
| <u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET</u> | | | | | | |
| N021842 002 | 5965584 | Jun 19, 2016 | DP U-1055 | | | |
| <u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET</u> | | | | | | |
| N022044 001 | 6890898 | Feb 02, 2019 | U-803 | | | |
| | 6890898 | Feb 02, 2019 | U-1038 | | | |
| | 6890898 | Feb 02, 2019 | U-1036 | | | |
| | 7078381 | Feb 02, 2019 | U-803 | | | |
| | 7078381 | Feb 02, 2019 | U-1038 | | | |
| | 7078381 | Feb 02, 2019 | U-1036 | | | |
| | 7125873 | Jul 26, 2022 | DP U-803 | | | |
| | 7125873 | Jul 26, 2022 | DP U-1038 | | | |
| | 7125873 | Jul 26, 2022 | DP U-1036 | | | |

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2010

See List footnote for information regarding List content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|-------------|------------------------------|-----------------|-------------------------------|------------------------|-----------------------------------|
| <u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET</u> | | | | | | |
| N022044 002 | 6890898 | Feb 02, 2019 | U-803 | | | |
| | 6890898 | Feb 02, 2019 | U-1038 | | | |
| | 6890898 | Feb 02, 2019 | U-1036 | | | |
| | 7078381 | Feb 02, 2019 | U-803 | | | |
| | 7078381 | Feb 02, 2019 | U-1038 | | | |
| | 7078381 | Feb 02, 2019 | U-1036 | | | |
| | 7125873 | Jul 26, 2022 | DP U-803 | | | |
| | 7125873 | Jul 26, 2022 | DP U-1038 | | | |
| | 7125873 | Jul 26, 2022 | DP U-1036 | | | |
| <u>METHYLPHENIDATE - DAYTRANA</u> | | | | | | |
| N021514 001 | | | | | NPP | Jun 29, 2013 |
| <u>METHYLPHENIDATE - DAYTRANA</u> | | | | | | |
| N021514 002 | | | | | NPP | Jun 29, 2013 |
| <u>METHYLPHENIDATE - DAYTRANA</u> | | | | | | |
| N021514 003 | | | | | NPP | Jun 29, 2013 |
| <u>METHYLPHENIDATE - DAYTRANA</u> | | | | | | |
| N021514 004 | | | | | NPP | Jun 29, 2013 |
| <u>METHYLPHENIDATE HYDROCHLORIDE - METHYLIN</u> | | | | | | |
| N021419 001 | 7691880 | Oct 07, 2024 | DP | | | |
| <u>METHYLPHENIDATE HYDROCHLORIDE - METHYLIN</u> | | | | | | |
| N021419 002 | 7691880 | Oct 07, 2024 | DP | | | |
| <u>MICONAZOLE - ORAVIG</u> | | | | | | |
| N022404 001 | 6916485 | Sep 11, 2022 | DP U-1051 | | NDF | Apr 16, 2013 |
| | 7651698 | Jan 08, 2026 | U-1051 | | | |
| <u>MICONAZOLE NITRATE - MICONAZOLE NITRATE</u> | | | | | | |
| A079114 001 | | | | | PC | Dec 24, 2010 |
| <u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u> | | | | | | |
| N050808 001 | >A> 7790705 | Nov 20, 2025 | U-1078 | | | |
| <u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u> | | | | | | |
| N050808 002 | >A> 7790705 | Nov 20, 2025 | U-1078 | | | |
| <u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u> | | | | | | |
| N050808 003 | >A> 7790705 | Nov 20, 2025 | U-1078 | | | |
| <u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u> | | | | | | |
| N050808 004 | >A> 7790705 | Nov 20, 2025 | U-1078 | | | |
| <u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u> | | | | | | |
| N050808 005 | >A> 7790705 | Nov 20, 2025 | U-1078 | | | |
| <u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u> | | | | | | |
| N050808 006 | >A> 5908838 | Feb 19, 2018 | U-917 | | | |
| | >A> 7790705 | Nov 20, 2025 | U-1078 | | | |
| <u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u> | | | | | | |
| N050808 007 | >A> 5908838 | Feb 19, 2018 | U-917 | | | |
| | >A> 7790705 | Nov 20, 2025 | U-1078 | | | |

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2010

See List footnote for information regarding List content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|--|-------------|------------------------------|-----------------|-------------------------------|------------------------|-----------------------------------|
| <u>MINOCYCLINE HYDROCHLORIDE - SOLODYNE</u> | | | | | | |
| N050808 008 | >A> 5908838 | Feb 19, 2018 | U-917 | | | |
| | >A> 7790705 | Nov 20, 2025 | U-1078 | | | |
| <u>MOMETASONE FUROATE MONOHYDRATE - NASONEX</u> | | | | | | |
| N020762 001 | | | | I-626 | | May 26, 2013 |
| <u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u> | | | | | | |
| N022321 001 | 7682633 | Jun 19, 2027 | U-443 | | | |
| | 7682634 | Jun 19, 2027 | DP | | | |
| <u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u> | | | | | | |
| N022321 002 | 7682633 | Jun 19, 2027 | U-443 | | | |
| | 7682634 | Jun 19, 2027 | DP | | | |
| <u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u> | | | | | | |
| N022321 003 | 7682633 | Jun 19, 2027 | U-443 | | | |
| | 7682634 | Jun 19, 2027 | DP | | | |
| <u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u> | | | | | | |
| N022321 004 | 7682633 | Jun 19, 2027 | U-443 | | | |
| | 7682634 | Jun 19, 2027 | DP | | | |
| <u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u> | | | | | | |
| N022321 005 | 7682633 | Jun 19, 2027 | U-443 | | | |
| | 7682634 | Jun 19, 2027 | DP | | | |
| <u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u> | | | | | | |
| N022321 006 | 7682633 | Jun 19, 2027 | U-443 | | | |
| | 7682634 | Jun 19, 2027 | DP | | | |
| <u>MOXIFLOXACIN HYDROCHLORIDE - VIGAMOX</u> | | | | | | |
| N021598 001 | 7671070 | Sep 29, 2019 | U-709 | | | |
| | 7671070*PED | Mar 29, 2020 | | | | |
| <u>NEBIVOLOL HYDROCHLORIDE - BYSTOLIC</u> | | | | | | |
| N021742 005 | 5759580 | Jun 02, 2015 | DP | | | |
| | 6545040 | Apr 08, 2020 | DP U-3 | | | |
| <u>NIACIN; SIMVASTATIN - SIMCOR</u> | | | | | | |
| N022078 004 | | | | NC | | Feb 15, 2011 |
| <u>NIACIN; SIMVASTATIN - SIMCOR</u> | | | | | | |
| N022078 005 | | | | NC | | Feb 15, 2011 |
| <u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER</u> | | | | | | |
| N019734 004 | 7659291 | Apr 18, 2027 | U-1029 | | | |
| <u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER</u> | | | | | | |
| N019734 003 | 7659291 | Apr 18, 2027 | U-1029 | | | |
| <u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER</u> | | | | | | |
| N019734 002 | 7659291 | Apr 18, 2027 | U-1029 | | | |
| <u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER</u> | | | | | | |
| N019734 005 | 7659291 | Apr 18, 2027 | U-1029 | | | |
| <u>NILOTINIB HYDROCHLORIDE MONOHYDRATE - TASIGNA</u> | | | | | | |
| N022068 001 | | | | I-627 | | Jun 17, 2013 |

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2010

See List footnote for information regarding List content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|-------------|------------------------------|-----------------|-------------------------------|------------------------|-----------------------------------|
| <u>OLMESARTAN MEDOXOMIL - BENICAR</u> | | | | | | |
| | N021286 001 | | | | NPP PED | Feb 04, 2013 Aug 04, 2010 |
| <u>OLMESARTAN MEDOXOMIL - BENICAR</u> | | | | | | |
| | N021286 003 | | | | NPP PED | Feb 04, 2013 Aug 04, 2010 |
| <u>OLMESARTAN MEDOXOMIL - BENICAR</u> | | | | | | |
| | N021286 004 | | | | NPP PED | Feb 04, 2013 Aug 04, 2010 |
| <u>OMEGA-3-ACID ETHYL ESTERS - LOVAZA</u> | | | | | | |
| | N021654 001 | 7732488 | Jan 30, 2025 | DS DP | | |
| <u>OMEPRAZOLE; SODIUM BICARBONATE - OMEPRAZOLE AND SODIUM BICARBONATE</u> | | | | | | |
| | A078966 001 | | | | PC | Dec 28, 2010 |
| <u>OMEPRAZOLE; SODIUM BICARBONATE - OMEPRAZOLE AND SODIUM BICARBONATE</u> | | | | | | |
| | A078966 002 | | | | PC | Dec 28, 2010 |
| <u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u> | | | | | | |
| | N021087 001 | | | | M-90 | Feb 22, 2013 |
| <u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u> | | | | | | |
| | N021087 002 | | | | M-90 | Feb 22, 2013 |
| <u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u> | | | | | | |
| | N021087 003 | | | | M-90 | Feb 22, 2010 |
| <u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u> | | | | | | |
| | N021246 001 | | | | M-90 | Feb 22, 2013 |
| <u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u> | | | | | | |
| | N020553 001 | 7674799 | Mar 30, 2025 | DS | | |
| | | 7674800 | Mar 30, 2025 | DS | | |
| | | 7683072 | Mar 30, 2025 | DS | | |
| <u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u> | | | | | | |
| | N020553 002 | 7674799 | Mar 30, 2025 | DS | | |
| | | 7674800 | Mar 30, 2025 | DS | | |
| | | 7683072 | Mar 30, 2025 | DS | | |
| <u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u> | | | | | | |
| | N020553 003 | 7674799 | Mar 30, 2025 | DS | | |
| | | 7674800 | Mar 30, 2025 | DS | | |
| | | 7683072 | Mar 30, 2025 | DS | | |
| <u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u> | | | | | | |
| | N020553 004 | 7674799 | Mar 30, 2025 | DS | | |
| | | 7674800 | Mar 30, 2025 | DS | | |
| | | 7683072 | Mar 30, 2025 | DS | | |
| <u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u> | | | | | | |
| | N020553 005 | 7674799 | Mar 30, 2025 | DS | | |
| | | 7674800 | Mar 30, 2025 | DS | | |
| | | 7683072 | Mar 30, 2025 | DS | | |

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2010

See List footnote for information regarding List content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|--|-----------|------------------------------|-----------------|-------------------------------|------------------------|-----------------------------------|
| <u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u> | | | | | | |
| N020553 006 | 7674799 | Mar 30, 2025 | DS | | | |
| | 7674800 | Mar 30, 2025 | DS | | | |
| | 7683072 | Mar 30, 2025 | DS | | | |
| <u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u> | | | | | | |
| N020553 007 | 7674799 | Mar 30, 2025 | DS | | | |
| | 7674800 | Mar 30, 2025 | DS | | | |
| | 7683072 | Mar 30, 2025 | DS | | | |
| <u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u> | | | | | | |
| N020553 008 | 7674799 | Mar 30, 2025 | DS | | | |
| | 7674800 | Mar 30, 2025 | DS | | | |
| | 7683072 | Mar 30, 2025 | DS | | | |
| <u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u> | | | | | | |
| N022272 001 | 5508042 | Apr 16, 2013 | | U-443 | | |
| | 6488963 | Jun 24, 2017 | | DP | | |
| | 7674799 | Mar 30, 2025 | | DP | | |
| | 7674800 | Mar 30, 2025 | | DS | | |
| | 7683072 | Mar 30, 2025 | | DS | | |
| <u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u> | | | | | | |
| N022272 002 | 5508042 | Apr 16, 2013 | | U-443 | | |
| | 6488963 | Jun 24, 2017 | | DP | | |
| | 7674799 | Mar 30, 2025 | | DP | | |
| | 7674800 | Mar 30, 2025 | | DS | | |
| | 7683072 | Mar 30, 2025 | | DS | | |
| <u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u> | | | | | | |
| N022272 003 | 5508042 | Apr 16, 2013 | | U-443 | | |
| | 6488963 | Jun 24, 2017 | | DP | | |
| | 7674799 | Mar 30, 2025 | | DP | | |
| | 7674800 | Mar 30, 2025 | | DS | | |
| | 7683072 | Mar 30, 2025 | | DS | | |
| <u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u> | | | | | | |
| N022272 004 | 5508042 | Apr 16, 2013 | | U-443 | | |
| | 6488963 | Jun 24, 2017 | | DP | | |
| | 7674799 | Mar 30, 2025 | | DP | | |
| | 7674800 | Mar 30, 2025 | | DS | | |
| | 7683072 | Mar 30, 2025 | | DS | | |
| <u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u> | | | | | | |
| N022272 005 | 5508042 | Apr 16, 2013 | | U-443 | | |
| | 6488963 | Jun 24, 2017 | | DP | | |
| | 7674799 | Mar 30, 2025 | | DP | | |
| | 7674800 | Mar 30, 2025 | | DS | | |
| | 7683072 | Mar 30, 2025 | | DS | | |

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2010

See List footnote for information regarding List content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|-----------|------------------------------|-----------------|-------------------------------|------------------------------|-----------------------------------|
| <u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u> | | | | | | |
| N022272 006 | 5508042 | Apr 16, 2013 | | U-443 | | |
| | 6488963 | Jun 24, 2017 | | DP | | |
| | 7674799 | Mar 30, 2025 | | DP | | |
| | 7674800 | Mar 30, 2025 | DS | | | |
| | 7683072 | Mar 30, 2025 | DS | | | |
| <u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u> | | | | | | |
| N022272 007 | 5508042 | Apr 16, 2013 | | U-443 | | |
| | 6488963 | Jun 24, 2017 | | DP | | |
| | 7674799 | Mar 30, 2025 | | DP | | |
| | 7674800 | Mar 30, 2025 | DS | | | |
| | 7683072 | Mar 30, 2025 | DS | | | |
| <u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u> | | | | | | |
| N021610 001 | 7276250 | Feb 04, 2023 | DP | U-826 | | |
| <u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u> | | | | | | |
| N021610 002 | 7276250 | Feb 04, 2023 | DP | U-826 | | |
| <u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u> | | | | | | |
| N021610 003 | 7276250 | Feb 04, 2023 | DP | U-826 | | |
| <u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u> | | | | | | |
| N021610 004 | 7276250 | Feb 04, 2023 | DP | U-826 | | |
| <u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u> | | | | | | |
| N021610 005 | 7276250 | Feb 04, 2023 | DP | U-826 | | |
| <u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u> | | | | | | |
| N021610 006 | 7276250 | Feb 04, 2023 | DP | U-826 | | |
| <u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u> | | | | | | |
| N021610 007 | 7276250 | Feb 04, 2023 | DP | U-826 | | |
| <u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - CREON</u> | | | | | | |
| N020725 001 | | | I-625 M-93 | | Apr 30, 2013 Jul 29, 2013 | |
| <u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - CREON</u> | | | | | | |
| N020725 002 | | | I-625 M-93 | | Apr 30, 2013 Jul 29, 2013 | |
| <u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - CREON</u> | | | | | | |
| N020725 003 | | | I-625 M-93 | | Apr 30, 2013 Jul 29, 2013 | |
| <u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - PANCREAZE</u> | | | | | | |
| N022523 001 | | | NCE | | Apr 12, 2015 | |
| <u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - PANCREAZE</u> | | | | | | |
| N022523 002 | | | NCE | | Apr 12, 2015 | |
| <u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - PANCREAZE</u> | | | | | | |
| N022523 003 | | | NCE | | Apr 12, 2015 | |
| <u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - PANCREAZE</u> | | | | | | |
| N022523 004 | | | NCE | | Apr 12, 2015 | |
| <u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u> | | | | | | |
| N022210 001 | 7658918 | Feb 20, 2028 | DP | | | |

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2010

See List footnote for information regarding List content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|--|-------------|------------------------------|-----------------|-------------------------------|------------------------|-----------------------------------|
| <u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u> | | | | | | |
| N022210 002 | 7658918 | Feb 20, 2028 | DP | | | |
| <u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u> | | | | | | |
| N022210 003 | 7658918 | Feb 20, 2028 | DP | | | |
| <u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u> | | | | | | |
| N022210 004 | 7658918 | Feb 20, 2028 | DP | | | |
| <u>PANTOPRAZOLE SODIUM - PROTONIX</u> | | | | | | |
| N022020 001 | 7544370 | Jun 07, 2026 | DP | | | |
| | 7544370*PED | Dec 07, 2026 | | | | |
| <u>PAROXETINE MESYLAATE - PEDEXVA</u> | | | | | | |
| N021299 001 | >A> 7598271 | Feb 11, 2023 | DS DP | | | |
| <u>PAROXETINE MESYLAATE - PEDEXVA</u> | | | | | | |
| N021299 002 | >A> 7598271 | Feb 11, 2023 | DS DP | | | |
| <u>PAROXETINE MESYLAATE - PEDEXVA</u> | | | | | | |
| N021299 003 | >A> 7598271 | Feb 11, 2023 | DS DP | | | |
| <u>PAROXETINE MESYLAATE - PEDEXVA</u> | | | | | | |
| N021299 004 | >A> 7598271 | Feb 11, 2023 | DS DP | | | |
| <u>PEMETREXED DISODIUM - ALIMTA</u> | | | | | | |
| N021462 001 | >A> 7772209 | Nov 24, 2021 | | U-1077 | | |
| <u>PEMETREXED DISODIUM - ALIMTA</u> | | | | | | |
| N021462 002 | >A> 7772209 | Nov 24, 2021 | | U-1077 | | |
| <u>PENCICLOVIR SODIUM - DENAVIR</u> | | | | | | |
| N020629 001 | 5866581 | Oct 04, 2014 | | U-501 | | |
| | 6124304 | Oct 04, 2014 | | U-501 | | |
| <u>PIOGLITAZONE HYDROCHLORIDE - ACTOS</u> | | | | | | |
| N021073 001 | >A> 5965584 | Jun 19, 2016 | | U-753 | | |
| | >A> 6329404 | Jun 19, 2016 | | U-753 | | |
| <u>PIOGLITAZONE HYDROCHLORIDE - ACTOS</u> | | | | | | |
| N021073 002 | >A> 5965584 | Jun 19, 2016 | | U-753 | | |
| | >A> 6329404 | Jun 19, 2016 | | U-753 | | |
| <u>PIOGLITAZONE HYDROCHLORIDE - ACTOS</u> | | | | | | |
| N021073 003 | >A> 5965584 | Jun 19, 2016 | | U-753 | | |
| | >A> 6329404 | Jun 19, 2016 | | U-753 | | |
| <u>POLIDOCANOL - ASCLERA</u> | | | | | | |
| N021201 001 | | | | | NCE | Mar 30, 2015 |
| <u>POLIDOCANOL - ASCLERA</u> | | | | | | |
| N021201 002 | | | | | NCE | Mar 30, 2015 |
| <u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u> | | | | | | |
| N022421 001 | 4886812 | Oct 08, 2010 | DS DP | | I-623 | Mar 19, 2013 |
| | 7695734 | Apr 26, 2028 | DP | | NDF | Feb 19, 2013 |
| <u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u> | | | | | | |
| N022421 002 | 4886812 | Oct 08, 2010 | DS DP | | I-623 | Mar 19, 2013 |
| | 7695734 | Apr 26, 2028 | DP | | NDF | Feb 19, 2013 |

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2010

See List footnote for information regarding List content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|--|-------------|------------------------------|-----------------|-------------------------------|------------------------|-----------------------------------|
| <u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u> | | | | | | |
| N022421 003 | 4886812 | Oct 08, 2010 | DS DP | | I-623 | Mar 19, 2013 |
| | 7695734 | Apr 26, 2028 | DP | | NDF | Feb 19, 2013 |
| <u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u> | | | | | | |
| N022421 004 | 4886812 | Oct 08, 2010 | DS DP | | I-623 | Mar 19, 2013 |
| | 7695734 | Apr 26, 2028 | DP | | NDF | Feb 19, 2013 |
| <u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u> | | | | | | |
| N022421 005 | 4886812 | Oct 08, 2010 | DS DP | | I-623 | Mar 19, 2013 |
| | 7695734 | Apr 26, 2028 | DP | | NDF | Feb 19, 2013 |
| <u>PRAMIPEXOLE DIHYDROCHLORIDE - PRAMIPEXOLE DIHYDROCHLORIDE</u> | | | | | | |
| A077724 001 | | | | | PC | Jul 03, 2010 |
| <u>PRAMIPEXOLE DIHYDROCHLORIDE - PRAMIPEXOLE DIHYDROCHLORIDE</u> | | | | | | |
| A077724 002 | | | | | PC | Jul 03, 2010 |
| <u>PRAMIPEXOLE DIHYDROCHLORIDE - PRAMIPEXOLE DIHYDROCHLORIDE</u> | | | | | | |
| A077724 003 | | | | | PC | Jul 03, 2010 |
| <u>PRAMIPEXOLE DIHYDROCHLORIDE - PRAMIPEXOLE DIHYDROCHLORIDE</u> | | | | | | |
| A077724 004 | | | | | PC | Jul 03, 2010 |
| <u>PRAMIPEXOLE DIHYDROCHLORIDE - PRAMIPEXOLE DIHYDROCHLORIDE</u> | | | | | | |
| A077724 005 | | | | | PC | Jul 03, 2010 |
| <u>PREDNISOLONE SODIUM PHOSPHATE - ORAPRED ODT</u> | | | | | | |
| N021959 001 | 6740341 | Nov 24, 2019 | DP | | | |
| <u>PREDNISOLONE SODIUM PHOSPHATE - ORAPRED ODT</u> | | | | | | |
| N021959 002 | 6740341 | Nov 24, 2019 | DP | | | |
| <u>PREDNISOLONE SODIUM PHOSPHATE - ORAPRED ODT</u> | | | | | | |
| N021959 003 | 6740341 | Nov 24, 2019 | DP | | | |
| <u>PREGABALIN - LYRICA</u> | | | | | | |
| N022488 001 | 5563175 | Oct 08, 2013 | | U-661 | | I-535 |
| | 6001876 | Dec 30, 2018 | | U-819 | | |
| | 6001876 | Dec 30, 2018 | | U-55 | | |
| | 6197819 | Dec 30, 2018 | DS DP | | | |
| <u>RALTEGRAVIR POTASSIUM - ISENTRESS</u> | | | | | | |
| N022145 001 | 7754731 | Mar 11, 2029 | DS DP | U-257 | | |
| <u>RAMELTEON - ROZEREM</u> | | | | | | |
| N021782 001 | 6034239 | Jul 22, 2019 | DS DP | U-674 | | |
| <u>REGADENOSON - LEXISCAN</u> | | | | | | |
| N022161 001 | 7655636 | Jun 22, 2019 | | U-869 | | |
| | 7655637 | Jun 22, 2019 | DS DP | U-869 | | |
| | 7683037 | Jun 22, 2019 | | U-1042 | | |
| <u>RIFAXIMIN - XIFAXAN</u> | | | | | | |
| N021361 002 | 7045620 | Jun 19, 2024 | DS | | NP ODE | Mar 24, 2013 Mar 24, 2017 |
| <u>RISEDRONATE SODIUM - ACTONEL</u> | | | | | | |
| N020835 005 | 7718634 | May 06, 2023 | | U-662 | | |
| | 7718634*PED | Nov 06, 2023 | | | | |

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2010

See List footnote for information regarding List content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|--|-------------|------------------------------|-----------------|-------------------------------|------------------------|-----------------------------------|
| <u>RITONAVIR - NORVIR</u> | | | | | | |
| N022417 001 | 5541206 | Jul 30, 2013 | DS DP U-688 | | | |
| | 5541206*PED | Jan 30, 2014 | | | | |
| | 5635523 | Jun 03, 2014 | U-688 | | | |
| | 5635523*PED | Dec 03, 2014 | | | | |
| | 5648497 | Jul 15, 2014 | DS | | | |
| | 5648497*PED | Jan 15, 2015 | | | | |
| | 5674882 | Oct 07, 2014 | U-688 | | | |
| | 5674882*PED | Apr 07, 2015 | | | | |
| | 6037157 | Jun 26, 2016 | U-688 | | | |
| | 6037157*PED | Dec 26, 2016 | | | | |
| | 6703403 | Jun 26, 2016 | U-688 | | | |
| | 6703403*PED | Dec 26, 2016 | | | | |
| | 7148359 | Jul 19, 2019 | DP | | | |
| | 7148359*PED | Jan 19, 2020 | | | | |
| | 7364752 | Nov 10, 2020 | DP U-688 | | | |
| | 7364752*PED | May 10, 2021 | | | | |
| <u>ROMIDEPSIN - ISTODAX</u> | | | | | | |
| N022393 001 | 4977138 | Jul 06, 2011 | DS DP | | ODE | Nov 05, 2016 |
| <u>ROSVASTATIN CALCIUM - CRESTOR</u> | | | | | | |
| N021366 002 | 7030152 | Apr 02, 2018 | U-1032 | | I-621 | Feb 08, 2013 |
| <u>ROSVASTATIN CALCIUM - CRESTOR</u> | | | | | | |
| N021366 003 | 7030152 | Apr 02, 2018 | U-1032 | | I-621 | Feb 08, 2013 |
| <u>ROSVASTATIN CALCIUM - CRESTOR</u> | | | | | | |
| N021366 004 | 7030152 | Apr 02, 2018 | U-1032 | | I-621 | Feb 08, 2013 |
| <u>ROSVASTATIN CALCIUM - CRESTOR</u> | | | | | | |
| N021366 005 | 7030152 | Apr 02, 2018 | U-1032 | | I-621 | Feb 08, 2013 |
| <u>RUFINAMIDE - BANZEL</u> | | | | | | |
| N021911 001 | 6740669 | Aug 17, 2020 | DS DP | | | |
| <u>RUFINAMIDE - BANZEL</u> | | | | | | |
| N021911 002 | 6740669 | Aug 17, 2020 | DS DP | | | |
| <u>RUFINAMIDE - BANZEL</u> | | | | | | |
| N021911 003 | 6740669 | Aug 17, 2020 | DS DP | | | |
| <u>SAPROPTERIN DIHYDROCHLORIDE - KUVAN</u> | | | | | | |
| N022181 001 | >A> 7727987 | Nov 17, 2024 | DP | | | |
| <u>SELEGILINE - EMSAM</u> | | | | | | |
| N021336 001 | >A> 7638140 | May 10, 2018 | DP | | | |
| <u>SELEGILINE - EMSAM</u> | | | | | | |
| N021336 002 | >A> 7070808 | May 10, 2018 | DS DP | | | |
| | >A> 7638140 | May 10, 2018 | DP | | | |
| <u>SELEGILINE - EMSAM</u> | | | | | | |
| N021336 003 | >A> 7070808 | May 10, 2018 | DS DP | | | |
| | >A> 7638140 | May 10, 2018 | DP | | | |

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2010

See List footnote for information regarding List content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|-----------|------------------------------|-----------------|-------------------------------|------------------------|-----------------------------------|
| <u>SITAGLIPTIN PHOSPHATE - JANUVIA</u> | | | | | | |
| N021995 001 | 6890898 | Feb 02, 2019 | U-775 | | | |
| | 6890898 | Feb 02, 2019 | U-1039 | | | |
| | 6890898 | Feb 02, 2019 | U-1036 | | | |
| | 7078381 | Feb 02, 2019 | U-775 | | | |
| | 7078381 | Feb 02, 2019 | U-1038 | | | |
| | 7078381 | Feb 02, 2019 | U-1037 | | | |
| | 7078381 | Feb 02, 2019 | U-1036 | | | |
| | 7125873 | Jul 26, 2022 | U-775 | | | |
| | 7125873 | Jul 26, 2022 | U-1038 | | | |
| | 7125873 | Jul 26, 2022 | U-1037 | | | |
| | 7125873 | Jul 26, 2022 | U-1036 | | | |
| <u>SITAGLIPTIN PHOSPHATE - JANUVIA</u> | | | | | | |
| N021995 002 | 6890898 | Feb 02, 2019 | U-775 | | | |
| | 6890898 | Feb 02, 2019 | U-1039 | | | |
| | 6890898 | Feb 02, 2019 | U-1036 | | | |
| | 7078381 | Feb 02, 2019 | U-775 | | | |
| | 7078381 | Feb 02, 2019 | U-1038 | | | |
| | 7078381 | Feb 02, 2019 | U-1037 | | | |
| | 7078381 | Feb 02, 2019 | U-1036 | | | |
| | 7125873 | Jul 26, 2022 | U-775 | | | |
| | 7125873 | Jul 26, 2022 | U-1038 | | | |
| | 7125873 | Jul 26, 2022 | U-1037 | | | |
| | 7125873 | Jul 26, 2022 | U-1036 | | | |
| <u>SITAGLIPTIN PHOSPHATE - JANUVIA</u> | | | | | | |
| N021995 003 | 6890898 | Feb 02, 2019 | U-775 | | | |
| | 6890898 | Feb 02, 2019 | U-1039 | | | |
| | 6890898 | Feb 02, 2019 | U-1036 | | | |
| | 7078381 | Feb 02, 2019 | U-775 | | | |
| | 7078381 | Feb 02, 2019 | U-1038 | | | |
| | 7078381 | Feb 02, 2019 | U-1037 | | | |
| | 7078381 | Feb 02, 2019 | U-1036 | | | |
| | 7125873 | Jul 26, 2022 | U-775 | | | |
| | 7125873 | Jul 26, 2022 | U-1038 | | | |
| | 7125873 | Jul 26, 2022 | U-1037 | | | |
| | 7125873 | Jul 26, 2022 | U-1036 | | | |
| <u>SODIUM OXYBATE - XYREM</u> | | | | | | |
| N021196 001 | 7668730 | Mar 07, 2024 | U-1028 | | | |
| | 7765106 | Jun 16, 2024 | U-1069 | | | |
| | 7765107 | Jun 16, 2024 | U-1070 | | | |
| <u>SODIUM PHOSPHATE, DIBASIC ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE - OSMOPREP</u> | | | | | | |
| N021892 001 | 7687075 | Jun 22, 2028 | DS DP | | | |
| <u>SOMATROPIN RECOMBINANT - HUMATROPE</u> | | | | | | |
| N019640 001 | | | | >A> ODE | | Nov 01, 2013 |
| <u>SOMATROPIN RECOMBINANT - HUMATROPE</u> | | | | | | |
| N019640 004 | | | | >A> ODE | | Nov 01, 2013 |
| <u>SOMATROPIN RECOMBINANT - HUMATROPE</u> | | | | | | |
| N019640 005 | | | | >A> ODE | | Nov 01, 2013 |

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2010

See List footnote for information regarding List content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|-------------|------------------------------|-----------------|-------------------------------|------------------------|-----------------------------------|
| <u>SOMATROPIN RECOMBINANT - HUMATROPE</u> | | | | | | |
| | N019640 006 | | | >A> | ODE | Nov 01, 2013 |
| <u>SOMATROPIN RECOMBINANT - HUMATROPE</u> | | | | | | |
| | N019640 007 | | | >A> | ODE | Nov 01, 2013 |
| <u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u> | | | | | | |
| N021148 008 | 5849700 | Dec 15, 2015 | U-1041 | I-572 | Oct 31, 2011 | |
| | 5849704 | Dec 15, 2015 | DP U-1041 | I-551 | Sep 20, 2010 | |
| | | | | I-536 | May 31, 2010 | |
| | | | | ODE | May 31, 2014 | |
| <u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u> | | | | | | |
| N021148 009 | 5849700 | Dec 15, 2015 | U-1041 | I-572 | Oct 31, 2011 | |
| | 5849704 | Dec 15, 2015 | DP U-1041 | I-551 | Sep 20, 2010 | |
| | | | | I-536 | May 31, 2010 | |
| | | | | ODE | May 31, 2014 | |
| <u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u> | | | | | | |
| N021148 010 | 5849700 | Dec 15, 2015 | U-1041 | I-572 | Oct 31, 2011 | |
| | 5849704 | Dec 15, 2015 | DP U-1041 | I-551 | Sep 20, 2010 | |
| | | | | I-536 | May 31, 2010 | |
| | | | | ODE | May 31, 2014 | |
| <u>TELAVANCIN HYDROCHLORIDE - VIBATIV</u> | | | | | | |
| N022110 001 | 7531623 | Jan 01, 2027 | DS | | | |
| | 7700550 | May 01, 2021 | | U-282 | | |
| <u>TELAVANCIN HYDROCHLORIDE - VIBATIV</u> | | | | | | |
| N022110 002 | 7531623 | Jan 01, 2027 | DS | | | |
| | 7700550 | May 01, 2021 | | U-282 | | |
| <u>TEMSIROLIMUS - TORISEL</u> | | | | | | |
| N022088 001 | | | | M-92 | Jul 09, 2013 | |
| | | | | M-91 | Apr 26, 2013 | |
| <u>TENOFOVIR DISOPROXIL FUMARATE - VIREAD</u> | | | | | | |
| N021356 001 | | | | NPP | Mar 24, 2013 | |
| <u>TERBINAFINE - LAMISIL AT</u> | | | | | | |
| N021958 001 | 5681849 | Oct 28, 2014 | DP | | | |
| | 5681849*PED | Apr 28, 2015 | | | | |
| | 5856355 | May 18, 2012 | DP U-540 | | | |
| | 5856355 | May 18, 2012 | DP U-504 | | | |
| | 5856355*PED | Nov 18, 2012 | | | | |
| <u>THALIDOMIDE - THALOMID</u> | | | | | | |
| N020785 001 | 7723361 | Mar 01, 2013 | | U-1058 | | |
| <u>THALIDOMIDE - THALOMID</u> | | | | | | |
| N020785 002 | 7723361 | Mar 01, 2013 | | U-1058 | | |
| <u>THALIDOMIDE - THALOMID</u> | | | | | | |
| N020785 003 | 7723361 | Mar 01, 2013 | | U-1058 | | |
| <u>THALIDOMIDE - THALOMID</u> | | | | | | |
| N020785 004 | 7723361 | Mar 01, 2013 | | U-1058 | | |
| <u>TIOTROPIUM BROMIDE MONOHYDRATE - SPIRIVA</u> | | | | | | |
| N021395 001 | 7642268 | Sep 24, 2021 | DS DP | | | |

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2010

See List footnote for information regarding List content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|-------------|------------------------------|-----------------|-------------------------------|------------------------|-----------------------------------|
| <u>TOLTERODINE TARTRATE - DETROL</u> | | | | | | |
| N020771 001 | 5559269 | Nov 05, 2013 | U-318 | Y | | |
| | 5559269*PED | May 05, 2014 | | | | |
| <u>TOLTERODINE TARTRATE - DETROL</u> | | | | | | |
| N020771 002 | 5559269 | Nov 05, 2013 | U-318 | Y | | |
| | 5559269*PED | May 05, 2014 | | | | |
| <u>TRANDOLAPRIL; VERAPAMIL HYDROCHLORIDE - TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE</u> | | | | | | |
| A079135 001 | | | | | PC | Dec 05, 2010 |
| <u>TRANDOLAPRIL; VERAPAMIL HYDROCHLORIDE - TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE</u> | | | | | | |
| A079135 002 | | | | | PC | Dec 05, 2010 |
| <u>TRANDOLAPRIL; VERAPAMIL HYDROCHLORIDE - TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE</u> | | | | | | |
| A079135 003 | | | | | PC | Dec 05, 2010 |
| <u>TRAZODONE HYDROCHLORIDE - OLEPTRO</u> | | | | | | |
| N022411 001 | 6607748 | Jun 29, 2020 | DP | | NDF | Feb 02, 2013 |
| <u>TRAZODONE HYDROCHLORIDE - OLEPTRO</u> | | | | | | |
| N022411 002 | 6607748 | Jun 29, 2020 | DP | | NDF | Feb 02, 2013 |
| <u>TREPROSTINIL SODIUM - TYVASO</u> | | | | | | |
| N022387 001 | | | | | ODE | Jul 30, 2016 |
| <u>TRIPTORELIN PAMOATE - TRELSTAR</u> | | | | | | |
| N022437 001 | 5776885 | Jul 07, 2015 | DP | | NP | Mar 10, 2013 |
| <u>TRIPTORELIN PAMOATE - TRELSTAR LA</u> | | | | | | |
| N021288 001 | 5776885 | Jul 07, 2015 | DP | | | |
| <u>TROSPiUM CHLORIDE - SANCTURA XR</u> | | | | | | |
| N022103 001 | 7759359 | Nov 04, 2024 | U-1071 | | | |
| | 7763635 | Nov 04, 2024 | U-1071 | | | |
| >A> | 7781448 | Nov 04, 2024 | U-1071 | | | |
| >A> | 7781449 | Nov 04, 2024 | U-1071 | | | |
| <u>ULIPRISTAL ACETATE - ELLA</u> | | | | | | |
| N022474 001 | | | | | >A> NCE | Aug 13, 2015 |
| <u>VALGANCICLOVIR HYDROCHLORIDE - VALCYTE</u> | | | | | | |
| N021304 001 | | | | | >A> D-125 | Aug 05, 2013 |
| <u>VALGANCICLOVIR HYDROCHLORIDE - VALCYTE</u> | | | | | | |
| N022257 001 | | | | | >A> D-125 | Aug 05, 2013 |
| <u>VARDENAFIL HYDROCHLORIDE - LEVITRA</u> | | | | | | |
| N021400 001 | 7696206 | Oct 31, 2018 | DS DP U-533 | | | |
| <u>VARDENAFIL HYDROCHLORIDE - LEVITRA</u> | | | | | | |
| N021400 002 | 7696206 | Oct 31, 2018 | DS DP U-533 | | | |
| <u>VARDENAFIL HYDROCHLORIDE - LEVITRA</u> | | | | | | |
| N021400 003 | 7696206 | Oct 31, 2018 | DS DP U-533 | | | |
| <u>VARDENAFIL HYDROCHLORIDE - LEVITRA</u> | | | | | | |
| N021400 004 | 7696206 | Oct 31, 2018 | DS DP U-533 | | | |
| <u>VARDENAFIL HYDROCHLORIDE - STAXYN</u> | | | | | | |
| N200179 001 | 6362178 | Oct 31, 2018 | U-155 | | NDF | Jun 17, 2013 |
| | 7696206 | Oct 31, 2018 | U-155 | | | |

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2010

See List footnote for information regarding List content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---------------------------------------|-----------|------------------------------|-----------------|-------------------------------|------------------------|-----------------------------------|
| <u>VARENICLINE TARTRATE - CHANTIX</u> | | | | | | |
| N021928 001 | 7265119 | Aug 03, 2022 | DS DP U-56 | | | |
| <u>VARENICLINE TARTRATE - CHANTIX</u> | | | | | | |
| N021928 002 | 7265119 | Aug 03, 2022 | DS DP U-56 | | | |
| <u>VELAGLUCERASE ALFA - VPRIV</u> | | | | | | |
| N022575 001 | | | | | NCE | Feb 26, 2015 |
| <u>VELAGLUCERASE ALFA - VPRIV</u> | | | | | | |
| N022575 002 | | | | | NCE | Feb 26, 2015 |
| <u>VORINOSTAT - ZOLINZA</u> | | | | | | |
| N021991 001 | 7652069 | Mar 04, 2023 | DS | | | |
| | 7732490 | Mar 04, 2023 | | U-892 | | |
| <u>ZOLPIDEM TARTRATE - ZOLPIMIST</u> | | | | | | |
| N022196 001 | 7632517 | Oct 01, 2017 | | U-70 | | |

Footnote:

1. Patents are published upon receipt by the Orange Book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).
2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor.
They may not be flagged with respect to other claims which may apply.
3. **** The expiration date for U.S. Patent No. 5,608,075 is March 4, 2009.

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 30th Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at
<http://www.accessdata.fda.gov/scripts/cder/ob/docs/patternsall.cfm>